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  ABSTRACT:	  
	  Aim:	  Despite	  being	  well	  validated	  as	  a	  therapeutic	  target,	  no	  chemokine	  receptor	  antagonists	  
to	  be	  used	  as	  therapeutic	  agents	  in	  inflammatory	  or	  metastatic	  disease	  have	  made	  it	  to	  market.	  
This	   is	   in	   part	   due	   to	   receptor	   redundancy,	   but	   also	   a	   lack	   of	   understanding	   with	   regard	   to	  
cytoplasmic	  signal	  transduction	  linking	  activated	  chemokine	  receptors	  to	  chemotaxis.	  	  Resolving	  
signal	  transduction	  pathways	  in	  model	  chemokine	  receptor	  systems	  may	  allow	  intracellular	  drug	  
targets	   to	   be	   identified,	   bypassing	   the	   difficulties	   associated	   with	   extracellular	   chemokine	  
receptor	  blockade.	  
Methodology:	  Experimentation	  was	  undertaken	  in	  THP-­‐1	  monocytes	  expressing	  the	  chemokine	  
receptors	   CCR5	   and	   CCR1	   and	   in	   stably	   CCR5-­‐transfected	   HeLa	   and	   CHO	   cell	   lines.	   Small	  
molecule	   inhibition	   and	   protein	   overexpression	   was	   used	   before	   chemotaxis	   and	   calcium	  
release	  assays	  to	  measure	  cellular	  responses.	  Immunocytology	  was	  used	  to	  determine	  the	  effect	  
of	   protein	   blockade	   on	   receptor	   internalisation,	   protein	   localisation	   and	   the	   formation	   of	  
cellular	   structures	   associated	   with	   migration.	   Experiments	   were	   also	   performed	   in	   activated	  
primary	  tissue	  for	  comparative	  analysis	  and	  validation	  of	  results	  in	  normal	  human	  tissue.	  
Results:	   A	   systematic	   blockade	   of	   signalling	   proteins	   by	   small	   molecule	  means	   revealed	   that	  
Gβγ,	  ERK1/2,	  p38	  and	  PI3K	  are	  not	  required	  for	  CCL3	  stimulated	  monocyte	  migration.	  GRK2	  and	  
PKC	  inhibition	  along	  with	  internalisation	  blockade	  showed	  antagonistic	  effects	  on	  the	  ability	  of	  
cells	  to	  migrate,	  suggesting	  arrestin	  dependent	  signalling	  was	  involved	  in	  chemotaxis.	  	  Inhibition	  
of	   dynamin,	   Grb2	   and	   non-­‐receptor	   tyrosine	   kinases	   were	   equally	   effective	   at	   blocking	  
migration	  in	  THP-­‐1	  cells	  but	  less	  effective	  at	  blocking	  CXCL11	  stimulated	  migration	  in	  activated	  
PBLs.	  
Conclusions:	   This	   study	   has	   shown	   that	   CCL3	   stimulated	   chemotaxis	   through	   CCR5	   does	   not	  
occur	   through	   typical	   G-­‐protein	  mediated	   signalling,	   but	  maybe	   therapeutically	   accessible	   by	  
inhibition	   of	   dynamin	   and	   Grb2.	   Additionally	   the	   differences	   in	   dynamin	   inhibitor	   efficacy	  
suggest	   that	   the	  production	  of	  migration	   specific	   dynamin	   inhibitors	  may	  be	  possible.	  Overall	  
the	   research	   in	   this	   thesis	  has	   identified	  novel	   targets	   for	   therapeutic	   intervention	   in	  diseases	  




Ab	   	   	   Antibody	  
ANOVA	   	   Analysis	  of	  variance	  
βARK	   	   	   β-­‐Adrenergic	  receptor	  kinase	  (GRK2)	  
BSA	   	   	   Bovine	  serum	  albumin	  
CCL	   	   	   C-­‐C	  motif	  chemokine	  receptor	  ligand	  
CCR	   	   	   C-­‐C	  motif	  (β)	  chemokine	  receptor	  
CHO.CCR5	   	   Chinese	  hamster	  ovary	  cells,	  CCR5	  stably	  transfected	  
c-­‐Src	   	   	   Cellular	  sarcoma	  non-­‐receptor	  tyrosine	  kinase	  
CXCL	   	   	   C-­‐X-­‐C	  motif	  chemokine	  receptor	  ligand	  
CXCR	   	   	   C-­‐X-­‐C	  motif	  chemokine	  receptor	  
DAPI	   	   	   4',6-­‐diamidino-­‐2-­‐phenylindole	  
DMEM	  	   	   Dulbecco’s	  modified	  Eagle’s	  medium	  
DMSO	  	   	   Dimethylsulphoxide	  
EC50	   	   	   Concentration	  at	  which	  50%	  of	  an	  effect	  occurs	  
EDTA	   	   	   Ethylenediaminetetraacetic	  acid	  
ERK1/2	   	   Extracellular	  signal-­‐regulated	  kinase	  1/2	  
FCS	   	   	   Foetal	  calf	  serum	  
Gα	   	   	   G-­‐Protein	  α	  subunit	  
Gβγ	   	   	   G-­‐Protein	  βγ	  subunit	  
GDP	   	   	   Guanosine	  diphosphate	  
GEF	   	   	   Guanine	  nucleotide	  exchange	  factor	  
GPCR	   	   	   G-­‐Protein	  coupled	  receptor	  
Grb2	   	   	   Growth	  factor	  receptor-­‐bound	  protein	  2	  
GRK	   	   	   G-­‐Protein	  coupled	  receptor	  kinase	  
GTP	   	   	   Guanosine	  triphosphate	  
HeLa.RC49	  	  	   	   Henrietta	  Lacks	  cell	  line,	  CCR5	  stably	  transfected	  
HIV	   	   	   Human	  immunodeficiency	  virus	  
IC50	   	   	   Concentration	  at	  which	  50%	  inhibition	  occurs	  
IL-­‐2/6	   	   	   Interleukin	  2/6	  
JAK	   	   	   Janus	  kinase	  
Lyn	   	   	   Lck/Yes-­‐related	  novel	  protein	  tyrosine	  kinase	  
MAPK	   	   	   Mitogen	  activated	  protein	  kinase	  
p38	   	   	   p38	  mitogen	  activated	  protein	  kinase	  
PBL	   	   	   Peripheral	  blood	  lymphocyte	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  PBMC	   	   	   Peripheral	  blood	  mononuclear	  cell	  
PBS	   	   	   Phosphate	  buffered	  saline	  
PH	   	   	   Pleckstrin	  homology	  
PI	   	   	   Phosphoinositide	  
PI3K	   	   	   Phosphoinositide-­‐3-­‐kinase	  
PKB	   	   	   Protein	  kinase	  B	  
PKC	   	   	   Protein	  kinase	  C	  
PLC	   	   	   Phospholipase	  C	  
PRD	   	   	   Proline	  rich	  domain	  
Pyk2	  	   	   	   Protein	  tyrosine	  kinase	  2	  
Ras	   	   	   Rat	  sarcoma	  GTPase	  
Rho	   	   	   Ras	  homology	  GTPase	  
RME	   	   	   Receptor	  mediated	  endocytosis	  
ROCK	   	   	   Rho	  kinase	  
RPMI	   	   	   Roswell	  Park	  memorial	  institute	  medium	  
RTK	   	   	   Receptor	  tyrosine	  kinase	  
SEM	   	   	   Standard	  error	  of	  the	  mean	  
SFK	   	   	   Src	  family	  kinase	  
SH2/3	   	   	   Src	  homology	  domain	  2/3	  
siRNA	   	   	   Small	  interfering	  ribonucleic	  acid	  
SOS	   	   	   Son	  of	  sevenless	  
STAT	   	   	   Signal	  transducer	  and	  activator	  of	  transcription	  
TG	   	   	   Thapsigargin	  
THP-­‐1	   	   	   Acute	  monocytic	  cell	  line	  THP-­‐1	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The	   chemokine	   receptor	   CCR5	   was	   discovered	   as	   a	   co-­‐receptor	   for	   the	   human	  
immunodeficiency	   virus	   1	   (HIV1)	   entry	   in	   to	   human	   macrophages	   [1-­‐3].	   	   Accordingly,	   large	  
amounts	  of	  research	  were	  undertaken	  to	  characterise	  CCR5-­‐HIV	  interaction	  [4-­‐9]	  with	  the	  hope,	  
that	  sufficient	  understanding	  would	  allow	  the	  production	  of	  effective	  anti-­‐HIV	  prophylactics	  to	  
combat	  the	  ever-­‐increasing	  global	  prevalence	  of	   infected	  individuals.	  HIV	  entry	  inhibitors	  were	  
eventually	  developed	  [10]	  with	  one,	  maraviroc,	  making	  it	  to	  market	  [11].	  	  Almost	  as	  an	  aside	  to	  
the	   research	   directly	   involving	   HIV,	   a	   great	   deal	   of	   information	   had	   been	   gained	   about	   CCR5	  
structure	   and	   function	   [4,	   12-­‐15].	   This	   chemokine	   receptor,	   after	   all,	   must	   have	   some	  
physiological	  function	  outside	  of	  HIV	  viral	  entry.	  The	  discovery	  that	  large	  numbers	  of	  individuals	  
carried	   the	  CCR5Δ32	  mutation	   that	   rendered	   the	   receptor	   non-­‐functional,	   but	   did	  not	   impact	  
significantly	  on	  carrier	  health	  [16],	  made	  the	  receptor	  an	  interesting	  point	  of	  research	  as	  CCR5	  
‘knockout’	  humans	  were	  readily	  available	  for	  study.	  	  
	  
Chemokine	  receptors	  are	  named	  for	  their	  ability	  to	  activate	  chemotaxis	  upon	  ligand	  binding	  so	  
it	   is	  not	  surprising	  that	  CCR5	   is	   linked	  to	  diseases	  where	  unwanted	  or	  excessive	  migration	   is	  a	  
cause.	  Chronic	  inflammatory	  diseases,	  such	  as	  atherosclerosis	  [17],	  rheumatoid	  arthritis	  [18,	  19]	  
and	  Crohn’s	  disease	  [20]	  are	   linked	  to	  CCR5	  signalling.	  These	  diseases	  result,	   in	  part,	   from	  the	  
dysregulation	   of	   immune	   cell	  migration	   and	   activation	   in	   the	   affected	   tissues.	   Understanding	  
pathological	   migration	   mediated	   by	   CCR5	   is	   also	   important	   for	   understanding	   cancer	   cell	  
metastasis,	  where	  chemokine	  receptors	  generally	   [21,	  22]	  and	  CCR5	  specifically	   [23,	  24],	  have	  
been	  shown	  to	  be	   important.	  For	   this	   reason,	  chemokine	  receptors	   including	  CCR5	  have	  been	  
identified	  as	  therapeutic	  targets	  for	  numerous	  diseases	  and	  many	  attempts	  have	  been	  made	  to	  
bring	   chemokine	   receptor	   based	   therapeutics	   to	   market	   [25].	   The	   complete	   absence	   of	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  chemokine	  receptor	  antagonist	  based	  therapies	  for	  chronic	  inflammatory	  or	  metastatic	  disease	  
at	   present,	   however,	   exemplifies	   the	   lack	   of	   understanding	   of	   how	   these	   receptors	   function.	  
Receptor	   redundancy,	   cross-­‐talk,	   transactivation	   and	   the	   often	   contradictory	   signalling	   events	  
linked	   to	   receptor	  activation	  suggest	   that	  direct	  blockade	  of	  chemokine	   receptors	  may	  not	  be	  
the	   most	   effective	   route	   for	   inhibiting	   their	   function.	   Understanding	   the	   intracellular	   signal	  
transduction	  events	  for	  specific	  receptors	  will	  help	  to	  identify	  therapeutic	  targets	  which	  bypass	  
the	  plasticity	  of	  extracellular	  receptor	  activation.	  The	  need	  for	  novel	  and	  specific	  anti-­‐migratory	  
therapies	   to	   treat	   chronic	   inflammatory	   and	  metastatic	   disease	   is	   great	   and	   the	   blockade	   of	  
chemokine	  receptor	  signalling	  may	  only	  be	  feasible	  at	  the	  cytoplasmic	  level.	  Therefore	  a	  greater	  
understanding	   of	   signal	   transduction	   events	   triggered	   by	   chemokine	   receptor	   activation	   is	  
imperative.	   CCR5	   makes	   a	   particularly	   interesting	   system	   to	   study	   due	   to	   the	   additional	  
relevance	  to	  HIV	  research	  and	  the	  presence	  of	  the	  CCR5Δ32	  mutation.	  	  
	  
1.2.	  Chemokine	  receptors	  
	  
All	  chemokine	  receptors	  are	  type	  A,	  or	  rhodopsin	  like,	  G-­‐protein	  coupled	  receptors	  and	  as	  such	  
share	  a	  certain	  amount	  of	  structural	  and	  functional	  homology,	  as	  all	  GPCRs	  do	  [26].	  Their	  name	  
derives	  from	  their	  ligands,	  the	  chemokines;	  a	  portmanteau	  of	  chemotactic	  cytokine.	  Chemokine	  
receptors	   are	   sub-­‐divided	   into	   families	   based	   on	   the	   homology	   of	   their	   ligands:	   CXC	   motif	  
chemokines	   (CXCLs)	   bind	   CXC	  motif	   or	   α	   chemokine	   receptors	   (CXCRs).	   CC	  motif	   chemokines	  
(CCL)	  bind	  CC	  motif	  or	  β	  chemokine	  receptors	  (CCRs),	  which	  together	  with	  the	  CXCRs	  make	  the	  
largest	  two	  families	  of	  chemokine	  receptors.	  There	  is	  often	  a	  high	  level	  of	  ligand	  sharing	  within	  a	  
chemokine	  receptor	  family,	  which	  is	  not	  present	  between	  families.	  CCL3	  for	  example	  binds	  CCR1	  
and	   CCR5	   [27,	   28]	   but	   shows	   no	   affinity	   for	   CXCR4,	   likewise	   CXCR4	   ligand	   CXCL12	   does	   not	  
interact	  with	  CCR1	  or	  5.	  Overall	  sequence	  homology	  is	  not	  a	  good	  indicator	  of	  ligand	  specificity,	  
as	  some	  α	  chemokine	  receptors	  have	  higher	  homology	  with	  β	  chemokine	  receptors	  than	  other	  α	  
chemokine	   receptors.	  Homology	  does	   seem	   to	   relate	   to	   the	  way	   the	   receptors	   function	  upon	  
activation	   [29],	  CCR5	  and	  CCR2	  which	  have	  79%	  total	   sequence	  homology	   (UniProt	  sequence/	  
Blast	   homology	   analysis)	   have	   some	   signalling	   in	   common	  which	   they	   don’t	   share	  with	   CCR1,	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  which	   has	   56%	   CCR5	   homology	  [30].	   It	   is	   these	   differences	   in	   structure	   which	   govern	   the	  
behaviour	  and	  signal	  transduction	  of	  different	  chemokine	  receptors.	  Differences	  in	  cytoplasmic	  
signalling	   are	   governed	   by	   factors	   such	   as	   the	   number	   of	   phosphorylation	   sites	   the	   receptor	  
expresses	   [31],	   e.g.	   CCR5	   possesses	   7	   sites	   whilst	   CXCR4	   possesses	   21.	   Comparisons	   and	  
contrasts	   between	   the	   structure	   and	   function	   of	   different	   chemokine	   receptors,	   chemokine	  
receptor	   families	   and	   GPCRs	   generally	   is	   crucial	   for	   identifying	   receptor	   or	   family	   specific	  
signalling.	   This	   signalling	   can	   then	   be	   used	   to	   identify	   therapeutic	   targets	   for	   diseases	  where	  
specific	  chemokine	  receptors	  are	  known	  to	  be	  involved.	  	  
	  
In	   contrast	   to	   structural	   similarities	   and	   differences	   that	   set	   receptors	   apart,	   comparative	  
analysis	   of	   chemokine	   receptor	   function	   is	   often	   important	   between	   receptors,	   which	   are	  
structurally	  different,	  but	  appear	   in	   the	  same	  cells,	  or	  are	  associated	  with	   the	  same	  biological	  
phenomena.	  CCR5	  and	  CXCR4,	   for	  example,	  have	   lower	  sequence	  homology,	  but	  are	  both	  HIV	  
co-­‐receptors.	   CCR5	   and	   CXCR3	   share	   no	   agonistic	   ligands,	   but	   are	   both	   found	   in	   activated	  
peripheral	  lymphocytes	  [32].	  Interestingly	  the	  CXCR3	  agonist	  CXCL11	  antagonises	  CCR5,	  hinting	  
at	   possible	   regulatory	   mechanisms.	   Careful	   analysis	   of	   the	   functional	   differences	   between	  
receptors	   linked	   to	   the	   same	   biological	   process	   or	   environment	   may	   offer	   insights	   into	   the	  
subtleties	  of	  specific	  receptor	  function.	  	  It	  is	  now	  important	  to	  understand	  what	  is	  known	  about	  












	  1.3.	  The	  G	  Protein	  coupled	  receptor	  	  	  
	  
As	   their	  name	  suggests,	  all	  GPCRs	  couple	  to	  G-­‐protein	  heterotrimers,	  which	  become	  activated	  
upon	   ligand	   binding	   and	   transduce	   signals	   via	   a	   wide	   range	   of	   intracellular	   molecules.	   The	  
duration	  and	   intensity	  of	  GPCR	  signalling	   is	  often	  more	   important	   than	   the	   fact	   signalling	  was	  
triggered,	   allowing	   cells	   utilising	   GPCRs	   to	   process	   complex	   but	   subtle	   physiological	  
environments	  and	  translate	  signalling	  into	  decisive	  responses	  such	  as	  chemotactic	  migration.	  As	  
such	   activated	  GPCRs	   are	   efficiently	   desensitised	   and	   internalised	   by	   recruitment	   of	   arrestins	  
after	   G	   protein	   coupled	   receptor	   kinases	   (GRKs)	   C-­‐terminal	   phosphorylation,	   which	   allows	  
signalling	   to	   quickly	   respond	   to	   small	   changes	   in	   the	   extracellular	   and	   intracellular	   milieu.	  
Activation	  and	  desensitisation	  utilising	  members	  of	   the	  heterotrimeric	  G-­‐protein,	   arrestin	   and	  
GRK	  protein	  families	  is	  a	  cornerstone	  of	  GPCR	  theory	  and	  widely	  held	  to	  be	  a	  quintessential	  trait	  
(Figure	   1.1.).	   In	   the	   classic	   model	   of	   GPCR	   signalling	   activated	   receptors	   bind	   to	   and	   active	  
heterotrimeric	   G	   proteins	   which	   dissociate	   into	   Gα	   and	   Gβγ	   subunits	   that	   are	   primarily	  
responsible	   for	   signal	   transduction,	   which	   is	   negatively	   regulated	   by	   arrestin	   binding.	   This	  
classical	   response	   was	   later	   expanded	   to	   include	   arrestin	   dependent	   signalling	   through	   the	  
formation	   of	   signalling	   protein	   scaffolds	   that	   could	   lead	   to	   specific	   and	   independent	   cellular	  
responses	   [33-­‐35].	   Aside	   from	   interacting	  with	   heterotrimeric	  G	   proteins,	  GRKs	   and	   arrestins,	  
GPCRs	  have	  an	  extensive	  range	  of	  proteins	  with	  which	  they	  can	  interact	  [36],	  which	  is	  why	  GPCR	  
signalling	  pathways	   for	   any	   receptor	  have	   yet	   to	  be	   fully	  unravelled.	   In	   this	   respect	  CCR5	   is	   a	  
typical	  GPCR	  with	  classical	  signalling	  through	  G	  proteins	  [27,	  37,	  38]	  and	  arrestins	  [39]	  and	  direct	  




Figure	  1.1.	  Simplified	  overview	  of	  GPCR	  signalling	  which	  represents	  the	  most	  upstream	  events	  
common	   to	   all	   GPCRs:	   signalling	   via	   heterotrimeric	   G	   proteins	   followed	   by	   desensitisation	  
through	   GRKs	   and	   arrestins	   is	   as	   definitive	   of	   GPCRs	   as	   structural	   features	   such	   as	   7	  
transmembrane	  domains.	  G	  protein	  and	  arrestin	  effectors	  are	  numerous	  and	  have	  the	  ability	  
to	  feedback	  into	  this	  simple	  system	  resulting	  in	  diverse	  functionality.	  Signalling	  to	  chemotaxis	  
can	   potentially	   occur	   via	  Gα,	  Gβγ	   or	   arrest	   scaffold	   signalling.	   (Adapted	   and	  modified	   from	  
[41]).	  
	  
1.4.	  CCR5	  Ligands	  and	  receptor	  activation	  	  
	  
CCR5	  is	  known	  to	  bind	  a	  range	  of	  natural	  and	  modified	  chemokine	  ligands	  however	  the	  effect	  of	  
ligand	  binding	  on	  receptor	  activation	  is	  not	  uniform	  between	  these	  ligands.	  Ligands	  CCL3,	  CCL4	  
and	  CCL5	  are	  the	  best	  characterised	  CCR5	  ligands,	  the	  binding	  of	  which	  results	   in	  full	  receptor	  
activation	   leading	   to	   C-­‐terminal	   phosphorylation	   and	   internalisation	   by	   clathrin	   dependent	  
means	   [15,	   27,	   42,	   43].	   Other	   ligands	   such	   as	   CCL2	   and	   CCL11	   can	   activate	   some	   receptor	  
functions	  but	  do	  not	  result	   in	  C-­‐terminal	  phosphorylation	  (Figure	  1.2.)	   [42].	  A	  further	  group	  of	  
ligands	  are	  described	  as	  CCR5	  antagonists	  due	  to	  their	  ability	  to	  prevent	  agonist	  binding	  without	  
inducing	  receptor	  activation;	  the	  accuracy	  of	  the	  antagonistic	  behaviour	  is	  in	  question	  however	  
due	   to	  conflicting	   reports	  on	   their	  ability	   to	  activate	  CCR5	   [27,	  42,	  44].	  Table	  1.1.	   summarises	  
the	  known	  CCR5	  binding	  ligands	  and	  their	  effects	  on	  the	  CCR5	  receptor.	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  Table	  1.1:	  CCR5	  ligands	  and	  binding	  information.	  CCR5	  C-­‐terminal	  phosphorylation	  does	  not	  occur	  upon	  activation	  with	  all	  ligands.	  
	  
Ligand	   Notes	   Refs.	  
CCL2	   Weak	  agonist.	  Displaces	  CCL4	  binding	  with	  an	  IC50	  of	  0.2	  nM.	   [5,	  42]	  
CCL3	   Higher	  potency	  and	  efficacy	  than	  CCR4	  and	  CCR5	  in	  chemotaxis	  and	  calcium	  release	  assays.	   [27]	  
CCL3	  L1	   Highest	  potency	  and	  efficacy	  of	  the	  natural	  CCR5	  ligands	  at	  inducing	  internalisation	  and	  [35S]GTPγS	  binding.	   [45]	  
CCL4	   Highest	  binding	  affinity	  for	  CCR5.	  Essentially	  CCR5	  specific	   [42]	  
CCL5	   Agonist	  that	  induces	  receptor	  phosphorylation,	  internalisation,	  migration	  and	  calcium	  release.	   [27]	  
Met	  RANTES	   Thought	  to	  be	  an	  antagonist	  but	  has	  shown	  partial	  agonism	  in	  [35S]GTPγS	  binding	  assays.	   [27,	  46]	  
CCL7	   Weak	  agonist:	  stimulates	  low	  levels	  of	  receptor	  activation	  but	  does	  not	  lead	  to	  receptor	  phosphorylation.	   [27,	  42]	  
CCL8	   Agonist	  in	  migration	  and	  internalisation	  but	  does	  not	  induce	  CCR5	  phosphorylation.	   [27,	  47]	  
CCL11	   Weak	  agonist.	  Displaces	  CCL4	  binding	  with	  an	  IC50	  of	  22	  nM.	  	   [42]	  
CCL13	   Weak	  agonist.	  Can	  induce	  internalisation	  but	  does	  not	  lead	  to	  CCR5	  phosphorylation.	  Prevents	  CCL4	  binding	  with	  6	  nM	  IC50.	   [27,	  42]	  





Figure	  1.2:	  The	  amino	  acid	  sequence	  of	  CCR5.	  Important	  intracellular	  residues	  are	  filled	  black	  
and	   represent	   the	   ‘DRYLAVVHA’	  motif	   known	   for	  G	  protein	  and	  arrestin	  binding,	   sites	  of	  C-­‐
terminal	   palmitoylation	   and	   the	   four	   serine	   residues	   required	   for	   arrestin	   binding	   and	  
internalisation	  [38].	  	  
	  
1.5.	  The	  Heterotrimeric	  G	  Proteins	  
	  
Of	   the	   three	   classically	   associated	  protein	   types	   the	  heterotrimeric	  G	  proteins	   are	   the	   largest	  
group	   and,	   accordingly,	   display	   a	   broad	   range	   of	   functions	   [48].	   The	  G	   proteins	  were	   initially	  
identified	  as	  a	  result	  of	  observations	  made	  regarding	  the	  effects	  of	  GPCR	  activation	  on	  adenylyl	  
cyclase	   activity	   and	   cyclic	   AMP	   accumulation:	   some	   GPCRs,	   upon	   activation,	   increase	   activity	  
whilst	   others	   decrease	   it	   [49].	   This	   phenomenon	  was	   attributed	   to	   stimulatory	   and	   inhibitory	  
GTPases	  termed	  Gs	  and	  Gi,	  which	  were	  shown	  to	  be	  heterotrimeric	  in	  nature	  being	  comprised	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  of	   Gα,	   β	   and	   γ	   subunits	   and	   display	   constitutive	   binding	   to	   GPCRs.	   Ligand	   induced	  
conformational	  changes	  in	  the	  GPCR	  allow	  the	  heterotrimeric	  G-­‐proteins	  to	  dissociate	  from	  the	  
receptor	  and	  the	  Gα	  subunit	  to	  dissociate	  from	  the	  heterotrimer	  and	  exchange	  GDP	  with	  GTP	  to	  
become	  an	  active	  signalling	  protein.	  The	  Gβγ	  dimer	  remains	  at	  the	  membrane,	  but	  is	  also	  free	  to	  
interact	  with	  non-­‐receptor	  signalling	  proteins	  [41].	  	  
	  
It	  became	  clear	  as	  GPCR	   investigations	  continued	  and	  more	  associated	  proteins	  were	  purified	  
and	   identified,	   that	   the	   Gα	   subunit	   is	   responsible	   for	   the	   ‘classical’	   signalling	   functionality	   of	  
heterotrimeric	   units	   as	   displayed	   by	   functional	   cAMP	   assays.	   Eventually	   sixteen	   different	   Gα	  
units	   were	   identified	   and	   the	   evidence	   suggested	   that	   stimulation	   and	   inhibition	   of	   adenylyl	  
cyclase	   was	   a	   feature	   common	   to	   only	   some	   of	   these	   α	   subunits	   with	   others	   capable	   of	  
regulating	   PLC,	   PI3K	   or	   Rho	   family	   proteins	   [50].	   Based	   on	   their	   functional	   similarities	   Gα	  
subunits	   are	   sorted	   into	   one	   of	   four	   sub-­‐families	   (Table	   1.2),	   however	   the	   nomenclature	   for	  
these	   subunits	   follows	   a	   historical	   precedent	   and	   does	   not	   allude	   to	   this	   grouping	   or	   their	  
function.	  
	  
Table	  1.2:	  G	  protein	  families	  and	  α	  subunits	  
	  









Adenylyl	  cyclase	  inhibition	  
PLC	  activation	  
Adenylyl	  cyclase	  activation	  
Rho	  GTPase	  activation	  
	  
The	  most	   interesting	   aspect	   of	   Gα	   units	   with	   regard	   to	   GPCR	   signalling	   is	   that	   a	   majority	   of	  
GPCRs	  can	  associate	  with	  heterotrimeric	  G	  proteins	  containing	  a	  variety	  of	  Gα	  units.	  Differential	  
recruitment	   of	   these	   Gα	   subunits	   may	   be	   governed	   by	   receptor-­‐ligand	   binding	   in	   a	   form	   of	  
biased	  signalling	  as	  seen	  in	  some	  GPCRs	  [51].	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  The	  Gβγ	  subunit	  dimer,	  once	  disassociated	  from	  the	  alpha	  units,	  has	  signalling	  capabilities	  of	  its	  
own,	  including	  inhibition	  or	  stimulation	  of	  adenylyl	  cyclase,	  stimulation	  of	  PLC	  [52],	  activation	  of	  
GRK2	  and	  3	  [53]	  and	  Pi3K	  stimulation	  [54].	  These	  are	  dependent	  upon	  GPCR	  type	  and	  associated	  
Gα	   subunits	   [48].	   Neptune	   et	   al.	   demonstrated	   that	   Gβγ	   dissociation	   from	   Gαi	   subunits	   is	  
essential	   for	   chemotaxis	   to	  occur	  downstream	  of	   non-­‐chemokine	   receptor	  GPCRs	   such	   as	   the	  
dopamine	  and	  opioid	  receptors	  [55].	  There	  is	  growing	  evidence	  as	  well,	  that	  Gβγ	  are	  responsible	  
for	  signalling	  to	  chemotaxis	  downstream	  of	  various	  chemokine	  receptors	  [56-­‐59].	  
	  
1.6.	  GRK	  signalling	  and	  CCR5	  
	  
G	  Protein	  Coupled	  Receptor	  Kinases	  (GRKs)	  represent	  seven	  proteins	  in	  three	  families;	  GRK1	  and	  
7	  are	   found	   in	   the	   retina	  and	   form	  one	   family,	  GRK	  2	  and	  3	   form	  one	  ubiquitously	  expressed	  
family	  and	  GRK	  4,5	  and	  6	   form	  the	  other	   [60].	  GRKs	  phosphorylate	  activated	  GPCR	  C-­‐terminal	  
serine	  residues,	  which	  promotes	   the	  recruitment	  of	  arrestins	  which,	   in	   turn,	   leads	   to	   receptor	  
desensitisation	  [12].	  GRK	  localisation	  to	  the	  GPCR	  C-­‐terminus	   is	  facilitated	  by	  interactions	  with	  
Gβγ	   [53]	   however	   CCR5	  C-­‐terminal	   phosphorylation	   can	   also	   occur	   via	   protein	   kinase	   C	   (PKC)	  
[46].	   The	   role	   of	   GRKs	   as	   potential	   signal	   transducers	   is	   however	   less	   clear.	   Although	   ligand	  
bound	   CCR5	   is	   a	   target	   for	   GRKs	   of	   various	   type	   under	   experimental	   conditions	   [12],	   the	  
significance	  of	  this	  relationship	   in	  vivo	  has	  yet	  to	  be	   investigated,	  especially,	  when	  considering	  
the	  potential	  for	  GRKs	  to	  interact	  with	  other	  signalling	  proteins	  and	  mediated	  arrestin	  scaffold	  
formation	   [61].	   CCR5	   is	   thought	   to	   bind	   predominantly	   to	   GRK2	   however	   [38],	   which	   may	  
simplify	   interpretation	  of	  potential	  signalling	  pathways	  associated	  with	  the	  receptor.	  GRKs	  are	  
known	  to	   interact	  with	  other	  proteins	   likely	  to	  be	  present	  at	  the	  activated	  CCR5	  receptor	  that	  
are	   known	  players	   in	   chemotaxis	   signalling,	   such	  as	  Gα	  and	  Gβγ	   subunits	   [53].	  GRK2	  has	   also	  
been	   shown	   to	   inhibit	   ERK	   activation	   in	   the	   CCR2	   signalling	   cascade,	   a	   process	   which	   is	   not	  
dependent	  on	  CCR2	  phosphorylation	  nor	  on	  the	  GRK	  Gαq	  or	  Gβγ	  binding	  domain	  function.	  This	  
suggests	   that	   GRKs	   have	   a	   protein	   binding	   function	   that	   works	   independently	   of	   G	   protein	  
subunits	  and	  the	  receptor	  itself	  [62].	  It	  also	  shows	  GRKs	  can	  form	  independent	  complexes	  with	  
non-­‐receptor	  proteins,	  however,	  their	  role	  in	  CCR5	  mediated	  signalling	  to	  migration	  is	  unknown.	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  1.7.	  Arrestins	  
	  
Like	   GRKs,	   arrestins,	   the	   third	   group	   of	   proteins	   common	   in	   GPCR	   signalling,	   were	   initially	  
underestimated	  in	  their	  ability	  to	  act	  as	  signalling	  molecules.	  As	  more	  information	  is	  discovered	  
about	  their	  role	  in	  receptor	  uncoupling	  and	  desensitisation,	  it	  becomes	  clear	  that	  arrestins	  can	  
bind	  a	  variety	  of	  signalling	  proteins	  in	  addition	  to	  activated	  receptors	  [35,	  63].	  This	  suggests	  that	  
mediation	  of	  desensitisation	  by	  binding	  to	  phosphorylated	  GPCR	  C	  termini	  and	  steric	  hindrance	  
of	  Gα	  units	  is	  just	  one	  of	  their	  roles.	  As	  research	  has	  continued,	  the	  nature	  and	  scope	  of	  arrestin	  
dependent	  signalling	  has	  become	  apparent	  [64,	  65],	  with	  the	  formation	  and	  function	  of	  arrestin	  
signalling	   scaffolds	  dependent	   to	   some	  degree	  upon	   factors	   such	  as	   receptor	   type,	  associated	  
GRKs	  and	  post	  transcriptions	  modifications	  [35,	  66].	  Signalling	  scaffolds	  have	  no	  exact	  definition	  
but	   generally	   function	   to	   localise	   signal	   transduction	  proteins	  with	  one	   another	   at	   a	   cytosolic	  
location	  relevant	  to	  specific	  cellular	  responses	  [67].	  In	  the	  case	  of	  GPCRs	  such	  as	  the	  angiotensin	  
receptor	  2,	  ligand	  activation	  in	  the	  presence	  of	  Gβγ	  binding	  GRK2	  family	  GRKs	  leads	  to	  classic	  G	  
protein	   signalling	   and	   internalisation	   via	   clathrin	   dependent	   mechanism.	   In	   this	   instance,	  
arrestin	  acts	  as	  an	  adaptor	  for	  the	  relevant	  endocytotic	  machinery	  such	  as	  clathrin.	  Conversely,	  
in	   the	  presence	  of	  GRK	  5	   family	  GRKs	  arrestin	  act	   as	   a	   scaffold	   for	   signalling	  proteins	   such	  as	  
MEK	  (MAPKK),	  which	  lead	  to	  arrestin	  dependent	  signalling	  through	  ERK	  and	  JNK.	  For	  both	  GRK2	  
and	  GRK5	  family	  proteins,	  however,	  these	  mechanisms	  are	  subject	  to	  some	  degree	  of	  crossover	  
i.e.	  GRK5	  is	  also	  responsible	  for	  recruiting	  arrestins	  for	  internalisation	  [60].	  (Figure	  1.3.).	  	  	  	  	  
	  
Arrestin	   dependent	   signalling	   has	   also	   been	   shown	   to	   extend	   to	   activation	   Src	   family	   kinases	  
(SFKs)	   demonstrating	   that	   arrestins	   are	   capable	   of	   interfacing	   a	   wide	   range	   of	   signal	  
transduction	   proteins	  with	   active	  GPCRs	   [41].	  Understanding	   the	   processes	   governing	   protein	  
availability	  for	  arrestin	  dependent	  recruitment	  to	  any	  particular	  receptor	  is	  likely	  to	  illuminate	  a	  
great	   deal	   about	   the	   receptor	   signalling	   capabilities.	   This	   fact	   needs	   to	   be	   considered	   when	  
investigating	  the	  ligand	  activated	  signal	  transduction	  pathways	  for	  CCR5.	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  Supplementary	   to	   ligand-­‐activated	   processes,	   it	   was	   discovered	   that	   arrestins	   can	   signal	  
constitutively,	  adding	  a	  new	  dimension	  to	  their	  role	  in	  controlling	  GPCR	  induced	  signalling.	  Like	  
activation	  dependent	  signalling,	   this	  constitutive	  activity	  varies	  between	  receptor	   types,	  but	   is	  
confined	   to	   members	   of	   the	   MAPK	   family;	   seemingly	   excluding	   other	   non-­‐receptor	   proteins	  
known	  to	  interact	  with	  β	  arrestins	  upon	  ligand	  activation.	  It	  is	  also	  dependent	  on	  localisation	  of	  
arrestins	   at	   the	   receptor,	   which	   indicates	   that	   arrestins	   can	   bind	   GPCRs	   that	   are	   not	  
phosphorylated	   and	   therefore	   it	   does	   not	   induce	   desensitisation/	   internalisation	   pathways	   in	  
these	   cases.	   [68]	   The	   relevance	   of	   these	   observations	   to	   CCR5	   mediated	   signalling	   events	  
remain	  to	  be	  clarified.	  
	  
	  
Figure	  1.3:	  Arrestins	  can	  act	  as	  mediators	  of	  endocytosis	  or	  signalling	  scaffolds	  depending	  on	  
associated	  GRKs.	  Between	  arrestins,	  GRKs	  and	  G	  proteins	  a	  plethora	  of	  signalling	   is	  possible	  
upon	   ligand	  activation	  of	   the	  receptor	   through	  a	  wide	  range	  of	  molecules:	  determination	  of	  
which	   of	   these	   pathways	   is	   relevant	   to	   CCR5	   is	   crucial	   to	   work	   out	   intracellular	   signalling	  
events.	  (Images	  from	  [60]).	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  A	   consideration	   for	   CCR5	   signal	   transduction	   determination	   is	   the	   way	   arrestins	   have	   been	  
shown	  to	  act	   in	  opposition	  or	   in	  synergy	  with	  established	  Gα	  signal	  transduction	  pathways	  for	  
some	   receptor	   types,	   inhibiting	   or	   enhancing	   the	  magnitude	   of	   their	   effects	   on	   downstream	  
targets,	   which	   can	   lead	   to	   unexpected	   results	   in	   functional	   assays	   [33].	   The	   most	   important	  
question	  to	  address	  is	  whether	  arrestins	  can	  function	  as	  signalling	  molecules	  and	  scaffolds	  in	  a	  
totally	   independent	   fashion	   from	   G	   protein	   activation.	   There	   is	   evidence	   to	   support	   that	  
internalisation	   and	   arrestin	   dependent	   signalling	   are	   indeed	   independent	   and	   that	   the	  
formation	   of	   arrestin	   dependent	   signalling	   scaffolds	   is	   controlled	   by	   phosphorylation	   of	   the	  
GPCR	   C-­‐terminus	   and	   post	   translation	   arrestin	   modification	   via	   ubiquitination	   [66].	  
Understanding	   the	   relevance	  of	   arrestin	   fate	   in	  CCR5	  mediated	   signalling	   to	  migration	  will	   be	  
important	   but	   there	   are	   other	   questions	   that	   must	   also	   be	   answered	   such	   as	   the	   role	   of	  
internalisation	  in	  CCR5	  mediated	  migration.	  Neptune	  et	  al.	  demonstrated	  that	  the	  β	  adrenergic	  
and	   Angiotensin	   receptor	   signalling	   to	   migration	   did	   not	   require	   internalisation	   but	   the	  
interaction	  of	  these	  GPCRs	  with	  arrestins	  is	   likely	  to	  be	  very	  different	  due	  to	  their	  much	  larger	  
third	  intracellular	  loops	  [38].	  	  
	  
1.8.	  Calcium	  release	  
	  
Although	  calcium	  release	  is	  associated	  with	  disease	  in	  highly	  active	  tissue	  such	  as	  the	  heart	  [69]	  
and	   nervous	   system	   [70],	   it	   is	   widely	   used	   as	   tool	   to	   monitor	   receptor	   activated	   responses.	  
Calcium	   release	   occurs	   quickly	   upon	   receptor	   activation	   and	   proportional	   to	   the	   level	   of	  
signalling	  [71]	  which	  makes	  monitoring	  of	  calcium	  release	  incredibly	  useful	  for	  determining	  the	  
extent	  of	  cellular	  activation	  in	  relation	  to	  ligand	  binding	  and	  in	  the	  presence	  of	  inhibitors.	  
	  
1.8.1.	  CCR5	  signalling	  to	  calcium	  release	  
	  
Stimulation	  of	  calcium	  release	  upon	  activation	  of	  CCR5	  is	  well	  researched	  and	  has	  been	  shown	  
to	  occur	   through	  G	  protein	  dependent	  means	   sensitive	   to	  both	  pertussis	   toxin	   treatment	  and	  
modifications	   to	   the	   second	   intracellular	   DRY	   motif	   which	   prevent	   heterotrimeric	   G	   protein	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  binding	   [72].	   Chemokine	   ligands	   CCL3,	   4	   and	   5	   stimulate	   CCR5	   mediated	   calcium	   release	   in	  
CHO.CCR5	  cells	  [73].	  CCR5	  ligands	  that	  do	  not	  result	  in	  receptor	  phosphorylation,	  however,	  like	  
CCL8	   and	   CCL13,	   also	   induce	   calcium	   release	   [27],	   which	   suggests	   that	   arrestin	   dependent	  
signalling	   is	  not	   involved	   in	   intracellular	   calcium	   fluxes.	  Cardaba	  et	  al.	   have	   investigated	  CCR5	  
mediated	  calcium	  release	  thoroughly	  and	  revealed	  a	  dependence	  on	  lipid	  raft	  integrity	  [74]	  that	  
may	   modulate	   Gα	   isotype	   specificity	   as	   cholesterol	   depletion	   results	   in	   a	   reduction	   in	   PTX	  
sensitivity	  without	  affecting	  calcium	  signalling.	  Signalling	  to	  calcium	  release	  is	  believed	  to	  occur	  
via	  Gβγ	  activation	  of	  PLC	  via	  PI3K	  which	  results	  in	  PLC	  cleaving	  PIP2	  into	  DAG	  and	  IP3,	  which	  act	  
as	   second	   messengers	   on	   calcium	   channels	   [52].	   Interestingly	   Cardaba	   et	   al.	   were	   able	   to	  
demonstrate	  that	  calcium	  release	  is	  independent	  of	  migration	  in	  chemotaxis	  mediated	  by	  CCL3	  
in	  THP-­‐1	  cells	  [75].	  This	  suggests	  that	  calcium	  dependent	  kinases	  such	  as	  Pyk2	  and	  PKC	  may	  not	  
be	   required	   for	  migration	   in	   this	   system	  and	  could	  explain	   the	   increase	   in	  migratory	   response	  
seen	  in	  PKC	  inhibited	  cells.	  Inhibition	  of	  PKC	  might	  allow	  an	  increase	  of	  GRK	  phosphorylation	  of	  
the	   CCR5	   C-­‐termini,	   which	   in	   turn	   can	   increase	   the	   GRK	   or	   arrestin	   dependent	   signalling	   on	  
which	   migration	   is	   dependent.	   Despite	   the	   apparent	   independence	   of	   CCR5	   mediated	  
chemotaxis	   and	   calcium,	   release	   the	   calcium	   flux	   assay	   (described	   by	  Grynkiewicz	   et	   al.	   [71])	  
represents	   an	   excellent	   tool	   for	   assessing	   receptor	   activation	   and	   so	   may	   be	   useful	   for	   the	  




1.9.1.	  Targeting	  chemotaxis	  in	  chronic	  immune	  and	  metastatic	  disease	  
	  
Chemotaxis	  is	  the	  process	  by	  which	  cells	  migrate	  towards	  a	  gradient	  of	  chemical	  stimulant	  and	  is	  
crucial	   for	   normal	   biological	   processes	   from	   embryological	   growth	   [76]	   and	   development,	   to	  
wound	   healing	   and	   in	   immune	   system	   function	   [77,	   78].	   Unwanted	   migration	   of	   cells	   is	  
etiological	  to	  numerous	  diverse	  disease	  conditions:	  chronic	  immune	  conditions	  such	  as	  asthma,	  
COPD	   and	   rheumatoid	   arthritis	   are	   characterised	   by	   excessive	   influx	   of	   immune	   cells	   which	  
result	   in	  physiologic	  alterations	  in	  the	  affected	  tissues.	  Cancer	  metastasis	  represents	  migration	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  and	  invasion	  of	  malignant	  tumour	  cells	  into	  healthy	  tissue	  and	  correlates	  to	  poor	  prognosis	  and	  
is	   the	   leading	   cause	   of	   death	   in	   hard	   to	   diagnose	   cancers	   such	   as	   lung	   and	   prostate	   cancer.	  
Current	   therapies	   for	   these	   conditions	   focus	  mainly	   on	   reducing	   the	   effects	   of	   this	   unwanted	  
migration	  by	  reducing	  inflammation	  or	  by	  surgical	  means.	  There	  is	  a	  clear	  need	  for	  preventative	  
anti-­‐migratory	   therapies	   particularly	   if	   they	   can	   be	   targeted	   against	   specific	   cell	   types	   or	  
receptor	  signalling	  axes.	  The	  reason	  for	  the	  paucity	  in	  anti-­‐migratory	  agents	  is	  that	  chemotaxis	  is	  
not	   fully	   characterised	   and	   research	   has	   produced	   a	   picture	   of	  multiple	   and	   often-­‐conflicting	  
signal	   transduction	   to	   migration.	   Current	   anti-­‐metastatic	   therapies,	   such	   as	   bosutinib	   [79]	  
doxorubicin	  [80]	  and	  cetuximab	  do	  not	  work	  on	  migratory	  machinery	  specifically,	  therefore	  they	  
have	   side	  effects	   and	   could	  not	  be	  used	   to	   target	   inflammatory	  disease.	  Although	   chemokine	  
receptors	   have	   been	   validated	   as	   targets	   for	   anti-­‐migratory	   therapies	   for	   chronic	   immune	  
disease	   and	   cancer	   [24,	   25,	   81],	   the	   fact	   that	   no	   chemokine	   receptor	   antagonist	   based	   anti-­‐
migratory	  therapeutics	  have	  made	  it	  to	  market,	   is	  not	  through	  lack	  of	  research	  but	  because	  of	  
problems	  with	  efficacy	  [25].	  This	  likely	  to	  be	  due	  to	  the	  fact	  that	  chemokine	  receptor	  signalling	  
contains	   redundancy	   between	   receptor	   family	   types	   and	   chemokine	   ligands	   often	   function	  
through	  more	  than	  one	  receptor.	  Receptors	  can	  also	  signal	  horizontally	  through	  dimerised	  [82,	  
83]	  and	  arrayed	  species	  [84]	  and	  transactivation	  between	  receptor	  types	  can	  occur	  [85].	  
	  
1.9.2.	  The	  cytoplasmic	  mechanism	  of	  chemotaxis	  
	  
Chemotaxis	   has	   been	   shown	   to	   be	  mediated	  by	  GPCRs	   and	   receptor	   tyrosine	   kinases	   such	   as	  
cytokine	   receptors.	   GPCRs	   such	   as	   β2-­‐adrenergic	   and	  M3-­‐muscarinic	   receptors	   are	   known	   to	  
signal	  to	  chemotaxis	  [55]	  but	   it	   is	  the	  chemokine	  receptors,	  as	  their	  name	  suggests,	  which	  are	  
most	   well-­‐known	   for	   signalling	   to	   migration.	   The	   specifics	   of	   signal	   transduction,	   which	   are	  
discussed	   below,	   are	   complex	   and	   have	   receptor	   and	   cell	   specific	   components	   which	   make	  
generalised	  signal	  transduction	  to	  migration	  difficult	  to	  describe.	  There	  are	  events	  that	  occur	  in	  
chemotaxis	   that	   are	   considered	   to	   be	   conserved	   however;	   migration	   is	   a	   process	   driven	   by	  





Figure	  1.4:	  The	  general	  processes	  and	  signalling	  molecules	  thought	  to	  be	  involved	  chemotaxis.	  
This	  overview	  does	  not	  take	  into	  account	  cell	  or	  receptor	  specific	  signalling	  events	  or	  explain	  
how	  monocytes,	  which	  do	  not	  require	  PI3K	  for	  polarisation,	  function.	  Image	  from	  [76].	  
	  
Polarisation	   allows	   the	   cell	   to	   determine	   the	   spatial	   orientation	   of	   an	   extracellular	   stimulant	  
concentration	   gradient	   by	   producing	   intracellular	   gradients	   of	   signalling	   molecules	   [76].	   The	  
cytoskeleton	   is	   re	   arranged	   to	   allow	  movements	   towards	   this	   gradient	   by	   interaction	   of	   the	  
cytoskeleton	   with	   motor	   proteins	   and	   this	   force	   is	   transmitted	   through	   adhesion	   present	   in	  
membrane	   structures	   such	   as	   filopodia	   [86]	   and	   podosomes	   [87-­‐89].	   Disassembly	   of	   this	  
machinery	   at	   the	   trailing	   edge	   of	   cells	   is	   also	   important	   and	   this	   is	   again	   controlled	   by	  
polarisation.	  Membrane	  structures	  such	  as	  podosomes	  [90]	  and	  invadopodia	  [91]	  also	  facilitate	  
the	  squeezing	  of	  cells	  into	  other	  tissue.	  Signalling	  to	  chemotaxis	  must	  involve	  a	  concerted	  effort	  
from	   numerous	   and	   diverse	   signalling	   proteins	   in	   multiple	   cascades	   from	   polarising	   PI3Ks	   to	  
regulatory	  Rho	  GTPases	  and	  cytoskeletal	  modulators	  such	  as	  cortactin,	  dynamin	  and	  nWASp.	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  Identification	   of	   CCR5	   receptor	   specific	   signalling	   events	   in	   chemotaxis	  will	   allow	  pathological	  
migration	  to	  be	  targetted	  without	  the	  problems	  associated	  chemokine	  receptor	  redundancy	  or	  
interference	   with	   signalling	   in	   non-­‐diseases	   tissue.	   In	   order	   to	   resolve	   CCR5	   specific	   signal	  
transduction	  events	  the	  current	  understanding	  of	  receptor	  signalling	  to	  cellular	  responses	  such	  
as	  migration	  and	  calcium	  release	  will	  be	  reviewed.	  
	  
1.9.3.	  Chemokine	  receptors	  and	  chemotaxis	  
	  
As	  described,	  chemokine	  receptors	  are	  well	  known	  for	  their	  ability	  to	  signal	  to	  chemotaxis	  upon	  
activation	  by	  their	  chemokine	   ligands.	  Signalling	  to	  chemotaxis	  does	  not	  appear	  to	  be	  uniform	  
between	  receptor	  types	  however.	  Gα	  protein	  isotype	  specificity	  explains	  only	  some	  differences	  
between	  receptor	  signalling	  as	  chemokine	  receptor	  signalling	  to	  chemotaxis	  also	  occurs	  through	  
Gβγ	  and	  β	  arrestin	  dependent	  pathways	  [34,	  39,	  55,	  92].	  	  CXCR4	  signalling	  to	  migration	  has	  been	  
shown	   to	  occur	   through	  a	  Gβγ-­‐PI3k-­‐ERK1/2	  dependent	  pathway	   [58,	  59,	  82];	  CCL3	   stimulated	  
CCR1	  mediated	  migration	   has	   been	   shown	   to	   be	   sensitive	   to	   pertussis	   toxin	   (PTX),	   treatment	  
and	  PLC	  and	  p38	  MAPK	  inhibition	  [51].	  CCL3	  stimulated	  CCR5	  mediated	  migration	  has	  also	  been	  
shown	  to	  be	  PTX	  sensitive	  [74,	  93]	  but	  chemotaxis	  signalling	  by	  the	  receptor	  also	  occurs	  through	  













	  1.9.4.	  CCR5	  mediated	  G	  protein	  signalling	  molecules	  associated	  with	  chemotaxis	  
	  
Gβγ	  subunits	  had	  been	  shown	  to	  be	  effectors	  of	  PI3K,	  the	  activation	  of	  which	  is	  known	  to	  be	  a	  
crucial	  mediator	  in	  chemotactic	  response	  [94].	  In	  addition,	  Gβγ	  subunits	  directly	  affect	  PLC,	  up-­‐
regulating	   second	  messenger	  production,	   and	  Ras2	  exchange	   factors	   that	   can	  also	  be	  directly	  
activated	   by	   second	  messengers	   suggesting	   signalling	   feedback	   in	   association	   with	   G	   protein	  
activation	  [57].	  Small	  molecule	  inhibition	  of	  PI3k	  in	  neutrophils,	  highly	  chemotactic	  leukocytes,	  
show	   a	  marked	   reduction	   in	   GPCR	  mediated	   chemotaxis	   [95].	   This	   indicates	   βγ	   subunits	  may	  
operate	   in	   a	   similar	   way	   down	   stream	   of	   activated	   CCR5.	   This	   may	   suggest	   an	   interaction	  
between	   Gβγ	   and	   the	   PI3K	   containing	   arrestin	   signalling	   scaffolds	   later	   shown	   to	   exist	   by	  
Cheung	  et	  al.	  however	  this	  interaction	  remains	  unresolved.	  The	  evidence	  to	  suggest	  that	  CCR5	  
signals	  mainly	  through	  Gαi	  [38]	  and	  to	  a	  lesser	  extent	  Gαq	  [40]	  is	  strong,	  however,	  there	  is	  still	  
the	   possibility	   of	   Gα12/13	   interaction	   as	   it	   has	   not	   been	   categorically	   disproven.	   If	   G	   protein	  
signalling	   is	   governed	   by	   the	   relative	   concentrations	   of	   Gα	   units	   present	   in	   the	   cytosol,	   then	  
G12/13	  signalling	  may	  have	  been	  overlooked	  if	  signalling	  is	  occurring	  at	  a	  lower	  levels,	  or	  can	  be	  
preferentially	   selected	   by	   ligand	   biased	   signalling.	   	   Figure	   1.4.	   demonstrates	   the	   breadth	   of	  
possible	   Gα	   signalling	   to	   chemotaxis	   [96],	   however	   the	   relevance	   of	   investigating	   non-­‐Gαi	   G	  
proteins	  in	  CCR5	  mediated	  migration	  may	  be	  irrelevant	  as	  it	  has	  been	  shown	  to	  be	  completely	  
abrogated	  by	  pertussis	  toxin	  treatment	  [74,	  93].	  Pertussis	  toxin	  is	  a	  well-­‐known	  inhibitor	  of	  Gαi	  
dependent	   signalling,	   but	   its	   use	   raises	   some	   questions	   as	   to	   the	   ability	   of	   PTX	   treated	   Gαi	  
receptors	   to	   signal	   normally	   through	   Gβγ	   and	   arrestins	   if	   Gαi	   dissociation	   cannot	   occur.	   The	  
observations	   made	   by	   Cheung	   et	   al.	   [39]	   (see	   below)	   describing	   arrestin	   scaffold	   dependent	  
signalling	   to	  migration	   from	  CCR5	   are	   certainly	   not	   explained	   if	   signalling	   to	  migration	   occurs	  





Figure	  1.5:	  Signal	  transduction	  pathways	  leading	  to	  migration	  in	  receptors	  signalling	  through	  
different	  G	  proteins.	  Rho	  and	  ROCK	  form	  a	  common	  signalling	  pathway	  making	  them	  possible	  
targets	  for	  SiRNA	  silencing.	  (Image	  from	  [96]).	  	  
	  
1.9.5.	  Arrestins	  and	  GRKs	  in	  CCR5	  signalling	  
	  
GRKs	   and	   β	   arrestin	   are	   known	   to	   be	   involved	   in	   CCR5	   phosphorylation	   and	   desensitisation.	  
Oppermann	   et	   al.	   were	   able	   to	   show	   that	   phosphorylation	   on	   four	   specific	   serines	   in	   the	   C-­‐
terminus	   of	   CCR5	   by	   GRKs	   is	   required	   for	   arrestin	   recruitment	   and	   internalisation	   [46].	   Over	  
expression	   of	   both	   GRK2	   and	   GRK5	   family	   GRKs	   increases	   CCR5	   phosphorylation,	   however,	  
knock	   down	   of	   GRK2	   and	   GRK3	   reduces	   phosphorylation	  markedly,	   although	   not	   completely.	  
Additional	   inhibition	   of	   PKC	   further	   reduces	   CCR5	   phosphorylation,	   showing	   that	   the	   arrestin	  
recruitment	   is	   controlled	  primarily	  by	  GRK2/3	  and	  PKC	  mediated	  phosphorylation.	   	  The	  group	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  expanded	  this	  work	  and	  provided	  additional	  evidence	  that	  GRK	  2	  and	  3	  and	  PKC	  are	  responsible	  
for	   phosphorylation	   and	   desensitisation	   of	   CCR5	   under	   normal	   cellular	   conditions	   [61].	  
Interestingly,	  it	  was	  shown	  that	  isolated	  β	  arrestins	  are	  able	  to	  bind	  to	  phosphorylated	  and	  non-­‐
phosphorylated	   CCR5	   C-­‐terminal	   derived	   peptides	   with	   equal	   affinity.	   This	   suggests	   that	   β	  
arrestin	   has	   numerous	   domains	   capable	   of	   CCR5	   binding,	   which	   might	   allow	   allosteric	  
modification	  of	  arrestin	  when	  involved	  in	  a	  signalling	  complex	  with	  the	  receptor	  in	  either	  active	  
or	   inactive	   forms	   [43].	  The	  DRYLAVVHA	  motif	   (Figure	  1.2.),	  which	   is	  highly	   conserved	   in	  many	  
chemokine	   receptors	   and	  has	  been	   shown	   to	  be	   involved	   in	   heterotrimeric	  G	  protein	  binding	  
[13]	   proves	   to	   be	   the	   second	   β	   arrestin	   binding	   site.	   Synthetic	   peptides	   representing	   CCR5	  
mutants,	   where	   DRY	   residues	   were	   replaced	   with	   inactive	   alanines,	   show	   no	   binding	   affinity	  
towards	   β	   arrestin	   compared	   with	   peptides	   representative	   of	   WT	   CCR5.	   Despite	   a	   lack	   of	  
relative	  conformation,	  the	  use	  of	  synthetic	  peptides	  provides	  strong	  evidence	  for	  the	  interaction	  
between	   β	   arrestin	   and	   the	   DRY	   motif	   and	   shows	   how	   desensitisation	   occurs	   by	   arrestin	  
mediated	  inhibition	  of	  heterotrimeric	  G	  protein	  binding	  at	  the	  second	  intracellular	  loop.	  Arrestin	  
binding	  to	  the	  DRY	  motif	  has	  been	  shown	  by	  Lagane	  et	  al.	  to	  be	  a	  prerequisite	  for	  chemotaxis	  
and	  the	  fact	  that	  arrestin	  can	  bind	  to	  non-­‐activated	  receptors	  [97]	  might	  suggest	  a	  role	  for	  the	  
protein	  in	  constitutive	  basal	  migration.	  
	  
Arrestin	   interaction	   with	   CCR5	   is	   not	   required	   for	   ERK	   MAPK	   phosphorylation,	   with	   levels	  
actually	  increasing	  for	  some	  truncated	  receptor	  species	  [98].	  As	  calcium	  levels	  also	  increase	  due	  
to	  a	  lack	  of	  desensitisation,	  this	  leads	  to	  the	  theory,	  that	  calcium	  activated	  kinases	  such	  as	  Pyk2	  
might	  be	  responsible	  for	  the	  increases	  in	  ERK	  phosphorylation.	  Pyk2	  can	  interact	  with	  numerous	  
signalling	   molecules	   (Figure	   1.6).	   Pyk2	   appears	   to	   represent	   an	   interesting	   target	   for	  
investigation	  in	  relation	  to	  CCR5	  mediated	  chemotaxis	  however	  the	  independence	  of	  migration	  





	  A	   relationship	   between	   Src	   family	   kinases	   (SFKs),	   such	   as	   lyn	   and	   the	   activation	   of	   ERK1/2	  
MAPKs	   downstream	   of	   CCR5	   was	   described	   by	   Tomkowicz	   et	   al.	   who	   showed	   that	   CCR5	  
mediated	   ERK1/2	   phosphorylation	   occurred	   via	   a	   nonspecific	   Src	   kinases	   inhibitor	   (PP2)	  
sensitive	  pathway	  [99].	  PP2	  inhibits	  numerous	  Src	  kinases	  such	  as	  Lyn	  and	  Hck,	  so	  to	  determine	  
which	  of	  these	  is	  activated	  by	  CCR5,	  specific	  inhibitory	  peptides	  for	  Lyn	  and	  Hck	  were	  produced	  
and	  used	  to	  treat	  CCR5	  expressing	  macrophages.	  The	  Lyn	  specific	  protein	  alone	  was	  shown	  to	  
have	  a	  significant	   inhibitory	  effect	  on	  CCL4	  stimulated	  migration	  [99].	  This	  shows	  that	   the	  SFK	  
Lyn	  operates	  downstream	  of	  CCR5	  and	  upstream	  of	  ERK1/2	  MAPKs	   in	  macrophages.	  Whether	  
this	  relationship	  is	  receptor	  or	  cell	  type	  specific	  was	  not	  addressed	  by	  the	  group,	  however.	  This	  
provides	   an	   interesting	   conundrum,	   because	   ERK	   and	   c-­‐Src	   activation	   is	   associated	   with	  
signalling	   to	   migration	   in	   many	   receptor	   systems	   [39,	   100-­‐102].	   The	   mechanism	   of	   CCR5	  
signalling	  through	  SFKs	  to	  chemotaxis	  was	  expanded	  by	  Cheung	  et	  al.	  who	  demonstrated	  that	  
arrestin	  acted	  as	  a	  scaffold	  protein	  for	  the	  formation	  of	  a	  Lyn/Pyk2/PI3K	  complex	  necessary	  for	  
chemotaxis	  in	  macrophages	  [39].	  Phosphorylation	  of	  Lyn,	  Pyk2	  and	  PI3K	  upon	  ligand	  binding	  to	  
CCR5	   was	   demonstrated,	   however	   the	   fact	   that	   inhibition	   of	   any	   of	   these	   proteins	   by	   small	  
molecules	  or	  silencing	  with	  siRNA	  resulted	  in	  a	  significant	  decrease	  in	  chemotaxis	  was	  puzzling.	  
This	  led	  Cheung	  et	  al.	  to	  investigate	  the	  possibility	  of	  a	  physical	  association	  between	  the	  three	  







Figure	  1.6:	  The	  arrestin	  scaffold	  proposed	  by	  Cheung	  et	  al.:	  If	  any	  one	  of	  the	  components	  are	  
missing,	  with	   the	  exception	  of	  ERK,	  chemotaxis	   is	   reduced.	  The	  role	  of	  GRKs	  and	  G	  proteins	  
with	  this	  scaffold	  remains	  to	  be	  seen.	  (Image	  from	  [39]).	  
	  
An	  arrestin-­‐Lyn-­‐PI3K-­‐Pyk2	  complex	  was	  identified	  by	  co-­‐precipitation;	  further	  investigation	  into	  
the	   relationship	   between	   arrestins	   and	   these	   binding	   partners	   showed	   a	   significant	   level	   of	  
constitutive	   association	   between	   all	   four	   components	   which	   not	   only	   considerably	   increased	  
upon	   ligand	   activation	   but	   promoted	   the	   additional	   co-­‐localisation	   of	   ERK.	   This	   is	   strong	  
evidence	  that	  arrestins	  are	  capable	  of	  promoting	  signalling	  events	  not	  related	  to	  desensitisation	  
or	   internalisation	   of	   CCR5.	   Signalling	   scaffolds	   of	   this	   nature	   have	   been	   shown	   to	   occur	   in	  
association	  with	  GRK5	  family	  GRKs	  [41].	  Investigations	  into	  whether	  GRK5	  associates	  with	  CCR5	  
to	   allow	   the	   formation	   of	   such	   complexes	   or	   whether	   arrestin	   are	   divided	   between	  
internalisation	   and	   scaffold	   roles	   is	   an	   important	   question	   that	   needs	   to	   be	   answered.	   In	  
particular	   the	   differential	   phosphorylation	   of	   the	   CCR5	   C-­‐terminal	   by	  GRK	   and	   PKC	   species	   in	  
relation	  to	  arrestin	  recruitment	  may	  reveal	  novel	  signalling	  to	  migration.	  
	  
It	  has	  been	  shown	  that	  CCR2,	  a	  chemokine	  which	  has	  a	  79%	  total	  sequence	  homology	  and	  80%	  
homology	   in	   the	   amino	   acid	   residues	   of	   the	   4th	   intracellular	   loop	   can	   bind	   to	   the	   protein	  
FROUNT	   in	   this	   highly	   homologous	   area	   [103].	   Suppression	   or	   over	   expression	   of	   FROUNT	  
correlates	  to	  a	  decrease	  or	  increase	  in	  chemotaxis,	  respectively	  [30].	  	  FROUNT	  can	  also	  regulate	  
chemotaxis	  in	  CCR5-­‐	  occupying	  the	  signal	  transduction	  location	  immediately	  downstream	  of	  the	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  receptor	   and	   immediately	   upstream	   of	   PI3K;	   [29]	   the	   previous	   most	   upstream	   transduction	  
protein	   known	   for	   CCR5	  mediated	   chemotaxis.	   [103]	   How	   FROUNT	   interacts	   with	   other	   PI3K	  
effectors	  such	  as	  βγ	  subunits	  and	  β	  arrestin	  scaffold	  has	  yet	  to	  be	  determined.	  	  
	  
	  
Over	  all	   it	   is	   clear	   that	   the	   role	  of	   arrestin	   in	  endocytosis	   and	   signalling	   is	   far	   from	  clear	  with	  
regards	   to	   CCR5	   mediated	   migration.	   The	   possible	   interactions	   between	   arrestins	   and	   other	  
proteins	  in	  the	  cytoplasmic	  milieu	  is	  only	  beginning	  to	  be	  resolved	  and	  may	  reveal	  novel	  signal	  
transduction	  to	  migration	  which	  could	  be	  therapeutically	  targeted.	  	  
	  
1.10.	  PI3Ks:	  linking	  Gβγ	  and	  arrestins	  to	  chemotaxis	  
	  
Phosphoinositide-­‐3-­‐Kinases	   (PI3Ks)	   are	   ubiquitously	   expressed	   kinases	   that	   phosphorylate	  
membrane	   bound	   phosphoinositides	   (PI).	   Phosphorylation	   of	   PI	   allows	   targeting	   of	   pleckstrin	  
homology	  domain	  containing	  effectors,	  such	  as	  PKB	  (Akt),	  phospholipase	  C	  [104]	  and	  dynamin	  2	  
[105-­‐107],	   to	   the	   cell	   membrane.	   PI3Ks	   work	   antagonistically	   with	   lipophophatases	   such	   as	  
PTEN	  and	  SHIP	   to	  maintain	  polarisation	   [78].	  This	  makes	  PI3K	  central	   to	  migration,	  where	  cell	  
polarisation	   is	   facilitated	   by	   the	   interplay	   of	   PI	   phosphorylation	   by	   PI3K	   [76,	   108]	   	   and	  
phosphatase	  action.	  PI3Ks	  are	  associated	  with	  other	  cellular	  processes	  such	  as	  proliferation	  and	  
protein	   expression	   [78]	   and	   are	   of	   particular	   interest	   to	   cancer	   biologist	   because	   of	   their	  
propensity	   to	   be	   over	   expressed	   in	   cancers	   cells	   [109].	   PI3K	   has	   several	   isotypes,	   with	   PI3Kγ	  
being	  associated	  with	  GPCR	  signalling	   through	  Gβγ	   [54,	  110,	  111]	  and	  the	  α,	  β	  and	  δ	   isotypes	  
with	  signalling	  via	  receptor	  tyrosine	  kinases	  (RTKs)	  [112,	  113].	  There	  is	  some	  evidence	  that	  the	  β	  
isotype	   can	   be	   activated	   by	   some	   GPCRs	   [114].	   It	   is	   therefore	   likely	   that	   CCR5	   mediated	  
signalling	  occurs	  through	  the	  γ	   isotype.	  PI3K	  has	  been	   linked	  to	  CCR5	  activation	  as	  part	  of	   the	  
arrestin	   dependent	   signalling	   scaffold	   describe	   by	   Cheung	   et	   al.	   [39]	   (see	   above),	   but	   Gβγ	  
released	  from	  activated	  CCR5	  should	  also	  be	  able	  to	  activate	  the	  protein	  and	  there	   is	  also	  the	  
possibility	   that	   Gαi	   could	   lead	   to	   PI3K	   signalling,	   too	   [96].	   Aramori	   et	   al.,	   however,	   failed	   to	  
detect	   phosphatidylinositol	   hydrolysis	   upon	  CCR5	   activation	   by	   CCL3,	   4	   and	   5,	   presumably	   by	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  lack	  of	  PLC	  recruitment	  by	  PI3K	  activity	  [12].	  This	  represents	  the	  kind	  of	  contradictory	  evidence	  
that	  complicates	  the	  understanding	  of	  signalling	  to	  migration.	  This	  is	  further	  complicated	  by	  the	  
report	   of	   Volpe	   et	   al.	   that	   monocytes	   do	   not	   require	   polarisation	   for	   migration	   like	   larger	  
adherent	   cells	   [115].	   How	   arrestin	   signalling	   scaffolds,	  which	   require	   PI3K	   for	   their	   formation	  
[39],	  fit	  into	  these	  observations	  remains	  to	  be	  clarified.	  	  
	  
What	   is	   clear	   is	   that	   clarification	   of	   PI3K	   function	   downstream	   of	   CCR5	   will	   be	   important	   in	  
understanding	  how	  chemotaxis	   is	  mediated	  by	  the	  receptor.	  Small	  molecule	   inhibitors	  such	  as	  
LY294002	  [116]	  and	  wortmannin	  [117]	  have	  been	  widely	  used	  to	  probe	  PI3K	  function	   in	  other	  
signalling	   systems	   and	   these,	   along	   with	   recently	   described	   PI3Kγ	   specific	   inhibitors	   [118],	  
should	   allow	   the	   role	   of	   PI3K	   in	   CCR5	   mediated	   chemotaxis	   to	   be	   better	   described	   without	  
resorting	  to	  costly	  proteomics.	  
	  
1.11.	  CCR5	  and	  JAK/STAT	  signalling	  
	  
In	  normal	  tissue	  the	  JAK/STAT	  signalling	  axis	  is	  best	  known	  for	  its	  role	  in	  up	  regulation	  of	  protein	  
transcription	   stimulated	   by	   cytokine	   receptors	   [119].	   JAK/STAT	   mediated	   up	   regulation	   of	  
protein	  transcription	  has	  been	  linked	  to	  migration	  and	  increased	  JAK/STAT	  activity	  is	  a	  marker	  in	  
some	  cancer	  cells,	  where	  metastasis	  occurs	  [120,	  121].	  JAK/STAT	  signalling	  may	  be	  relevant	  to	  
CCR5	  mediated	  chemotaxis	  because	  cytokine	  receptor	  transactivated	  GPCRs	  are	  thought	  to	  link	  
through	   signalling	   scaffolds	   that	  may	   contain	   JAK/STAT	   proteins	   [85];	   	   and	  more	   importantly	  
JAK2	  has	  been	  shown	  to	  interact	  directly	  with	  CCR5	  [40,	  122].	  The	  interaction	  with	  chemokine	  
receptors	  has	  been	  described	  by	   several	   groups	   [122]	  and	   it	  has	  been	   shown	   that	   chemokine	  
receptor	  activation	  leads	  to	  JAK-­‐STAT	  phosphorylation	  in	  a	  similar	  fashion	  to	  cytokine	  receptors,	  
which	   presumably	   leads	   to	   increases	   in	   protein	   transcription	   in	   a	   similar	   way.	   Additionally,	  
JAK/STAT	   and	  PI3K	   signalling	  has	   been	   linked	   to	   cytokine	  mediated	  migration	   and	   invasion	  of	  
hepatocellular	   carcinoma	  cells	   [123].	  What	   is	  not	   known	   is	  whether	   the	   JAK2	   interaction	  with	  
CCR5	   has	   any	   cytoplasmic	   signalling	   role	  with	   regard	   to	   chemotaxis.	   JAK/STAT	   are	   associated	  
with	   migration	   through	   other	   receptors	   [124]	   and	   have	   been	   linked	   to	   calcium	   release	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  downstream	  of	  chemokine	  receptors	  [125].	  Understanding	  the	  role,	  if	  any,	  of	  JAK2	  and	  STAT	  in	  
migration	   will	   be	   important	   in	   characterising	   CCR5	   function	   and	   the	   small	   molecule	   tools	   to	  
investigate	  the	  idea	  are	  readily	  available.	  Chemically	  diverse	  species	  such	  as	  cucurbitacin	  I	  [126],	  
JAK2	   inhibitor	   2	   [127]	   and	   STAT3	   inhibitors	   III	   and	   VIII	   [128]	   have	   all	   been	   shown	   to	   reduce	  
STAT3	  phosphorylation.	  These	  inhibitors	  will	  make	  useful	  tools	  to	  investigate	  the	  exact	  nature	  of	  




Dynamin	   is	   a	   100	   kD	   protein,	   that	   was	   first	   identified	   in	   1989,	   when	   it	   was	   isolated	   from	  
microtubules	  with	  which	  it	  was	  bound:	  the	  interaction	  with	  microtubules	  was	  initially	  linked	  to	  
ATPase	  activity	   [129].	   Later	  on	   it	  was	  shown	  that	  dynamin	   is,	   in	   fact,	  a	  GTPase	   [130]	  and	  that	  
there	  are	  several	  types:	  dynamin	  I	  is	  primarily	  found	  in	  neurones	  where	  it	  is	  involved	  in	  synaptic	  
vesicle	  endocytosis	  [131,	  132]	  and	  it	  has	  been	  linked	  with	  several	  neurological	  processes	  such	  as	  
long-­‐term	  memory	  formation	  [133].	  Dynamin	  2	  is	  ubiquitously	  expressed	  and	  is	  found	  in	  all	  cell	  
types,	  dynamin	  3	  is	  primarily	  found	  in	  the	  testis.	  Dynamin	  2	  interacts	  with	  numerous	  GPCRs	  as	  
well	  as	  non-­‐GPCR	  receptors,	  including	  the	  chemokine	  receptor	  CCR5	  [134]	  and	  various	  cytokine	  
receptors	  [135].	  Dynamin	  2	  is	  of	  particular	  interest,	  firstly	  because	  of	  its	  ubiquitous	  expression,	  
and	  secondly	  because	  of	  the	  range	  of	  proteins	  and	  functions	  dynamin	  has	  been	  associated	  with,	  
which	   are	   directly	   relevant	   to	   CCR5	  mediated	   chemotaxis.	   Dynamin	   2	   has	   been	   shown	   to	   be	  
involved	  with	  internalisation	  [136],	  during	  which	  it	  associates	  with	  clathrin	  coated	  pits	  [137]	  and	  
arrestins	   [64],	   but	   it	   also	   has	   direct	   links	   to	  migration	   [77].	   The	   range	   of	   dynamin	   interacting	  
proteins,	  which	  have	  also	  been	  linked	  to	  migration	  is	  great	  and	  offers	  many	  potential	  routes	  of	  
signal	  transduction	  from	  CCR5	  to	  mediate	  dynamin	  function	  (see	  below).	  	  
	  
1.12.1	  Dynamin	  in	  disease	  
	  
Mutations	   in	   the	   dynamin	   2	   gene	   have	   been	   shown	   to	   be	   causal	   in	   Charcot–Marie-­‐Tooth	  
disease,	  [138],	  peripheral	  neuropathy	  and	  centronuclear	  myopathy	  [139].	  Dynamin	  2	  has	  been	  
40
	  identified	  as	  a	   susceptibility	  gene	   for	   late	  onset	  Alzheimer’s	  disease	   [140].	   It	   is	  not	   surprising,	  
due	  to	  the	  role	  of	  dynamin	  in	  synaptic	  vesicle	  formation,	  that	  mutations	  in	  dynamin	  also	  affect	  
psychological	   function	   and	   have	   been	   associated	  with	   alcohol	   tolerance	   in	   drosophila	  models	  
[141].	  	  
	  
More	   relevant	   to	   this	   thesis	   is	   the	   function	   of	   dynamin	   in	   diseases	  where	   internalisation	   and	  
migration	  are	  causal.	  Inhibition	  of	  dynamin	  has	  been	  shown	  to	  block	  botulin	  neurotoxin	  uptake	  
[142]	  but	   this	  process	  has	  been	   shown	   to	  be	  both	   clathrin	  dependent	   [143]	   and	   independent	  
[144],	   suggesting	   that	   caveolin	   dependent	   endocytosis	   is	   also	   dependent	   on	   dynamin.	   Similar	  
discrepancies	  are	  observed	  with	  HIV	   internalisation.	   	  Carter	  et	  al.	  demonstrated	   that	  dynamin	  
and	   clathrin	   are	   required	   for	   CCR5	   mediated	   viral	   entry	   in	   macrophages	   [145],	   but	   CCR5	  
mediated	  viral	  entry	  in	  trophoblasts	  is	  independent	  of	  dynamin	  [146].	  Differences	  in	  cytoplasmic	  
proteins	   between	   cell	   types	   may	   explain	   these	   observations,	   but	   there	   is	   also	   evidence	   that	  
different	   HIV	   strains	   can	   recruit	   endocytosis	   machinery	   differentially,	   with	   some	   strains	  
internalising	   through	   dynamin	   dependent	   means	   and	   others	   not	   [147].	   The	   differential	  
recruitment	   of	   endocytosis	   machinery	   by	   activated	   CCR5	   receptors	   may	   be	   important	   in	  
explaining	  cell	  specific	  signalling	  to	  migration.	  	  
	  
Dynamin	   2	   has	   been	   linked	   to	   migration	   dependent	   pathologies	   such	   as	   the	   growth	   and	  
malignancy	   in	   several	   cancer	   types	   such	   as	   breast	   cancer	   [148],	   pancreatic	   ductal	   carcinoma	  
[149]	  and	   in	   immortalised	  cancer	  cell	   lines	   [150].	  The	  role	  of	  dynamin	   in	  migration	  extends	  to	  
non-­‐cancerous	   cells	   (reviewed	   in	   [77]),	   which	   means	   that	   it	   may	   be	   a	   potential	   target	   in	  
immunological	   disorders	  where	   unwanted	   or	   excessive	  migration	   of	   immune	   cells	   causes	   the	  
disease,	  	  such	  as	  asthma,	  COPD	  and	  rheumatoid	  arthritis,	  where	  CCR5	  receptor	  activation	  is	  also	  






	  1.12.2.	  Dynamin	  structure	  
	  
Dynamin	   is	   a	   100	   kD	   proteins	   that	   consists	   of	   a	  GTPase	   domain,	   a	  middle	   or	   stalk	   domain,	   a	  
pleckstrin	   homology	   domain,	   a	   GTPase	   effector	   domain	   (GEF)	   and	   a	   low	   order	   pleckstrin	  
homology	   domain	   [151,	   152].	   Resolution	   of	   the	   crystal	   structure	   of	   dynamin	  without	   the	   low	  
order	  PRD	  demonstrated	  that	  the	  protein	  folds	  back	  along	  its	  self	  at	  the	  PH	  domain	  so	  that	  the	  
GTPase	  and	  PRD	  would	  be	  in	  close	  proximity	  [153,	  154]	  (Figure	  1.7.).	  
	  
The	   domains	   of	   dynamin	   have	   been	   linked	   with	   various	   protein-­‐protein	   interactions	   and	  
processes:	  	  The	  GTPase	  domain	  is	  the	  site	  of	  GTPase	  turnover	  and	  is	  associated	  with	  changes	  in	  
conformation	  which	  result	   in	  the	  motor	  action	  of	  dynamin	  [155,	  156].	  Mutation	  of	  the	  GTPase	  
domain	   results	   in	   the	   dynamin	   K44A	   dominant	   negative	   mutant,	   which	   has	   been	   used	   to	  
investigate	  the	  role	  of	  dynamin	  GTPase	  function	  in	  both	  endocytosis	  [157]	  and	  migration	  assays	  
[158].	   The	   GTPase	   effector	   domain	   has	   been	   shown	   to	   regulate	   self-­‐assembly	   in	   a	   Src	  
phosphorylation	   dependent	   fashion	   [159],	   indicating	   that	   regulation	   by	   cytosolic	   kinases	   can	  
promote	  dynamin	  function.	  The	  pleckstrin	  homology	  domain	  of	  dynamin	  is	  associated	  with	  the	  
targeting	  of	  dynamin	  to	  phospholipids,	  such	  as	  PI3K	  product	  PIP2,	  at	  the	  membrane	  [105,	  106]	  a	  
process	   that	   has	   been	   shown	   to	   be	   a	   prerequisite	   for	   phagocytosis	   [160,	   161].	   The	   middle	  
domain	  of	  dynamin	  has	  been	  shown	  to	  be	  the	  site	  of	  self-­‐assembly	  [105,	  162],	  but	  also	  to	  be	  the	  
site	   of	   direct	  microtubule	   [163]	   and	   actin	   binding	   [164].	   These	   interactions	   enhance	   dynamin	  
GTPase	   function	  and	  promote	  assembly	   into	  polymerised	  dynamin	   rings.	  The	  most	   interesting	  
dynamin	  domain	  with	  regard	  to	  CCR5	  mediated	  migration	  is	  the	  proline	  rich	  domain	  (PRD).	  The	  
PRD	   facilitates	  binding	  of	  dynamin	   to	  SH3	  domain	   containing	  proteins	   such	  as	  Grb2	   [165]	  but	  
also	  with	   other	   adaptor	   proteins	   [100]	   and	   directly	  with	  microtubules	   [166].	   Interaction	  with	  
proteins	   at	   the	   PRD	   can	   increase	   dynamin	   GTPase	   activity	   [167]	   and	   promote	   self-­‐assembly.	  
Phosphorylation	  of	  the	  PRD	  by	  the	  MAP	  Kinase	  ERK	  can	  also	  down	  regulate	  microtubule	  binding	  
whilst	  increasing	  GTPase	  activity	  [168]	  which	  suggests	  that	  the	  regulatory	  effects	  of	  the	  PRD	  on	  
dynamin	   function	  are	  manifold.	  Binding	  of	  adaptor	  proteins	   such	  as	  Grb2	   to	   the	  PRD	  has	  also	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  been	  shown	  to	  target	  dynamin	  to	  phosphorylated	  tyrosine	  residues,	  presumably	  through	  Grb2	  
SH2	  domains,	  which	  may	  explain	  how	  dynamin	  function	  is	  directed	  in	  the	  cytoplasm.	  	  	  	  	  
	  
	  
Figure	  1.7:	  The	  structure	  of	  Dynamin.	  (a)	  An	  overview	  of	  the	  dynamin	  1	  AA	  sequence	  and	  its	  
relationship	   to	   the	   functional	   domains	   of	   the	   protein	   (stalk	   =	   middle)	   (Bundled	   signalling	  
element	   (BSE)	   =	   GTPase	   effector	   domain	   (GED)).	   (b)	   The	   solved	   ΔPRD	   dynamin	   crystal	  
structure	  dominstrating	  the	  spatial	  relationship	  between	  domains.	  (c)	  Cartoon	  representation	  
of	   the	   3D	   structure	  of	   dynamin	   representing	   the	   spatial	   relationship	  between	   the	  domains.	  
(a&b)	  image	  from	  [153].	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  1.12.3.	  Endocytosis	  
	  
Dynamins	   are	   primarily	   known	   for	   their	   role	   in	   clathrin	   coated	   pit	   dependent	   endocytosis,	  
considered	   its	   classic	   mode	   of	   action	   [157],	   however,	   not	   all	   endocytosis	   is	   dependent	   on	  
dynamin.	  Acetylcholine	  receptors,	  for	  example,	  have	  been	  shown	  to	  internalise	  via	  a	  cholesterol	  
dependent,	   dynamin	   independent	   mechanism	   in	   CHO	   and	   C2C12	   muscle	   cells	   [169].	   	   Also	  
dynamin	  2	   is	  not	  required	  for	  massive	  endocytosis	  (MEND),	  a	  process	  where	  up	  to	  75%	  of	  the	  
plasma	   membrane	   can	   be	   reversibly	   endocytosed.	   MEND	   is	   also	   independent	   of	   actin	  
cytoskeletal	   rearrangement	   and	   other	   mediators	   of	   classic	   endocytosis	   and	   thought	   to	   be	  
dependent	   on	   calcium	   flux.	   [170]	   Dynamin	   is	   also	   involved	   with	   endocytosis	   in	   a	   CCP	  
independent	  fashion:	  clathrin	  independent	  dynamin	  2	  dependent	  endocytosis	  that	  also	  requires	  
Rho	  is	  utilised	  by	  the	  IL-­‐2	  receptor	  and	  in	  the	  endocytosis	  of	  Clostridium	  toxin.	  This	  shows	  that	  
dynamin	  can	  recruit	  a	  range	  of	  proteins	  to	  facilitate	  internalisation,	  which	  may	  be	  dependent	  on	  
receptor	  mediated	   signalling	   or	   the	   available	   cytoplasmic	   protein	   complement	   [143].	   ‘Typical’	  
endocytosis	   involving	   clathrin	   coated	   pit	   formation	   and	   vesicle	   stabilisation	   and	   scission	   by	  
dynamin	  is	  well	  described	  with	  numerous	  groups	  proposing	  models	  for	  the	  exact	  mechanism	  of	  
the	  process	  [171-­‐176].	  The	  precise	  details	  of	  dynamin	  vesicle	  scission	  are	  not	  relevant	  here,	  but	  
there	  are	   important	  points	  about	  the	  process	  which	  should	  be	  mentioned.	  Firstly,	  endocytosis	  
requires	   dynamin	   in	   two	   individual	   steps;	   for	   the	   formation	   of	   stabilised	   ‘U’	   shaped	   pits	   and	  
later	  for	  the	  pinching	  of	  ‘O’	  shaped	  vesicles	  [177].	  Secondly,	  dynamin	  polymerisation	  into	  a	  ring	  
is	  required	  for	  endocytosis	  with	  the	  pinching	  action	  dependent	  on	  GTPase	  hydrolysis	  conveying	  
conformational	   changes	   to	   the	   ring	  macro	   structure.	  Dynamin	   rapidly	   dissembles	   post	   vesicle	  
scission	   [105].	   Finally,	   the	   most	   recent	   models	   based	   on	   crystallographic	   structures	   have	  
proposed	   that	   the	   vehicle	   scission	   function	   of	   dynamin	   can	   occur	   without	   the	   PRD	   domain	  
attached,	  which	  suggests	  that	  the	  PRD	  may	  be	  more	  important	  for	  the	  targeting	  of	  dynamin	  or	  
for	  other	  protein	  interactions	  with	  the	  molecule	  [155].	  	  
	  
Dynamin	  dependent	  endocytosis	  is	  directly	  relevant	  to	  CCR5	  function:	  the	  dynamin	  2	  dominant	  
negative	   mutant	   K44A	   has	   been	   used	   to	   show	   that	   CCR5	   internalisation	   is	   dependent	   on	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  dynamin	   2	   [12]	   and	   that	   dynamin	   dependent	   internalisation	   occurs	   in	   THP-­‐1	   cells	   [134,	   178]	  
which	   raises	   the	   possibility	   that	   other	   dynamin	   dependent	   signalling	  may	   originate	   from	   this	  
interaction.	   This	   is	   particularly	   interesting	   as	   other	   GPCR	   signalling	   proteins	   present	   at	   the	  
activated	  CCR5	   receptor	   are	   known	   to	   interact	  with	  dynamin	   such	   as	   arrestin	   2	   [64]	   and	  Gβγ	  
[107]	  which	  themselves	  have	  been	  linked	  to	  chemotaxis	  [39,	  57].	  
	  
1.12.4	  Dynamin	  and	  cell	  migration	  
	  
As	  more	  is	  discovered	  about	  dynamin	  interactions	  and	  its	  cellular	  localisation	  it	  becomes	  more	  
apparent	  that	  it	  is	  also	  involved	  in	  cell	  migration	  (reviewed	  in	  [77]).	  The	  work	  of	  McNiven	  et	  al.	  
demonstrated	   that	   in	   addition	   to	   functioning	   as	   a	   scission	   mediator	   during	   endocytosis,	  
dynamin	  formed	  interactions	  with	  numerous	  actin	  binding	  and	  cytoskeletal	  modelling	  proteins	  
[179],	   such	   as	   nWASp,	   Arp2/3	   and	   links	   to	   actin	   via	   PRD	   interaction	   with	   Abp1.	   Binding	   of	  
dynamin	   to	   the	   actin	   binding	   protein	   cortactin	   was	   demonstrated	   to	   be	   a	   requisite	   for	  
morphological	   changes	   in	   fibroblast	  which	  occur	  during	  migration	  and	  spreading	   [180].	  This	   is	  
interesting	   because	   cortactin,	   like	   dynamin	   binds	   to	  Grb2	  which	  may	   indicate	   cross	   linking	   of	  
these	   proteins.	   Even	   more	   interesting	   is	   the	   fact	   that	   c-­‐Src	   mediated	   phosphorylation	   of	  
cortactin	  in	  facilitated	  by	  Grb2	  [181],	  which	  suggests	  that	  targeting	  of	  Grb2	  SH2	  domains	  via	  c-­‐
Src	  phosphorylation	   targets	  may	  be	  central	   to	  dynamin	  cortactin	   interaction	  and	   function	  and	  
therefore	   ultimately	   migration.	   These	   observations	   were	   made	   in	   fibroblasts,	   so	   cell-­‐type	  
dependent	   factors,	   such	  as	  phospoinositide	  based	  polarisation	  need	   to	  be	  validated.	  Dynamin	  
appears	  to	  link	  the	  actin	  cytoskeleton	  to	  the	  membrane,	  however,	  dynamin	  is	  not	  just	  acting	  as	  
an	  anchor.	  The	  dynamin-­‐cortactin	  interaction	  governs	  actin	  filament	  organisation	  in	  membrane	  
structure	   [182,	  183],	  an	  observation	  which	  was	   later	  validated	  with	   the	  use	  of	   small	  molecule	  
dynamin	   inhibitors	   [184].	   The	   role	   of	   dynamin	   in	   the	   organisation	   of	   actin	   fibres	   is	   not	   fully	  
characterised,	  however	  there	  is	  experimental	  evidence	  which	  may	  go	  some	  way	  to	  describe	  this	  
function.	  Dynamin	  has	  been	  shown	  to	  be	  crucial	  in	  the	  uncapping	  of	  the	  actin	  regulatory	  protein	  
gleosin	  from	  the	  barbed	  end	  of	  actin	  fibres	  [164].	  Actin	  polymerisation	  occurs	  predominantly	  at	  
the	  barbed	  end	  with	  the	  disassembly	  occurring	  at	  the	  pointed	  end	  [185].	  This	  data	  indicates	  that	  
45
	  dynamin	   may	   directly	   mediate	   actin	   dynamics	   as	   a	   complex	   with	   gelosin,	   however,	   gelosin	  
function	   is	   also	   known	   to	   be	   calcium	   dependent	   [186],	   which	   makes	   this	   interaction	  
contradictory	  to	  CCR5	  mediated	  chemotaxis	  in	  THP-­‐1,	  which	  has	  been	  shown	  to	  be	  independent	  
of	   calcium	   [75].	   The	   interaction	   of	   dynamin	  with	   actin	   is	   not	   limited	   to	   binding	   through	   PRD	  
associated	  actin	  binding	  proteins	  such	  as	  gelosin	  and	  Abp1/2;	  Gu	  et	  al.	  demonstrated	  that	  PRD	  
deficient	  dynamin	  mutants	  not	  only	  bind	  to	  actin	  but	  are	  able	  to	  facilitate	  actin	  polymerisation.	  
This	  suggests	  that	  the	  function	  of	  the	  PRD	  is	  primarily	  to	  target	  dynamin	  within	  the	  cytoplasm.	  
The	   effect	   of	   PRD	   truncation	   on	   chemotaxis	   was	   not	   determined,	   so	   the	   effect	   of	   decreased	  
dynamin	   targeting	   on	   migration	   has	   not	   been	   described.	   This	   effect	   may	   also	   be	   cell	   type	  
specific.	  Knock	  down	  studies	  with	  dynamin	  have	  shown	  that	  actin	  polymerisation	  can	  still	  occur	  
and	  mice	  lacking	  dynamin	  show	  increases	  in	  the	  number	  of	  focal	  adhesion	  in	  fibroblasts	  [187].	  
These	   observations	   suggest,	   that	   opposed	   to	   acting	   as	   a	   primary	   instigator	   of	   actin	  
polymerisation,	   dynamin	   regulates	   and	   directs	   actin	   polymerisation	   alongside	   other	   proteins.	  	  
The	  evidence	  for	  the	  role	  of	  dynamin	  in	  migration	  extends	  into	  disassembly	  of	  focal	  adhesions,	  
which	  has	  shown	  also	  to	  be	  dependent	  on	  clathrin	  which	  indicates	  endocytosis	  may	  be	  involved	  
in	   this	  process	   [188].	  The	   list	  of	  potential	  proteins	   through	  which	  dynamin	  may	  regulate	  actin	  
dynamics	   is	   increasing	   continually	   [189]	   but	   interactions	   with	   cortactin	   [190],	   Rho	   [191]	   and	  
ROCK	  [192]	  are	  obvious	  places	  to	  start	  and	  are	  likely	  to	  fit	  into	  CCR5	  mediated	  responses.	  
	  
There	   is	   a	   considerable	   evidence	   for	   a	   role	   for	   dynamin	   in	   conjunction	   with	   non-­‐receptor	  
tyrosine	   kinases	   and	   SH2/SH3	   domain	   containing	   adaptor	   proteins	   in	   the	   formation	   and	  
stabilisation	  of	  membrane	  protrusions	  such	  as	  podosomes	  and	  filopodia	  [87-­‐90,	  100,	  135,	  183,	  
193]	  which	  are	  important	  for	  migration	  and	  invasion	  [76]	  and	  may	  offer	  more	  potential	  targets	  
for	  therapeutic	  intervention.	  
	  
1.12.5.	  Grb2	  and	  chemotaxis	  
	  
As	   stated	   above,	   Grb2	   is	   known	   to	   interact	  with	   dynamin	   via	   the	   PRD,	  where	   it	   can	   increase	  
basal	  GTPase	  activity	  and	  also	  target	  dynamin	  to	  phosphorylated	  tyrosine	  residues.	  There	  is	  also	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  a	  link	  between	  Grb2	  and	  migration	  that	  may	  or	  may	  not	  be	  linked	  with	  dynamin,	  and	  is	  certainly	  
an	  interesting	  area	  for	  investigation.	  Canonical	  Grb2	  function	  involves	  receptor	  tyrosine	  kinase	  
activation	   leading	   to	   Ras,	   Sos	   and	  Grb2	   signalling	   to	   PI3K	   [112]	  which	   leads	   to	   RTK	  mediated	  
migration	  [135].	  Rationally	  designed	  Grb2	  inhibitors	  have	  successfully	  targeted	  RTK	  signalling	  to	  
migration	   [112,	  113]	  and	  siRNA	  knockdown	  of	  Grb2	  also	   results	   in	  a	   reduction	   in	  migration	   in	  
this	   system.	   Interestingly	   Grb2	   has	   been	   shown	   to	   associate	   with	   dynamin	   through	   guanine	  
nucleotide	  exchange	  factors	  (GEFS)	  in	  the	  RTK	  signalling	  system.	  The	  association	  between	  Grb2,	  
dynamin	  and	  migration	  occurs	  elsewhere.	  Grb2	  is	  thought	  to	  link	  dynamin	  to	  Scr	  tyrosine	  kinase	  
sensitive	  adapter	  protein	  complexes,	  which	  are	  required	  for	  actin	  polymerisation	  in	  podosomes.	  
Interestingly,	   ΔPRD	   dynamin	   did	   not	   prevent	   actin	   polymerisation	   in	   this	   system,	   which	  
indicates,	  that	  the	  Grb2	  PRD	  interaction	  is	  more	  important	  in	  the	  targeting	  of	  dynamin	  than	  in	  
enhancing	   its	   function.	   Gilleron	   et	   al.	   demonstrated	   that	   c-­‐Src	   inhibition	   reduces	   dynamin	  
targeting	   to	   the	   membrane,	   which	   might	   be	   explained	   by	   Grb2	   interactions	   [194].	   The	  
association	   of	   dynamin	   and	   Grb2	   with	   membrane	   protrusions	   such	   as	   podosomes	   has	   been	  
shown	  in	  other	  research	  [88,	  89,	  195],	  which	  may	  suggest	  that	  CCR5	  signalling	  to	  such	  structures	  
may	   also	   involve	   these	   proteins.	   There	   is	   evidence	   to	   suggest	   that	   GPCRs	   can	   signal	   to	   Grb2	  
signalling:	   CCR1	   homologous	   virally	   encoded	   chemokine	   receptor	   US28	   activation	   by	   CCL5	  
confers	  pertussis	  toxin	  sensitive	  signal	  transduction	  which	  results	  in	  the	  association	  of	  Grb2	  and	  
focal	   adhesion	   kinases	   in	   fibroblasts	   [134].	   This	   interaction	   is	   required	   for	  migration	   in	   US28	  
transfected	   smooth	  muscle	   cells,	   however,	   this	   also	   raises	   questions	   regarding	   receptor/	   cell	  
type	  specificity	  described	  above.	  If	  polarisation	  via	  PI3K	  activation	  is	  not	  required	  for	  chemotaxis	  
in	  monocytes,	  other	  signal	   transduction	  processes	  cannot	  be	  assumed	  to	  be	  conserved	  either.	  
There	   is	   no	   literature	   linking	   CCR5	   signal	   transduction	   through	   Grb2	   directly	   to	   migration,	  
however,	  there	  are	  reports	  of	  Grb2	  being	  involved	  in	  phosphatase	  regulation	  in	  CCR5	  mediated	  
macrophage	   chemotaxis	   stimulated	   by	   CCL4	   [101]	   and	   even	   suggestions	   that	   Grb2	   might	  
interact	  directly	  with	  CCR5	  C-­‐terminal	   tyrosine	  339	   [196].	  Considering	  the	   links	   to	  chemotaxis,	  
dynamin	  function	  and	  CCR5,	  Grb2	  represents	  an	  interesting	  point	  of	  investigation	  in	  relation	  to	  
the	   signalling	   events	   that	   occur	   upon	   receptor	   action	   and	  may	  offer	   novel	   insights	   into	   these	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  events.	   Small	   molecule	   inhibitors	   for	   Grb2	   SH2	   domains	   do	   exist	   but	   are	   not	   commercially	  
available.	  	  
	  
1.12.6.	  Other	  cytosolic	  interactions	  of	  dynamin	  
	  
Outside	  of	  dynamin’s	   interaction	  with	  cytoskeletal	  chemotaxis	  mediators,	   there	  are	  numerous	  
other	  protein	  interactions	  that	  may	  link	  dynamin	  to	  the	  CCR5	  signalling	  cascade.	  The	  interaction	  
between	  PIP2	  via	  its	  PH	  domain	  has	  been	  discussed,	  however,	  this	  interaction	  may	  extend	  to	  a	  
more	  intimate	  relationship	  with	  PI3Ks.	  For	  example,	  dynamin	  2	  is	  required	  for	  the	  formation	  of	  
phagosomes	  and	  Pi3K	  is	  required	  for	  dynamin	  recruitment	  to	  the	  phagosome.	  This	  suggests	  that	  
Pi3K	  operates	  upstream	  of	  dynamin	  2	  in	  this	  interaction	  [160].	  Gridin,	  a	  ubiquitously	  expressed	  
mammalian	  actin	  binding	  protein,	  accumulates	  at	  the	   leading	  edges	  of	  polarised	  cells	  and	  also	  
interacts	  with	  PKB	  and	  activated	  dynamin	  2	  [197],	  suggesting	  that	  this	  protein	  might	  scaffold	  the	  
well	   know	  PI3K	   target	   to	   the	   site	   of	   phospoinositide	   phosphorylation.	   The	   idea	   that	   dynamin	  
targets	   PIP2	   effectors	   is	   expanded	   by	   the	   fact	   that	   dynamin	   2	   PRD	   interacts	   with	   PLC	   SH3	  
domains	   [180,	   198],	   which	   suggests,	   that	   dynamin	   may	   facilitate	   calcium	   release	   by	   second	  
messenger	   generation.	   Calcium	   sensitive	   PKC	   phosphorylate	   dynamin	   PH	   domains,	   which	  
increases	  GTPase	  activity	  and	   interaction	  with	  Gβγ	   [199]	  and	  therefore	   the	  possibility	   for	  self-­‐
regulation	   or	   GPCR	   dependent	   function	   is	   present.	   The	   possibility	   for	   GPCR	   dependent	  
regulation	   of	   dynamin	   is	   cemented	   by	   the	   fact	   that	   arrestins	   target	  GPCRs	   to	   clathrin	   coated	  
vesicles	   [136],	   which	   potentially	   put	   arrestins,	   Gβγ	   subunits	   and	   dynamin	   at	   the	   same	   locus	  
upon	   ligand	   activation	   of	   receptors.	   The	   complexity	   of	   dynamin	   signalling	   is	   redoubled	  when	  
considering	  the	  evidence	  that	  links	  dynamin	  to	  MAPK	  signalling.	  Dynamin	  2	  is	  required	  for	  MAPK	  
activation	  in	  COS-­‐7	  cells,	  where	  overexpression	  of	  dynamin	  K44A	  prevents	  activated	  MEK	  from	  
accumulating	   in	   the	   cytosol.	   This	   suggests	   that	   dynamin	   mediated	   endocytosis	   of	   activated	  
MEKs	   is	   required	   for	   phosphorylation	   of	   MAP	   kinases	   [200].	   CCR2	   activation	   also	   leads	   to	  
dynamin	  dependent	  phosphorylation	  of	  ERK	  in	  THP-­‐1	  cells	  [178].	  ERK	  phosphorylates	  dynamin	  2	  
at	   the	   PRD	   domain	   which	   results	   in	   a	   decreased	   GTPase	   activity	   and	   microtubule	   binding	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  affinity,	   which	   opens	   up	   another	   potential	   self-­‐regulatory	   signalling	   system	   relevant	   to	   CCR5	  
signalling	  [168].	  	  
	  
1.12.7.	  Small	  molecule	  inhibition	  of	  dynamin	  
	  
Inhibition	  of	  dynamin	  function	  is	  necessary	  to	  allow	  its	  function	  in	  dynamic	  cellular	  responses	  to	  
be	  determined.	  Prior	  to	  the	  discovery	  of	  small	  molecule	  inhibitors	  of	  dynamin	  overexpression	  of	  
dominant	   negative	   or	   truncated	   mutants	   or	   knock	   down	   with	   siRNA	   were	   the	   only	   realistic	  
methods	   to	   modulate	   dynamin	   in	   cells.	   These	   methods,	   whilst	   successful,	   have	   distinct	  
disadvantages,	   such	   as	   the	   long	   time	   frame	   of	   transfection	   and	   the	   altered	   cytoplasmic	  
concentrations	   of	   protein,	   which	   in	   turn	   may	   alter	   signalling.	   The	   need	   for	   small	   molecule	  
inhibitors	   of	   dynamin,	   which	   would	   allow	   quick	   and	   reversible	   modulation	   of	   the	   protein	  
function,	  was	  therefore	  great.	  The	  first	  dynamin	  inhibitor,	  dynasore,	  	  was	  identified	  by	  Macia	  et	  
al.	   from	   a	   screen	   of	   over	   16,000	   compounds	   and	   it	   reversibly	   binds	   dynamin	   and	   prevents	  
internalisation	  [158].	  Soon	  after,	  numerous	  other	  dynamin	  inhibitors	  were	  discovered	  by	  other	  
groups	   (Table	   1.3.),	   which	   interact	   with	   dynamin	   at	   different	   domains	   and	   have	   a	   range	   of	  
inhibitory	  potencies.	  Dynasore	  has	  been	  used	  widely	  and	  has	  allowed	  for	  a	  better	  understanding	  
of	  the	  role	  of	  dynamin	  in	  various	  cellular	  processes.	  Dynasore	  validates	  the	  classical	  functions	  of	  
dynamin,	  such	  as	  preventing	  receptor	  mediated	   internalisation	   [158]	  and	  even	  preventing	  HIV	  
viral	  entry	  for	  some	  viral	  strains	  [147].	  Dynasore	  treatment	  is	  highly	  disruptive	  to	  the	  formation	  
of	   lamellpodia	   at	   the	   leading	   edge	   of	   migrating	   cells	   and	   therefore	   this	   inhibitor	   helps	   to	  
understand	   the	   involvement	  of	  dynamin	  with	   cytoskeletal	   rearrangements	   [184].	   For	  example	  
dynasore	   increases	   the	   rate	   of	   neurotransmitter	   exocytosis	   in	   neuronal	   cells,	   but	   it	   also	  
increases	   intracellular	   calcium	   concentrations.	   These	   increases	   intracellular	   calcium	  were	  only	  
partially	   reversed	  by	   removal	  of	   calcium	   from	  the	  assay	  buffer	   suggesting	  dynasore	  may	  have	  
some	   as	   yet	   unidentified	   effect	   on	   calcium	  mobilisation	   [201].	   Dyngo-­‐4a	  was	   discovered	   as	   a	  
result	   of	   structure	   activity	  modification	   of	   dynasore	   and	   is	   a	   close	   structural	   analogue	   [202].	  
Dyngo-­‐4a	   increases	  GTPase	   and	  RME	   inhibitory	   potency	   and	   acts	   as	   in	   inhibitor	   of	   Botulinum	  
toxin,	  by	  inhibiting	  dynamin	  mediated	  endocytosis	  [142].	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  Table	  1.3:	  Dynamin	  inhibitors	  and	  their	  properties.	  Dynamin	  inhibitor	  binding	  data	  is	  derived	  indirectly	  from	  observations	  of	  their	  inhibitory	  kinetics	  and	  their	  ability	  to	  
prevent	  dynamin	  interaction	  with	  other	  cytoplasmic	  molecules.	  PH–	  Pleckstins	  homology,	  GA-­‐	  GTPase	  allosteric,	  DA–	  Dynamin	  assembly	  (middle),	  nd	  –	  not	  determined.	  	  
Compound	  series	   Compound	   Binding	  
locus	  









MiTMAB	   PH	   Compounds	  shown	  to	  be	  non-­‐competitive	  
GTPase	  inhibitors	  and	  capable	  of	  preventing	  
PL	  binding	  to	  PH.	  No	  crystal	  data	  available	  
3.15	  ±	  0.64	   20.9	   No	   [202-­‐204]	  
	  OcTMAB	   PH	   1.9	  ±	  0.24	   16	   No	  
Mystric	  acid	   PH	   >300	   >300	   No	  
Imino-­‐chromines	  
	  
Iminodyn	  22	   GA	   Compounds	  shown	  to	  be	  uncompetitive	  with	  
GTP	  and	  therefore	  to	  bind	  to	  ‘GTPase	  
allosteric	  domain’	  theorised	  to	  be	  at	  the	  
GTPase	  domain	  due	  to	  uncompetitive	  
nature.	  
0.39±0.15	   10.7	  ±	  4.5	   Yes	   [202,	  205]	  
	  







Compounds	  shown	  to	  be	  uncompetitive	  with	  
GTP	  and	  therefore	  to	  bind	  to	  ‘GTPase	  
allosteric	  domain’	  theorised	  to	  be	  at	  the	  
GTPase	  domain	  due	  to	  uncompetitive	  
nature.	  
1.30	  ±	  0.30	  
	  
















GTPase	  allosteric	  based	  on	  non-­‐competitive	  
inhibition.	  Does	  not	  inhibit	  lipid	  or	  GRB2	  
binding	  in	  vitro.	  	  Thought	  to	  occur	  at	  GTPase	  
domain	  due	  to	  inhibitory	  effect	  on	  isolated	  
Dyn	  1	  and	  2	  GTPase	  domains.	  
15	  
	  







	  Dyngo-­‐4a	   GA	   0.3	   16.0	  ±	  1.2	   Yes	  
Dimeric	  
Tyrphostins	  
Bis-­‐T	   GA/DA	   GTPase	  ‘Allosteric’	  site	  –	  non-­‐competitive	  
binding.	  Acts	  upon	  Dynamin	  assembly	  
domain.	  	  
1.7	   ~100	  	   Yes	   [209]	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  The	   McClusky	   group,	   who	   identified	   dyngo-­‐4a,	   also	   described	   numerous	   other	   chemically	  
diverse	  dynamin	  inhibitors,	  including	  dimeric	  tyrphostin	  ‘bis-­‐T’	  [209],	  longchain	  ammonium	  salts	  
MiTMAB	   and	   OcTMAB	   [203,	   204],	   iminochromene	   [205]	   and	   indole	   species	   [206].	   All	   these	  
inhibitors	  were	  designed	  from	  libraries	  of	  modified	  small	  molecule	  precursors	  against	  dynamin	  
GTPase	  function	  and	  as	  such	  can	  all	  affect	  internalisation.	  The	  way	  the	  molecules	  interact	  with	  
dynamin	   results	   in	   some	   differences	   in	   function	   however;	   inhibitor-­‐protein	   interactions	   are	  
important	   in	   determining	   binding	   site	   interactions	   and	  mechanisms	   for	   allosteric	   interactions	  
and	  are	  ideally	  determined	  by	  in	  silico	  or	  co-­‐crystallisation	  and	  X-­‐ray	  crystallography.	  In	  the	  case	  
of	  the	  dynamin	  inhibitors,	  the	  binding	  to	  dynamin	  is	  not	  of	  sufficiently	  high	  affinity	  to	  allow	  co-­‐
crystallisation	   and	   no	   in	   silico	   models	   have	   been	   presented	   in	   the	   literature.	   The	   binding	  
mechanisms	   for	   the	   inhibitors	   are	   putative	   and	   based	   on	   their	   ability	   to	   block	   phospholipid	  
binding,	   as	   for	   MiTMAB	   and	   OcTMAB	   or	   their	   kinetics	   during	   GTPase	   inhibition.	   Dynasore,	  
dyngo-­‐4a	  and	  bis-­‐t	  are	  non-­‐competitive	  inhibitors	  of	  GTPase	  function,	  which	  suggests	  binding	  to	  
a	  site	  allosteric	  to	  the	  GTP	  turnover	  active	  site.	  Dynasore	  does	  not	  prevent	  lipid	  binding	  and	  has	  
been	   shown	   to	   affect	   isolated	   GTPase	   domains,	   which	   places	   its	   binding	   zone	   in	   GTPase	  
allosteric	  locus.	  Dynole	  34-­‐2	  and	  iminodyn	  22	  are	  uncompetitive	  inhibitors	  [210],	  which	  means	  
they	  bind	  the	  enzyme-­‐substrate	  complex	  placing	  their	  binding	  site	  in	  close	  proximity	  to	  GTP	  at	  
the	   GTPase	   binding	   site.	  Whilst	   this	   binding	   identification	   is	   crude,	   it	   offers	   information	   that	  
might	   allow	   a	   better	   understanding	   of	   the	   function	   of	   dynamin	   in	   migration,	   particularly,	   as	  
these	  inhibitors	  have	  a	  range	  of	  GTPase	  and	  RME	  potencies.	  Another	  point	  of	  comparison	  is	  the	  
ability	   of	   these	   inhibitors	   to	   stabilise	   dynamin	   rings,	   which	   has	   recently	   been	   published	   in	   a	  
patent	  application	  by	  Robinson	  et	  al.	  of	  McCluskeys	  group	  [202].	  	  	  
	  
Dynasore	  has	  been	  shown	  to	  prevent	  CCR2	  [178]	  and	  CCR5	  [134]	   internalisation	  in	  THP-­‐1	  cells	  
which	  demonstrates	  that	  this	  process	  occurs	  via	  dynamin	  interaction	  with	  the	  cell	  membrane	  in	  
this	   cell	   line	   and	   suggests,	   that	   dynamin	   is	   present	   at	   the	   locus	   of	   CCR5	   during	   receptor	  
activation.	  There	  is	  little	  information	  regarding	  the	  role	  of	  dynamin	  in	  migration	  of	  highly	  mobile	  
cells,	  such	  as	  monocytes	  and	  leukocytes,	  however.	  Considering	  the	  differential	  roles	  of	  PI3K	  and	  
cell	  polarisation	  in	  these	  cells	  dynamin	  function	  with	  regard	  to	  chemotaxis	  makes	  an	  interesting	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  point	  of	  investigation.	  The	  range	  of	  dynamin	  inhibitors	  with	  their	  differential	  effects	  on	  dynamin	  
may	  allow	  specific	  interactions	  within	  signal	  transduction	  to	  be	  deduced.	  For	  example	  MiTMAB	  
and	  OcTMAB,	  which	   bind	   dynamin	   at	   the	   pleckstin	   homology	   domain,	  would	   be	   expected	   to	  
inhibit	  localisation	  with	  PIP2,	  both	  compounds	  inhibit	  migration	  in	  fibroblasts	  but	  in	  THP-­‐1	  cells	  
where	  PI3K	  mediated	  polarisation	  is	  not	  required	  for	  migration	  the	  effect	  might	  be	  different.	  	  
	  
The	   final	   consideration	   regarding	   the	  dynamin	   inhibitors	   is	   that	   they	  were	  all	   screened	   for	  or	  
rationally	  designed	  against	  dynamin	  GTPase	  function.	  Determining	   if	  dynamin	  GTPase	  potency	  
correlates	  with	  any	  observed	  effect	  on	  migration	  will	  be	  an	   important	  step	   in	  determining	  the	  
relationship	  between	  the	  protein	  and	  chemotaxis.	  If	  GTPase	  potency	  is	  shown	  not	  to	  correlate	  
with	  any	  observed	  effects,	  then	  the	  other	  known	  traits	  of	  the	  inhibitors,	  such	  as	  protein	  binding	  
location,	   receptor	  mediated	   internalisation	   potency	   or	   their	   ability	   to	   stabilise	   dynamin	   rings	  




The	   dysregulation	   of	   migration	   is	   causative	   to	   numerous	   disease	   states	   that	   make	   an	  
understanding	   of	   the	   governing	   processes	   critical	   for	   the	   identification	   of	   potential	  
therapeutical	   targets	   for	   these	   diseases.	   The	   chemokine	   receptor	   CCR5	   is	   directly	   linked	   to	  
inflammatory	  and	  metastatic	  diseases,	  but	  is	  also	  widely	  characterised	  intra-­‐	  and	  extracellularly	  
due	  to	  its	  involvement	  with	  HIV	  viral	  entry.	  This	  makes	  CCR5	  a	  particularly	  good	  model	  system	  in	  
which	  the	  specifics	  of	  cell	  migration	  can	  be	  determined	  with	  numerous	  cell	  lines	  available	  which	  
either	   endogenously	   express	   CCR5	   (THP-­‐1	   cells	   and	   activated	   PBLs)	   or	   are	   stably	   transfected	  
with	  the	  receptor	  DNA	  .	  A	  large	  amount	  of	  research	  has	  been	  undertaken	  over	  the	  last	  decade	  
to	   describe	   the	   cytoplasmic	   signalling	   events	  which	   govern	   cellular	   processes	   downstream	   of	  
activated	  CCR5,	  there	  are	  still	  many	  contradictory	  or	  unresolved	  areas	  to	  be	  explored.	  There	  is	  
evidence	   to	   support	   that	   the	   signalling	   from	  CCR5	   to	  migration	   could	   be	  Gα,	   Gβγ	   or	   arrestin	  
dependent	   and	   that	   CCR5	   binding	   proteins,	   such	   as	   JAK2,	  might	   play	   a	   role	   as	  well.	  Many	   of	  
these	   contradicting	   results	   in	   the	   literature,	   such	   as	   the	   role	   of	   Gβγ,	   non-­‐receptor	   tyrosine	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  kinase	   signalling	   and	   PI3K	   mediated	   cell	   polarisation,	   may	   be	   cell	   type	   rather	   than	   receptor	  
specific,	  but	  without	  further	  investigation	  this	  cannot	  be	  said	  for	  sure.	  The	  fact	  that	  PI3K	  is	  not	  
required	  for	  THP-­‐1	  cell	  migration	  for	  example	  has	  not	  been	  directly	  attributed	  to	  CCR5	  signalling	  
nor	   has	   it	   been	   pharmacologically	   investigated	   to	   determine	   if	   small	   molecule	   inhibition	   can	  
replicate	  the	  proteomic	  observations.	  Other	  protein	  targets	  known	  to	  be	  involved	  in	  migration,	  
such	  as	  dynamin	  and	  Grb2,	  have	  not	  been	  well	   characterised	   for	   their	   interaction	  with	  CCR5.	  
There	  are	  a	  large	  number	  of	  diverse	  inhibitors	  available	  for	  use	  against	  these	  proteins	  and	  small	  
molecules	   still	   represent	   the	  most	   realistic	   route	   to	   intracellular	   signal	   transduction	   inhibition	  
with	  potential	  therapeutic	  effects.	  Despite	  advances	  in	  antibody	  based	  pharmaceuticals	  and	  the	  
potential	   for	   gene	   targeted	   therapeutics	   based	   around	   RNA	   interference,	   these	  methods	   are	  
likely	  to	  be	  limited	  due	  to	  delivery	  problems.	  Exploration	  of	  CCR5	  signalling	  to	  chemotaxis	  with	  
cell	   permeable	   small	   molecule	   inhibitors	   has	   the	   advantage	   over	   proteomic	   techniques	   of	  
identifying	  such	  mechanisms	  in	  that	  the	  ‘targetability’	  of	  a	  process	  is	  validated	  as	  it	  is	  described.	  
Knockdown	  or	   over	   expression	  of	   proteins	   can	   reveal	   potential	   drug	   targets	   but	   says	   nothing	  
about	  how	  accessible	  the	  interaction	  is	  pharmacologically.	  For	  this	  reason	  the	  primary	  method	  
of	   investigation	   of	   the	   signalling	   events	   will	   be	   through	   small	   molecular	   inhibition.	   These	  
inhibitors	  will	   be	  used	   in	   an	  attempt	   to	   clarify	   cell	   type	   specific	   from	   receptor	   specific	   events	  
and	  to	  examine	  the	  roles	  of	  poorly	  characterised	  proteins	  such	  as	  Grb2	  in	  an	  attempt	  to	  identify	  
novel,	  small	  molecule	  targetable	  processes	  which	  can	  down	  regulate	  migration.	  This	  thesis	  will	  
outline	  protein	   interactions	  of	   interest	   that	  can	  then	  become	  the	  focus	  of	   targeted	  proteomic	  
analysis.	  	  
	  
1.14.	  Research	  objectives	  
	  
Pharmacological	   disruption	   of	   chemokine	   receptor	   mediated	   processes	   represents	   a	   path	   to	  
therapeutic	  intervention	  in	  many	  diseases.	  Despite	  this	  there	  are	  no	  chemokine	  receptor	  based	  
therapies	  for	   immunological	  or	  metastatic	  disease	  available,	  the	  reason	  for	  this	   is,	   in	  part,	  due	  
to	  the	  lack	  of	  understanding	  of	  chemokine	  receptor	  mediated	  signalling.	  It	  has	  been	  shown	  that	  
signalling	   form	   CCR5	   to	   chemotaxis	   is	   far	   from	   resolved	   due	   in	   part	   to	   the	   large	   number	   of	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  protein	   interactions	   which	   can	   potentially	   be	   involved.	   The	   introduction	   demonstrated	   that	  
based	  on	  the	  current	  understanding	  CCR5	  signal	  transduction	  could	  be	  attributed	  wholly	  to	  Gα,	  
Gβγ	  and	  arrestin	  dependent	  signal	  transduction.	  Other	  proteins	  such	  as	  FROUNT,	  SFKs	  and	  PI3K	  
may	   also	   be	   linked	   to	   CCR5	   mediated	   migration	   perhaps	   through	   interactions	   with	   poorly	  
characterised	   CCR5	   interacting	   proteins	   such	   as	   JAK2.	  Other	   proteins	   prominently	   involved	   in	  
migration	  downstream	  of	  other	  receptor	  types	  such	  as	  dynamin	  and	  Grb2	  do	  not	  have	  a	  clearly	  
defined	  relationship	  with	  CCR5	  or	  chemokine	  receptors	  generally.	  Clearly	  all	  of	   these	  proteins	  
cannot	   simultaneously	   be	   involved;	   identifying	   which	   of	   these	   interactions	   are	   receptor,	  
receptor	  family	  or	  cell	  type	  specific	  will	  form	  the	  focus	  of	  this	  thesis.	  Resolving	  the	  specifics	  of	  
chemokine	   receptor	   signalling	   by	   small	   molecule	   disruption	   of	   protein	   signalling	   and	  
comparative	   analysis	   with	   other	   chemokine	   receptor	   signalling	   systems	   has	   the	   potential	   to	  
identify	  novel	  receptor	  specific	  targets	  for	  disruption	  of	  chemokine	  receptor	  function.	  In	  order	  
to	  achieve	  this,	  the	  following	  experimentation	  will	  be	  undertaken:	  
	  
CHAPTER	  3:	  An	  investigation	  into	  the	  chemotactic	  responses	  stimulated	  by	  various	  CCR5	  ligands	  
in	  the	  THP-­‐1	  cell	   line	  and	  whether	  CCR5	  specific	  responses	  can	  be	  resolved	  through	  the	  use	  of	  
small	  molecule	  chemokine	  receptor	  antagonists.	  
	  
Chapter	  4:	  Will	  explore	  the	  identification	  of	  ‘way	  points’	  in	  CCR5	  mediated	  THP-­‐1	  cell	  migration	  
so	   that	   the	   conflicting	   reports	   in	   the	   scientific	   literature	   can	   be	   clarified	   and	   used	   to	   direct	  
further	  research.	  
	  
Chapter	   5:	   An	   investigation	   into	   the	   potential	   role	   of	   JAK/STAT	   signalling	   as	   a	   player	   in	  
cytoplasmic	  signal	  transduction	  to	  migration	  outside	  of	  their	  role	  as	  transcription	  factors.	  	  
	  
Chapter	  6:	  In	  chapter	  six	  proteins	  which	  have	  been	  shown	  to	  be	  important	  in	  migration	  in	  other	  
receptor	  signalling	  systems	  such	  as	  PI3K,	  dynamin	  and	  Grb2	  will	  be	   investigated	   in	   relation	   to	  
CCR5	  mediated	  migration.	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  CHAPTER	  2:	  MATERIALS	  AND	  METHODS	  
	  
2.1.	  Cell	  lines	  and	  tissue	  culture	  
	  
2.1.1.	  Acute	  monocytic	  leukaemia	  cell	  line	  THP-­‐1	  	  
	  
THP-­‐1	  cells	  are	  derived	  form	  a	  one	  year	  old	  male	  donor	  with	  acute	   leukaemia.	  THP-­‐1	  cells	  are	  
known	  to	  represent	  a	  good	  model	  for	  healthy	  monocyte	  behaviour	  and	  endogenously	  express	  a	  
number	   of	   human	   chemokine	   receptors.	   	   THP-­‐1	   cells	   were	   obtained	   from	   American	   Type	  
Culture	   Collection	   (ATCC)	   (Teddington,	   UK)	   and	   were	   cultured	   using	   RPMI	   (PAA,	   Yeovil,	   UK)	  
supplemented	  with	  10%	  v/v	  Foetal	   calf	   serum	   (FCS)	   (Invitrogen),	   100	  U/mL	  penicillin	   and	  100	  
µg/mL	   streptomycin	   (Invitrogen),	   100	   µM	   non-­‐essential	   amino	   acids	   (Gibco)	   and	   2	   mM	  
glutamine	  (Invitrogen).	  	  
	  
2.1.2.	  HeLa.RC49	  cervical	  cancer	  fibroblasts	  
	  
HeLa.RC49	   cells	   represent	   immortalised	   fibroblasts	   which	   stably	   express	   human	   CCR5	   with	  
negligible	  expression	  levels	  of	  non-­‐transfected	  chemokine	  receptors	  and	  were	  acquired	  from	  D.	  
Kabat	   [211].	  HeLa.RC49	  are	  cells	   that	   contain	  human	  signalling	  machinery	   in	   conjunction	  with	  
high	   levels	   of	   human	   CCR5	   receptors	   and	   have	   proven	   robust	   in	   in	   vitro	   assays.	   Briefly,	   HI-­‐R	  
clone	   of	   HeLa-­‐CD4	   cells	   identified	   with	   low	   expression	   of	   CD4	   were	   transfected	   with	   the	  
retroviral	  vector	  SFF-­‐CCR5.	  CCR5	  expression	  was	  validated	  by	  susceptibility	   to	   infection	  by	  the	  
Ba-­‐L	  M-­‐tropic	   HIV-­‐1	   isolate.	   The	   RC49	   clone	  was	   shown	   to	   express	   the	   highest	   level	   of	   CCR5	  
membrane	   receptors.	   HeLa.RC49	   cells	   were	   grown	   in	   complete	   Dulbecco’s	   Modified	   Eagle’s	  
Medium	  (DMEM)	  (PAA)	  (10%	  v/v	  FCS,	  100	  U/mL	  penicillin	  and	  100	  µg/mL	  streptomycin,	  100	  µM	  




	  2.1.3.CHO.CCR5	  stably	  transfected	  Chinese	  Hamster	  Ovary	  fibroblasts	  
	  
Chinese	  hamster	  ovary	  (CHO)	  cells	  have	  proven	  to	  be	  easy	  to	  culture,	  fast	  growing	  and,	  due	  to	  
their	   relatively	   large	   size,	   excellent	   for	   microscopy.	   CHO.CCR5	   cells	   were	   acquired	   from	   J.	  
McKeating,	  Reading.	  CHO	  were	   transfected	  with	  pcDNA3	  encoding	  Human	  CCR5	  and	   selected	  
for	  stable	  expression	  in	  10%	  FCS	  DMEM	  with	  glutamine	  (2	  mM)	  In	  the	  presence	  of	  the	  selective	  
aminoglycoside	   antibiotic	   G418	   (Invitrogen)	   (400	   μg/mL).	   CHO.CCR5	   cells	   were	   cultured	   in	  
complete	  DMEM	  (10%	  v/v	  FCS,	  100	  U/mL	  penicillin	  and	  100	  µg/mL	  streptomycin,	  100	  µM	  non-­‐
essential	   amino	   acids	   and	   2	   mM	   glutamine	   supplemented	   with	   400	   µg/mL	   G418	   to	   ensure	  
continued	  expression	  of	  CCR5.	  
	  
2.1.4.	  Routine	  tissue	  culture	  procedures	  for	  cell	  lines	  
	  
Both	   adherent	   and	   suspension	   cell	   lines	   were	   cultured	   in	   75cm2	   flasks	   (Corning/	   SPL	   Life	  
Sciences)	  in	  a	  humidified	  atmosphere	  at	  37°C	  with	  5%	  CO2.	  At	  80-­‐95	  %	  confluence	  adherent	  cells	  
were	  removed	  from	  the	  flask	  by	  adding	  PBS	  (1.5	  mM	  potassium	  phosphate	  monobasic,	  3	  mM	  
potassium	   phosphate	   dibasic,	   150	   mM	   NaCl;	   pH	   7.2)	   supplemented	   with	   2.5	   mM	   EDTA	   and	  
incubating	  them	  for	  15-­‐20	  minutes	  at	  37°C	  and	  5%	  CO2.	  After	  this	  period,	  cells	  were	  suspended	  
by	   gentle	   agitation	   of	   the	   flask.	   Cells	   were	   then	   centrifuged	   at	   700	   g	   for	   5	   minutes	   and	  
resuspended	   in	   the	   relevant	   growth	   medium	   after	   which	   cell	   density	   was	   determined	  
microscopically	  with	  the	  use	  of	  a	  haemocytometer.	  Cells	  were	  then	  used	  for	  experimentation	  or	  
passaged	  by	  reducing	  cell	  density	  by	  80-­‐90%	  and	  continued	  culturing.	  The	  suspension	  cell	   line	  
THP-­‐1	  was	  cultured	  for	  1	  week	  or	  until	  cell	  density	  reached	  6x104/mL	  (which	  ever	  was	  sooner)	  
at	  which	  point	  cell	  density	  was	  reduced	  to	  2x104/mL	  by	  removal	  of	  suspended	  cells	  and	  addition	  
of	   fresh	   media.	   Where	   cells	   were	   to	   be	   cryopreserved,	   1x106	   cells	   were	   centrifuged,	  
resuspended	   into	   1	   ml	   of	   10%	   (v/v)	   dimethyl	   sulfoxide	   (DMSO)	   in	   FCS	   and	   transferred	   into	  
cryotubes.	   To	   prevent	   damage	   by	   freezing	   these	   cryotubes	   were	   first	   wrapped	   in	   tissue	   and	  
chilled	  to	  -­‐80	  °C	  for	  at	  least	  24hr	  before	  long	  term	  storage	  in	  liquid	  nitrogen	  at	  -­‐196	  °C.	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  2.1.5.	  Peripheral	  Blood	  Mononuclear	  Cell	  (PBMC)	  collection	  
	  
Venous	   blood	   from	   healthy	   human	   volunteers	   was	   collected	   into	   falcon	   tubes	   containing	  
approximately	  10%	  sodium	  citrate	  anti-­‐coagulant	  (4%	  w/v)	  then	  mixed	  with	  an	  equal	  volume	  of	  
HEPES	   buffered	   saline	   solution	   (HBSS).	   Peripheral	   blood	   mononuclear	   Cells	   (PBMCs)	   were	  
isolated	  by	  centrifugation	  through	  Ficoll	  Paque	  Plus	  (General)	  (15mL/25ml	  of	  blood)	  at	  400g	  for	  
35	  min	   RT.	   The	   PBMC	   containing	   fraction	  was	  washed	   twice	   in	   pre-­‐warmed	   HBSS	   before	   re-­‐
suspension	  in	  simple	  RPMI-­‐1640.	  	  
	  
2.1.5.1.	  Isolation	  and	  Activation	  of	  Peripheral	  Blood	  Lymphocytes	  
	  
Cells	   were	   added	   to	   a	   75cm2	   flask	   for	   adherence	   depletion	   of	   monocytes.	   After	   4hr	   non-­‐
adherent	  cells	  were	  removed,	  washed	  in	  simple	  RPMI-­‐1640,	  then	  resuspended	  at	  1x106mL-­‐1	   in	  
complete	   RMPI-­‐1640	   (10%	   FCS,	   1%	   NEAA,	   2	   mM	   glutamine).	   Peripheral	   blood	   lymphocytes	  
(PBLs)	  were	  activated	  by	  addition	  of	  (30	  mg/mL)	  concanavalin	  A	  (Con	  A)	  (Sigma-­‐Aldrich)	  and	  200	  
µg/mL	  IL-­‐2	  (Peprotech)	  and	  incubated	  for	  at	  least	  10	  days	  before	  use	  in	  chemotaxis	  and	  calcium	  
flux	  assays.	  PBLs	  were	  cultured	  by	  addition	  of	  1	  mL	  of	  complete	  RMPI-­‐1640	  at	  2	  day	   intervals	  
after	   activation	   was	   complete.	   Due	   to	   variability	   between	   donor	   PBLs	   all	   experiments	   using	  
these	  cells	  represent	  at	  least	  3	  donors.	  Individual	  donor	  data	  (n=1)	  represents	  the	  mean	  values	  











	  2.2.	  Small	  molecule	  and	  oligomeric	  inhibitors	  
	  
A	  complete	  list	  of	  the	  small	  molecule	  and	  protein	  inhibitors	  is	  detailed	  below.	  
	  
Table	  2.1.	  JAK/STAT	  inhibitors:	  
	  
Inhibitor	   Supplier	   Stock	  Conc/Vehicle	   Working	  Conc	  
Cucurbitacin	  I	   Tocris	  Bioscience	  
	  




JAK2	  inhibitor	  II	   Calbiochem	  
	  




STAT3	  inhibitor	  III	   Calbiochem	  
	  
100	  mM	  DMSO	  
	  
10	  µM	  
STAT3	  inhibitor	  VIII	   Calbiochem	   100	  mM	  DMSO	   10	  µM	  
	  
	  
Table	  2.2.	  PI3K	  inhibitors:	  	  
	  
Inhibitor	   Supplier	   Stock	  Conc/Vehicle	   Working	  Conc	  
LY294002	   Abcam	  
	  




Wortmannin	   SigmaAldrich	  
	  




AS605240	   Selleck	  Biochem	   1	  mM	  DMSO	   5-­‐1000	  nM	  
	  
Table	  2.3.	  Cytoskeletal	  inhibitors:	  	  
	  
Inhibitor	   Supplier	   Stock	  Conc/Vehicle	   Working	  Conc	  













	  Table	  2.4.	  Kinase	  inhibitors:	  
	  
Inhibitor	   Supplier	   Stock	  Conc/Vehicle	   Working	  Conc	  
PD98059	   Calbiochem	  
	  




SB203580	   Calbiochem	  
	  




βARK1	  inhibitor	   Calbiochem	  
	  





Calbiochem	   2.5	  mM	  DMSO	   2.5	  µM	  
PKCζ	   pseudo	  
substrate	  inhibitor	  
Calbiochem	   1	  mM	  DMSO	   10	  µM	  
Bosutininb	   Selleck	  Biochem	   10	  mM	  DMSO	   10	  µM	  
Farnesylthiosalysilic	  
acid	  
Abcam	   12.5	  mM	  DMSO	   12.5-­‐250	  µM	  
CGP078850	   Novartis	   50	  mM	  DMSO	   50-­‐500	  µM	  
	  
Table	  2.5.	  Endocytosis	  inhibitors:	  
	  
Inhibitor	   Supplier	   Stock	  Conc/Vehicle	   Working	  Conc	  
Sucrose	   SigmaAldrich	   4M	  water	   0.4	  M	  
Filipin	   Tocris	   15	  mM	  DMSO	   15	  µM	  
Pit	  stop	  2	   Abcam	   30	  mM	  DMSO	   30	  µM	  
Pit	   stop	   2	   negative	  
control	  
Abcam	   30	  mM	  DMSO	   30	  µM	  
MiTMAB	   Ascent	  Scientific	   10	  mM	  DMSO	   10	  µM	  
OcTMAB	   Ascent	  Scientific	   5	  mM	  DMSO	   5	  µM	  
Promystric	  acid	   Ascent	  Scientific	   15	  mM	  DMSO	   15	  µM	  
Iminodyn	  22	   Ascent	  Scientific	   1	  mM	  DMSO	   1	  µM	  
Iminodyn	  17	   Ascent	  Scientific	   1	  mM	  DMSO	   1	  µM	  
Dynole	  34-­‐2	   Ascent	  Scientific	   15	  mM	  DMSO	   15	  µM	  
Dynole	  31-­‐2	   Ascent	  Scientific	   15	  mM	  DMSO	   15	  µM	  
Dynasore	   Abcam	   80	  mM	  DMSO	   15-­‐80	  µM	  




	  Table	  2.6.	  Chemokine	  receptor	  antagonists:	  
	  
Inhibitor	   Supplier	   Stock	  Conc/Vehicle	   Working	  Conc	  




J113863	   Tocris	  Bioscience	  	   10	  mM	  ethanol	   1-­‐10000	  nM	  
	  
	  
2.2.1.	  Chemokine	  Receptor	  Ligands	  
	  
The	  chemokine	  used	  for	  CCR5/CCR1	  activation	  was	  CCL3	  (D26A),	  which	  was	  generously	  donated	  
by	   Lloyd	   Czaplewski	   of	   British	   Biotech.	   The	   isoform	   has	   been	   reffered	   to	   in	   a	   previous	  
publication	  as	  CCL3	  (2–70)	  (D26A)	  in	  comparison	  with	  the	  full	  gene	  sequence	  for	  CCL3.	  CCL3	  (2-­‐
70)	   (D26A)	   is	   referred	   to	   in	   this	   text	   as	   CCL3.	   CCR5	   agonist	   CCL4	   (MIP1β)	   (Peprotech,	   New	  
Jersey,	  USA)	  stock	  was	  made	  up	  to	  10	  µM	  for	  use	  in	  chemotaxis	  assays	  at	  concentration	  of	  1nM.	  
CXCR3	  ligand	  CXCL11	  (ITAC)	  (Peprotech.	  New	  Jersey,	  USA)	  stock	  was	  made	  up	  to	  1µM	  in	  purified	  
water	  for	  use	  in	  chemo	  attractant	  assays	  at	  20nM.	  CXCR4	  ligand	  CXCL12	  (SDF1)	  (Peprotech.	  New	  
Jersey,	   USA)	   stock	   was	   made	   up	   to	   10	   µg	   per	   mL	   in	   purified	   water	   for	   use	   at	   working	  
concentration	   of	   1	   µg	   per	   mL	   in	   chemo	   attractant	   assays	   (about	   10nM).	   Chemokine	   ligands	  
CCL2,	  CCL5	  and	  CCL8	  (all	  Peprotech)	  stock	  solutions	  were	  made	  up	  to	  1	  mM	  in	  purified	  water	  for	  












	  2.3.	  Antibodies	  
	  
Table	  2.7:	  Primary	  and	  secondary	  antibodies	  used	  for	  experiments.	  IF=	  Immunofluorescence,	  
WB=	  Western	  Blotting.	  
	  
Primary	  Antibody	   Supplier	   Target	   Dilution	   factor/	  
Assay	  
HEK/1/85a/7a	   rat	  
monoclonal	  
A	  gift	  from	  J.A.McKeating,	  
Reading	  
Human	  CCR5	   1:100	  








ab49876	   mouse	   mono-­‐
clonal	  




Secondary	   Supplier	   Assay	  use	   Dilution	  factor	  
Goat	  anti-­‐mouse	  FITC	  	   Sigma-­‐Aldrich	   IF	   1:1000	  
Goat	  anti-­‐rabbit	  Alexa-­‐
514	  	  
Invitrogen	   IF	   1:1000	  
Goat	  anti-­‐rabbit	  Alexa-­‐
595	  	  
Invitrogen	   IF	   1:1000	  
Anti	  rat	  IgG	  horseradise	  
peroxidase	  
Sigma-­‐Aldrich	   WB	   1:10000	  
Anti	  rabbit	  IgG	  
horeradish	  peroxidase	  










	  2.4.	  Plasmid	  DNA	  
The	   pEGFP	   arrestin	   2/3	   plasmids	   were	   produced	   by	   cloning	   relevant	   arrestin	   DNA	   into	   Hind	  
III/Apa	   I	   	   digested	  pEGFP-­‐N1	  plasmids	   (Clontech,	   Saint-­‐Germain-­‐en-­‐Laye,	   France)	   as	   described	  
and	  validated	   [212,	  213]	   and	  were	  a	   gift	   from	  E.	  Kelly	   (Bristol).	   pEGFP.C2	  plasmids	   (Clontech)	  
were	  used	  as	  mock	  transfection	  controls.	  Dynamin	  K44A	  plasmids	  were	  a	  generous	  gift	  from	  S.	  
Mundell	  (Bristol).	  	  
	  
2.4.1	  Preparation	  of	  plasmid	  DNA	  from	  bacterial	  colonies	  
	  
E.	   coli	   DH5αF1	   (Invitrogen)	   were	   transformed	   with	   the	   required	   plasmid	   DNA	   to	   allow	  
amplification	  of	  plasmids.	  50	  μL	  of	  E.	  coli	  DH5αF1	  were	  thawed	  in	  iced-­‐water	  and	  gently	  broken	  
down	  with	  a	  pipette	  to	  form	  homogenous	  slurry.	  1-­‐5	  μg	  of	  the	  relevant	  plasmid	  DNA	  construct	  
was	  added	  to	  the	  E.	  coli	  and	   incubated	  for	  30	  minutes	   in	  the	   iced-­‐water	  bath.	  Transformation	  
was	  then	   induced	  by	  heat	  shocking	  the	  bacteria	  at	  42°C	  for	  90	  sec	  before	  2	  min	   incubation	   in	  
iced-­‐water.	  1	  mL	  of	  pre-­‐warmed	  Lennox	  Broth	  (LB)	  was	  added	  to	  the	  heat	  shocked	  E.	  coli	  before	  
incubation	  in	  a	  rotary	  shaker	  at	  37°C,	  200	  rpm	  for	  2	  hours.	  25μl	  of	  the	  resulting	  bacterial	  broth	  
was	  spread	  on	  prepared	  LB	  agar	  plates	  containing	  kanamycin	  (100	  μg/	  ml)	  and	  grown,	  upside-­‐
down,	   overnight	   at	   37°C.	   Viable	   colonies	   were	   picked	   then	   incubated	   overnight	   in	   20	   ml	   LB	  
containing	  kanamycin	  (100	  μg/	  ml).	  The	  cultured	  bacterial	  broth	  was	  then	  frozen	  down	  at	  -­‐80°C	  
or	  used	  for	  plasmid	  amplification	  described	  below.	  
	  
2.4.2.	  Amplification	  of	  Plasmid	  DNA	  
	  
Plasmid	  DNA	  was	  purified	  using	  the	  Qiagen	  MIDI	  kit	  (Qiagen).	  The	  relevant	  transformed	  DH5αF1	  
strain	  was	  grown	  overnight	  and	  the	  bacterial	  broth	  was	  centrifuged	  at	  4000rpm	  for	  10	  minutes.	  
The	  supernatant	  was	  removed	  and	  4mL	  of	  P1	  buffer	  containing	  RNAase	  was	  added	  to	  resuspend	  
the	  pellet.	  4mL	  of	  P2	  buffer	  was	  added	  to	  the	  suspension	  then	  agitated	  sufficiently	  to	  turn	  the	  
solution	  a	  uniform	  blue	  before	  incubation	  for	  5	  minutes	  at	  room	  temperature.	  4mL	  of	  P3	  buffer	  
was	  added	  to	  precipitate	  protein	  then	  the	  solution	  was	  centrifuges	  at	  4000rpm	  for	  10	  minutes.	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  Supernatant	  was	   filtered	   through	   an	   activated	  Qiagen	   column,	   filtered	   and	   then	   flushed	  with	  
10mL	  QC	   buffer.	   Plasmid	   DNA	  was	   then	   eluted	  with	   5mL	  QF	   buffer.	   3.5	  mL	   propan-­‐2-­‐ol	   was	  
added	   to	   the	   eluent	   to	   precipitate	   DNA	   during	   centrifugation	   for	   1h	   at	   4000rpm.	   The	  
supernatant	  was	  removed	  and	  the	  pellet	  washed	  in	  ethanol	  before	  being	  dried	  and	  dissolved	  in	  
1mL	  deionised	  water.	  Plasmid	  DNA	  purity	  was	  determined	  by	  gel	  electrophoresis	  after	  digestion	  
with	   EcoRI	   restriction	   enzyme	   (Promega).	   Plasmid	   DNA	   concentration	   was	   determined	   by	  
absorbance	  at	  260	  nm	  using	  the	  Nanodrop	  spectrometer	  system	  (Thermo	  Scientific).	  	  
	  
2.5.	  Electroporation	  transfection	  
	  
Cells	  were	  counted	  and	  spun	  down	  to	  give	  1x106	  cells	  per	  tube.	  Cells	  were	  resuspended	  in	  105	  
µL	  simple	  RPMI	  or	  Hepes	  buffered	  electroporation	  solution	  (Hepes	  20	  mM,	  NaCl	  137	  mM,	  KCl	  5	  
mM,	  Dextrose	  6	  mM,	  Na2HPO4	  0.7	  mM	  pH	  7.5)	  to	  which	  5µL	  t-­‐RNA	  and	  1µg	  plasmid	  DNA	  and	  
1%	   DMSO	   was	   added	   before	   incubation	   at	   room	   temperature	   for	   20-­‐30minutes.	   Cells	   were	  
resuspended	  and	  100µL	  of	  the	  transfection	  mixture	  was	  added	  to	  a	  0.2cm	  transfection	  cuvette	  
and	  electroporated	  at	  the	  relevant	  setting	  (U-­‐001	  for	  THP-­‐1).	  100µL	  of	  simple	  RPMI	  was	  added	  
to	   the	  cuvette	  and	   the	  contents	   incubated	  at	   room	  temperature	   for	  10	  minutes.	  The	  solution	  
was	   removed	   with	   a	   pipette	   and	   transferred	   to	   a	   pre-­‐incubated	   6-­‐well	   plate	   containing	   the	  
relevant	   growth	   media.	   Cells	   were	   incubated	   for	   48h	   before	   assessment	   of	   transfection	  
efficiency	  by	   fluorescence	  microscopy.	  For	  0.4cm	  cuvettes	  all	   volumes	  are	   increased	  by	   factor	  
2.5.	  
	  
2.6.	  Calcium	  flux	  
	  
Adherent	  cell	  lines	  were	  harvested	  by	  addition	  of	  PBS	  containing	  25	  mM	  EDTA.	  THP-­‐1	  cells	  were	  
collected,	  centrifuged	  at	  2000	  g	  for	  5	  minutes.	  All	  cells	  were	  resuspended	  in	  calcium	  flux	  buffer	  
(137	  mM	  NaCl,	  5	  mM	  KCl,	  2	  mM	  MgCl2,	  1.5	  mM	  CaCl2,	  10mM	  HEPES	  pH	  7.4,	  25mM	  D-­‐Glucose.	  
Cells	  were	  spun	  down	  and	  washed	  twice	  more	  in	  calcium	  flux	  buffer	  before	  resuspension	  in	  1mL	  
of	  calcium	  flux	  buffer	  to	  give	  a	  concentration	  of	  1x106	  cells/mL.	  Cells	  were	  then	  treated	  with	  the	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  relevant	   concentrations	   of	   inhibitor	   and	   loaded	   with	   the	   membrane	   permeable	  
acetoxymethylester	  conjugated	  form	  of	  Fura-­‐2	  (Invitrogen).	  2	  µM	  of	  Fura-­‐2	  was	  added	  to	  all	  cell	  
samples	  before	  incubation	  a	  37ºC,	  CO2	  5%	  for	  30	  minutes.	  Cells	  were	  then	  centrifuged	  at	  2000	  g	  
and	  washed	  with	  1mL	   calcium	   flux	  buffer	   3	   times.	   100µL	  of	   cell	  was	   added	   to	   each	  well	   of	   a	  
black,	  opaque,	  reader	  plate	  (Fischer	  Scientific,	  UK)	  before	  calcium	  flux	  assessment	  by	  addition	  of	  
different	  agonist/antagonist	   injected	  directly	   into	   the	  wells	  using	   the	  BMG	  Labtech	  Fluorostar	  
optima	  plate	  reader	  (BMG	  Labtech,	  Germany).	  Changes	  in	  calcium	  release	  were	  determined	  by	  
ratiometric	  analysis	  of	  alteration	  in	  fluorescence	  sequentially	  stimulated	  by	  340	  nm	  and	  380	  nm	  
light	  a	  detected	  at	  a	  fixed	  emission	  frequency	  of	  510	  nm.	  Data	  were	  recorded	  and	  analysed	  us	  
BMG	  optima	  software	  and	  were	   represented	  as	   the	   ratio	  of	   the	   fluorescence	  detected	  at	  340	  
nm/380	   nm.	   The	   change	   in	   fluorescence	   was	   calculated	   as	   the	   difference	   between	   the	   pre-­‐
stimulated	  340/380	  nm	  ratio	  and	  the	  peak	  value	  after	  stimulation.	  
	  	  
2.7.	  Migration	  assays	  
	  
2.7.1.	  Transwell	  chemotaxis	  assay	  
	  
Chemotaxis	   assays	   for	   THP-­‐1	   and	   PBLs	   were	   carried	   out	   in	   ChemoTX	   5	   µm	   pore	   transwell	  
chemotaxis	   plates	   (Neuroprobe	   Inc,	   USA).	   Wells	   to	   be	   used	   in	   the	   chemotaxis	   plate	   were	  
blocked	   with	   30µL	   blocking	   buffer	   (1%	   BSA	   in	   simple	   RPMI	   for	   at	   least	   30	   minutes	   at	   room	  
temperature.	  Chemokine	  solutions	  were	  prepared	  at	  1-­‐5	  nM,	  depending	  on	  assay	  requirements,	  
in	  working	  buffer	   (0.1%	  BSA	   in	  simple	  RPMI).	  THP-­‐1	  cells	  were	  micro-­‐centrifuged	  at	  5000	  rpm	  
for	   5	   mins,	   washed	   once	   in	   simple	   RPMI	   	   and	   resuspended	   in	   39	   µL	   working	   buffer	   to	   give	  
25x104	  cells	  per	  well	  with	  two	  wells	  worth	  of	  cells	  per	  sample	  for	  stimulated	  and	  unstimulated	  
runs.	  Relevant	  treatments	  or	  vehicle	  control	   	   	  were	  added	  before	  an	   incubation	  for	  30mins	  at	  
37°C,	  5%	  CO2	  for	  0.5hr.	  The	  blocking	  buffer	  was	  removed	  from	  the	  plate	  and	  replaced	  with	  31µL	  
of	  the	  relevant	  chemokine	  solution	  (working	  buffer	  for	  unstimulated	  samples).	  The	  membrane	  
was	   attached	   and	   20µL	   of	   cell	   suspension	   was	   added	   to	   the	   top	   surface.	   The	   plate	   was	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  incubated	   in	  a	  fully	  humidified	  chamber	  for	  5h	  before	  membrane	  was	  dried	  and	  removed	  and	  
the	  cells	  in	  each	  well	  counted	  with	  a	  haemocytometer.	  	  	  	  	  
	  
2.7.2.	  Scratch	  assay	  
	  
Initially	  sterile	  6	  well	  plates	  were	  prepared	  by	  marking	  the	  outside	  of	  the	  bottom	  surface	  with	  
two	   parallel	   lines	   in	   indelible	   marker	   per	   well	   which	   forms	   the	   reference	   points	   for	   wound	  
healing	  quantification-­‐	  this	  must	  be	  done	  before	  addition	  of	  cells.	  
Adherent	   cells	   were	   cultured	   until	   around	   90%	   confluence	  was	   reached	   and	   resuspended	   by	  
incubation	   with	   PBS	   with	   0.25	   mM	   EDTA	   for	   15	   mins.	   Cells	   were	   washed	   in	   PBS	   then	  
resuspended	  in	  12	  mL	  of	  complete	  DMEM	  at	  a	  density	  of	  5x105	  cells	  per	  mL.	  Cells	  were	  pipetted	  
into	   pre-­‐marked	   6	   well	   plates	   (2	   mL	   per	   well)	   and	   incubated	   for	   24	   hours	   at	   37ºC	   to	   allow	  
adherence	  and	  spreading	  of	  the	  cells.	  Scratches	  were	  made	  in	  the	  cell	  layer	  perpendicular	  to	  the	  
reference	   lines	  using	   a	   200µL	  pipette	   tip	  drawn	  along	   the	   side	  of	   the	  plate	   lid.	   The	   complete	  
medium	   was	   then	   removed	   and	   the	   cells	   washed	   twice	   in	   PBS	   to	   remove	   loosened	   and	  
suspended	  cells.	  1	  mL	  of	  simple	  DMEM	  containing	  1%	  FCS	  was	  then	  placed	  in	  each	  well	  and	  the	  
wounds	  were	  imaged	  in	  duplicate	  using	  a	  Leica	  inverted	  microscope	  in	  bright	  field	  mode	  in	  such	  
a	  way	  that	  the	  horizontal	  reference	  line	  was	  visible	  in	  all	  images.	  	  
	  
The	  relevant	  chemokine/inhibitor	  mix	  was	  prepared	  in	  another	  mL	  of	  1%	  FCS	  DMEM	  which	  was	  
added	  to	  the	  wells	  giving	  a	  total	  volume	  of	  2	  mL.	  Images	  were	  then	  collected	  at	  6,	  24	  and	  48h	  
after	   addition	   of	   treatments.	   Would	   healing	   was	   quantified	   use	   Photoshop	   CS5	   (Adobe)	   by	  
aligning	  the	  horizontal	  reference	  line	  to	  vertical	  then	  aligning	  vertical	  guides	  to	  the	  midpoint	  of	  
the	  cell	  which	  was	  closest	  to	  the	  centre	  of	  the	  scratch	  but	  part	  of	  the	  confluent	  monolayer.	  The	  
perpendicular	  pixel	  width	  between	  the	  two	  edges	  of	  the	  scratch	  could	  then	  be	  determined.	  For	  
time	   point	   images	   the	   transformation	   setting	   used	   for	   the	   t=0	   images	   were	   used	   and	  




	  2.8.	  Imaging	  techniques	  
	  
2.8.1.	  Phalloidin	  actin	  stain	  
	  	  
CHO.CCR5	   or	   HeLa.RC49	   cells	   were	   split	   at	   around	   95%	   confluence	   with	   4ml	   PBS	   EDTA	   and	  
0.5mL	  was	  placed	  over	  washed	  coverslips	  in	  a	  6	  well	  plate.	  Cells	  were	  incubated	  for	  24	  hours	  to	  
allow	   the	   cells	   to	   become	   adherent.	   Once	   95%	   confluence	   was	   reached,	   the	   inhibitors	   were	  
added	  at	  working	  concentrations	  and	  left	  for	  30minutes.	  CCL3	  was	  then	  added	  to	  relevant	  wells	  
to	  a	  concentration	  of	  100	  nM	  and	  cells	  were	  then	  incubated	  for	  1-­‐2hr.	  Cells	  were	  washed	  twice	  
in	  PBS	  and	   fixed	  by	  adding	  500	  µL	   ice	   cold	  4%	   formaldehyde	   solution	   for	  10	  mins.	  Cells	  were	  	  
washed	  twice	  in	  PBS	  then	  washed	  3	  times	  for	  5	  minutes	  in	  0.1%	  Triton	  X-­‐100	  (FischerBioTech)	  
solution.	   Cells	  were	  washed	   twice	   in	   PBS	   and	   then	   2	   µL	   of	   Alexa	   Fluor	   488	   tagged	   phalloidin	  
(invitrogen)	  was	  added	  to	  200	  µL	  PBS	  and	  placed	  onto	  the	  slides	  before	  incubation	  in	  the	  dark	  
for	  20	  minutes.	  Cells	  were	  washed	  twice	  in	  PBS	  and	  mounted	  onto	  glass	  slides	  with	  Citiflour	  AF1	  
(Citiflour,	  UK),	  a	  fluorescence	  stabilising	  mounting	  medium.	  Cells	  were	  analysed	  immediately	  by	  
fluorescence	  microscopy.	  	  
	  
2.8.2.	  Antibody	  staining	  Immunofluorescence	  
	  
Cells	   were	   seeded	   on	   coverslips	   overnight	   as	   described	   above.	   Once	   95%	   confluence	   was	  
reached	   the	   inhibitors	  were	   added	   at	  working	   concentrations	   and	   left	   for	   30minutes.	  Where	  
necessary	  CCL3	  was	  added	  at	  100	  nM	  concentration	  and	   left	   for	  1-­‐2hrs.	  Growth	  medium	  was	  
removed	   and	   cells	   were	   washed	   once	   in	   PBS	   before	   being	   fixed	   with	   500	   µL	   ice	   cold	   4%	  
formaldehyde	   solution.	   Fixing	   solution	  was	   removed	  and	   cells	  were	  permeabilised	  by	   3	   times	  
addition	  of	  0.1%	  Triton	  X-­‐100	  (FischerBioTech)	  solution.	  The	  cells	  are	  washed	  with	  1x	  PBS	  and	  
incubated	  overnight	  at	  4	  °C	  with	  the	  primary	  antibodies	  in	  1x	  PBS	  supplemented	  with	  4	  %	  BSA	  
(Sigma).	  Where	  dual	  antibody	  stains	  were	  required	  both	  primary	  antibodies	  were	  added	  to	  the	  
solution.	  	  The	  following	  day	  the	  cells	  are	  washed	  4	  times	  for	  10	  minutes	  each	  with	  1x	  PBS	  and	  
incubated	   for	   1.5	   hours	   at	   room	   temperature	   with	   the	   secondary	   antibodies	   in	   1x	   PBS	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  supplemented	  with	  4%	  BSA.	  Where	  dual	  stains	  were	  required	  both	  secondary	  antibodies	  were	  
added	  at	  the	  same	  time.	  Cells	  were	  washed	  twice	  in	  1xPBS.	  If	  an	  actin	  stain	  was	  required	  Alexa	  
Fluor	  488	  tagged	  phalloidin	  was	  added	  at	  this	  point	  as	  described	  above.	  Post	  actin	  staining,	  and	  
if	  actin	  staining	  was	  not	  required	  a	  final	  wash	  of	  1xPBS	  containing	  0.6	  µM	  DAPI	  nuclear	  stain	  was	  
added	   to	   the	   cells	   before	  mounting.	   Cells	   were	  mounted	   onto	   glass	   slides	   with	   Citiflour	   AF1	  
(Citiflour,	  UK).	  Cells	  were	  analysed	  immediately	  by	  fluorescence	  microscopy.	  	  
	  
For	   THP-­‐1	   cell	   staining	   the	   procedure	   above	   was	   followed	   although	   cells	   were	   prepared	   in	  
suspension	  in	  eppendorfs	  tubes	  and	  centrifuged	  between	  treatments	  and	  washes.	  Mounting	  of	  
THP-­‐1	   cells	  was	   achieved	  by	   resuspending	  pelleted	   cells	   in	  100	  µL	   after	   the	   final	  wash	   in	  PBS	  
then	  pipetting	  20	  µL	  or	   the	   resulting	  suspension	   into	  a	  glass	  cover	  slip.	  These	  coverslips	  were	  
allowed	  to	  dry	  in	  a	  laminar	  airflow	  hood	  then	  mounted	  directly	  onto	  a	  glass	  slide	  using	  Citiflour	  
AF1	  mounting	  medium.	  	  
	  
2.8.3.	  CCR5	  receptor	  Internalisation	  
	  
Cells	  were	  seeded	  overnight	  onto	  coverslips.	  Once	  95%	  confluence	  was	  reached	  the	   inhibitors	  
were	  added	  at	  working	  concentrations	  and	  left	  for	  30minutes.	  Cells	  were	  then	  stimulated	  with	  
100	  nM	  CCL3	   and	   incubated	   at	   37°C,	   5%	  CO2	   for	   1hr.	   	   Cells	  were	  washed	  once	  with	  PBS	   and	  
HEK/1/85a/7a	   (1:100)	   in	   1	   mL	   simple	   DMEM	   was	   placed	   onto	   the	   cells	   which	   were	   then	  
incubated	  at	  4°C	  for	  2hrs.	  Cells	  were	  washed	  4	  times	  for	  10	  minutes	  in	  PBS	  before	  fluorescently	  
tagged	  secondary	  Ab	  (1:1000)	  was	  added	  in	  1	  mL	  PBS	  and	  incubated	  for	  1hr	  at	  4°C.	  Cells	  were	  
washed	  three	  times	  in	  PBS	  and	  mounted	  onto	  glass	  slides	  with	  Citiflour	  AF1	  (Citiflour,	  UK).	  Cells	  







	  2.8.4.	  Microscopy	  
	  
Fluorescently	   stained	   slides	   were	   imaged	   using	   either	   a	   Leica	   wide	   field	   fluorescence	  
microscope	  fitted	  with	  10,	  40	  and	  63x	  inverted	  air	  objectives	  fitted	  with	  a	  colour	  CCD	  camera,	  
or,	   a	   Zeiss	   upright	   wide	   field	   fluorescence	   microscope	   fitted	   with	   10,	   40,	   63	   and	   100x	   oil	  
objectives	  fitted	  with	  a	  monochrome	  CCD.	  Leica	   images	  were	  captures	  and	  analysed	  using	  the	  
Leica	  imaging	  suite	  software	  (overlays	  represent	  true	  colours)	  and	  Zeiss	  images	  were	  captured	  
and	   analysed	   using	   the	   Axio2	   imaging	   software	   (all	   colours	   assigned	   post	   capture).	   Confocal	  
images	   were	   obtained	   using	   a	   Leica	   TCS	   SP2	   UV	   system	   laser	   scanning	   microscope.	   Images	  
represent	   a	   single	   z	   axis	   slice	   of	   around	   5	  microns.	   All	   immunofluorescence	  was	   validated	   by	  
testing	  for	  non-­‐specific	  secondary	  anti-­‐body	  binding.	  	  
	  
2.9.	  Flow	  cytometry	  
	  
THP-­‐1	   cells	   were	   washed	   in	   PBS	   and	   resuspended	   to	   give	   1	   mL	   with	   1x106/mL.	   Cells	   were	  
treated	  with	  2	  µM	  cytochalasin	  D	  for	  0.5hr	  or	  left	  untreated	  as	  controls	  before	  activation	  with	  
100	  nM	  CCL3.	  Cells	  were	  then	  permeablised,	  as	  described	  above,	  then	  washed	  and	  resuspended	  
in	  500	  µL	  PBS	  and	  treated	  with	  10	  µL	  Alexafluor-­‐488	  tagged	  phalloidin	  for	  20	  mins.	  Cells	  were	  
washed	  twice	  and	  resuspended	   in	  500	  µL	  PBS	  after	  which	  a	  10	  µL	  aliquot	  of	   the	  samples	  was	  
viewed	  by	  fluorescence	  microscopy	  to	  ensure	  staining	  could	  be	  observed.	  Differences	  in	  cellular	  
fluorescence	   were	   then	   determined	   using	   an	   Accuri	   C6	   flow	   cytometer	   (BDBiosciences)	  








	  2.10.	  Westernblotting	  
	  
2.10.1.	  Sample	  preparation	  	  
	  
5x105	  cells	  were	  	  spun	  down	  at	  2000	  g	  for	  5	  mins	  and	  the	  supernatant	  was	  removed.	  Cells	  were	  
then	  either	  frozen	  as	  a	  pellet	  for	  later	  analysis	  or	  used	  immediately.	  On	  the	  day	  of	  analysis	  the	  
pellet	   was	   defrosted	   (where	   necessary)	   and	   40	   µL	   of	   lysis/sample	   buffer	   (4%	   SDS,	   0.02%	  
bromophenol	  blue,	  20%	  glycerol,	  1.5	  mM	  DTT,	  80	  mM	  Tris,	  pH	  6.8)	  was	  added	  and	  mixed	  until	  a	  
homogenous	   consistency	  was	   reached.	   Cell	   lysing	  was	   facilitated	   by	   sonication	   (3	   pulses	   of	   3	  
seconds	  at	  90%	  amplitude	  and	  0.9	  pulse).	  The	  sonicated	  suspension	  was	   the	  placed	   in	  boiling	  
water	  for	  5	  minutes	  to	  denature	  proteins	  further.	  	  The	  lysis	  mixture	  was	  then	  immediately	  spun	  
down	   at	   14000	   g	   for	   ten	   minutes	   and	   the	   supernatant	   was	   removed	   in	   preparation	   for	   gel	  
electrophoresis,	  the	  pellet	  was	  discarded.	  	  
	  
2.10.2.	  SDS-­‐PAGE	  sample	  separation	  
	  
SDS-­‐PAGE	  gels	  consisted	  of	  a	  stacking	  phase	   for	  sample	   loading	   (0.1089g	  Tris,	  SDS	  2%	  pH	  8.8,	  
4.5%	  acrylamide	  v/v,	   0.1%	  ammonium	  persulphate	  w/v,	   0.01%	  TEMED	  v/v)	  which	   constituted	  
the	  top	  20%	  of	  the	  gel	  and	  a	  12%	  acrylamide	  running	  phase	  (0.67155g	  Tris/SDS	  2%	  pH	  8.8,	  12%	  
acrylamide	   v/v,	   0.1%	   ammonium	   persulphate	   w/v,	   0.01%	   TEMED	   v/v).	   20	   µL	   of	   sample	   was	  
loaded	  into	  the	  stacking	  phase	  wells	  with	  a	  Hamilton	  microsyringe	  along	  with	  5	  µL	  broad-­‐range	  
protein	   ladder	   (BIO-­‐RAD,	   UK).	   Unused	  wells	   were	   loaded	  with	   20	   µL	   loading	   buffer	   (4%	   SDS,	  
0.02%	   bromophenol	   blue,	   20%	   glycerol,	   80	   mM	   Tris,	   pH	   6.8)	   to	   allow	   identification	   of	   the	  
elution	  front.	  Gels	  were	  run	  at	  a	  constant	  30	  mA	  until	  the	  elution	  front	  reached	  the	  running	  gel	  
when	   the	   current	  was	   increased	   to	   50	  mA	   constant	   until	   the	   elution	   front	   ran	   off	   the	   gel	   at	  





	  2.10.3.	  Protein	  transfer	  
	  
The	  gel	  plates	  were	  removed	  from	  the	  clamp	  assembly	  and	  separated	  so	  that	  the	  gel	  remained	  
intact	  on	  one	  plate.	  The	  gel	  was	  then	  transferred	  to	  a	  nitrocellulose	  membrane	  (Whatman)	  pre-­‐
soaked	   with	   deionised	   water.	   The	   membrane	   and	   gel	   were	   placed	   between	   sheets	   of	  
(Whatman)	   filter	   paper	   pre-­‐soaked	   in	   transfer	   buffer	   (25	   mM	   Tris,	   192	   mM	   glycine,	   10%	  
methanol,	  pH	  8.3),	  sufficient	  sheets	  were	  used	  to	  allow	  a	  good	  contact	  between	  electrodes	  of	  
the	   transfer	   plate	   (BIO-­‐RAD	   semi-­‐dry	   transfer	   kit).	   The	   transfer	   was	   undertaken	   at	   15	   volts	  
constant	  for	  45minutes.	  Successful	  protein	  transfer	  was	  evaluated	  by	  the	  transfer	  of	  the	  protein	  
marker	  to	  the	  nitrocellulose	  membrane.	  	  	  
	  
2.10.4.	  Immunostaining	  and	  imaging	  	  
	  
After	   protein	   transfer	   was	   verified	   the	   nitrocellulose	   membranes	   where	   initially	   blocked	   for	  
non-­‐specific	   binding	  with	  PBS-­‐T	   (0.5%	   (v/v)	   Tween-­‐20	   in	   PB)	   containing	  5%	   (w/v)	   low-­‐fat	  milk	  
powder	   (Marvel)	   for	   1hr	   at	   room	   temperature.	   Blocking	   buffer	   was	   then	   removed	   and	   the	  
relevant	  primary	  antibody	  (see	  table	  2.7.)	  was	  diluted	  in	  blocking	  buffer	  before	  overnight	  rolled-­‐
agitation.	  The	  following	  day	  the	  primary	  anti-­‐body	  was	  removed	  and	  the	  membrane	  washed	  3	  
times	   for	   10	  min	  with	   PBS-­‐T	   before	   addition	  of	   the	   relevant	   secondary	   peroxidase	   tagged	  Ab	  
was	   added	   at	   1:10000	   in	   10	   mL	   blocking	   buffer.	   After	   1hr	   roller-­‐agitation	   the	   secondary	  
antibody	  solution	  was	  removed	  and	  the	  membrane	  was	  washed	  3	  times	  for	  10	  minutes	  in	  a	  tray	  
with	  gentle	   shaking	   to	   facilitate	   flattening.	  Proteins	  were	  visualised	  by	  addition	  of	  2-­‐sprays	  of	  
the	  one-­‐pot	  RapisStep	  ECL	  (Calbiochem)	  after	  which	  the	  membrane	  was	  sandwiched	  between	  2	  
acetate	  sheets	  and	  imaged	  using	  the	  G-­‐Box	  imaging	  system	  (Syngene,	  UK)	  set	  to	  automatically	  






	  2.11.	  Enzyme	  linked	  immunosorbance	  assay	  
	  
The	   InstantOne™	  STAT3	  phosphotyrosine	  705	  ELISA	  (eBiosciences,	  UK)	  was	  used	  to	  determine	  
the	  effectiveness	  of	  JAK	  and	  STAT	  inhibitors.	  The	  ELISA	  kit	  contained	  all	  the	  required	  sample	  and	  
lysis	  buffers	  and	  antibodies.	  HeLa.RC49	  cells	  were	  grown	  to	  95%	  confluence	  and	  harvested	  using	  
PBS	  containing	  25	  mM	  EDTA	  to	  give	  1x106	  cells.	  Cells	  were	  centrifuged	  at	  700	  g	  for	  5	  minutes	  
and	  resuspended	  in	  simple	  DMEM	  before	  treatment	  with	  10µM	  Stat	   inhibitors	  to	  final	  volume	  
of	  200	  µL.	  Controls	  cells	  were	  treated	  with	  the	  relevant	  concentration	  of	  DMSO	  vehicle	  and	  all	  
treatments	  were	  then	  incubated	  at	  37°C,	  5%	  CO2	  for	  30	  minutes.	  After	  incubation	  0.5	  µL	  of	  IL-­‐6	  
(40	  ng/mL)	  (Peprotech)	  was	  added	  to	  relevant	  cells	  and	  incubated	  for	  15min.	  Cells	  were	  washed	  
once	  in	  PBS	  and	  centrifuged	  at	  700	  g	  for	  5	  minutes	  and	  the	  supernatant	  was	  removed	  to	  leave	  a	  
pellet.	  50	  µL	  of	  the	  supplied	  1x	  lysis	  buffer	  was	  added	  to	  the	  pellet	  and	  aspirated	  to	  mix	  before	  
10	  minutes	   shaking	   at	   room	   temperature.	   50	   µL	   of	   the	   lysate	   was	   added	   to	   the	   ELISA	   plate	  
(except	  in	  –ve	  control	  wells)	  and	  50	  µL	  of	  the	  supplied	  antibody	  cocktail	  was	  added	  to	  the	  lysate	  
samples	   before	   shaking	   for	   1hr	   at	   140	   rpm.	   Samples	   were	   then	   washed	   3	   times	   with	   the	  
supplied	  wash	  buffer	  and	  100	  µL	  of	  pre-­‐equilibrated	  detection	   reagent	  was	  added	   to	  all	  wells	  
and	   incubated	  at	   room	  temperature	   for	  30	  minutes.	  100	  µL	  of	   the	  supplied	  stop	   reagent	  was	  
added	  to	  all	  well	  and	  the	  plate	  was	  read	  at	  450	  nm	  using	  a	  BMG	  Labtech	  micro	  plate	  reader.	  	  
	  
2.12.	  MTS	  cytotoxicity	  assay	  
The	  CellTiter	  96®	  AQueous	  Non-­‐Radioactive	  Cell	  Proliferation	  Assay	  (Promega)	  was	  used	  to	  
determine	  if	  compounds	  were	  cytotoxic.	  The	  assay	  is	  colourimetric	  and	  works	  on	  the	  principle	  
that	  healthy	  cells	  can	  metabolise	  [3-­‐(4,5-­‐dimethylthiazol-­‐2-­‐yl)-­‐5-­‐(3-­‐carboxymethoxyphenyl)-­‐2-­‐
(4-­‐sulfophenyl)-­‐2H-­‐tetrazolium	  (MTS)	  into	  its	  formazan	  product,	  which	  shows	  significantly	  
higher	  absorbance	  at	  490	  nm	  than	  the	  parent.	  	  2.5x105	  cells	  were	  used	  per	  well	  for	  the	  MTS	  
assay;	  cells	  were	  washed	  in	  PBS	  then	  made	  up	  the	  correct	  density	  so	  that	  100	  µL	  could	  be	  
placed	  in	  a	  96-­‐well	  plate.	  The	  relevant	  test	  compounds	  were	  added	  to	  the	  cells	  in	  duplicate	  the	  
samples	  were	  incubated	  at	  37°C,	  5%	  CO2	  for	  30	  minutes.	  10	  µL	  of	  the	  CellTiter	  96	  MTS	  solution	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  was	  added	  to	  the	  relevant	  wells	  (except	  background	  controls)	  and	  the	  plate	  was	  incubated	  for	  
5hr	  at	  after	  which	  the	  plate	  was	  read	  at	  490	  nm	  using	  a	  BMG	  Labtech	  Fluorostar	  microplate	  
reading	  fluorometer.	  	  
2.13.	  Curve	  prediction	  and	  statistical	  analysis 
All	   data	   were	   analysed	   using	   Graphpad	   Prism	   5	   and	   represent	   at	   least	   3	   independent	  
experiments	  (unless	  stated	  otherwise).	  For	  human	  PBL	  experiments	  individual	  donor	  cells	  were	  
used	  to	  perform	  3	   independent	  experiments	  and	  the	  mean	  result	  was	  taken	  as	  n=1,	  at	   least	  3	  
donors	  were	  used.	  All	  concentration	  response	  sigmoidal	  curves	  used	  to	  calculate	  EC50	  and	  IC50	  
values	  were	  fitted	  assuming	  a	  Hill	  coefficient	  of	  1.	  Statistical	  significance	  were	  determined	  using	  
unpaired	  students	  t-­‐tests	  where	  applicable	  or	  one-­‐way	  ANOVA	  analysis	  of	  variance	  followed	  by	  
Bonferroni	  multiple	   comparison	   post-­‐test	  where	   3	   or	  more	   data	   sets	  were	   to	   be	   analysed.	   A	  
significance	  value	  of	  95%	  was	  used	  with	  p	  values	  indicated	  as	  follows	  p≤0.05	  =	  *,	  p≤0.01	  =	  **,	  
p≤0.001	   =***.	   P	   values	   above	   0.05	  where	   therefore	   considered	   not	   significant	   (ns).	   All	   error	  











	  CHAPTER	   3:	   Determination	   of	   chemokine	   receptor	  




The	   immortalised	  monocytic	   leukaemia	   cell	   line	   THP-­‐1	   has	   been	   used	   widely	   as	   a	  model	   for	  
monocyte	   behaviour	   in	   in	   vitro	   assays	   and,	   despite	   some	   minor	   functional	   differences	   with	  
primary	   monocytes,	   has	   been	   validated	   as	   a	   model	   for	   several	   human	   diseases	   [214,	   215].	  
Proteomics	  analyses	  of	  THP-­‐1	  cells	  have	  revealed	  expression	  of	  numerous	  chemokine	  receptor	  
families	  and	  isotypes	  including	  CCR5	  [134,	  178,	  216-­‐219]	  (Table	  3.1).	  	  
	  
Table	  3.1:	  Chemokine	  receptors	  expressed	  in	  THP-­‐1	  cells	  







CCR2	   Western	  Blotting	   [178,	  216]	  
CCR5	   Western	  blotting	   [134,	  219]	  
CXCR4	   Western	  blotting	   [134,	  220]	  
	  
Due	  to	  the	  validity	  of	  the	  cell	  line	  as	  a	  model	  for	  disease,	  the	  fact	  that	  it	  is	  widely	  validated	  in	  in	  
vitro	  chemotaxis	  assay	  and	  the	  fact	  that	  they	  express	  high	  levels	  of	  CCR5,	  THP-­‐1	  cells	  were	  used	  
as	   the	   primary	  model	   system	   to	   investigate	   CCR5	  mediated	   signalling	   events	   associated	  with	  
migration	   stimulated	   by	   CCL3,	   4	   and	   5.	   Specific	   chemokine	   receptor	   signalling	   stimulated	   by	  
chemokines	  can	  be	  difficult	  to	  isolate	  however,	  due	  to	  the	  propensity	  of	  chemokines	  to	  either	  
share	  more	   than	  one	   receptor	   [28,	  221]	  or	   for	  activated	   receptors	   to	   transactivate	  dimeric	  or	  
arrayed	  partners	   [84].	   For	   this	   reason,	   proteomic	   receptor	   identification	   alone	   cannot	  predict	  
THP-­‐1	   cellular	   responses	   to	   chemokines	   let	   alone	   attribute	   these	   responses	   to	   specific	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  receptors.	   Therefore	   it	   is	   important	   to	   identify	   THP-­‐1	   cellular	   response	   to	   CCL3/4/5	   and	   then	  
determine	  whether	   the	  responses	  specific	   to	  CCR5	  can	  be	  determined	  experimentally,	   so	   that	  
clear	  conclusions	  about	  the	  role	  of	  the	  individual	  receptors	  in	  chemotaxis	  can	  be	  reached.	  	  
	  
The	   production	   of	   high	   affinity	   chemokine	   receptor	   antagonists,	   such	   as	   the	   CCR5	   inhibitor	  
maraviroc	   and	   the	  CCR1	   antagonist	   J113863	   allows	   the	   inhibition	   of	   specific	   receptors	   during	  
stimulation	  with	  chemokines.	  The	  fact	  that	  chemokines	  are	  usually	  specific	  to	  a	  small	  number	  of	  
well-­‐characterised	   intra-­‐motif	   chemokine	   receptor	   types	   should	   allow	   a	   functional	   profile	   of	  
cellular	   responses	   to	   specific	   chemokines	   to	   be	   determined	   and	   compared	   to	   receptor	   types	  
present	   on	   the	   cell	   surface.	   If,	   for	   example,	   the	   use	   of	   CCR1	   antagonists	   allows	   signalling	  
through	   CCR5	   receptors	   to	   occur	   normally,	   then	   these	   antagonists	   can	   be	   used	   in	   all	   future	  
experimentation	  to	  ensure	  that	  only	  CCR5	  specific	  responses	  are	  observed.	  
	  
3.2.	  Chapter	  Aims	  
	  
In	   order	   to	   determine	   which	   characteristics	   of	   THP-­‐1	   cellular	   responses	   can	   be	   attributed	   to	  
CCR5	   signalling,	   analysis	   of	   responses	   in	   calcium	   flux	   and	   chemotaxis	   assays	   to	   a	   range	   of	  
different	  chemokines	  can	  be	  determined.	  When	  these	  assays	  are	  performed	  in	  the	  presence	  of	  
CCR1	  and	  CCR5	  receptor	  antagonists,	  then	  any	  observed	  alterations	  in	  cellular	  responses	  can	  be	  
noted.	   The	   results	   of	   these	   experiments	   will	   allow	   conclusions	   to	   be	   drawn	   as	   to	   whether	  
further	  experimental	  data	  can	  be	   related	   to	  CCR5	  specific	  events.	  The	  experimentation	   in	   the	  
presence	  of	   other	   chemokine	   receptor	   antagonists	  will	   be	   used	   to	   determine	   if	   CCR5	   specific	  
signalling	  can	  be	  isolated.	   If	  this	   is	  the	  case	  this	  will	  simplify	  the	  analysis	  of	  receptor	  mediated	  







	  3.3.	  Results	  
	  
3.3.1:	  	  The	  determination	  of	  basal	  responses	  to	  CCL3	  stimulation	  	  
	  
	  
Figure	  3.1:	  THP-­‐1	  cells	  express	  CCR5	  and	  undergo	  calcium	  release	  upon	  CCL3	  stimulation.	  (a)	  
Western	  blotting	  reveals	  THP-­‐1,	  HeLa.RC49	  and	  CHO.CCR5	  cells	  express	  the	  38	  kD	  GPCR	  CCR5	  
(characteristic	   double	   band	   shown).	   (b)	   Concentration	   response	   curve	   for	   increasing	  
concentrations	   of	   CCL3	   stimulating	   intracellular	   calcium	   release	   in	   THP-­‐1,	   Hela.RC49	   and	  




	  The	   model	   cell	   lines	   used	   in	   this	   thesis	   express	   CCR5	   either	   endogenously	   or	   are	   stably	  
transfected	   to	   express	   the	   CC-­‐motif	   chemokine	   receptor	   CCR5	   as	   determined	   by	   western	  
blotting	  (Figure	  3.1a).	  The	  38	  kD	  GPCR	  was	  identified	  with	  HEK/1/85a/7a	  rat	  anti-­‐CCR5	  Ab	  and	  
showed	  two	  bands	  which	  are	  generally	  associated	  with	  a	  monomeric	  and	  a	  dimerised	  form	  of	  
the	  receptor	  [6].	  The	  β-­‐chemokine	  receptor	  ligand	  CCL3,	  which	  is	  known	  as	  a	  CCR5	  agonist	  but	  
has	   also	  been	   shown	   to	   activate	  CCR1	   [28],	   induces	   calcium	   release	   in	   THP-­‐1,	  HeLa.RC49	  and	  
CHO.CCR5	  cells	  in	  a	  concentration	  dependent	  fashion	  (Figure	  3.1b).	  The	  EC50	  for	  calcium	  release	  
in	  this	  system	  was	  determined	  by	  sigmoidal	  concentration-­‐response	  regression	  (assuming	  a	  Hill	  
co-­‐efficient	  of	  1,	  see	  methods	  and	  materials)	  and	  calculated	  as	  EC50	  =	  40.0±6.2	  nM.	  Since	  CCL3	  
activates	  both	  CCR5	  and	  CCR1,	   and	  both	   receptors	   are	  present	  on	  THP-­‐1	   cells,	   the	   calculated	  
EC50	  must	  be	  taken	  as	  representative	  of	  the	  combined	  action	  of	  these	  receptors.	  	  
	  
The	   Chemo-­‐TX	   transwell	   chemotaxis	   assay	   was	   used	   to	   determine	   the	   migration	   response	  
induced	  by	  CCL3	  stimulation.	  THP-­‐1	  cells	  migrated	   towards	  a	   stimulus	  of	  CCL3	  with	  maximum	  
migration	   occurring	   at	   1	   nM	   CCL3	   (Figure	   3.2a).	   The	   migration	   response	   seen	   is	   typical	   of	  
migrating	  cells	  activated	  via	  chemokines,	  with	  chemotaxis	  being	  concentration	  dependent	  up	  to	  
an	  optimal	  level	  then	  dropping	  of	  steeply	  with	  further	  increases	  in	  stimulus	  [13,	  39].	  It	  was	  also	  
noted	  that	  non-­‐stimulated,	  or	  basal,	  migration	  always	  occurred,	  and	  was	  consistent	  at	  around	  
30x104mL-­‐1	  cells	   in	  all	  assays	  performed.	  Basal	  migration	   is	   important	  to	  consider	   in	  migration	  
assays	   as	   it	   can	   provide	   information	   about	   non-­‐specific	   effects	   of	   treatments.	   DMSO	   is	   the	  
primary	  vehicle	  for	  most	  inhibitors	  used	  in	  the	  thesis,	  so	  the	  effects	  of	  DMSO	  concentration	  on	  
stimulated	  THP-­‐1	  cell	  migration	  were	  determined.	  DMSO	  has	  been	  shown	  to	  affect	  viability	  and	  
protein	   expression	   levels	   at	   concentrations	   above	   1%	   v/v	   (personal	   communication	   from	   Dr	  
O’Connells	   research	   group)	   when	   incubated	   with	   cells	   for	   longer	   periods	   of	   time,	   but	   in	   the	  
5.5hr	  exposure	  of	  the	  migration	  assay	  concentrations	  up	  to	  2.5%	  v/v	  had	  no	  significant	  effect.	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Figure	   3.2:	   THP-­‐1	   cells	   migrate	   towards	   CCL3	   in	   the	   Neuroprobe	   Chemo-­‐TX	   transwell	  
chemotaxis	  assay.	  (a)	  Migration	  of	  THP-­‐1	  cells	  towards	  CCL3	  is	  concentration	  dependent	  up	  to	  
a	  peak	  chemotaxis	  at	  1	  nM.	  	  (b)	  Concentrations	  of	  inhibitor	  vehicle	  DMSO	  significantly	  affect	  
the	   ability	   of	   THP-­‐1	   to	   migrate	   towards	   1	   nM	   CCL3	   at	   levels	   at	   and	   above	   2.5%	   v/v	  
concentration	   (p≤0.01	   n≥3).	   Results	   represent	   the	   mean	   ±	   SEM	   of	   at	   least	   3	   independent	  




	  Increases	  in	  protein	  expression	  are	  unlikely	  to	  affect	  THP-­‐1	  migration,	  with	  the	  duration	  of	  the	  
assay	  being	  shorter	  than	  the	  time	  frame	  for	  protein	  synthesis.	  At	  5%	  v/v	  DMSO	  begins	  to	  affect	  
migration	   in	   THP-­‐1	   cells	   and	   significantly	   reduces	   the	   ability	   of	   the	   cells	   to	   migrate.	   Vehicle	  
doses	  of	  DMSO	  were	  therefore	  kept	  at	  0.1%	  or	  below	  where	  possible	  but,	  when	  necessary	  2.5%	  
DMSO	  can	  be	  used	  as	  shown	  above.	  	  
	  
3.3.2.	   Inhibition	   of	   CCR5	  with	   the	   potent	   CCR5	   antagonist	  maraviroc	   does	   not	   inhibit	   CCL3	  
stimulated	  calcium	  release	  in	  THP-­‐1	  cells	  
	  
Maraviroc	  has	  been	  shown	  to	  inhibit	  chemokine	  induced	  signalling	  in	  a	  CCR5	  expressing	  HEK	  cell	  
line	   as	   stimulated	  by	  CCL3,	   CCL4	   and	  CCL5	  with	   an	   IC50	   ≤30	  nM	   [11].	   Pre-­‐treatment	   of	   THP-­‐1	  
cells	  with	  100	  nM	  maraviroc	  did	  not	  affect	  the	  EC50	  of	  CCL3	  for	  calcium	  release,	  which	  can	  be	  
calculated	   as	   25.7±5.4	   nM	   for	   CCL3	   vs.	   7.73±0.307	   for	   maraviroc	   treated	   cells	   (Figure	   3.3a).	  
Conversely	   100	   nM	  maraviroc	   completely	   inhibits	   THP-­‐1	   cell	   migration	   towards	   CCL3	   (Figure	  
3.3b.)	   (unpaired	   t-­‐test,	   p<0.05).	   These	   data	   therefore	   suggest	   that	   either	   CCL3	   stimulated	  
calcium	   release	   occurs	   completely	   via	   activation	   of	   CCR1	   or	   that	   maraviroc	   is	   not	   a	   neutral	  
antagonist	  CCR5	  in	  certain	  cellular	  assays.	  	  
	  
To	   further	   qualify	   receptor	  mediated	   responses,	   β-­‐chemokine	   ligand	   CCL4,	  which	   shows	   high	  
affinity	  toward	  CCR5	  [42]	  but	  no	  significant	  	  interaction	  with	  CCR1	  in	  its	  natural	  form	  [222],	  was	  
used	  to	  stimulate	  calcium	  release	  in	  THP-­‐1	  cells.	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Figure	  3.3:	  CCR5	  antagonist	  maraviroc	  does	  not	  inhibit	  CCL3	  stimulated	  calcium	  flux	  in	  THP-­‐1	  
cells	   but	   does	   block	   migration.	   (a)	   Concentration	   response	   curves	   for	   increasing	  
concentrations	  of	  CCL3	  stimulating	  intracellular	  calcium	  release	  in	  THP-­‐1	  treated	  with	  100	  nM	  
maraviroc.	  (b)	  Maraviroc	  significantly	  reduces	  THP-­‐1	  migration	  towards	  1	  nM	  CCL3	  (Data	  from	  
C.	   Moyano	   Cardaba).	   Results	   represent	   the	   mean	   ±	   SEM	   of	   at	   least	   3	   independent	  
experiments.	  (Unpaired	  t-­‐test,	  ns	  	  p>0.05,	  *	  p<0.05).	  
	  
The	   concentration	   response	   for	   calcium	   release	   (Figure	   3.4a)	   shows	   no	   marked	   difference	  
between	   treatments	  with	   the	  calculated	   	  EC50	  of	  CCL4	  which	   is	  62.7±8.8	  nM	  for	  untreated	  vs.	  
45.6±6.1	  nM	  for	  maraviroc	  treated	  cells.	  An	  unpaired	  t-­‐test	  showed	  stimulation	  at	  75	  nM	  CCL4	  
stimulation	   was	   not	   significantly	   different	   between	   treated	   and	   untreated	   cells.	   These	   data	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  clearly	  show	  that	  CCR5	  signalling	  via	  CCL4	  can	  stimulate	  calcium	  release	  and	  also	  that	  maraviroc	  
is	  unable	  to	  antagonise	  CCR5	  signalling	  to	  calcium	  release	  in	  THP-­‐1	  cells.	  
	  
	  
Figure	  3.4:	  CCR5	  antagonist	  maraviroc	  does	  not	  inhibit	  CCL4	  stimulated	  calcium	  flux	  in	  THP-­‐1	  
cells.	   (a)	   Concentration	   response	   curve	   for	   increasing	   concentrations	   of	   CCR5	   ligand	   CCL4	  
stimulating	   intracellular	   calcium	   release	   in	   THP-­‐1	   cells	   treated	   with	   100	   nM	  maraviroc.	   (b)	  
Maraviroc	  inhibition	  does	  not	  significantly	  affect	  THP-­‐1	  calcium	  release	  stimulated	  by	  75	  nM	  




Figure	  3.5:	  CCR5	  antagonist	  maraviroc	  does	  not	  inhibit	  CCL2	  stimulated	  calcium	  flux	  in	  THP-­‐1	  
cells.	   (a)	   Concentration	   response	   curve	   for	   increasing	   concentrations	   of	   CCR2	   ligand	   CCL2	  
stimulating	   intracellular	   calcium	   release	   in	   THP-­‐1	   cells	   treated	   with	   100	   nM	  maraviroc.	   (b)	  
Maraviroc	  inhibition	  does	  not	  significantly	  affect	  THP-­‐1	  cell	  calcium	  release	  stimulated	  by	  75	  
nM	  CCL2.	  Results	  represent	  the	  mean	  ±	  SEM	  of	  at	  least	  3	  independent	  experiments.	  (Unpaired	  






	  CCR2	  and	  CCR5	  share	  a	  high	  sequence	  homology	  compared	  with	  other	  receptors	  in	  the	  CC	  motif	  
α-­‐chemokine	  receptor	  family.	  Although	  CCR2	  ligand	  CCL2	  shows	  low	  activity	  towards	  CCR5	  [223]	  
and	   CCR5	   ligands	   show	   no	   activity	   against	   CCR2;	   CCR2-­‐CCR5	   heterodimerisation	   and	  
transactivation	   is	   well	   characterised	   [84].	   To	   determine	   if	   CCR5	   inhibition	   had	   any	   effect	   on	  
CCR2	  activation	  in	  THP-­‐1	  cells	  pre-­‐treated	  with	  maraviroc	  (100	  nM)	  were	  stimulated	  with	  CCL2.	  
It	  should	  be	  noted	  that	  CCL2	  has	  been	  shown	  to	  bind	  to	  CCR1	  [224],	  however	  this	  interaction	  is	  
unable	  to	  induce	  migration	  and	  induces	  calcium	  release	  at	  1µM	  CCL2	  treatment	  [225].	  For	  these	  
reasons	  CCL2	  activation	  of	  CCR1	  is	  not	  likely	  under	  the	  test	  conditions	  and	  does	  not	  need	  to	  be	  
accounted	  for.	  	  	  
	  
The	  concentration	  response	  for	  CCL2	  stimulated	  calcium	  release	  (Figure	  3.5a)	  was	  unaffected	  by	  
maraviroc,	   with	   calculated	   EC50	   values	   of	   40.3±9.3	   nM	   for	   the	   control	   vs.	   47.2±4.1	   nM	   for	  
maraviroc	   treated	   cells.	   The	   level	   of	   calcium	   release	   stimulated	   at	   75nM	   CCL2	   was	   also	   not	  
significantly	   different	   (Figure	   3.5b)	   (unpaired	   t-­‐test	   p>0.05).	   These	   data	   show	   that	   CCR2	  
receptors	  are	  present	  and	   functional	  on	  THP-­‐1	  cells	  and	  that	  maraviroc	  has	  no	  effect	  on	  their	  
stimulation	  with	   CCL2.	   CCR5	   specific	   signalling	  was	   determined	   by	   stimulation	  with	   CCL4	   but	  
maraviroc	   was	   unable	   to	   affect	   this	   interaction.	   CCL3	   stimulated	   calcium	   release	   was	   also	  
unaffected	   by	  maraviroc	   treatment	   but	   because	   CCL3	   also	   signals	   through	   CCR1,	   the	   lack	   of	  
inhibition	  by	  maraviroc	   suggests	   that	  CCL3	  only	  acts	   through	  CCR1	   in	  THP-­‐1	   cells.	   To	   test	   this	  
idea	  further	  CCR1	  antagonist	  J113863	  was	  used	  in	  conjunction	  with	  CCL3	  stimulation.	  The	  CCR1	  
inhibitor	   was	   used	   at	   an	   excess	   concentration	   to	   ensure	   that	   100%	   of	   CCR1	   signalling	   was	  









	  3.3.3.	   The	   potent	   CCR1	   antagonist	   J113863	   significantly	   inhibits	   CCL3	   stimulated	   calcium	  
release	  in	  THP-­‐1	  but	  does	  not	  affect	  CCL3	  EC50	  
	  
	  
Figure	  3.6:	  CCR1	  antagonist	  J113863	  significantly	  inhibits	  CCL3	  stimulated	  calcium	  flux	  in	  THP-­‐
1	   cells.	   (a)	   Concentration	   response	   curve	   for	   increasing	   concentrations	   of	   CCL3	   stimulating	  
intracellular	  calcium	  release	  in	  THP-­‐1	  cells	  treated	  with	  10	  µM	  J113863.	  (b)	  J113863	  inhibition	  
significantly	   affects	   THP-­‐1	   cell	   calcium	   release	   stimulated	  by	  75	  nM	  CCL3.	  Results	   represent	  
the	  mean	  ±	  SEM	  of	  at	  least	  3	  independent	  experiments.	  (*	  indicates	  p≤0.05	  n≥3	  compared	  to	  




	  J113863	  is	  a	  highly	  potent	  low	  nanomolar	  IC50	  antagonist	  for	  CCR1	  [226]	  and	  is	  inactive	  against	  
CCR2	  and	  CCR5	  [227].	  THP-­‐1	  cells	  pre-­‐treated	  with	  10	  µM	  J113863	  showed	  no	  significant	  shift	  in	  
CCL3	  EC50	  (29.6±6.7	  nM	  for	  control	  vs.	  37.8±8.7	  for	  J113863	  treated	  cells	  (Figure	  3.6a)).	  Treated	  
THP-­‐1	  cells	  did	  show	  a	  significant	  reduction	  in	  calcium	  release	  of	  ≈50%	  (unpaired	  t-­‐test	  p≤0.05	  
vs.	  control)	  (Figure	  R6b),	  demonstrating	  that	  CCR1	  was	  responsible	  for	  at	   least	  some	  signalling	  
to	   calcium	   release	   stimulated	   by	   CCL3.	   The	   peak	   CCL3	   efficacy	   for	   was	   46±10	   %	   lower	   for	  
J113863	   treated	   THP-­‐1	   cells	   based	   on	   predictions	   from	   the	   sigmoidal	   concentration	   response	  
curve.	  The	  concentration	  of	  J113863	  used	  was	  1000	  times	  higher	  than	  was	  necessary	  according	  
to	   the	   IC50	   however,	   and	   should	   have	   completely	   inhibited	   all	   signalling	   were	   CCR1	   the	   only	  
receptor	  being	  activated.	  These	  data	  provided	  evidence	   that	  CCL3	  was	  acting	   though	  CCR1	   (≈	  
50%)	  and	  another	  receptor,	  which	  the	   literature	  and	  proteomics	  analysis	   (Figure	  3.1a)	  suggest	  
might	  be	  CCR5.	  
	  
CCL3	   interacts	   with	   only	   CCR1	   and	   CCR5,	   so	   treatment	   of	   THP-­‐1	   cells	   simultaneously	   with	  
J113863	   and	   maraviroc	   should	   completely	   inhibit	   calcium	   release.	   THP-­‐1	   cells	   treated	   with	  
100nM	  maraviroc	   +	   10µM	   J113863	   show	   a	   rise	   in	   calcium	   in	   response	   to	   CCL3	   (Figure	   3.7a)	  
although	  at	  ≈50%	  efficacy	  at	  75	  nM	  CCL3	  (Figure	  3.7b)	  which	  represents	  the	  same	  reduction	  in	  
signalling	   seen	   with	   J113863	   treatment	   alone.	   	   These	   data	   suggest	   that	   either	   maraviroc	  
potentially	  is	  not	  functioning	  as	  an	  antagonist	  in	  this	  system	  or	  it	  could	  be	  reflection	  of	  agonistic	  





Figure	   3.7:	   A	   combination	   of	   maraviroc	   and	   J113863	   significantly	   reduces	   CCL3	   stimulated	  
calcium	  release	  in	  THP-­‐1	  cells.	  a)	  Concentration	  response	  curve	  for	  increasing	  concentrations	  
of	  CCL3	   stimulating	   intracellular	   calcium	   release	   in	  THP-­‐1	   treated	  with	  both	  10	  µM	   J113863	  
(J113)	   &	   100	   nM	   maraviroc	   (Mara).	   (b)	   J113+Mara	   inhibition	   significantly	   affects	   THP-­‐1	  
calcium	   release	   stimulated	  by	  75	  nM	  CCL3.	  Results	   represent	   the	  mean	  ±	   SEM	  of	   at	   least	   3	  







Figure	   3.8:	   CCR1	   antagonist	   J113863	   does	   not	   inhibit	   CCL3	   stimulated	   calcium	   flux	   in	  
HeLa.RC49.	   (a)	   Concentration	   response	   curve	   for	   increasing	   concentrations	   of	   CCL3	  
stimulating	  intracellular	  calcium	  release	  in	  HeLa.RC49	  treated	  with	  10	  µM	  J113863	  (J113).	  (b)	  
J113	   inhibition	   does	   not	   significantly	   affect	   calcium	   release	   stimulated	   by	   75	   nM	   CCL3	  
compared	   with	   untreated	   control.	   Results	   represent	   the	   mean	   ±	   SEM	   of	   at	   least	   3	  
independent	  experiments.	  (Unpaired	  t-­‐test,	  p>0.05).	  
	  
The	   adherent	   cell	   line	   HeLa.RC49	   is	   stably	   transfected	   with	   CCR5	   and	   shows	   high	   levels	   of	  
receptor	   expression	   (Figure	   3.1a)	   and,	   as	   the	   cells	   are	   fibroblasts,	   negligible	   CCR1	   expression	  
was	  expected.	  Treatment	  of	  HeLa.RC49	  with	  10	  µM	  J113863	  did	  not	  alter	   the	  EC50	  of	   calcium	  
release	  significantly	  for	  CCL3	  induced	  signalling	  nor	  did	  it	  affect	  the	  response	  at	  75	  nM	  for	  cells	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  stimulated	  with	  CCL3	   (Figure	  3.8).	  These	  data	  clearly	   indicate	   that	  CCL3	  can	  stimulate	  calcium	  




Figure	   3.9:	   CCR1	   antagonist	   J113863	  does	   not	   inhibit	   CCL2	   stimulated	   calcium	   flux	   in	   THP-­‐1	  
cells.	   (a)	   Concentration	   response	   curve	   for	   increasing	   concentrations	   of	   CCR2	   ligand	   CCL2	  
stimulating	   intracellular	  calcium	  release	   in	  THP-­‐1	  cells	  treated	  for	  0.5hr	  with	  10	  µM	  J113863	  
prior	   to	   assay.	   (b)	   J113863	   inhibition	   does	   not	   significantly	   affect	   THP-­‐1	   cellular	   calcium	  
release	   stimulated	   by	   75	   nM	   CCL2.	   Results	   represent	   the	   mean	   ±	   SEM	   of	   at	   least	   3	  
independent	  experiments.	  (Unpaired	  t-­‐test.	  ns	  =	  not	  significant	  p>0.05,	  n=3).	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  J113863	   did	   not	   significantly	   affect	   ‘non-­‐target’	   chemokine	   receptor	   signalling	   in	   HeLa.RC49	  
cells	   but	   to	   determine	   whether	   this	   observation	   was	   true	   in	   THP-­‐1	   cells	   the	   effect	   of	   pre-­‐
treatment	   with	   J113863	   (10µM)	   on	   CCL2	   stimulated	   calcium	   release	   was	   determined.	   Pre-­‐
treated	   cells	   showed	   a	   non-­‐significant	   (unpaired	   t-­‐test	   p>0.05)	   trend	   towards	   decreased	  
signalling	  stimulated	  by	  CCL2	  (Figure	  3.9).	  Whilst	  this	  trend	  may	  be	  explained	  by	  the	  inhibition	  
of	   CCR1-­‐CCR2	   heterodimer	   signalling	   a	   simpler	   explanation	   is	   that	   some	   cytotoxicity	   or	   non-­‐
specific	   disruption	   is	   being	   induced	  by	  high	   inhibitor	   concentrations.	   This	   is	   supported	  by	   the	  
fact	  that	  THP-­‐1	  cells	  are	  known	  to	  be	   less	  resilient	  than	  the	   immortalised	  adherent	  fibroblasts	  
such	   as	   HeLa	   and	   CHO	   cells	   [228].	   The	   non-­‐significant	   decrease	   in	   CCR2	   stimulated	   calcium	  
release	   was	   also	   too	   low	   to	   explain	   the	   results	   seen	   with	   CCL3	   stimulation	   (Figure	   3.6.)	  




















	  3.3.4.	  Maraviroc	  stimulates	  calcium	  release	  in	  THP-­‐1	  cells	  
	  
	  
Figure	  3.10:	  Maraviroc	  behaves	  as	  an	  agonist	   in	  THP-­‐1	  cell	   calcium	  flux	  assay	  by	  stimulating	  
calcium	   release.	   (a)	   Stimulation	   of	   THP-­‐1	   cells	   with	   CCR1	   antagonist	   J113863	   has	   no	  
concentration	  dependent	   effect	   on	   THP-­‐1	   intracellular	   calcium	   release.	   (b)	   Stimulation	  with	  
maraviroc	  (M)	  stimulates	  intracellular	  calcium	  flux	  in	  a	  concentration	  dependent	  fashion	  with	  
300-­‐1000	   nM	   stimulation	   not	   significantly	   different	   from	   75	   nM	   CCL3	   (One-­‐way	   ANOVA,	  
Bonferroni	  multiple	  comparison.	  p>0.05	  n	  =	  4).	  Results	  represent	  the	  mean	  ±	  SEM	  of	  at	  least	  3	  
independent	  experiments.	  
	  
Because	   J113863	   was	   shown	   not	   to	   be	   interfering	   with	   non-­‐specific	   receptor	   activation	   the	  
remaining	   explanation	   for	   the	   observed	   lack	   of	   CCR5	   signalling	   inhibition	  was	   that	  maraviroc	  
was	   stimulating	   calcium	   release	   in	   THP-­‐1	   cells.	   To	   test	   this	   hypothesis,	   THP-­‐1	   cells	   were	  
stimulated	   with	   increasing	   concentrations	   of	   J113863	   and	   maraviroc	   (Figure	   3.10)	   and	   the	  
resulting	  calcium	  flux	  was	  compared	  with	  control	  cells	  stimulated	  only	  with	  75	  or	  100	  nM	  CCL3,	  
respectively.	  Although	  J113863	  had	  a	  minor	  effect	  on	  calcium	  release,	  the	  ratio	  of	  fluorescence	  
intensity	  remained	  significantly	   lower	  than	  that	  seen	  with	  the	  75	  nM	  CCL3	  in	  control	  cells	  and	  
did	  not	  show	  any	  kind	  of	  concentration	  dependent	  relationship.	  Maraviroc,	  on	  the	  other	  hand,	  
was	   able	   to	   stimulate	   calcium	   release	   in	   THP-­‐1	   cells;	   stimulation	   with	   concentrations	   of	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  maraviroc	  of	  300	  nM	  and	  above	   induced	  a	  concentration	  dependent	  calcium	  release	  that	  was	  
not	  significantly	  lower	  than	  that	  achieved	  with	  75nM	  CCL3	  in	  control	  cells.	  These	  data	  indicate	  
that	  the	  allosteric	  CCR5	  inhibitor	  maraviroc	  acts	  as	  an	  agonist	  on	  THP-­‐1	  cells	  for	  calcium	  release.	  
However,	   whether	   this	   is	   via	   direct	   stimulation	   of	   CCR5	   or	   via	   a	   ‘non-­‐specific’	   cell	   type	  
dependent	  mechanism	  cannot	  be	  said.	  It	  has	  been	  shown	  that	  maraviroc	  can	  successfully	  inhibit	  
CCR5	   mediated	   calcium	   release	   in	   other	   cell	   lines	   [11]	   so	   the	   latter	   may	   be	   the	   better	  
explanation.	   CCR5	   signalling	   has	   been	   shown	   to	   be	   function	   differently	   in	   THP-­‐1	   cells	   than	   in	  
adherent	   fibroblasts	   particularly	   in	   response	   to	   alterations	   in	   membranes	   fluidity.	   Cell	   type	  
specific	   differences	   in	   CCR5	   signalling	   may	   explain	   the	   effect	   of	   maraviroc	   but	   this	   does	   not	  
change	  the	  fact	  that	  the	  inhibitor	  is	  not	  suitable	  for	  use	  in	  THP-­‐1	  where	  calcium	  release	  is	  to	  be	  
measured.	  	  
	  
3.3.5.	  Analysis	  of	  CC	  motif	  chemokine	  receptor	  activation	  and	  chemotaxis	  in	  THP-­‐1	  cells	  	  
	  
The	   experimentation	   with	   CCL3	   induced	   calcium	   release	   revealed	   an	   unexpected	   agonistic	  
effect	   of	   maraviroc	   at	   high	   antagonist	   concentration.	   There	   are	   reasons	   to	   believe	   that	   the	  
effect	  of	  maraviroc	  may	  be	  limited	  to	  calcium	  release	  in	  THP-­‐1	  cells	  and	  the	  inhibitor	  may	  still	  be	  
of	   use	   in	   clarifying	   chemokine	   receptor	   activated	   chemotaxis.	   Firstly	   our	   research	   group	   has	  
already	   shown	   that	   100	   nM	   inhibits	   THP-­‐1	   chemotaxis	   towards	   1	   nM	   CCL3	   (unpublished	  
observation)	  and	  secondly	  CCR5	  mediated	  calcium	  release	  and	  chemotaxis	  are	   independent	   in	  
THP-­‐1	   cells	   as	   shown	   by	   Cardaba	   et	   al.	   [75].	   With	   these	   facts	   in	   mind	   it	   was	   important	   to	  
determine	   if	   CCL3	  mediated	   chemotaxis	   could	   be	   attributed	   to	   a	   specific	   receptor	   and	   if	   the	  





Figure	  3.11:	  Inhibition	  of	  CCR1	  reduces	  THP-­‐1	  cell	  migration	  towards	  1	  nM	  CCL3	  to	  sub-­‐basal	  
levels.	   0.5hr	   Pre-­‐treatment	   of	   THP-­‐1	   cells	   with	   10	   µM	   J113863	   significantly	   reduces	   THP-­‐1	  
chemotaxis	   stimulated	   by	   CCL3	   to	   sub	   basal	   levels	   (One-­‐way	   ANOVA,	   Bonferroni	   multiple	  
comparison.	  ***	  =	  p≤0.001	  n≥3).	  Results	  represent	  the	  mean	  ±	  SEM	  of	  at	  least	  3	  independent	  
experiments.	  
	  
Treatment	   of	   THP-­‐1	   cells	   with	   10	   µM	   J113863	   was	   used	   to	   determine	   the	   role	   of	   CCR1	   in	  
chemotaxis	   stimulated	   by	   1	   nM	   CCL3	   (Figure	   3.11).	   Chemotaxis	   was	   significantly	   reduced	   to	  
below	   unstimulated	   (basal)	   levels	   (one	   way	   ANOVA	   followed	   by	   Bonferroni	   multiple	  
comparison,	   p≤0.001	   vs.	   stimulated	   vehicle	   control).	   Stimulated	   control	   cells	   migrated	  
significantly	  higher	  than	  unstimulated	  control	  (p≤0.001)	  but	  a	  distinct	  trend	  towards	  reduction	  
was	   also	   observed	   in	   basal	   migration	   of	   cells	   treated	   with	   J113863	   compared	   with	   vehicle	  
controls	  although	  this	  was	  deemed	  to	  be	  not	  significant	   (p>0.05).	  Considering	  that	  chemokine	  
receptor	   agonists	   target	   the	   extracellular	  membrane	   and	  would	   not	   be	   expected	   to	   interfere	  
with	  basal	  migration	  this	  came	  as	  a	  surprise	  and	   indicated	  that	  the	   inhibitor	  maybe	  disrupting	  
migration	   in	  an	  non-­‐specific	   fashion	  as	  postulated	   for	  CCL2	  stimulated	  calcium	  release	   (Figure	  
3.9).	  	  To	  test	  this	  hypothesis	  THP-­‐1	  cell	  migration	  was	  tested	  against	  decreasing	  concentrations	  
of	  J113863.	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Figure	   3.12:	   J113863	   significantly	   inhibits	   THP-­‐1	   cell	   chemotaxis	   towards	   1	   nM	   CCL3	   at	  
concentrations	  down	  to	  1	  nM.	  THP-­‐1	  cells	  pre-­‐treated	  for	  0.5hr	  with	  J113863	  at	  500,	  10	  and	  1	  
nM	   all	   show	   significant	   inhibition	   of	   migration	   down	   to	   and	   below	   basal	   levels.	   Results	  
represent	   the	   mean	   ±	   SEM	   of	   at	   least	   3	   independent	   experiments.	   (One-­‐way	   ANOVA,	  
Bonferroni	  multiple	  comparison.	  ***Indicates	  p≤0.001	  vs.	  vehicle	  n≥3).	  
	  
THP-­‐1	  pre-­‐treated	  with	  500,	  10	  and	  1	  nM	  J113863	  showed	  a	  significant	  reduction	  in	  migration	  
(p≤0.001)	  compared	  to	  vehicle	  control	  (Figure	  3.12).	  At	  500	  nM	  basal	  migration	  of	  treated	  cells	  
was	  still	   lower	  than	  vehicle	  basal	  but	  basal	  treated	  migration	  was	  restored	  to	  control	   levels	  at	  
10	   and	   1	   nM	   treatments.	   Surprisingly	   the	   reduction	   in	   chemotaxis	   towards	   CCL3	   at	   1	   nM	  
J113863,	  which	  represents	  the	  calculated	  IC50	  [227],	  was	  not	  significantly	  different	  from	  vehicle	  
basal	  migration	  (p>0.05).	  To	  determine	  if	  the	  effect	  of	  J113863	  treatment	  was	  specific	  to	  CCL3	  
stimulation	  THP-­‐1	  cells	  treated	  the	  same	  decreasing	  concentrations	  of	  J113863	  were	  stimulated	  





Figure	   3.13:	   J113863	   significantly	   inhibits	   THP-­‐1	   cell	   chemotaxis	   towards	   1	   nM	   CCL4	   at	  
concentrations	  down	  to	  1	  nM.	  THP-­‐1	  cells	  pre-­‐treated	  for	  0.5hr	  with	  J113863	  at	  10	  µM,	  500,	  
10	   and	   1	   nM	   all	   show	   significant	   inhibition	   of	   migration	   down	   to	   and	   below	   basal	   levels.	  
Results	  represent	  the	  mean	  ±	  SEM	  of	  at	  least	  3	  independent	  experiments.	  (One-­‐way	  ANOVA,	  
Bonferroni	  multiple	  comparison.***Indicates	  p≤0.001	  vs.	  vehicle	  n≥3).	  
	  
As	  with	  CCL3	  stimulation	  the	  four	  pre-­‐treatment	  concentrations	  of	  J113863	  (10	  µM,	  500,	  10	  and	  
1	   nM)	   all	   significantly	   reduced	   THP-­‐1	   chemotaxis	   (Figure	   3.13)	   (p≤0.001,	   n≥3).	   The	   level	   of	  
reduction	  at	  10	  µM	  and	  500	  nM	  was	  significantly	  lower	  than	  basal	  migration	  in	  untreated	  cells	  
and	  basal	  migration	  in	  treated	  cell	  was	  also	  significantly	  lower	  than	  control	  basal	  (p≤0.001).	  As	  
with	   CCL3	   stimulation,	   a	   recovery	   of	   basal	   migration	   occurred	   at	   10	   and	   1	   nM	   J113863	  
treatment	  (p>0.05	  vs.	  control	  basal).	  This	  was	  surprising	  considering	  J113863	  had	  no	  significant	  
effect	  on	  CCL4	  stimulated	  calcium	  release	  and	  strongly	  suggested	  that	  ‘off	  target’	  effects	  were	  






Figure	   3.14:	   J113863	   significantly	   inhibits	   THP-­‐1	   cell	   chemotaxis	   towards	   1	   nM	   CCL5	   at	  
concentrations	  down	  to	  1	  nM.	  THP-­‐1	  cells	  pre-­‐treated	  for	  0.5hr	  with	  J113863	  at	  10	  µM,	  500,	  
10	   and	   1	   nM	   all	   show	   significant	   inhibition	   of	   migration	   towards	   1	   nm	   CCL5	   down	   to	   and	  
below	  basal	  levels.	  Results	  represent	  the	  mean	  ±	  SEM	  of	  at	  least	  3	  independent	  experiments.	  
(One-­‐way	  ANOVA,	  Bonferroni	  multiple	  comparison.	  ***Indicates	  p≤0.001	  vs.	  vehicle).	  
	  
CCL5	  stimulation	  was	  also	  used	  to	  determine	  if	  the	  effect	  of	  J113864	  could	  be	  abrogated.	  1	  nM	  
CCL5	   stimulated	   a	   greater	   control	  migration	   that	   that	   seen	  with	   either	   CCL3	   or	   CCL4	   but	   the	  
same	   pattern	   in	   inhibition	   was	   seen	   with	   the	   four	   concentration	   treatments	   of	   J113863.	   All	  
treatments	   significantly	   reduced	   migration	   to	   that	   of	   control	   basal	   or	   below	   (p0.01	   vs.	  
stimulated	   control)	   with	   10	   and	   1	   nM	   treatments	   showing	   control	   migration	   restored	   to	  








Figure	   3.15:	   J113863	   significantly	   inhibits	   THP-­‐1	   cell	   chemotaxis	   towards	   1	   nM	   CCL8	   at	  
concentrations	  down	  to	  1	  nM.	  THP-­‐1	  cell	  pre-­‐treated	  for	  0.5hr	  with	  J113863	  at	  10	  µM,	  500,	  10	  
and	  1	  nM	  all	  show	  significant	  inhibition	  of	  migration	  down	  to	  and	  below	  basal	  levels.	  Results	  
represent	   the	   mean	   ±	   SEM	   of	   at	   least	   3	   independent	   experiments.	   (One-­‐way	   ANOVA,	  
Bonferroni	  multiple	  comparison.	  ***Indicates	  p≤0.001	  vs.	  vehicle).	  
	  
CCL8	  interacts	  with	  CCR1,	  2	  and	  5	  [5]	  and	  THP-­‐1	  cells	  migrate	  towards	  1	  nM	  	  CCL8	  strongly	  [47]	  
(Figure	   3.15).	   Despite	   being	   able	   to	   interact	   with	   three	   chemokine	   receptors	   known	   to	   be	  
expressed	   on	   THP-­‐1,	   J113863	   at	   the	   four	   pre-­‐treatment	   concentrations	   significantly	   inhibited	  
stimulated	   migration	   (p≤0.001,	   n≥3)	   and	   reduced	   non	   stimulated	   migration	   to	   levels	  
significantly	  lower	  than	  control	  basal	  at	  10	  µM	  and	  500	  nM	  (p≤0.01).	  
	  
These	   combined	   data	   provide	   support	   for	   the	   idea	   that	   J113863	   disrupts	  migration	   in	   THP-­‐1	  
cells	  in	  an	  ‘off	  target‘	  fashion;	  the	  three	  classical	  CCR5	  agonists	  CCL3/4/5	  have	  differing	  affinity	  
for	   CCR5	   and	  CCR1	  but	   show	   similar	   responses	   to	   J113863	   inhibition	  which	   seems	  unfeasible	  
unless	   all	   signalling	  was	   occurring	   via	   CCR1	   alone.	   This	   hypothesis	   also	   does	   not	   fit	   the	   data:	  
firstly	   CCL4	   does	   not	   interact	  with	   CCR1	   and	   secondly	   the	   J113863	   IC50	   for	   CCR1	   inhibition	   is	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  around	  1	  nM.	  If	  the	  effect	  of	  J113863	  was	  wholly	  through	  inhibition	  of	  CCR1	  then	  the	  expected	  
inhibition	   at	   1	   nM	   would	   be	   significantly	   lower	   than	   the	   complete	   inhibition	   observed.	   The	  
effects	  of	  J113863	  on	  calcium	  release	  also	  do	  support	  this	  idea,	  as	  10	  µM	  J113863	  only	  reduces	  
calcium	  release	  by	  ≈50%,	  the	  remainder	  of	  release	  occurring	  via	  CCR5	  activation.	  	  This	  suggests	  
CCR5	  is	  being	  activated	  by	  CCL3	  and	  the	  activation	  of	  CCR5	  is	  known	  to	  stimulate	  to	  migration	  
[29].	   It	   is	  clear	   that	   the	  effects	  of	   J113863	  on	  migration	  are	  not	  related	  to	   its	  ability	   to	   inhibit	  
CCR1,	  but	  the	  data	  do	  not	  provide	  adequate	  information	  to	  clarify	  the	  mechanism	  by	  which	  this	  
additional	   inhibition	   occurs.	   HeLa.RC49	   pre-­‐treated	   with	   10µM	   J113863	   showed	   no	  
abnormalities	   in	   actin	   polymerisation	   (data	   not	   shown),	   which	   eliminates	   disruption	   of	   actin	  
fibre	  formation	  as	  an	  explanation.	  	  
	  
	  
Figure	   3.16:	   J113863	   and	   maraviroc	   do	   not	   stimulate	   chemotaxis	   in	   THP-­‐1	   cells,	   but	   block	  
basal	  level	  of	  migration	  in	  the	  absence	  of	  chemokine.	  Untreated	  THP-­‐1	  cells	  showed	  levels	  of	  
migration	  significantly	  lower	  than	  basal	  towards	  either	  10	  µM	  J113863	  or	  100	  nM	  maraviroc	  
(p≤0.001	   vs.	   basal	   n≥3).	   Results	   represent	   the	   mean	   ±	   SEM	   of	   at	   least	   3	   independent	  





	  The	  observations	  would	  be	  explained	  if	  J113863	  acted	  as	  an	  agonist	  and	  stimulated	  migration.	  If	  
this	  was	  the	  case,	  then	  treatment	  of	  THP-­‐1	  cells	  with	  J113863	  prior	  to	  a	  chemotaxis	  assay	  would	  
be	  tantamount	  to	  placing	  chemoattractant	   in	  apical	  and	  basal	  wells	  of	  the	  transwell	  migration	  
assay	   therefore	   eliminating	   any	   gradient	   towards	   which	   cell	   could	   migrate.	   To	   test	   this	   idea	  
untreated	  THP-­‐1	  cells	  were	  stimulated	  in	  a	  transwell	  migration	  assay	  with	  10	  nM	  J113863	  or	  100	  
nM	  maraviroc	   (in	   the	  basal	  chamber).	  Both	   J113863	  and	  maraviroc	  significantly	   reduced	  basal	  
migration,	  i.e.	  migration	  not	  in	  response	  to	  a	  chemokine,	  (Figure	  3.16)	  of	  THP-­‐1	  cells	  (p≤0.01	  vs.	  
non	  treated	  cells).	  This	  indicates	  not	  only	  that	  the	  inhibitors	  do	  not	  stimulate	  migration	  but	  also	  
that	  basal	  migration	  is	  reduced	  in	  their	  presence.	  This	  additionally	  provides	  clear	  evidence	  that	  
maraviroc	  does	  not	  behave	  as	  a	  CCR5	  agonist	  in	  chemotaxis	  assay.	  
	  
	  
Figure	  3.17:	  J113863	  affects	  THP-­‐1	  cell	  viability	  after	  5hr	   incubation.	  Pre-­‐treatment	  of	  THP-­‐1	  
with	   varying	   concentrations	   of	   J113863	   followed	   by	   5hr	   incubation	   with	   MTS	   reveals	   a	  
significant	  reduction	  on	  MTS	  metabolism	  for	  cells	  treated	  with	  10	  µM	  and	  500	  and	  10	  nm	  J113	  
(n=3).	   Results	   represent	   the	  mean	   ±	   SEM	   of	   at	   least	   3	   independent	   experiments	   (One-­‐way	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  An	  alternate	  explanation	  to	  the	  observed	  effects	  of	  J113863	  treatment	  on	  THP-­‐1	  cell	  migration	  
could	   be	   cytotoxic	   effects.	   The	   colourimetric	   (3-­‐(4,5-­‐dimethylthiazol-­‐2-­‐yl)-­‐5-­‐(3-­‐
carboxymethoxyphenyl)-­‐2-­‐(4-­‐sulfophenyl)-­‐2H-­‐tetrazolium)	  (MTS)	  metabolism	  assay	  was	  used	  to	  
determine	  any	  cytotoxic	  effects	  on	  THP-­‐1	  cells	  treated	  with	  10	  µM,	  500,	  10	  and	  1	  nM	  for	  0.5hr	  
and	   then	   incubated	  with	  MTS	   for	   a	   further	   5hr	   (described	   in	  material	   and	  methods).	   (Figure	  
3.17).	  J113863	  at	  10	  µM,	  500	  and	  10	  nM	  significantly	  reduced	  MTS	  metabolism	  (p≤0.001)	  over	  
5hrs	   however	   MTS	   metabolism	   was	   also	   significantly	   higher	   than	   in	   the	   negative	   control	  
(p≤0.001).	   This	   reduction	   in	   viability	   was	   not	   concentration	   dependent	   and	   1	   nM	   J113863	  
showed	   no	   significant	   cytotoxicity	   vs.	   the	   vehicle	   control,	   which	   means	   that	   any	   cytotoxic	  
effects	  of	  J113863	  do	  little	  to	  explain	  the	  observed	  reductions	  in	  migration	  in	  THP-­‐1	  cells.	  
	  
3.3.6.	  THP-­‐1	  cells	  do	  not	  migrate	  towards	  α	  chemokine	  ligand	  CXCL12	  
	  
	  
Figure	   3.18:	   THP-­‐1	   cells	   do	   not	   migrate	   towards	   CXCR4	   agonist	   CXCL12.	   Stimulation	   of	  
untreated	   THP-­‐1	   cells	   with	   10	   nM	   CXCL12	   showed	   no	   significant	   migration	   (n=3).	   Results	  
represent	   the	   mean	   ±	   SEM	   of	   3	   independent	   experiments.	   (One-­‐way	   ANOVA,	   Bonferroni	  
multiple	  comparison.	  ***	  =	  p≤0.001.)	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  It	  has	  been	  shown	  that	  CXCR4	   is	  expressed	  on	  THP-­‐1	  cells	   [134],	  however	   in	  our	  hands	  THP-­‐1	  
cells	   did	   not	   migrate	   towards	   10	   nM	   CXCL12	   (Figure	   3.18),	   a	   concentration	   widely	   used	   to	  
promote	   chemotaxis	   towards	   CXCL12.	   This	   data	   may	   represent	   absence	   of	   CXCR4	   in	   the	  
subpopulation	   of	   THP-­‐1	   or	   a	   failure	   of	   activated	   cell	   to	   transduce	   signalling	   into	   chemotactic	  
machinery.	   In	   either	   case	   the	   inability	   of	   cells	   to	   undergo	   migration	   towards	   CXC-­‐motif	  




The	  aim	  of	  this	  chapter	  was	  to	  determine	  if	  THP-­‐1	  cellular	  responses	  could	  be	  modulated	  with	  
small	   molecule	   chemokine	   receptor	   antagonists,	   so	   that	   conclusions	   about	   CCR5	   specific	  
signalling	   could	   be	  made.	   This	   experimentation	  was	   required	   because	   chemokine	   ligands	   can	  
stimulate	   numerous	   receptors	   and	   activated	   receptors	   are	   susceptible	   to	   signalling	   cross	   talk	  
and	   transactivation	   [84].	   Therefore	   it	   seemed	   paramount	   to	   start	   with	   an	   overview	   of	   the	  
different	   cellular	   responses	   in	   THP-­‐1	   cells	   and	   use	   small	   molecule	   inhibitors	   to	   differentiate	  
between	  signal	  transduction	  pathways	  of	  different	  chemokine	  receptors,	  aiming	  at	  isolating	  the	  
CCR5	   specific	   responses	   in	   these	   cells.	   The	   importance	   of	   determining	   receptor	   signalling	  
through	   functional	   responses	   as	   opposed	   to	   relying	   on	   proteomics	   or	   the	   literature	   is	  
exemplified	  by	   the	   response	  of	  THP-­‐1	  cells	   to	  CXCL12.	  Although	  CXCR4	   is	  widely	   shown	   to	  be	  
expressed	  on	  THP-­‐1	  in	  the	  literature	  [134],	  no	  significant	  migratory	  response	  was	  observed	  with	  
the	  THP-­‐1	  cell	  population	  used	  in	  the	  assays	  here.	  This	  shows	  that	  in	  this	  system	  no	  conclusions	  
can	  be	  drawn	  about	  the	  function	  role	  of	  CXCR4	  regardless	  of	  whether	  or	  not	  they	  are	  expressed.	  
	  
The	  experimental	  data	  concerning	  C-­‐C	  motif	  chemokine	  receptor	  mediated	  responses	  in	  THP-­‐1	  
cells	   presents	   a	   conflicting	   picture	   when	   taken	   at	   face	   value.	   THP-­‐1	   calcium	   release	   can	   be	  
stimulated	  by	  CCL2,	  CCL3	  and	  CCL4	  which	  correspond	  to	  the	  chemokine	  receptors	  CCR1,	  CCR2	  
and	   CCR5	   as	   identified	   in	   the	   literature	   [178,	   216-­‐219].	   	  Maraviroc	   treatment,	   however,	   was	  
unable	   to	   inhibit	   CCL3	   stimulated	   calcium	   fluxes	   which	   suggested	   that	   CCL3	   was	   acting	  
predominantly	  through	  CCR1.	  The	  failure	  of	  maraviroc	  to	   inhibit	   the	  CCR5	  specific	   ligand	  CCL4	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  provided	  contrary	  evidence	  and	   indicated	  that	   the	   inhibitor	  was	  either	  not	   functioning	  or	  was	  
stimulating	   calcium	   release.	  Maraviroc	   is	  well	   characterised	   as	   an	   inhibitor	   of	   CCR5	  mediated	  
signalling	   in	   CCR5	   expressing	   fibroblasts	   [11],	   so	   these	   observations	   came	   as	   a	   surprise.	   	   The	  
potent	  CCR1	  inhibitor	  J113863,	  which	  shows	  no	  activity	  against	  CCR2	  and	  CCR5	  [227]	  was	  used	  
to	  examine	  the	  nature	  of	  CCL3	  stimulated	  calcium	  release.	  J113863	  was	  used	  at	  excess	  so	  that	  
inhibition	   of	   CCR1	   mediated	   response	   was	   certain.	   Treatment	   with	   J113863	   at	   this	  
concentration	   reduced	  calcium	  release	  by	  ≈	  50%	   indicating	   that	  CCL3	   induced	  calcium	  release	  
was	   mediated	   by	   CCR1	   and	   CCR5	   in	   approximately	   equal	   proportions,	   at	   least	   in	   terms	   of	  
cellular	  response.	  These	  data	  supported	  the	  idea	  that	  J113863	  could	  be	  used	  to	  force	  signalling	  
through	  CCR5	  so	  that	  signalling	  pathways	  specific	  to	  the	  receptor	  could	  be	  isolated.	  The	  failure	  
of	  maraviroc	   to	  affect	  CCR2,	  3	   and	  4	   stimulated	   calcium	   release	   can	  be	  explained	  by	   the	   fact	  
that	   stimulation	  of	   THP-­‐1	  with	  maraviroc	   lead	   to	   a	   concentration	  dependent	   calcium	   release.	  
Whilst	   the	   concentrations	   of	  maraviroc	   that	   induced	   the	   largest	   response	   (1	   µM)	  was	   higher	  
than	  that	  used	  to	  inhibit	  CCR5	  (100	  nM),	  the	  exposure	  time	  to	  stimulants	  in	  calcium	  flux	  assay	  is	  
considerably	   shorter	   than	   the	   0.5hr	   incubation	   time	   used	   for	   inhibition.	  We	   can	   hypothesise	  
that	   prolonged	   exposure	   to	   a	   lower	   level	   of	   maraviroc	   would	   disrupt	   calcium	   signalling	   and	  
mask	  any	   inhibitory	  effects	   that	  may	  have	  arisen	   from	  the	   inhibition	  of	  CCR5	  agonist	  binding.	  
Whilst	   the	   data	   do	   not	   provide	   sufficient	   information	   to	   form	   definite	   conclusions	   about	   the	  
nature	  of	  this	  stimulation	  beyond	  speculation,	  they	  do	  show	  that	  maraviroc	  cannot	  be	  used	  with	  
THP-­‐1	  where	  calcium	  release	   is	   to	  be	  determined.	  This	  did	  not	   rule	  maraviroc	  out	  as	  a	  useful	  
tool	   for	   manipulating	   chemokine	   receptor	   signalling	   because	   chemotaxis	   in	   THP-­‐1	   has	   been	  
shown	  to	  be	  independent	  of	  calcium	  release	  [75]	  and	  sensitive	  to	  maraviroc	  inhibition.	  
	  
Despite	  J113863	  behaving	  as	  expected	  in	  THP-­‐1	  cell	  calcium	  flux	  assays,	  treatment	  of	  cells	  with	  
the	   inhibitor	   prior	   to	   chemotaxis	   assays	   resulted	   in	   inhibition	   of	   CCL3,	   4,	   5	   and	   8	   stimulated	  
migration	  which	  was	  not	  consistent	  with	  CCR1	  inhibition	  alone.	  	  The	  effect	  of	  J113863	  on	  THP-­‐1	  
chemotaxis	   suggested	   that	   the	   inhibitor	   was	   altering	   the	   ability	   to	   migrate	   in	   an	   unspecific	  
fashion	   by	   virtue	   of	   the	   fact	   that	   chemotaxis	   in	   treated	   cells	  was	   reduced	   to	   sub-­‐basal	   levels	  
(Chapter	   3.3.5).	   Although	   CCR1	   is	   known	   to	   be	   expressed	   in	   THP-­‐1	   cells,	   direct	   proteomic	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  identification	  of	  the	  receptor	  was	  not	  carried	  out	   in	  this	  sub-­‐population,	  however,	  as	  with	  the	  
results	  with	   CXCR4,	   the	   aim	  of	   this	   chapter	  was	   to	   outline	   the	   functional	   receptor	   profile	   for	  
THP-­‐1	  so	  whether	  any	  of	  the	  effects	  of	  J11386	  can	  be	  considered	  ‘on-­‐target’	  are	  irrelevant.	  	  	  
	  
Cytotoxic	   effects,	  which	  were	   shown	   to	   be	   significant	   at	   higher	   J113863	   concentrations,	  may	  
explain	   some	   of	   these	   observations	   but	   provide	   no	   answers	   as	   to	   why	   1	   nM	   J113863	   is	   so	  
effective	   at	   blocking	   chemotaxis	   when	   the	   calculated	   IC50	   value	   for	   inhibition	   ≈	   1	   nM	   and	  
therefore	  the	  antagonist	  should	  not	  be	  able	  to	  completely	  block	  migration	  at	  this	  concentration	  
[227].	  Due	  to	  these	  observations	  the	  use	  of	  J113863	  in	  future	  assays	  to	  promote	  CCR5	  mediated	  
responses	  cannot	  be	  reasonably	  considered,	  as	  it	  will	  add	  variables	  that	  are	  not	  fully	  accounted	  
for	   and	  which	  may	   alter	   signalling	   responses	  of	   CCR1	   and	  CCR5	   in	   unpredictable	  ways.	  Other	  
CCR1	   [229,	   230]	   and	  CCR5	   [10]	   antagonists	   are	   available,	   but	   as	   both	   J113863	   and	  maraviroc	  
have	   displayed	   unspecific	   effects,	   any	   potential	   chemokine	   inhibitor	   must	   also	   be	   carefully	  
characterised	   to	   determine	   any	   irregularity	   before	   use.	   As	   the	   introduction	   of	   variables	   that	  
have	  unpredictable	  effects	  on	  signal	  transduction	  is	  clearly	  more	  detrimental	  than	  having	  more	  
poorly	   resolved	   but	   predictable	   signalling	   chemokine	   receptor	   antagonist	   will	   not	   be	   used	   in	  
future	  assays.	  
	  
This	   still	   leaves	   the	  question	  of	  how	   to	  attribute	  cellular	   responses	   stimulated	  by	  chemokines	  
that	  are	  known	  to	   interact	  with	  both	  CCR1	  and	  CCR5.	  Protein	  knock	  down	  via	  siRNA	  could	  be	  
employed	   to	   prevent	   CCR1	   expression	   but	   this	   then	   adds	   a	   range	   of	   other	   variables	   to	   be	  
accounted	   for	   not	   to	  mention	   the	   increase	   in	   time	   needed	   for	   simple	   assays.	   THP-­‐1	   cells	   are	  
known	   as	   a	   ‘difficult	   to	   transfect’	   cell	   line	   [228],	   so	   adding	   additional	   experimental	   stages,	  
including	   the	   associated	   exposure	   to	   chemical	   vehicles	   and	   electroporation	   etc.	   are	   likely	   to	  
decrease	   the	   resolution	   with	   which	   signalling	   events	   can	   be	   determined.	   A	   simpler	   solution,	  
based	  on	  the	  experimental	  data	  from	  this	  chapter,	  would	  be	  to	  introduce	  the	  caveat	  that	  from	  
here	   forth	   CCL3	   stimulated	   responses	   though	   CCR1	   and	   CCR5	   will	   be	   called	   CCR5	   mediated	  
responses.	   HeLa.RC49	   cells	   (which	   highly	   express	   CCR5	   and	   not	   CCR1)	   and	   CHO.CCR5	   cells	  
(which	  only	   express	   the	  human	   receptor	  CCR5)	   can	  be	  used	   to	   cross	   analyse	   the	   results.	   Any	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  discrepancies	  in	  the	  observations	  seen	  can	  then	  be	  attributed	  in	  part	  to	  CCR1	  activity	  in	  THP-­‐1.	  
In	  the	  worst	  case	  scenario	  observations	  are	  being	  made	  from	  two	  highly	  homologous	  receptors	  
of	  the	  same	  family	  [231]:	  	  J113863	  and	  maraviroc	  did	  not	  affect	  CCR2	  signalling	  and	  there	  was	  
not	  migratory	   response	   to	   the	   α-­‐chemokine	   ligand	   CXCL12	   (and	   CXCL11	   see	   later	   chapter).	   If	  
conclusions	  drawn	  using	  this	  approach	  are	  unclear	  then	  receptor	  knockdown	  with	  siRNA	  can	  be	  
used	  to	  resolve	  CCR5	  specific	  mediation	  from	  CCR1.	  The	  simplicity	  of	   the	  proposed	  solution	   is	  
likely	   to	   allow	   a	   greater	   amount	   of	   experimentation	   to	   be	   obtained	   per	   unit	   time	   without	  
adversely	  affecting	  the	  sensitivity	  or	  reliability	  of	  the	  assays	  used.	  	  
	  
3.5.	  Chapter	  Conclusions	  
	  
The	  final	  conclusions	  to	  be	  drawn	  from	  this	  chapter	  are:	  
1) Chemokine	   receptors	   CCR1,	   CCR2	   and	   CCR5	   are	   expressed	   by	   THP-­‐1	   cells	   and	   can	  
induce	  cellular	  responses	  through	  the	  binding	  of	  chemokine	  ligands.	  
2) CXCR4	  is	  not	  present	  or	  cannot	  induce	  migration	  in	  THP-­‐1	  cells	  
3) The	  chemokine	   receptor	  antagonists	  maravoric	  and	   J113863	  cannot	  be	  used	   to	  block	  
specific	  chemokine	  receptor	  activation	  in	  THP-­‐1	  because	  they	  have	  non-­‐specific	  effects	  
which	  unpredictably	  affect	  cellular	  responses.	  	  
4) To	  reduce	  to	  likelihood	  of	  these	  unpredictable	  effects	  resulting	  in	  erroneous	  conclusion	  
regarding	   the	   nature	   of	   CCR5	   signal	   transduction,	   CCR5	   specific	   signalling	   will	   be	  
determine	  by	  cross	  analysis	  of	  responses	  in	  CCR5	  positive,	  stably	  transfected	  cell	  lines	  








	  CHAPTER	  4:	  Gα,	  Gβγ	  or	  arrestin:	  Resolution	  of	  the	  initial	  
signal	  transduction	  route	  to	  chemotaxis 
	  
	  
4.1.	  Introduction	  	  
	  
CCR5	   is	   a	   GPCR	   and	   a	   β-­‐chemokine	   receptor	   and	   as	   such	   there	   are	   many	   possible	   routes	  
describes	  in	  the	  literature	  by	  which	  receptor	  activation	  could	  lead	  to	  signal	  transduction	  which	  
results	   in	   the	   relevant	   cytoskeletal	   rearrangements	   necessary	   for	   migration.	   Even	   signal	  
transduction	  events	  specific	  to	  CCR5	  seem	  contradictory	  [29,	  39,	  43,	  115,	  232]	  and	  determining	  
whether	  these	  observations	  are	  receptor	  or	  cell	  type	  specific	  is	  not	  possible	  from	  the	  literature	  
alone.	  There	  are	  also	  unanswered	  questions	  about	  the	  role	  of	  signalling	  proteins	  known	  to	  be	  
involved	   in	   CCR5	   mediated	   signal	   transduction	   and	   their	   role	   in	   migration,	   such	   as	   arrestin	  
scaffolds,	  which	   have	   been	   shown	   to	   form	   in	   numerous	   different	  ways	   [35,	   39,	   65]	   and	   non-­‐
receptor	  tyrosine	  kinases	  which	  have	  been	  shown	  to	  be	  involved	  with	  Gαi	  signalling	  [29,	  96]	  and	  
arrestin	   scaffolds	   [35,	   39].	   For	   a	  more	   in-­‐depth	   dissection	   of	   chemotaxis	   in	   THP-­‐1	   cells	   to	   be	  
possible	   it	  will	  be	   important	   to	   identify	  key	  points	   in	   signal	   transduction.	  These	  points	   should	  
allow	  comparisons	  to	  be	  made	  with	  CCR5	  specific	  events	  identified	  in	  the	  literature	  so	  that	  any	  
conflicting	   information	   could	  be	  brought	   into	   context,	   ultimately	   allowing	  a	   clearer	  picture	  of	  
the	   signal	   transduction	   to	   arise.	   Conclusions	   drawn	   from	   this	   chapter	   will	   allow	   further	  
investigation	  into	  migration	  to	  be	  targeted	  towards	  specific	  and	  pertinent	  protein	  interactions.	  	  
	  
4.2.	  Chapter	  Aims	  
	  
The	  primary	  aim	  of	  this	  chapter	  is	  to	  identify	  by	  proteomic	  and	  inhibitory	  means	  the	  ‘route’	  by	  
which	  activated	  CCR5	  receptors	  transduce	  signals	  to	  chemotaxis.	  These	  techniques	  will	  be	  used	  
against	   Gβγ,	   arrestin	   and	   arrestin	   recruitment	   kinases	  which	   should	   allow	   the	   initial	   route	   of	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  signal	  to	  be	  clarified.	  This	  will	  allow	  future	  observations	  to	  be	  related	  to	  a	  specific	  signalling	  axis	  




4.3.1:	  Gβγ	  is	  not	  required	  for	  CCL3	  stimulated	  THP-­‐1	  cell	  migration	  
	  
	  
Figure	   4.1:	  Gβγ	   inhibitor	   gallein	   has	   no	   significant	   effect	   on	   THP-­‐1	  migration	   towards	   CCL3.	  
Pre-­‐treatment	   for	   0.5hr	   with	   10,	   20	   or	   30	   µM	   gallein	   does	   not	   significantly	   alter	   THP-­‐1	  
chemotaxis	  towards	  1	  nM	  CCL3	  vs.	  vehicle	  control.	  All	  results	  represent	  the	  mean	  ±	  SEM	  of	  6	  








	  As	   discussed	   in	   the	   introduction	  GPCR	   signalling	   to	   chemotaxis	   is	   canonically	   associated	  with	  
Gβγ	   signalling	   through	   PI3K,	   PKB	   and	   MAPKs	   [55,	   57].	   Gβγ	   interaction	   with	   GRK2	   is	   also	   a	  
documented	   route	   for	   transduction	   to	   signalling	   [53].	   Protein	   knock	   down	   of	   Gβγ	   subunits	   is	  
difficult	  due	   to	   the	   large	  number	  of	   isotypes	  present	   in	  cells	  and	   the	   redundancy	   in	   signalling	  
seen	   in	  Gβγ	  dependent	   axes.	   Therefore	   the	   small	  molecule	   inhibitor	   of	  Gβγ,	   gallein,	   [57]	  was	  
used	  to	   investigate	  the	  role	  of	   the	  protein	  heterodimer	   in	  CCR5	  mediated	  chemotaxis.	  Gallein	  
binds	   to	   the	  Gβγ	  binding	   ‘hotspot’	   preventing	   interactions	  with	   PI3K	   and	  GRK2	   and	  has	   been	  
shown	  to	  inhibit	  fMLP	  stimulated	  chemotaxis	  in	  HL60	  cells	  which	  supports	  the	  canonical	  view	  of	  
Gβγ	  signalling	  in	  GPCR	  mediated	  migration	  [57].	  THP-­‐1	  cells	  were	  pre-­‐treated	  with	  10,	  20	  and	  30	  
µM	  gallein	  for	  0.5hr	  prior	  to	  stimulation	  with	  1	  nM	  CCL3	  in	  a	  transwell	  migration	  assay	  (Figure	  
4.1).	  Gallein	  was	  unable	   to	   significantly	  affect	  THP-­‐1	  cell	  migration	   towards	  CCL3	  at	   the	   three	  
treatment	   concentrations	   (p>0.05	   vs.	   vehicle	   control,	   n=6).	   These	   data	   suggest	   that	   CCR5	  
chemotaxis	  is	  not	  Gβγ	  dependent.	  Gallein	  was	  used	  up	  to	  1.2	  mM	  pre-­‐treatment	  concentrations	  
(data	  not	  shown)	  with	  no	  affect	  to	  CCR5	  migration.	  	  
	  
It	  was	  important	  to	  determine	  the	  relevance	  of	  these	  finding	  in	  primary	  tissue.	  Whilst	  THP-­‐1	  are	  
validated	  as	  models	  for	  leukaemia	  and	  chronic	  inflammatory	  disease,	  there	  is	  the	  possibility	  that	  
abnormalities	  in	  signalling	  in	  the	  immortalised	  cancer	  cell	  line	  are	  producing	  signal	  transduction	  
pathways	  with	  no	  relevance	  to	  normal	  human	  tissue.	  To	  validate	  the	  findings	  in	  THP-­‐1	  cells	  IL-­‐2	  
and	  concanavalin	  A	  activated	  peripheral	  blood	  lymphocytes	  (PBLs),	  which	  have	  been	  shown	  to	  
express	   CXCR3	   and	   CCR5	   upon	   activation	   [32],	   were	   used.	   PBLs	   are	   derived	   from	   adherence	  
depleted	  Peripheral	  Blood	  Mononuclear	  Cells	  (PBMCs)	  and	  represent	  a	  population	  of	  T-­‐cells,	  B-­‐
cells	   and	   Natural	   Killer	   cells.	   Activation	   with	   IL-­‐2	   and	   concanavalin	   A	   (Con	   A)	   stimulates	   the	  
upregulation	  of	  CXCR3	  and	  CCR5	  on	  T-­‐cells	   [32],	  so	  migratory	  responses	  seen	   in	  PBLs	  towards	  
CXCL11	   and	   CCR5	   ligands	   are	   likely	   to	   represent	   T-­‐cells.	   The	   fact	   that	   CXCR3	   and	   CCR5	   are	  
upregulated	   on	   T-­‐cells	   also	   allows	   direct	   comparisons	   between	   α	   and	   β	   chemokine	   receptor	  
signalling.	   These	   receptors	   recruit	   different	   G	   proteins	   and	   there	   is	   some	   evidence	   that	  
signalling	  to	  non-­‐receptor	  tyrosine	  kinases	  may	  also	  differ	  [96].	  	  Most	  importantly,	  the	  signalling	  
pathways	  for	  CC-­‐	  and	  CXC-­‐chemokine	  receptors	  can	  be	  compared	  and	  contrasted	  in	  these	  cells.	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Activated	   Peripheral	   Blood	   Lymphocytes	   migrated	   towards	   20	   nM	   CXCL11	   (Figure	   4.2a)	   but	  
unlike	   with	   THP-­‐1	   cells,	   pre-­‐treatment	   of	   activated	   PBLs	   with	   10	   µM	   gallein	   resulted	   in	   a	  
significant	   reduction	   in	  migration	   vs.	   stimulated	   vehicle	   controls	   (p≤0.01,	   n=3).	   This	  was	   clear	  
evidence	   that	   α	   chemokine	   receptors	   function	   differently	   form	   β	   chemokine	   receptors	   in	  
chemotaxis	  and	  that	  Gβγ	  is	  required	  in	  some	  chemokine	  receptor	  signalling	  to	  chemotaxis.	  The	  
effect	   of	   gallein	   pre-­‐treatment	   on	   CXCL11	   and	   CCL3	   stimulated	   calcium	   release	   showed	   non-­‐
significant	   differences:	   100	   nM	   CXCL11	   showed	   marked	   but	   non	   significant	   increase	   vs.	   the	  
normalised	   control	  when	   treated	  with	  10	  µm	  Gallein	   (p>0.05,	  n=3).	   CCL3	  was	  also	   capable	  of	  
inducing	  calcium	  release	  in	  PBL’s,	  suggesting	  that	  CCR5	  or	  CCR1	  was	  indeed	  expressed,	  but	  this	  







Figure	  4.2:	  Gallein	   significantly	   reduces	  activated	  Peripheral	  Blood	   Lymphocytes	   chemotaxis	  
towards	   CXCL11	   but	   increases	   calcium	   release.	   (a)	   Activated	   Peripheral	   Blood	   Lymphocytes	  
(PBLs)	   treated	   with	   10	   µM	   Gallein	   show	   significantly	   reduced	   ability	   to	   migrate	   towards	  
CXCL11	  vs.	  vehicle	  control.	  (b)	  PBL	  calcium	  release	  stimulated	  by	  100	  nM	  CXCL11	  show	  a	  trend	  
towards	   increase	   by	   treatment	   with	   Gallein	   stimulation	   but	   100	   nM	   CCL3	   is	   unaffected	   by	  
Gallein.	  All	  results	  represent	  the	  mean	  ±	  SEM	  of	  at	  least	  3	  donor’s	  PBLs	  where	  n=1	  is	  the	  mean	  
of	   3	   independent	   experiments	   for	   1	   donor’s	   PBLs.	   (One-­‐way	   ANOVA,	   Bonferroni	   multiple	  
comparison,	  **	  =	  p≤0.01).	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  4.3.2.	  Investigation	  of	  arrestin	  recruitment	  in	  THP-­‐1	  cell	  chemotaxis	  
	  
Non-­‐visual	   arrestins	   are	   known	   to	   function	   either	   as	   mediators	   of	   GPCR	   desensitisation	   and	  
internalisation	  or	   independently	  as	  scaffolds	   for	  signalling.	  The	  two	  functions	  of	  arrestin	  allow	  
cellular	  responses	  to	  be	  tied	  directly	  to	  either	  arrestin	  dependent	  or	  ‘classical’	  heterotrimeric	  G	  
protein	   dependent	   signalling.	   Overexpression	   of	   arrestins	   should	   have	   opposing	   effects	   with	  
each	   type	   of	   processes:	   enhancing	   arrestin	   dependent	   signalling	   and	   reducing	   ‘classical’	  
signalling	   by	   enhancing	   homologous	   GPCR	   desensitisation.	   To	   determine	   if	   CCR5	   mediated	  
calcium	   release	   was	   arrestin	   dependent	   cells	   were	   transfected	   (described	   in	   materials	   and	  
methods)	  with	   either	   EGFP	   tagged	   arrestin	   2	   (Arr2)	   or	   arrestin	   3	   (Arr3)	   plasmid	  DNA.	   Control	  
cells	  were	  transfected	  with	  pEGFP.C2	  plasmids,	  which	  would	  express	  green	  fluorescent	  protein	  





Figure	  4.3:	  EGFP	  Arrestin	  2	  and	  3	  overexpression	  in	  HeLa.RC49	  significantly	  reduces	  the	  ability	  
of	   CCL3	   to	   stimulate	   calcium	   release.	   (a)	   Concentration	   response	   curve	   for	   calcium	  
mobilisation	   in	   HeLa.RC49	   electroporation	   transfected	   with	   plasmid	   DNA	   coding	   for	   EGFP	  
tagged	   arrestin	   2	   and	   3	   (EGFP.Arr2	   &	   EGFP.Arr3)	   and	   non	   functional	   pEGFP.C2	   as	   a	   mock	  
control.	   The	   transient	   transfection	   of	   EGFP.Arr	   2	   &	   3	   resulted	   in	   a	   significant	   reduction	   in	  
calcium	   release	   stimulated	   by	   75	   nm	   CLC3	   (p≤0.05	   vs.	   C2.EGFP	   transfected	   control)	   Results	  
represent	   the	   mean	   ±	   SEM	   of	   at	   least	   3	   independent	   experiments	   (One-­‐way	   ANOVA,	  




	  HeLa.RC49	  transiently	  overexpressing	  arrestin	  2	  or	  3	  (Figure	  4.3)	  showed	  no	  significant	  shift	   in	  
CCL3	  EC50	  for	  calcium	  release	  with	  values	  calculated	  as	  61.7±4.8	  nM	  for	  mock	  controls,	  63.5±8.7	  
nM	   for	   arrestin	   2	   transfection	   and	   65.5±5.3	   nM	   for	   arrestin	   3	   transfection	   (assuming	  Hill	   co-­‐
efficient	   of	   1).	   Predicted	   efficacies	   for	   the	   three	   treatments	   were	   not	   significantly	   different	  
(p.0.05)	   there	   was,	   however,	   a	   significant	   reduction	   in	   the	   level	   of	   calcium	   release	   for	   both	  
arrestin	   isotypes	   vs.	   control	   THP-­‐1	   cells	   stimulated	  by	   75	  nM	  CCL3.	  Arrestin	   2	  overexpression	  
reduced	   significantly	   calcium	   release	   by	   28±10%	   (p≤0.05)	   and	   arrestin	   3	   overexpression	  
significantly	   reduced	   calcium	   release	   by	   37±7%	   (p≤0.001).	   These	   data	   indicate	   that	   CCR5	  
mediated	   calcium	   release	   in	   HeLa	   cells	   occurs	   via	   ‘classical’	   G-­‐protein	   signalling	  with	   arrestin	  
acting	   as	   a	   desensitising	   protein,	   the	   difference	   in	   reduction	   of	   calcium	   release	   between	   the	  
arrestin	   isotypes	   cannot	   be	   accounted	   for	   as	   differences	   in	   expression	   level	   of	   both	   arrestins	  
were	  not	  quantified.	  	  
	  
	  
Figure	   4.4:	   Electroporation	   transfection	   of	   THP-­‐1	   affects	   their	   ability	   to	   migrate.	   (a)	   Single	  
experimental	  plot	  of	  THP-­‐1	  migration	  towards	  0,	  1	  and	  5	  nM	  after	  transient	  transfection	  with	  
EGFP.Arr2&3	   and	   C2.EGFP	   control.	   Electroporation	   transfection	   resulted	   in	   a	   disruption	   in	  
control	   migration	   in	   THP-­‐1	   with	   cells	   often	   not	   migrating	   at	   all.	   Plot	   represents	   typical	  
migration.	  Note	  control	  stimulated	  migration	  10	  fold	  lower	  than	  expected.	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  Arrestin	   overexpression	   appeared	   to	   enhance	   CCR5	   desensitisation,	   indicating	   mediation	   of	  
calcium	   release	   occurred	   via	   ‘classical’	   G-­‐protein	   signalling,	   however,	   it	   is	   important	   to	  
determine	   if	   chemotaxis	   occurs	   in	   an	   arrestin	   dependent	   or	   independent	   fashion.	   This	   is	  
particularly	   important	   if	  signalling	  to	  chemotaxis	  can	  be	  shown	  to	  be	  divergent	  at	  the	  arrestin	  
level	  then	  this	  might	  explain	  why	  calcium	  release	  and	  migration	  are	  independent	  in	  THP-­‐1	  [74].	  
THP-­‐1	  cells	  were	  electroporation	  transfected	   in	  the	  same	  way	  as	  for	  calcium	  release,	  however	  
the	  process	  of	  transfection	  appeared	  to	  disrupt	  the	  ability	  of	  THP-­‐1	  cells	  to	  migrate.	  Figure	  4.4	  
demonstrates	   representative	   results	   from	   transfected	   THP-­‐1	   cells	   in	   the	   transwell	   migration	  
assay;	   control	   stimulated	  migration	   was	   reduced	   to	   levels	   10	   times	   lower	   than	   normal	   basal	  
migration.	  Cells	  in	  some	  assays	  showed	  no	  migration	  at	  all,	  which	  demonstrated	  the	  unreliability	  
of	   transfected	  THP-­‐1	  cells	   in	   this	  assay.	   	  Other	  methods	  of	   transfection,	  via	   chemical	   reagent,	  
were	  available	  but	  the	  efficiency	  of	  these	  protocols	  had	  been	  shown	  to	  be	  low	  with	  THP-­‐1	  (data	  
not	  shown),	  which	  supports	  the	  consensus	   idea	  that	  THP-­‐1	  are	  difficult	  to	  transfect	  effectively	  
[228].	   The	   inability	   to	   directly	   observe	   the	   effects	   of	   arrestin	   overexpression	   in	   THP-­‐1	   were	  
disappointing	  but	  indirect	  methods	  of	  determining	  arrestin	  function	  were	  available	  with	  the	  use	  






Figure	   4.5:	   Inhibition	   of	   GRK2	   with	   β	   Adrenergic	   Receptor	   Kinase	   inhibitor	   1	   significantly	  
reduces	   chemotaxis	   in	   THP-­‐1.	   Pre-­‐treatment	   of	   THP-­‐1	   with	   190	   µM	   β	   Adrenergic	   Receptor	  
Kinase	   inhibitor	   1	   (βARK1)	   significantly	   reduced	   migration	   toward	   1	   nM	   CCL3	   vs.	   vehicle	  
control.	  Results	  represent	  the	  mean	  ±	  SEM	  of	  at	   least	  3	   independent	  experiments	  (One-­‐way	  
ANOVE,	  Bonferroni	  multiple	  comparison,	  ***	  indicates	  p≤0.001	  vs.	  control).	  	  
	  
βARK1	   inhibitor	   is	   a	   rationally	   designed	   small	   molecule	   inhibitor	   of	   β-­‐Adrenergic	   Receptor	  
Kinase	  1	  (later	  termed	  GRK2)	  with	  an	  IC50	  ≈	  125	  µM	  [233].	   	  βARK1	  inhibitor	  binds	  to	  the	  GRK2	  
ATP	   binding	   site	   preventing	   ATP	   turnover	   and	   therefore	   GRK2	   kinase	   function.	   Due	   to	  
limitations	  on	  the	  solubility	  of	  the	  inhibitor	  and	  the	  requirement	  to	  keep	  DMSO	  vehicle	  levels	  as	  
low	  as	  possible	  a	   treatment	  concentration	  of	  190	  µM	  at	  1%	  DMSO	  vehicle	  was	   the	  maximum	  
used.	  Pre-­‐treatment	  of	  THP-­‐1	  cells	  for	  0.5hr	  prior	  to	  transwell	  chemotaxis	  assay	  stimulated	  by	  1	  
nM	  CCL3	  (Figure	  4.5).	  βARK1	  inhibitor	  significantly	  reduced	  the	  ability	  of	  THP-­‐1	  cells	  to	  migrate	  
by	  66±7%	  (p≤0.001,	  n=6),	  which	  is	  representative	  of	  the	  expected	  reduction	  based	  on	  the	  IC50.	  	  
Cytotoxic	  effects	  of	  βARK1	  inhibitor	  were	  determined	  with	  the	  MTS	  assay	  (data	  not	  shown)	  and	  
no	  significant	  reduction	  in	  cell	  viability	  was	  seen	  after	  5hrs.	  These	  data	  indicate	  that	  migration	  is	  
GRK2	  dependent	  which	  in	  turn	  suggests	  that	  recruitment	  of	  arrestin	  via	  GRK2	  phosphorylation	  is	  
a	  prerequisite	  for	  CCR5	  signalling	  to	  chemotaxis.	  There	  is	  some	  evidence	  that	  GRK2	  can	  act	  as	  an	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  independent	   signalling	  molecule,	  which	  must	   also	   be	   considered.	   	   These	   data	   cannot	   explain	  
whether	  the	  observed	  affect	  is	  due	  to	  the	  inhibition	  of	  arrestin	  dependent	  signalling	  or	  whether	  
the	  arrestin	  dependent	  desensitisation	  and	  internalisation	  is	  the	  signal	  transduction	  dependent	  
factor.	  Protein	  kinase	  C	  (PKC)	  also	  recruits	  arrestins	  to	  GPCRs	  but	  with	  different	  kinetics	  to	  GRK2	  
[38].	   Pan	   isotype	   PKC	   inhibition	   does	   not	   inhibit	   THP-­‐1	   directly	   but	   depletes	   internal	   calcium	  
[75].	  The	  involvement	  of	  specific	  isotypes	  has	  not	  been	  well	  characterised	  particularly	  as	  there	  is	  




Figure	  4.6:	  Pan-­‐Isotype	  Protein	  Kinase	  C	   inhibitor	  bisindolylmaleimide	  significantly	   increases	  
THP-­‐1	  migration	  towards	  CCL3.	  Pretreatment	  for	  0.5hr	  with	  2.5	  µM	  bisindolylmaleimide	  (Bis-­‐
1)	  significantly	  increases	  THP-­‐1	  chemotaxis	  towards	  1	  nM	  CCL3	  vs.	  vehicle	  control.	  All	  results	  
represent	   the	   mean	   ±	   SEM	   of	   3	   independent	   experiments	   (One-­‐way	   ANOVA,	   Bonferroni	  
multiple	  comparison,	  ***	  indicates	  p≤0.001).	  
	  
Pre-­‐treatment	  of	  THP-­‐1	  with	  the	  pan-­‐isotype	  PKC	  inhibitor	  Bisindolylmaleimide	  (Bis-­‐1)	  was	  used	  
to	   determine	   the	   effect	   of	   general	   PKC	   function	   of	   CCR5	   mediated	   signalling	   to	   chemotaxis	  
(Figure	  4.6).	  Treated	  THP-­‐1	  cells	  showed	  a	  significant	  increase	  in	  migration	  towards	  1	  nM	  CCL3	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  (p≤0.001,	   n=3),	   which	   agreed	   with	   observations	   made	   by	   Cardaba	   et	   al.	   at	   higher	   inhibitor	  
concentration	   [75].	   This	   observation	   combined	   with	   those	   made	   using	   the	   GRK2	   inhibitor	  
suggest	  that	  arrestin	  recruitment	  via	  PKC	  and	  GRK2	  leads	  to	  differential	  cellular	  responses	  with	  
PKC	   mediated	   recruitment	   leading	   to	   desensitisation	   and	   GRK2	   mediated	   signalling	   leading	  
arrestin	   dependent	   signal	   transduction	   to	   chemotaxis.	   	   This	   hypothesis	   is	   supported	   by	  
investigation	   of	   the	   role	   of	   Gβγ	   signalling	   inhibition	   with	   gallein,	   which	   showed	   it	   was	   not	  
required	  for	  CCR5	  mediated	  chemotaxis,	  therefore	  activation	  of	  Gβγ	  by	  GRK2	  was	  independent	  
of	  migration[53].	  	  
	  
At	  2.5	  µM	  Bis-­‐1	  will	  inhibit	  all	  conventional	  isotypes	  but	  not	  atypical	  protein	  kinase	  c	  ζ.	  PKCζ	  has	  
been	  shown	  to	  be	  crucial	   for	  THP-­‐1	  migration	  mediated	  by	  cytokine	   receptors	   [235]	   so	   it	  was	  
important	  to	  determine	  if	  inhibition	  of	  other	  PKC	  isotypes	  lead	  to	  altered	  PKCζ	  function	  that	  was	  
responsible	   for	   the	   observations	   seen	   with	   Bis-­‐1	   treatment.	   The	   cell	   membrane	   permeable	  
oligomeric	   protein	   PKCζ	   pseudo-­‐substrate	   inhibitor	   (PKCζ	   PSI)[236]	   was	   used	   to	   probe	   the	  
involvement	  of	  this	  specific	  atypical	  PCK	  isotype	  on	  CCR5	  signal	  transduction.	  Pre-­‐treatment	  of	  
THP-­‐1	  cells	  with	  10	  µM	  PCKζ	  PSI	  for	  0.5hr	  prior	  to	  intracellular	  calcium	  release	  assay	  (Figure	  4.7)	  
induced	   a	   significant	   reduction	   on	   calcium	   release	   stimulated	   by	   75	   nM	   CCL3	   (p≤0.01,	   n=3)	  
without	  affecting	  CCL3	  EC50	  values.	  Accordingly,	  predicted	  efficacy	  for	  CCL3	  stimulated	  calcium	  
release	  was	   significantly	   reduced	   (unpaired	   t-­‐test,	   p<0.05)	  with	  maximal	   ratiometric	   response	  
over	   basal	   for	   control	   cells	   predicted	   as	   0.573±0.067	   vs.	   0.247±0.035	   for	   treated	   cells.	   As	  
described	   in	   chapter	   2	   the	   possibility	   of	   these	   observations	   resulting	   from	   CCR1	   specific	  






Figure	  4.7:	  Inhibition	  of	  Protein	  Kinase	  C	  ζ	  with	  Protein	  Kinase	  C	  ζ	  pseudo	  substrate	  inhibitor	  
significantly	   reduces	   calcium	   release	   in	   THP-­‐1	   cells.	   (a)	   Concentration	   response	   curve	   for	  
calcium	  release	  in	  THP-­‐1	  pre-­‐treated	  with	  10	  µM	  oligomeric	  peptide	  Protein	  Kinase	  C	  ζ	  pseudo	  
substrate	  inhibitor	  (PKCζ	  PSI).	  PCKζ	  PSI	  significantly	  reduces	  calcium	  release	  stimulated	  by	  75	  
nm	  CCL3.	  Results	  represent	  the	  mean	  ±	  SEM	  of	  at	  least	  3	  independent	  experiments	  (Unpaired	  






Figure	  4.8:	  Inhibition	  of	  Protein	  Kinase	  C	  ζ	  with	  Protein	  Kinase	  C	  ζ	  pseudo	  substrate	  inhibitor	  
does	   not	   affect	   calcium	   release	   in	  HeLa.RC49.	   (a)	   Concentration	   response	   curve	   for	   calcium	  
release	  in	  HeLa.RC49	  pretreated	  with	  10	  µM	  oligopeptide	  Protein	  Kinase	  C	  ζ	  pseudo	  substrate	  
inhibitor	  (PKCζ	  PSI).	  PCKζ	  PSI	  shows	  no	  significant	  effect	  on	  calcium	  release	  stimulated	  by	  75	  
nm	  CCL3.	  Results	  represent	  the	  mean	  ±	  SEM	  of	  at	  least	  3	  independent	  experiments	  (Unpaired	  






	  Pre-­‐treatment	  of	  HeLa.RC49	  cells	  with	  10	  µM	  PCKζ	  PSI	  for	  0.5hr	  had	  no	  significant	  effect	  on	  the	  
EC50	   or	   the	   levels	   of	   calcium	   release	   observed	   (unpaired	   t-­‐test	   p>0.05,	   n≥3)	   (Figure	   4.8)	   and	  
predicted	  efficacy	  was	  not	  significantly	  different	  between	  control	  and	  treated	  cells	  (unpaired	  t-­‐
test,	   p>0.05).	   This	   indicated	   that	   CCR5	   mediated	   calcium	   release	   was	   either	   independent	   of	  
PCKζ	   mediated	   recruitment	   of	   arrestins	   or	   that	   PCKζ	   was	   not	   involved	   in	   arrestin	   mediated	  
desensitisation	  or	  signalling	  downstream	  of	  CCR5	  in	  HeLa	  cells.	  
	  
Figure	  4.9:	  Inhibition	  of	  Protein	  Kinase	  C	  ζ	  with	  Protein	  Kinase	  C	  ζ	  pseudo	  substrate	  inhibitor	  
does	  not	   affect	  CCL3	   stimulated	  migration	   in	   THP-­‐1.	   Pretreatment	  with	  10	  µM	  oligopeptide	  
Protein	  Kinase	  C	  ζ	  pseudo	  substrate	  inhibitor	  	  (PKCζ	  PSI)	  does	  not	  significantly	  affect	  migration	  
of	  THP-­‐1	  towards	  1	  nM	  CL3.	  Results	  represent	  the	  mean	  ±	  SEM	  of	  6	  independent	  experiments.	  
(Unpaired	  t-­‐test,	  ns=	  p>0.05).	  
	  
The	  idea	  that	  PCKζ	  is	  not	  involved	  in	  arrestin	  mediated	  desensitisation	  or	  signalling	  downstream	  
of	  CCR5	  is	  supported	  by	  the	  observed	  effect	  of	  10	  µM	  PKCζ	  PSI	  on	  THP-­‐1	  cell	  chemotaxis	  (Figure	  
4.9).	   Pre-­‐treatment	  with	   PKCζ	   PSI	   has	   no	   significant	   effect	   on	   THP-­‐1	  migration	   towards	   1	   nM	  
CCL3	  (p>0.05,	  n≥3)	  clearly	  showing	  that	  if	  PKC	  isotypes	  are	  involved	  in	  CCR5	  signal	  transduction	  
to	  migration	  PCKζ	   is	  not	  one	  of	   them	  and	  provided	  further	  support	   for	   the	   idea	  that	   interplay	  
between	   conventional	   PKC	   isotypes	   and	   GRK2	   is	   responsible	   for	   the	   observed	   increase	   in	  
migration	  THP-­‐1	  cells	  with	  bisindolylmaleimide	  inhibition.	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  4.3.3:	  Triangulating	  signalling	  to	  chemotaxis:	  MAPK,	  Rho	  and	  c-­‐Src	  	  
	  
	  
Figure	   4.10:	   Extracellular	   Signal-­‐Related	  Kinase	   (ERK)	   1/2	   inhibitor	   PD98059	  does	   not	   affect	  
THP-­‐1	  cell	  chemotaxis	  towards	  1	  nM	  CCL3.	  Incubation	  with	  25	  µM	  PD98059	  for	  0.5hr	  did	  not	  
significantly	  reduce	  the	  ability	  of	  THP-­‐1	  to	  migrate	  towards	  1	  nM	  CCL3.	  All	   results	  represent	  
the	   mean	   ±	   SEM	   of	   3	   independent	   experiments.	   (One-­‐way	   ANOVA,	   Bonferroni	   multiple	  
comparison,	  ns	  =	  p>0.05	  vs.	  vehicle).	  
	  
ERK	  1/2	  and	  p38	  Mitogen	  Activated	  Protein	  Kinases	  (MAPK)	  are	  associated	  with	  canonical	  Gβγ	  
signalling	  to	  chemotaxis	  [57]	  and	  are	  also	  used	  more	  generally	  as	  markers	  of	  receptor	  mediated	  
protein	   activation	   associated	   with	   Gβγ	   and	   arrestin	   dependent	   signalling	   [39,	   43,	   57].	   It	   was	  
important	  to	  determine	  if	  CCR5	  signal	  transduction	  occurred	  through	  either	  of	  these	  proteins	  so	  
that	   the	   role	   of	   phosphorylated	  MAP	   kinases	   in	   THP-­‐1	   chemotaxis	   would	   be	   better	   defined.	  	  
PD98059	   is	  a	  small	  molecule	   inhibitor	  of	  ERK1/2	  MAPK	  phosphorylation	  and	  was	  used	  to	  pre-­‐
treat	   THP-­‐1	   cells	   at	   25	   µM	   before	   chemotaxis	   assay.	   0.5hr	   treatment	   with	   PD98059	   had	   no	  
significant	   effect	   on	   THP-­‐1	   migration	   towards	   CCL3	   (p≤0.05,	   n=3)	   (Figure	   4.10).	   The	  




Figure	   4.11:	   P38	   Mitogen	   Activated	   Kinase	   inhibitor	   SB203580	   does	   not	   affect	   THP-­‐1	   cell	  
chemotaxis	  towards	  1	  nM	  CCL3.	  Incubation	  with	  2	  µM	  SB203580	  for	  0.5hr	  did	  not	  significantly	  
reduce	  the	  ability	  of	  THP-­‐1	  to	  migrate	  towards	  1	  nM	  CCL3.	  All	   results	   represent	  the	  mean	  ±	  
SEM	  of	  3	   independent	  experiments	  (One-­‐way	  ANOVA,	  Bonferroni	  multiple	  comparison,	  ns	  =	  
p>0.05).	  
	  
SB203580	  is	  a	  potent	  p38	  MAPK	  inhibitor	  with	  an	  IC50	  for	  p38	  inhibition	  in	  THP-­‐1	  of	  cells	  ≈	  100	  
nM	   [237].	   THP-­‐1	   cells	   treated	   with	   2.5	   µM	   SB203580	   prior	   to	   chemotaxis	   assay	   showed	   no	  
significant	   alteration	   in	   migration	   compared	   with	   vehicle	   control	   cells	   (Figure	   4.11)	   (p>0.05,	  
n=6).	   Combined	   with	   the	   observations	   made	   with	   PD98059	   inhibition,	   these	   data	   clearly	  
indicate	   that	   chemotaxis	   signalling	   through	   CCR5	   is	   independent	   of	   ERK1/2	   and	   p38	   MAPK	  
which	   in	   turn	  supports	   the	  hypothesis	   that	  Gβγ	  signalling	   is	  also	  not	   required	  and	  chemotaxis	  
and	  arrestin	  dependent	  signalling	  is	  responsible,	  in	  the	  first	  instance,	  for	  transduction	  of	  signals	  
to	  cytoskeletal	  machinery	  and	  migration.	  These	  experiments	  suggest	  that	  CCR5	  utilises	  atypical	  
signal	   transduction	   to	   chemotaxis	  which	   is	   not	   described	   by	   the	   proposed	   transduction	   from	  





Figure	   4.12:	   Rho	   Kinase	   (ROCK)	   inhibitor	   Y27632	   significantly	   reduces	   THP-­‐1	   cell	   migration	  
towards	  CCL3.	  Pre-­‐treatment	  of	  THP-­‐1	  with	  20	  µM	  ROCK	  inhibitor	  Y27632	  (Y276)	  significantly	  
reduced	   their	   ability	   to	   undergo	   CCL3	   stimulated	   chemotaxis	   vs.	   vehicle	   control.	   Results	  
represent	   the	   mean	   ±	   SEM	   of	   6	   independent	   experiments	   (One-­‐way	   ANOVA,	   Bonferroni	  
multiple	  comparison,	  ***	  indicates	  p≤0.001	  vs.	  vehicle).	  
	  
The	   Rho	   family	   of	   small	   GTPases	   is	   generally	   considered	   crucial	   for	   chemotaxis	   with	   Rho	  
responsible	   for	   actin	   dynamics	   and	   the	   disassembly	   of	   adhesions	   to	   allow	   progression	   of	  
migration	  [192,	  238,	  239].	  	  To	  determine	  if	  CCR5	  mediated	  chemotaxis	  in	  THP-­‐1	  is	  dependent	  on	  
Rho	  kinase,	   the	   small	  molecule	   inhibitor	  Y27632	  was	  used	   to	  prevent	  Rho	  activation	   in	  THP-­‐1	  
cells	  (Figure	  4.12).	  Pre-­‐treated	  THP-­‐1	  cells	  showed	  a	  significant	  reduction	  in	  migration	  towards	  1	  
nM	   CCL3	   (p≤0.001	   n=3)	   that	   was	   not	   significantly	   higher	   than	   untreated	   basal	   migration	  
(p>0.05).	  These	  data	  indicated	  that	  CCR5	  mediated	  migration	  shared	  some	  signalling	  in	  common	  
with	  classical	  pathways.	  
	  
Non-­‐receptor	  tyrosine	  kinases	  such	  as	  Lyn	  and	  c-­‐Src	  have	  been	  linked	  with	  CCR5	  signalling	  [99]	  
with	  Lyn	  in	  particular	  associated	  with	  the	  arrestin	  signalling	  scaffold	  identified	  by	  Cheung	  et	  al.	  
[39]	   and	   signalling	   to	   Grb2	   [100].	   As	   ERK1/2	   activation,	   does	   not	   seem	   to	   be	   involved	   in	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  migration	  (see	  Figure	  4.10),	  the	  non-­‐receptor	  tyrosine	  kinase	  bosutinib*	  was	  used	  to	  determine	  
if	   non	   receptor	   tyrosine	   kinases	   of	   the	   c-­‐Src/Lyn	   family	   are	   required	   for	   CCR5	   mediated	  
chemotaxis	  (*see	  Materials	  and	  methods	  for	  note	  on	  bosutinib	  isomerism	  issue).	  	  
	  
	  
Figure	  4.13:	  Non-­‐receptor	   tyrosine	  kinase	   inhibitor	  bosutinib	  significantly	   reduces	  THP-­‐1	  cell	  
chemotaxis.	  THP-­‐1	  pre-­‐treated	  with	  the	  cellular	  sarcoma	  (c-­‐Src)	  non-­‐receptor	  tyrosine	  kinase	  
inhibitor	   bosutinib	   do	   not	  migrate	   to	   a	   higher	   extent	   than	   the	   basal	   levels	   after	   activation	  
with	   CCL3.	   Results	   represent	   the	   mean	   ±	   SEM	   of	   6	   independent	   experiments	   (One-­‐way	  
ANOVA,	  Bonferroni	  multiple	  comparison,	  ***	  indicates	  p≤0.001	  vs.	  vehicle).	  
	  
Bosutinib	  has	  been	  shown	  to	  be	  a	  potent	   inhibitor	  of	  Src	   family	  non	  receptor	  tyrosine	  kinases	  
with	  an	   IC50	  of	  around	  100	  nM	  and	  shows	  anti-­‐proliferative	  effects	   in	   leukemia	  cell	   lines	   [79].	  
Pre-­‐treatment	  of	  THP-­‐1	  with	  10	  µM	  bosutinib	  significantly	  reduced	  the	  ability	  of	  THP-­‐1	  cells	  to	  
migrate	   towards	   a	   1	   nM	   stimulus	   of	   CCL3	   (Figure	   4.13)(p≤0.001,	   n=6).	   To	   determine	   if	   this	  
observation	   could	   be	   attributed	   to	   disruption	   of	   CCR5	   signal	   transduction	   a	   wound-­‐healing	  




Figure	   4.14:	   Bosutinib	   significantly	   reduces	  wound	   healing	   in	   HeLa.RC49	   cells.	   (a)	   Graphical	  
plot	  of	  HeLa.RC49	  wound	  healing	  under	  basal	  and	  stimulated	  conditions	  and	  in	  the	  presence	  
of	  10	  µM	  bosutinib.	  (b)	  Bosutinib	  treatment	  significantly	  reduced	  wound	  closing	  in	  a	  confluent	  
monolayer	  of	  HeLa.RC49	   to	  ≈	  10%	  after	   48hr	   vs.	   CCL3	   stimulated	   control.	  Results	   represent	  
the	  mean	  ±	  SEM	  of	  at	  least	  3	  independent	  experiments	  (One-­‐way	  ANOVA,	  Bonferroni	  multiple	  
comparison,	  *	  indicates	  p≤0.05	  &	  ***	  ≤	  0.001,	  n=3).	  
	  
The	  wound-­‐healing	  or	  scratch	  assay	  measures	  the	  ability	  of	  cells	  in	  a	  low	  serum	  environment	  to	  
move	   into	  a	   freshly	  made	  scratch	   in	  a	  confluent	  monolayer.	  The	  maintenance	  of	  a	   low	  serum	  
environment	  ensures	  that	  wound	  healing	  is	  mostly	  a	  result	  of	  cellular	  migration	  and	  not	  entirely	  
due	   to	   proliferation.	   It	   should	   be	   noted	   that	   migration	   assays	   using	   8	   µm	   pore	   Corning	   HTS	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  transwell	   Boyden	   chambers	   were	   attempted	   with	   CHO.CCR5	   and	   HeLa.RC49	   cell	   but	   they	  
proved	  to	  be	  unreliable	  (data	  not	  shown)	  and	  the	  scratch	  assay	  was	  adopted	  instead.	  	  
	  
HeLa.RC49	  cells	  exposed	  to	  bosutinib	  showed	  ≈	  10%	  regrowth	  over	  48hr,	  significantly	  less	  than	  
the	  ≈40%	  see	  with	  stimulated	  control	   cells	   (p≤0.001,	  n=3)	   (Figure	  4.14).	  Bosutinib	   treated	  cell	  
appeared	   normal	   throughout	   the	   duration	   of	   the	   assay	   with	   no	   significant	   alteration	   is	   cell	  
morphology	  or	  signs	  of	  cytotoxicity	  such	  as	  detachment	  (not	  shown).	  These	  data	  supported	  the	  
evidence	   provided	   by	   THP-­‐1	   cell	   treatment	   and	   suggested	   that	   bosutinib	   did	   affect	   CCR5	  
mediated	  migration	  by	   interfering	  with	   signal	   transduction	  and	   that	   c-­‐Src	   family	  non-­‐receptor	  




Figure	   4.15:	   Bosutinib	   significantly	   reduces	   activated	   PBL	   chemotaxis.	   Activated	   PBLs	   pre-­‐
treated	  with	  bosutinib	  showed	  a	  significant	  reduction	  in	  chemotaxis	  towards	  20	  nM	  CXCL11.	  
All	   results	  represent	  the	  mean	  ±	  SEM	  of	  at	   least	  3	  donor’s	  PBLs	  where	  n=1	   is	  the	  mean	  of	  3	  
independent	   experiments	   for	   1	   donor’s	   PBLs.	   (One-­‐way	   ANOVA,	   Bonferroni	   multiple	  
comparison,	  **	  indicates	  p≤0.01	  vs.	  vehicle	  control).	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  Pre-­‐treatment	   of	   PBLs	   with	   10	   µM	   bosutinib	   resulted	   in	   a	   significant	   reduction	   in	   migration	  
(Figure	  4.15)	  (p≤0.01,	  n=3).	  The	  mean	  reduction	  in	  basal	  was	  not	  as	  low	  as	  that	  seen	  with	  THP-­‐1,	  
however,	   which	   may	   indicate	   that	   non-­‐receptor	   tyrosine	   kinases	   are	   of	   less	   importance	   in	  
CXCR3	   mediated	   migration.	   A	   difference	   in	   donor	   PBL	   phenotype	   may	   also	   explain	   these	  
observations.	  	  
	  
4.4.	  Chapter	  discussion	  
	  
There	   are	   three	   ‘classical’	   routes	   through	   which	   CCR5	   signal	   transduction	   could	   be	  
communicated	   immediately	   downstream	   of	   the	   activated	   receptor:	   Gα,	   Gβγ	   or	   arrestin	  
dependent	  signalling.	  Identifying	  which	  of	  these	  pathways	  is	  involved	  would	  be	  crucial	  to	  make	  
sense	  of	  contradictory	  observations	  in	  the	  literature	  and	  will	  allow	  further	  investigation	  into	  the	  
specifics	  of	  signal	  transduction	  to	  be	  targeted	  against	  specific	  interactions.	  	  
	  
Gβγ	   subunits	  are	  widely	  associated	  with	   chemokine	   receptor	   signalling	  via	  activation	  of	  PI3Kγ	  
which	   signals	   to	   PKB	   and	   eventually	   to	   MAPK	   dependent	   signalling	   to	   cytoskeletal	  
rearrangements	   and	   migration	   [57,	   58].	   The	   Gβγ	   inhibitor	   gallein	   has	   been	   shown	   to	   inhibit	  
chemotaxis	   in	   other	   CCR	   systems	   [57]	   and	   represented	   an	   opportunity	   to	   disrupt	   signalling	  
downstream	   of	   CCR5	   without	   resulting	   to	   proteomic	   techniques.	   Gallein	   represents	   a	   useful	  
investigative	   tool	   because	   the	   knock	   down	   of	   Gβ	   and	   Gγ	   units	   via	   siRNA,	   which	   is	   the	   other	  
alternative	  approach	  to	  this	  experiment,	  would	  be	  difficult	  due	  to	  the	  large	  number	  of	  isotypes	  
and	  redundancy	  in	  signalling	  between	  isotypes	  [240].	  Gallein	  treatment	  did	  not	  affect	  THP-­‐1	  cell	  
chemotaxis	  which	   indicted	  the	   ‘classical’	   signal	   transduction	  through	  Gβγ	  did	  not	  occur	   in	   this	  
system.	   These	   data	   suggested	   that	   CCR5	   mediated	   migration	   was	   effected	   by	   either	   Gαi	   or	  
arrestin	  dependent	  signalling.	  Chemotaxis	  through	  CCR5	  has	  been	  shown	  to	  be	  pertussis	  toxin	  
(PTX)	   sensitive	   [74,	  93]	  which	  would	   suggest	   that	  all	   signalling	  occurs	  via	  Gαi,	  however,	   there	  
are	   still	   questions	   regarding	   the	   nature	   of	   PTX	   inhibition,	   such	   as	   whether	   or	   not	   Gβγ	   and	  
arrestin	   can	   function	   normally	   with	   covalently	   inactivated	   Gα	   subunits	   interacting	   with	   the	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  receptor.	  With	  this	  in	  mind	  it	  was	  decided	  to	  investigate	  the	  possible	  role	  of	  arrestin	  dependent	  
signalling	  to	  chemotaxis	  through	  CCR5	  activation. 
	  
Non-­‐visual	   arrestins	   2	   and	   3	   are	   ubiquitously	   expressed	   and	   highly	   researched	   mediators	   of	  
GPCR	  signalling.	   In	  their	  canonical	  role	   ‘arrest’	  GPCR	  activity	  by	  binding	  phosphorylated	  serine	  
and	  threonine	  residues	  on	  the	  GPCR	  C-­‐terminus	  [38]	  that	  leads	  to	  receptor	  desensitisation	  and	  
internalisation	  [213,	  241].	  As	  described	  in	  the	  introduction,	  arrestins	  were	  shown	  to	  function	  as	  
signalling	   scaffold	   with	   unique	   signalling	   capabilities;	   this	   arrestin	   dependent	   signalling	   was	  
distinct	   from	   its	   role	   in	   internalisation	   [43]	   and	   is	   thought	   to	  be	   responsible	   for	   ligand-­‐biased	  
signalling	   observed	   through	   GPCRs	   [242,	   243].	   As	   discussed	   arrestin	   dependent	   signalling	   is	  
important	   because	   1)	   it	  may	   be	   arrestin	   isotype	   specific	   in	   some	   systems	   [243]	   and	   2)	   it	   has	  
been	  linked	  with	  signal	  transduction	  to	  chemotaxis	  [39].	  There	  is	  evidence	  to	  support	  the	  idea	  
that	  recruitment	  of	  arrestin	  isotypes	  is	  governed	  by	  GRK	  and	  PKC	  phosphorylation	  of	  the	  GPCR	  
C-­‐terminus	   and	   even	   that	   alterations	   to	   this	   phosphorylation	   can	   directly	   alternate	   signal	  
transduction	  through	  specific	  arrestin	  isotypes	  [243].	  
	  
Overexpression	   of	   arrestins	   2	   and	   3	   resulted	   in	   significant	   reductions	   in	   calcium	   release	  
suggesting	   that	   activated	   CCR5	   signalling	   to	   calcium	   release	   was	   dependent	   on	   classical	   G	  
protein	  mediated	  signal	  transduction	  sensitive	  to	  arrestin	  mediated	  homologous	  desensitisation	  
[43].	  The	  effects	  of	  arrestin	  overexpression	  on	  migration	  could	  not	  be	  directly	  observed	  due	  to	  
disruptive	   effects	   of	   the	   electroporation	   process.	   Indirect	  modulation	   of	   arrestin	   recruitment	  
was	   attempted	   by	   treatment	   of	   THP-­‐1	   cells	   with	   the	   βARK1	   inhibitor	   which	   inhibits	   GRK2	  
phosphorylation	  of	  GPCR	  C-­‐	  terminal	  domains.	  Although	  GRKs	  2,	  3,	  5	  and	  6	  have	  been	  shown	  to	  
phosphorylate	  CCR5	  C-­‐terminal	  serines	  at	  supra-­‐cytosolic	  concentrations	  [12]	  at	  normal	  cellular	  
expression	  levels	  GRK2	  is	  considered	  the	  primary	  mediator	  of	  arrestin	  recruitment	  [46].	  βARK1	  
significantly	   reduced	   THP-­‐1	   migration	   towards	   CCL3	   suggesting	   that	   recruitment	   of	   arrestins	  
enhanced	   signalling	   to	   chemotaxis	   therefore	   indicating	   that	   CCR5	   mediated	   chemotaxis	  
occurred	   via	   arrestin	   dependent	   signal	   transduction.	   These	   data,	   however,	   do	   not	   initially	  
appear	  to	  support	  previous	  findings.	  Firstly	  GRK2	  +/-­‐	  murine	  t-­‐cells	  ,	  which	  express	  half	  cytosolic	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  concentrations	  of	  GRK2	  showed	  significant	  increases	  in	  migration	  and	  ERK/PKB	  phosphorylation	  
but	   ~50%	   reduction	   in	   CCR5	   phosphorylation	   [232].	   A	   possible	   explanation	   for	   these	  
observations	   is	   that	   other	   GRK	   isotypes	   act	   redundantly	   or	   that	   alteration	   in	   the	   temporal	  
kinetics	   of	   receptor	   phosphorylation/	   arrestin	   recruitment	   are	   important	   to	   migration.	  
Huttenrauch	   et	   al.	   demonstrated	   that	   CCR5	   receptor	  mutants	   with	   C	   terminal	   serine/alanine	  
mutations	  would	  recruit	  arrestins	  with	  any	  two	  of	  the	  four	  phosphorylation	  sites	  intact,	  but	  that	  
receptor	   desensitisation	   required	   specific	   serine	   phosphorylation	   [43].	   The	   reduction	  of	  GRK2	  
may	   therefore	   represent	   a	   reduction	   in	   desensitisation	   by	   arrestin	   binding	  whilst	  maintaining	  
sufficient	   arrestin	   interaction	   to	   facilitate	   arrestin	   mediated	   signalling	   to	   chemotaxis.	   The	  
second	  contradictory	  observation	   is	   that	  CCR5	  C-­‐terminal	   truncation	  mutants	   show	  significant	  
increases	  in	  migration.	  Binding	  of	  arrestin	  solely	  to	  the	  ligand	  activated	  DRY	  motif	  may	  explain	  
this	  observation	  and	  is	  supported	  by	  the	  fact	  that	  C-­‐terminal	  induced	  desensitisation	  would	  be	  
impossible	  allowing	  prolonged	  signalling.	  Arrestin	  mediated	  signalling	  scaffolds	  bound	  only	  via	  
their	   secondary	   binding	   site	   to	   DRY	   motifs	   is	   an	   interesting	   idea	   and	   is	   supported	   the	  
observation	  of	  Huttenrauch	  et	  al.	  that	  oligomeric	  protein	  sequences	  representing	  the	  DRY	  motif	  
of	   CCR5	   constitutively	   bind	   arrestin	   [43].	   More	   relevant	   is	   to	   observation	   that	   CCR5	   with	   a	  
mutated	   DRY	   motif	   could	   not	   signal	   to	   chemotaxis	   [97].	   The	   observed	   effects	   of	   C-­‐terminal	  
truncation	   also	   support	   the	   idea	   that	   the	   un-­‐phosphorylated	   C-­‐terminus	   acts	   as	   a	   negative	  
regulator	   of	   signalling	   via	   CCR5	   [43].	   The	   observed	   effect	   of	   βARK1	   inhibitor	   treatment	   is	  
explained	  in	  two	  ways,	  firstly	  the	  190	  µM	  concentration	  is	  sufficient	  to	  inhibit	  over	  50%	  of	  GRK2i	  
therefore	  reducing	  any	  pro-­‐migratory	  effects	  of	  limited	  GRK2	  expression/inhibition	  as	  seen	  with	  
GRK2+/-­‐	   mice.	   Secondly,	   as	   small	   molecule	   inhibition	   does	   not	   remove	   the	   GRK2	   from	   the	  
cytoplasm	  steric	  hindrance	  of	  localised	  but	  inactivated	  GRK	  might	  enhance	  inhibitory	  effects	  by	  
preventing	  interaction	  between	  the	  receptor	  C-­‐terminus	  and	  non-­‐inhibited	  proteins.	  The	  effect	  
of	   the	   pan-­‐isotype	   PKC	   inhibitor	   bisindolylmaleimide	   may	   also	   support	   the	   role	   of	   GRK2	  
mediated	  arrestin	  recruitment	  in	  CCR5	  mediated	  chemotaxis.	  Treatment	  of	  THP-­‐	  cells	  with	  the	  
inhibitor	   enhanced	   the	   migratory	   response	   towards	   CCL3,	   an	   observation	   which	   would	   be	  
explained	  by	  a	  decrease	   in	   the	   rapid	   serine	  337	  phosphorylation	  known	   to	  occur	  via	  PKC	   [38]	  
and	  a	  shift	  to	  the	  less	  rapid	  GRK2	  mediated	  phosphorylation	  sites	  (Figure	  4.16).	  If	  this	  were	  the	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  case,	   it	   may	   also	   suggest	   that	   GRK2	   mediated	   phosphorylation	   of	   serine	   337	   may	   induce	  
conformational	   changes	   that	   increase	   arrestin	   mediated	   signalling	   to	   migration.	   A	   further	  
implication	  of	  these	  observations	  is	  that	  C-­‐terminal	  phosphorylation	  at	  different	  loci	  can	  induce	  
conformational	   changes	   in	   arrestin	   which	   can	   direct	   signalling	   to	   either	   desensitisation	   or	  
arrestin	  dependent	  signalling.	  	  Another	  explanation	  for	  these	  observations	  however	  may	  be	  that	  
the	   inhibition	   of	   the	   conventional	   protein	   kinase	   C	   with	   bisindolylmaleimide	   enhances	   PKCζ	  
signalling.	   PKCz	   has	   been	   linked	   with	   migration	   in	   numerous	   cells	   types	   [236]	   and	   has	   been	  
shown	  to	  specifically	  be	  required	  of	  THP-­‐1	  migration	  towards	  the	  cytokine	  CSF	  where	  it	  plays	  a	  
role	  in	  facilitating	  actin	  polymerisation	  [235].	  
	  
Figure	  4.16:	  Possible	  explanations	  for	  the	  observed	  effects	  of	  GRK2	  inhibitor	  βARK1i	  and	  PKC	  
inhibitor	  bisindolylmaleimide.	  Usually	  CCR5	  activation	  leads	  to	  arrestin	  mediated	  homologous	  
desensitisation	   (H/D)	   or	   arrestin	   dependent	   signalling	   in	   a	   ratio	   determined	   by	   cytoplasmic	  
protein	   complement.	   Treatment	   with	   bisindolylmaleimide	   prevents	   rapid	   PKC	  
phosphorylation	   of	   CCR5	   and	   shifts	   signalling	   towards	   arrestin	   dependent	   signalling	   to	  
chemotaxis.	   Treatment	  with	  βARK1	   inhibitor	   results	   in	   a	   decrease	   in	   all	   arrestin	  dependent	  
processes.	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  Treatment	  of	  THP-­‐1	  cells	  with	  the	  oligomeric	  PKCζ	  pseudosubstrate	  inhibitor	  significantly	  affects	  
the	  efficacy	  of	  CCL3	  stimulated	  calcium	  release	  but	  has	  no	  effect	  on	  migration.	  This	  effect	  on	  
calcium	   reduction	   is	   not	   observed	   in	   similarly	   treated	   HeLa.RC49	   cells	   suggesting	   that	   the	  
observations	  seen	   in	  THP-­‐1	  cells	  are	  CCR1	  specific	  or	  cell	   line	  specific.	   In	  either	  case,	   the	  data	  
indicate	   that,	   unlike	   for	   CSF	   stimulated	   cytokine	   receptor	   mediated	   migration,	   PCKζ	   is	   not	  
required	  for	  CCR5	  mediated	  migration	  in	  THP-­‐1	  cells.	  This	  also	  supports	  the	  idea	  that	  cytokine	  
receptor	  transactivation,	  which	  has	  been	  shown	  to	  occur	  with	  numerous	  GPCRs	  [96]	  and	  CCR5	  
[85]	   specifically,	   is	  not	   involved	   in	   the	  chemotactic	   response.	  These	  observations	  also	  support	  
the	   idea	   that	   bisindolylmaleimide	   treatment	   is	   reducing	   conventional	   PKC	   phosphorylation	   of	  
the	  CCR5	  C-­‐terminus	   and	  altering	   arrestin	   recruitment	   kinetics.	   The	  observed	  effects	  of	  GRK2	  
and	   PKC	   inhibitors	   on	   THP-­‐1	   chemotaxis	   do	   not	   explain	   the	   role	   of	   arrestin	   mediated	  
internalisation	  or	  the	  interaction	  with	  cytoskeletal	  mediators	  of	  the	  process	  such	  as	  clathrin	  and	  
dynamin	  which	  may	  be	  instrumental	  in	  the	  migratory	  response	  [77].	  	  
	  
ERK1/2	   MAPK	   phosphorylation	   is	   often	   used	   as	   a	   marker	   for	   Gβγ	   and	   arrestin	   dependent	  
pathway	  signalling	  and	  there	  are	  numerous	  studies	  suggesting	  a	  signal	  transduction	  axis	  for	  the	  
ERK1/2	   to	   chemotaxis	   via	   Gβγ	   or	   as	   part	   of	   arrestin	   signalling	   scaffolds	   [43].	   However,	  
particularly	   where	   arrestin	   dependent	   signalling	   is	   concerned,	   it	   is	   not	   clear	  whether	   ERK1/2	  
phosphorylation	  is	  a	  prerequisite	  of	  migration	  or	  a	  consequence	  of	  scaffold	  formation	  unrelated	  
to	   migratory	   responses	   [39].	   The	   potent	   ERK1/2	   MAPK	   inhibitor	   PD98059	   was	   used	   to	  
investigate	  this	  and	  revealed	  that	  THP-­‐1	  migration	  via	  CCR5	  activation	  is	  not	  sensitive	  to	  ERK	  1/2	  
inhibition.	   Although	   this	   data	   may	   appear	   to	   suggest	   that	   either	   Gβγ	   and	   arrestin	   mediated	  
signalling	   are	   not	   occurring,	   they	   can	   be	   interpreted	   as	   evidence	   to	   support	   arrestin	   scaffold	  
signalling,	  as	   the	  non-­‐phosphorylated	  ERK	  are	   still	   available	   to	   form	  signalling	  complexes	  with	  
arrestin	  [39].	  Conversely	  the	  ‘linear’	  transduction	  from	  Gβγ	  –PI3K-­‐PKB-­‐ERK-­‐migration	  associated	  
with	   classical	   G	   protein	   signalling	   [57,	   58]	  would	   be	   ERK	   activation	   dependent.	   Cheung	   et	   al.	  
demonstrated	   that	   macrophage	   migration	   is	   dependent	   on	   both	   ERK	   and	   PI3K	   type	   1A	  
phosphorylation	  but	  it	  was	  not	  made	  clear	  if	  phosphorylation	  is	  required	  for	  scaffold	  formation.	  
The	   potential	   diversity	   of	   these	   arrestin	   scaffolds	   was	   also	   not	   addressed;	   the	   calcium	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  dependent	  Pyk2	  was	  shown	  to	  be	  important	  in	  the	  formation	  of	  the	  arrestin	  scaffold	  but	  in	  THP-­‐
1	  cells,	  where	  calcium	  release	  and	  migration	  are	  known	  to	  be	  independent,	  alternative	  proteins	  
may	  be	  recruited	  to	  arrestin	  scaffolds.	  For	  this	  reason	  it	  was	  important	  to	  determine	  the	  role	  of	  
other	   MAPKs	   and	   reinforced	   the	   importance	   of	   understanding	   PI3K	   function	   downstream	   of	  
activated	  chemokine	  receptors.	  	  	  
	  
The	   p38	   MAP	   kinase	   has	   been	   associated	   with	   α-­‐chemokine	   receptor	   mediated	   arrestin	  
dependent	  signalling	  [244]	  and	  with	  chemokine	  stimulated	  migration	  in	  vivo	  [245].	  Therefore	  it	  
was	  important	  to	  determine	  the	  effect	  of	  p38	  inhibition	  in	  CCR5	  mediated	  chemotaxis	  on	  THP-­‐1.	  
The	  potent	  small	  molecule	  inhibitor	  SB203580	  was	  unable	  to	  affect	  THP-­‐1	  migration,	  suggesting	  
the	  p38	  protein	  played	  no	  role	   in	  the	  cytoplasmic	  (non-­‐transcriptional)	  signalling	  to	  migration.	  
The	  MAPK	   c-­‐Jun	  N-­‐terminal	   kinase	   (JNK)	   has	   been	   shown	   to	   associate	  with	   arrestin	   scaffolds	  
[246]	  but	  it	   is	  associated	  with	  increases	  in	  transcription,	  which	  is	  unlikely	  to	  affect	  cytoplasmic	  
signal	   transduction	  protein	  concentrations	   in	  the	  time	  frame	  of	  the	  chemotaxis	  assay.	  For	  this	  
reason	   JNK	   inhibition	   was	   not	   investigated.	   The	   effects	   of	   ERK1/2	   and	   p38	   inhibition	   clearly	  
show	  that	  although	  these	  proteins	  have	  been	  shown	  to	  be	  activated	  by	  arrestins	  and	  Gβγ	  their	  




Figure	   4.17:	   An	   Overview	   of	   chapter	   4	   results	   and	   possible	   lines	   of	   research.	   Arrestin	  
dependent	   signalling	   directly	   or	   indirectly	   through	   Src	   family	   tyrosine	   kinases	   appears	   to	  
represent	   an	   important	   axis	   in	   CCR5	   mediated	   migration	   in	   THP-­‐1	   cells.	   (?)	   Represents	  
interactions	  that	  should	  be	   investigated	  to	  clarify	  the	  nature	  of	  signal	  transduction	  between	  
receptor	  activation	  and	  migration	  of	  cells.	  	  
	  
The	   data	   outlined	   a	   picture	   of	   CCR5	  mediated	   chemotaxis	   which	   seemed	   to	   vary	   from	  what	  
might	   be	   expected	   based	   on	   what	   has	   been	   published	   about	   other	   GPCRs	   and	   chemokine	  
receptors	   (Figure	   4.17).	   It	   seemed	   unlikely	   that	   migration	   in	   THP-­‐1	   stimulated	   by	   CCL3	  
represented	   a	   unique	   signalling	   axis	   from	   start-­‐to-­‐finish,	   so	   it	   was	   therefore	   important	   to	  
identify	   which	   signalling	   proteins	   further	   downstream	   are	   shared	   with	   canonical	   migratory	  
signalling.	   	   Rho	   family	   proteins	   are	   known	   to	   be	   crucial	   for	   transduction	   into	   actin	   dynamics	  
[247]	  and	  are	   involved	  with	   filopodia	   formation	  and	   focal	  adhesion	  disassembly	   [96,	  192]	  and	  
are	  linked	  to	  chemotaxis	  via	  numerous	  receptors	  types.	  Inhibition	  of	  Rho	  Kinase	  (ROCK)	  with	  the	  
small	  molecule	   inhibitor	  Y27632	  resulted	   in	  a	  significant	  reduction	   in	  migration	  demonstrating	  
that	   downstream	   signalling	   from	   CCR5	   converged	   at	   this	   point	   with	   other	   chemotactic	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  signalling.	   These	   data	   indicate	   that	   the	   novel	   CCR5	  mediated	   signalling	   events	   to	   chemotaxis	  
occur	  between	  the	  recruitment	  of	  arrestins	  and	  the	  activation	  of	  ROCK	  and	  that	  transactivation	  
through	  receptor	  tyrosine	  kinases	  is	  not	  likely.	  The	  role	  of	  non-­‐receptor	  tyrosine	  kinases	  in	  CCR5	  
mediated	  chemotaxis	  in	  THP-­‐1	  cells	  was	  investigated,	  as	  non-­‐RTKs	  such	  as	  Lyn	  are	  important	  in	  
migration	   [79].	   Lyn	   forms	   part	   of	   the	   CCR5	   associated	   arrestin	   scaffolded	   signalling	   complex	  
identified	  by	  Cheung	  et	  al.	  [39],	  but	  have	  also	  been	  associated	  with	  	  trimeric	  G	  protein	  signalling	  
[96].	  	  The	  non-­‐receptor	  tyrosine	  kinase	  inhibitor	  bosutinib	  has	  been	  shown	  to	  inhibit	  c-­‐Src	  and	  
Lyn	  with	  an	  IC50	  around	  500	  nM	  [79].	  Treatment	  of	  THP-­‐cells	  with	  10	  µM	  bosutinib	  significantly	  
reduced	  migration,	  this	  indicates	  that	  non	  receptor	  tyrosine	  kinases	  are	  crucial	  for	  signalling	  to	  
migration.	   These	   data	   do	   not	   explain	   how	   this	   may	   occur	   mechanistically:	   tyrosine	  
phosphorylation	   is	   important	   in	   targeting	   proteins	   with	   SH2	   binding	   sites	   such	   as	   PI3K	  
regulatory	   domains,	   STATS	   and	   adaptor	   proteins	   such	   ad	   Grb2.	   This	   suggested	   that	   a	   key	  
process	  in	  CCL3	  mediated	  migration	  might	  be	  the	  targeting	  of	  these	  adaptor	  protein	  complexes.	  
	  
Bosutinib	   treatment	  was	  also	  effective	  at	  preventing	  HeLa.RC49	  wound	  healing	   stimulated	  by	  
CCL3,	  which	  suggested	  that	  non-­‐receptor	  tyrosine	  kinase	  activity	  is	  important	  in	  CCR5	  mediated	  
migration	  in	  this	  system	  as	  well.	  Direct	  comparison	  between	  the	  two	  migration	  assays	  must	  be	  
considered	  carefully	  for	  two	  reasons.	  Firstly	  there	  has	  been	  evidence	  to	  suggest	  that	  fibroblast	  
and	  leukocytes	  migration	  requires	  different	  machinery	  [115,	  248],	  with	  adherent	  cell	  migration	  
being	   dependent	   on	   PI3K	   mediated	   cell	   polarisation,	   which	   is	   not	   important	   for	   monocyte	  
migration	  [115].	  Secondly,	  the	  extended	  time	  over	  which	  scratch	  assays	  occur	  allows	  increases	  
in	   protein	   transcription	   stimulated	   by	   receptor	   activation	   to	   potentially	   alter	   the	   cytoplasmic	  
signal	   transduction	   complement.	   	   For	   these	   reasons	   it	   was	   important	   to	  move	   the	  migration	  
assay	  into	  cells	  which	  better	  represented	  THP-­‐1	  monocytes.	  
	  
Activated	  peripheral	  blood	   leukocytes	   represent	  a	  population	  of	  primary	  human	  cells	   that	  are	  
highly	  mobile	  and	  known	  to	  express	  CCR5	  and	  CXC	  motif	  chemokine	  receptors	   [32].	  Activated	  
PLBs	  were	  used	   to	  determine	   if	   signalling	   through	  CXC	  motif	  chemokine	  receptors	  shared	  any	  
similarities	   with	   CCR5	   signalling	   to	  migration	   in	   small	   highly	  motile	   cells.	   Treatment	   of	   these	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  cells	  immediately	  revealed	  differenced	  in	  cellular	  responses	  and	  gallein	  pre-­‐treatment	  resulted	  
in	  significant	  reductions	  in	  migration	  indicating	  ‘classical’	  signalling	  to	  migration	  through	  Gβγ	  to	  
PI3K,	  PKB	  and	  ERK.	   	  Calcium	  release	   in	  response	  to	  CXCL11	  and	  CCL3	  was	  also	  determined	  for	  
activated	  PBLs.	  Both	  chemokines	  stimulated	  calcium	  release	  suggesting	   functional	  CC	  and	  CXC	  
motif	   chemokines	   were	   present.	   Pre-­‐treatment	   with	   gallein	   resulted	   in	   a	   non-­‐significant	  
increase	   in	   calcium	   release	   for	   both	   CCL3	   and	   CXCL11	   stimulated	   responses	   although	   a	   clear	  
trend	  towards	  increase	  was	  observed	  with	  CXCL11	  stimulated	  responses.	  The	  observed	  increase	  
in	   calcium	   release	  has	  been	  noted	   in	  THP-­‐1	   signalling	   to	   calcium	   release	   in	  THP-­‐1	   cells	   so	   the	  
observed	  response	  is	  not	  what	  would	  be	  expected	  (unpublished	  data,	  Kerr	  et	  al.)	  and	  likely	  to	  be	  
due	   to	   differences	   in	   cell	   type	  what	   can	   be	   concluded	   is	   that	   the	   CCR5	   and	   CXCR3	   signalling	  
functions	  differentially	  within	  a	  cell	  type	  which	  indicates	  that	  recruitment	  of	  signalling	  proteins	  
to	  these	  receptors	  is	  not	  shared.	  	  
	  
PBLs	   make	   a	   useful	   comparative	   system	   for	   CCL3	   stimulated	   THP-­‐1	   cells	   without	   the	  
disadvantages	   rationalising	   the	   differences	   between	   adherent	   vs.	   suspension	   cell	   chemotaxis	  
[95,	  115].	  The	  use	  of	  PBLS	  also	  produces	  data	  with	  more	  clinical	  significance,	  as	  THP-­‐1	  cells,	  by	  
their	  nature	  and	  despite	  validation	  as	  a	  model	  for	  disease,	  are	  abnormal.	  	  
 
The	   non-­‐receptor	   tyrosine	   kinase	   inhibitor	   bosutinib,	  which	   significantly	   reduced	  migration	   in	  
THP-­‐1	   cells	   to	   basal	   levels	   was	   used	   to	   determine	   if	   PBL	   migration	   was	   similarly	   affected.	  
Significant	  reductions	  in	  migration	  towards	  CXCL3	  were	  noted	  however	  the	  mean	  reduction	  was	  
not	  as	  great	  as	  that	  seen	  in	  THP-­‐1	  cells	  (≈60%	  reduction	  in	  PBLs	  vs.	  ≈	  100%	  reduction	  in	  THP-­‐1	  
cells).	  This	  observation	  may	  be	  explained	  by	  the	   fact	   that	  PBLs	  show	   large	  variability	  between	  
donors	  in	  terms	  of	  the	  efficacy	  of	  bosutinib	  with	  one	  donor	  showing	  no	  reduction	  in	  migration.	  
This	   variability	   can	   be	   attributed	   to	   genetic	   variability	   between	   donors	   but	   taken	   as	   a	  whole	  
suggest	  that	  non	  receptor	  tyrosine	  kinases	  represent	  a	  common	  focus	  for	  signalling	  to	  migration	  
downstream	  of	  both	  receptors	  like	  Rho	  Kinases	  are	  theorised	  to	  be.	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  Broadly,	  CCR5	  signalling	  is	  known	  to	  occur	  via	  Gαi,	  Gβγ	  or	  arrestin	  dependent	  pathways	  at	  the	  
most	   ‘upstream’	   level	   post	   receptor	   activation.	   Due	   to	   the	   potential	   misrepresentation	   of	  
signalling	   which	   might	   occur	   with	   pertussis	   toxin	   treatment	   it	   was	   decided	   to	   focus	   on	  
eliminating	  Gβγ	  and	  arrestin	  mediated	  pathways	  experimentally.	  THP-­‐1	  migration	  through	  CCR5	  
stimulation	   was	   shown	   to	   be	   Rho	   kinase	   dependent,	   which	   suggested	   activation	   of	   well	  
documented	  chemotactic	  signalling	  at	  some	  level.	   	  Treatment	  with	  a	  Gβγ	  inhibitors	  and	  MAPK	  
inhibitors	  suggested	  Gβγ	  signalling	  was	  not	  involved,	  which	  was	  interesting	  as	  this	  represented	  
the	   ‘classic’	   route	   to	   chemotaxis	   via	   chemokine	   receptors	   [43,	   57].	   The	   evidence	   strongly	  
supported	  a	  role	  for	  arrestin	  dependent	  signalling	  however	  both	  at	  the	  recruitment	  and	  scaffold	  
signalling	   level	   (Figure	  4.17).	   	  These	  observations	   leave	  some	  unanswered	  questions	  however:	  
the	  exact	  nature	  of	  arrestin	   in	   signal	   transduction	   is	  not	   clear,	  particularly	  with	   regard	   to	  any	  
link	   to	  endocytosis	  or	  associated	  machinery	  such	  as	  clathrin	  and	  dynamin.	  This	   is	  because	  the	  
observations	  made	  using	  GRK2	  inhibitors	  could	  be	  also	  attributed	  to	  a	  failure	  of	  these	  processes	  
affecting	  migration	   in	   some	  way.	   The	   role	   of	   non-­‐receptor	   tyrosine	   kinases	   is	   also	   unclear	   as	  
their	   function	   seems	   to	   be	   conserved	   in	   CXCR3	   stimulated	  migration	   in	   activated	   PBLs.	   Non-­‐
receptor	  tyrosine	  kinase	  involvement	  with	  chemokine	  receptor	  mediated	  chemotaxis	  has	  been	  
associated	   with	   Gα,	   Gβγ	   and	   transactivated	   cytokines	   receptors	   so	   more	   work	   is	   needed	   to	  
unravel	  its	  true	  function	  in	  THP-­‐1	  cells.	  	  These	  questions	  will	  be	  addressed	  in	  chapter	  6.	  	  
	  	  
4.5.	  Chapter	  Conclusions	  
	  
The	  final	  conclusions	  to	  be	  drawn	  from	  this	  chapter	  are:	  
1) The	  evidence	  supports	  that	  arrestin	  dependent	  signalling	  to	  chemotaxis	  through	  CCR5	  
in	  THP-­‐1	  cells	  represents	  the	  most	  likely	  route	  for	  signalling	  post	  receptor	  activation.	  
2) Downstream	   signalling	   through	   non-­‐receptor	   tyrosine	   kinases	   and	   Rho	   kinase	   is	   also	  
involved	  with	  signalling	  migration,	  which	   is	  also	  seen	   in	  CXCR3	  mediated	  chemotaxis,	  
and	  may	  therefore	  represent	  a	  common	  signal	  transduction	  pathway.	  
3) The	   role	  of	   internalisation	  and	   the	  mechanistics	  of	  non-­‐receptor	   tyrosine	  kinases	  will	  
be	  crucial	  in	  clarifying	  CCR5	  mediated	  signal	  transduction.	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  CHAPTER	  5	  –	  JAK/STAT:	  Cytoplasmic	  mediators	  of	  




The	  JAK/STAT	  signalling	  axis	  consists	  of	  Janus	  Kinase	  (JAK)	  and	  Signal	  Transducer	  and	  Activator	  
of	  Transcription	  (STAT)	  which	  transduce	  signalling	  from	  activated	  membrane	  bound	  receptors	  to	  
up	   regulate	   protein	   expression.	   JAK/STAT	   signalling	   is	   classically	   associated	   with	   activated	  
cytokine	  receptors	  [119]	  and	  is	  well	  characterised	  as	  oncogenic	  in	  numerous	  cancers	  [126,	  249].	  
Upon	   activation,	   cytokine	   receptors	   promote	   JAK	   autophosphorylation,	   that	   in	   time,	   leads	   to	  
STAT	  phosphorylation	  and	  homodimerisation.	  STAT	  homodimers	   translocate	   to	   the	  nucleus	   to	  
induce	  protein	  transcription	  for	  a	  range	  of	  proteins	  [126,	  250].	  	  Although	  JAK2	  association	  with	  
CXCR4	  has	  been	  documented	   [251];	  Mueller	  et	  al.	  demonstrated	  direct	   JAK2-­‐CCR5	   interaction	  
[40],	  the	  nature	  of	  this	  association	  has	  not	  been	  well	  characterised.	  There	  is	  evidence	  to	  show	  
CCR5	  associated	  JAK2	  activate	  STATs	  [122]	  and	  that	  this	  activation	  is	  G	  protein	  independent	  [40,	  
122].	   If	   CCR5-­‐activated	   JAK/STAT	   behaves	   solely	   as	   transcription	   factors	   or	  whether	   they	   can	  
behave	   as	   cytoplasmic	   mediators	   of	   signal	   transduction	   to	   cellular	   responses	   is	   not	   known.	  
JAK/STAT	  signalling	  has	  been	  associated	  with	  chemotaxis	  via	  a	  range	  of	  GPCRs	  [125,	  252],	  and	  
considering	  that	  signal	  transduction	  via	  G	  protein	  signalling	  to	  chemotaxis	  seem	  to	  be	  G-­‐protein	  
independent,	   the	   role	   of	   JAK/STAT	   in	   association	   with	   CCR5	   makes	   an	   interesting	   target	   for	  
investigation.	  JAK	  and	  STAT	  isotypes	  show	  preferential	  interactivity,	  with	  the	  canonical	  signalling	  
of	  JAK1/STAT3	  from	  type	  1	  cytokine	  receptors	  and	  JAK2/STAT5	  through	  type	  2	  cytokines.	  These	  
canonical	  pathways	  do	  not	  represent	  all	  possible	  JAK/STAT	  signalling	  with	  many	  combinations	  of	  
JAK/STAT	  interaction	  appearing	   in	  the	   literature.	  The	  JAK2/STAT3	  axis	  appears	  to	  be	  of	  clinical	  
importance	  as	   it	   is	  associated	  with	  abnormal	   signalling	   in	  breast	  and	  other	  cancers	   [121,	  126,	  
249]	  and	  STAT3	  has	  associations	  with	  chemotaxis	  [252].	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  5.2.	  Chapter	  Aims	  
	  
To	  determine	  if	  the	  JAK2	  association,	  which	  has	  been	  shown	  to	  occur	  with	  CCR5,	  is	  involved	  in	  
STAT3	  activation	  or	  cytosolic	  signal	  transduction	  associated	  with	  CCR5	  mediated	  chemotaxis.	  
A	   range	   of	   small	   molecule	   inhibitors	   of	   JAKs	   and	   STATs	   will	   be	   used	   to	   characterise	   calcium	  

























	  5.3.	  Results	  
	  
5.3.1:	   JAK2/STAT3	   inhibitor	  cucurbitacin	   I	   completely	   inhibits	  CCR5	  mediated	  chemotaxis	  by	  
disrupting	  actin	  polymerisation	  
	  
	  
Figure	  5.1:	  JAK2/STAT3	  inhibitor	  cucurbitacin	  I	  does	  not	  significantly	  affect	  THP-­‐1	  cell	  calcium	  
release	   stimulated	   by	   CCL3.	   (a)	   Concentration	   response	   curve	   for	   calcium	   release	   in	   THP-­‐1	  
cells	   stimulated	   by	   CCL3	   with	   and	  without	   treatment	   with	   cucurbitacin	   I	   (Cucurb).	   (b)	   Pre-­‐
treatment	   for	   0.5hr	   with	   10	   µM	   cucurbitacin	   I	   does	   not	   significantly	   affect	   intracellular	  
calcium	   flux.	   Results	   represent	   the	   mean	   ±	   SEM	   of	   at	   least	   3	   independent	   experiments	  
(Unpaired	  t-­‐test,	  ns	  =	  not	  significant	  vs.	  vehicle	  control).	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Cucurbitacin	  I	  is	  one	  of	  a	  series	  of	  over	  20	  naturally	  occurring	  cucurbitacin	  homologues	  derived	  
from	   the	  Cucurbitaceae	   (pumpkin)	   family	   of	   plants.	   Cucurbitacin	   I	   has	   been	   shown	   to	   inhibit	  
phosphorylation	   of	   both	   JAK2	   and	   STAT3	   [126]	   and	   inhibits	   cellular	   functions	   dependent	   on	  
JAK2/STAT3	   signalling	   [253].	   There	   is	   some	  evidence,	   however,	   that	   cucurbitacin	   affects	   actin	  
fiber	  formation	  in	  some	  cell	  lines	  [254].	  Pre-­‐treatment	  of	  THP-­‐1	  cells	  with	  10	  µM	  Cucurbitacin	  I	  
for	  0.5hr	  did	  not	  affect	  the	  concentration	  response	  of	  CCL3	  stimulated	  calcium	  release	  (Figure	  
5.1a)	  (EC50	  45.5±9.6	  nM	  control	  vs.	  36.9±5.7	  nM	  cucurbitacin	  I)	  and	  did	  not	  significantly	  reduce	  




Figure	   5.2:	   Cucurbitacin	   I	   completely	   inhibits	   CCL3	   stimulated	   migration	   in	   THP-­‐1	   cells.	  	  
Incubation	   with	   10	   µM	   cucurbitacin	   I	   (Cucurb)	   for	   0.5hr	   completely	   inhibited	   THP-­‐1	   cell	  
migration	   1	   nM	  CCL3.	   All	   results	   represent	   the	  mean	   ±	   SEM	  of	   3	   independent	   experiments	  
(One-­‐way	  ANOVA,	  Bonferroni	  multiple	  comparison.	  ***	  indicated	  p≤0.001,	  n=3).	  
	  
Treatment	  with	  10	  µM	  cucurbitacin	  had	  a	  marked	  effect	  on	  CCL3	  mediated	  migration	  in	  THP-­‐1,	  
however,	  with	  migration	  in	  treated	  cells	  reduced	  to	  zero	  (Figure	  5.2.).	  This	  marked	  reduction	  in	  
chemotaxis	   could	   not	   be	   attributed	   to	   cytotoxic	   effect	   because	   calcium	   flux	   was	   unaffected	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  which	   suggested	   that	   the	   inhibitor	   was	   inducing	   a	   failure	   in	   cellular	   processes	   crucial	   to	  
chemotaxis	   but	   not	   calcium	   release.	   Actin	   polymerisation	   was	   the	   obvious	   candidate:	   a	  
functioning	  actin	  cytoskeleton	  is	  a	  prerequisite	  for	  all	  forms	  of	  cytoskeletal	  rearrangement	  and	  
Knecht	  et	  al.	  had	  shown	  cucurbitacin	  I	  affected	  actin	  polymerisation	  [254].	  	  	  
	  
	  
Figure	   5.3:	  Actin	   polymerisation	   inhibitor	   cytochalasin	   D	   does	   not	   significantly	   affect	   THP-­‐1	  
intracellular	  calcium	  release	  stimulated	  by	  CCL3.	  (a)	  Concentration	  response	  curve	  for	  calcium	  
release	   in	   THP-­‐1	   cells	   stimulated	   by	   CCL3	  with	   and	  without	   treatment	   with	   cytochalasin	   D	  
(CCD).	   (b)	   Pre-­‐treatment	   for	   0.5hr	   with	   2	   µM	   cytochalasin	   D	   does	   not	   significantly	   affect	  
intracellular	   calcium	   flux.	   Results	   represent	   the	   mean	   ±	   SEM	   of	   at	   least	   3	   independent	  





Figure	   5.4:	   Cytochalasin	   D	   completely	   inhibits	   CCL3	   stimulated	   migration	   in	   THP-­‐1	   cells.	  	  
Incubation	  with	  2	  µM	  cytochalasin	  D	  (CCD)	  for	  0.5hr	  completely	  inhibited	  THP-­‐1	  to	  migration	  
1	  nM	  CCL3.	  All	   results	   represent	   the	  mean	  ±	   SEM	  of	  6	   independent	  experiments.	   (One-­‐way	  
ANOVA,	  Bonferroni	  multiple	  comparison.	  ***	  =	  p≤0.001	  vs.	  vehicle	  control).	  
	  
It	   was	   decided	   to	   use	   the	   actin	   polymerisation	   inhibitor	   cytochalasin	   D	   to	   draw	   comparisons	  
with	  the	  effects	  of	  cucurbitacin	  I	  in	  THP-­‐1	  cells.	  Like	  cucurbitacin	  I,	  pre-­‐treatment	  with	  the	  actin	  
polymerisation	  inhibitor	  2	  µM	  cytochalasin	  D	  had	  no	  significant	  affect	  on	  the	  EC50	  (Figure	  5.3a)	  
or	   the	   level	   of	   intracellular	   calcium	   mobilisation	   stimulated	   by	   75	   nM	   CCL3.	   The	   effect	   of	  
cytochalasin	   D	   pre-­‐treatment	   on	   THP-­‐1	   chemotaxis	   was	   comparable	   to	   that	   seen	   with	  
cucurbitacin	   I	   (figure	   5.4).	   Migration	   towards	   1	   nM	   CCL3	   was	   completely	   inhibited	   by	   the	  
disruption	   of	   the	   actin	   cytoskeleton.	  Whilst	   this	   effect	   on	  migration	   is	   not	   surprising	   the	   fact	  
that	  calcium	  release	  is	  completely	  independent	  of	  a	  functional	  actin	  cytoskeleton	  is	  remarkable	  
and	   adds	   strong	   support	   to	   the	   conclusions	   of	   Cardaba	   et	   al.	   [75]	   that	   calcium	   flux	   and	  






Figure	   5.5:	   Cucurbitacin	   I	   disrupts	   actin	   polymerisation	   in	   HeLa.RC49	   cells.	   Micrographs	   of	  
HeLa.RC49	  monolayers	  treated	  with	  100	  nM	  CCL3	  and	  10	  µM	  cucurbitacin	  I	  (Cucurb)	  and	  2	  µM	  
cytochalasin	   D	   (CCD).	   Cells	   were	   fixed	   and	   stained	   with	   Alexa-­‐488	   phalloidin	   actin	   stain	  
(green).	  Images	  representative	  of	  population.	  Acquired	  with	  Leica	  imaging	  suite.	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Fluorescence	  microscopy	  was	  used	  to	  determine	  if	  cucurbitacin	  I	  disrupts	  the	  cytoskeleton	  using	  
Alexa-­‐488	  phalloidin	  stained	  HeLa.RC49	  (Figure	  5.5).	  These	  cells	  were	  grown	  as	  a	  monolayer	  on	  
coverslips	  to	  high	  confluence	  (methods	  and	  materials)	  and	  were	  treated	  for	  0.5hr	  with	  10	  µM	  
cucurbitacin	  I	  and	  then	  100	  nM	  CCL3	  for	  2hr	  prior	  to	  fixing	  and	  staining.	  Negative	  control	  cells	  
were	  stimulated	  with	  100	  nM	  CCL3	  for	  2hr	  prior	  to	  fixing	  and	  staining	  and	  the	  positive	  control	  
were	  pretreated	  with	  2	  µM	  cytochalasin	  D	  for	  0.5hr	  prior	  to	  1hr	  CCL3	  stimulation	  and	  staining.	  
Although	   actin	   filaments	   were	   not	   widely	   evident	   in	   the	   negative	   control	   the	   distribution	   of	  
actin	  was	  uniform.	  Cytochalasin	  D	  treated	  cells	  showed	  a	  marked	  disruption	  to	  actin	  localisation	  
with	  no	  stress	  fibers	  evident	  and	  the	  uniformity	  of	  actin	  abrogated.	  Cucurbitacin	  I	  treated	  cells	  
showed	  obvious	  disruption	  to	  the	  actin	  cytoskeleton	  although	  less	  pronounced	  than	  that	  seen	  






Figure	   5.6:	   Cucurbitacin	   I	   disrupts	   actin	   polymerisation	   in	   CHO.CCR5	   cells.	   Micrographs	   of	  
CHO.CCR5	  monolayers	   treated	   with	   100	   nM	   CCL3	   and	   10	   µM	   cucurbitacin	   I	   (Cucurb).	   Cells	  
were	  fixed	  and	  stained	  with	  Alexa-­‐488	  phalloidin	  actin	  stain	  (green).	  Images	  representative	  of	  
population.	  Acquired	  with	  Leica	  imaging	  suite.	  
	  
The	  phalloidin	  actin	  stain	  was	  also	  carried	  out	  in	  CHO.CCR5	  cells,	  which	  are	  larger	  and	  allow	  for	  
easier	   identification	  of	   cellular	   structures.	   Alexa-­‐488	   tagged	  phalloidin	   stain	   in	   CCL3	   activated	  
CHO.CCR5	  produced	   large	  numbers	   a	   clearly	   visible	   actin	   stress	   fibers	   (Figure	  5.6).	   Treatment	  
with	   10	   µM	   cucurbitacin	   I	   completely	   disrupted	   the	   ability	   for	   actin	   fibers	   to	   form,	   clearly	  
indicating	  that	  cucurbitacin	  I	  acts	  as	  an	  inhibitor	  or	  disruptor	  of	  actin	  polymerisation.	  Although	  it	  
seems	   likely	   that	   disruption	   of	   actin	  was	   responsible	   for	   the	   blocking	   of	   chemotaxis	   in	   THP-­‐1	  
cells,	   phalloidin	   staining	  of	   cucurbitacin	   I	   treated	   cells	  was	   inconclusive	  as	   the	   relatively	   small	  
size	  of	  the	  cell	  made	  if	  difficult	  to	  distinguish	  differences	  between	  control	  and	  treated	  cell	  actin	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  structures	   (data	  not	   shown).	   It	  was	  decided	   that	  a	  pilot	   flow	  cytometry	  experiment	  would	  be	  
run	   to	  determine	   if	   the	   technique	  could	  be	  used	   to	  differentiate	  between	  THP-­‐1	  cells	  with	  an	  
intact	  and	  cytochalasin	  D	  disrupted	  cytoskeleton.	  	  
	  
	  
Figure	  5.7:	  Cytochalasin	  D	  treatment	  produces	  a	  shift	  in	  phalloidin	  stained	  THP-­‐1	  fluorescence	  
as	  determined	  by	  flow	  cytometry.	  (a)	  THP-­‐1	  treated	  with	  2	  µM	  cytochalasin	  D	  show	  reduced	  
fluorescence	  intensity	  (black	  trace)	  compared	  to	  untreated	  controls	  (red	  trace).	  (b)	  Front/Side	  
scattering	  gating	  parameters.	  	  
	   	  
THP-­‐1	  cells	  were	  activated	  with	  100	  nM	  CCL3	  for	  1hr	  before	  treatment	  with	  cytochalasin	  D	  (2	  
µM	  for	  0.5hr)	  and	  then	  stained	  with	  Alexa-­‐488	  phalloidin.	  Cytochalasin	  D	  treated	  cells	  showed	  a	  
marked	   reduction	   in	   fluorescent	   intensity	   vs.	   control	   cells	   as	   determined	   by	   flow	   cytometry	  
(Figure	  5.7a)	  using	  the	  front/side	  scan	  gating	  shown	  (Figure	  5.7b).	  	  The	  data	  indicated	  that	  flow	  
cytometry	  could	  be	  used	   to	  analyse	   the	  effects	  of	  actin	  disruption	   in	  actin	   in	  THP-­‐1	  cells	  with	  
sufficient	  difference	  between	  treated	  and	  untreated	  cells	  to	  allow	  intermediated	  effects	  to	  be	  
distinguished.	  However,	  due	  to	  the	  relatively	  low	  resolution	  between	  control	  and	  cytochalasin	  D	  
treated	  cells,	  and	  due	  to	  the	  fact	  that	  HeLa.RC49	  and	  CHO.CCR5	  imaging	  had	  revealed	  a	  notable	  
disruption	   of	   the	   actin	   cytoskeleton	   with	   cucurbitacin	   treatment,	   it	   seemed	   reasonable	   to	  






	  5.3.2:	   JAK2	   and	   STAT3	   specific	   inhibitors	   have	   differential	   effects	   on	   CCL3	   induced	   calcium	  
release	  and	  migration	  in	  THP-­‐1	  
	  
A	   range	   of	   JAK2	   and	   STAT3	   specific	   inhibitors	   have	   been	   described	   [127,	   128,	   255]	   that	  
represent	  a	   line	  of	   research	   that	   could	  allow	   the	  observations	  made	  with	  cucurbitacin	   I	   to	  be	  
broken	   down	   and	   analysed	   in	   term	   of	   specific	   proteins	   in	   the	   JAK/STAT	   axis.	   The	   inhibitors,	  
known	   as	   JAK2	   inhibitor	   2,	   STAT3	   inhibitor	   III	   and	   STAT3	   inhibitor	   VIII	   target	   either	   JAK2	   or	  
STAT3	  respectively,	  which	  would	  allow	  the	   roles	  of	   these	  proteins	   to	  be	  assessed	   individually.	  
JAK2	   inhibitor	   II	   or	   1,2,3,4,5,6-­‐Hexabromocyclohexane,	   targets	   JAK2	   in	   and	   prevents	  
autophosphorylation	   with	   a	   maximal	   effect	   at	   50	   µM	   [127].	   STAT3	   inhibitor	   III	   is	   a	   small	  
molecule	  tyrphostine,	  which	  targets	  STAT3	  and	  inhibits	  tumour	  cell	  proliferation	  with	  an	  IC50	  of	  
≈	  5µM	  [255].	  STAT3	  inhibitor	  VIII	  is	  a	  porphyrin	  species	  which	  inhibits	  STAT3	  SH2	  binding	  but	  not	  
other	  SH2	  domains	  such	  as	  those	  on	  Grb2	  at	  around	  1µM	  and	  prevents	  STAT3	  dimerisation	  with	  
an	  IC50	  10	  µM	  [128].	  Therefore	  this	  inhibitor	  was	  used	  at	  10	  µM,	  in	  line	  with	  STAT3	  inhibitor	  III,	  




Figure	   5.8:	   STAT3	   inhibitors	   III	   &	   VIII	   but	   not	   JAK2	   inhibitor	   II	   significantly	   reduce	   calcium	  
release	  in	  THP-­‐1	  cells.	  (a)	  Concentration	  response	  curve	  for	  calcium	  release	  in	  THP-­‐1	  cells	  pre-­‐
treated	  with	   50	   µM	   JAK2	   inhibitor	   II	   (JAK2	   II)	   or	   10	   µM	   of	   either	   STAT3	   inhibitors	   II	   or	   VII	  
(STAT3	  III	  &	  STAT3	  VIII	  respectively).	  (b)	  STAT3	  inhibitors	  significantly	  reduced	  calcium	  release	  
in	  THP-­‐1	  cells	  stimulated	  by	  75	  nM	  CCL3.	  JAK2	  II	  shows	  no	  significant	  effect.	  	  Results	  represent	  
the	  mean	  ±	  SEM	  of	  at	  least	  3	  independent	  experiments	  (One-­‐way	  ANOVA,	  Bonferroni	  multiple	  





	  THP-­‐1	  cells	  were	  pre-­‐treated	  for	  0.5hr	  with	  the	  relevant	  concentrations	  of	  JAK2/STAT3	  inhibitors	  
before	  the	  release	  of	  intracellular	  calcium	  stimulated	  by	  increasing	  concentrations	  of	  CCL3	  was	  
determined.	  The	  concentration	  response	  curves	  for	  calcium	  release	  (Figure	  5.8a)	   indicated	  the	  
EC50	  for	  all	  treatments	  was	  comparable	  to	  the	  vehicle	  control	  (EC50	  =	  29.8±2.0	  nM	  (control)	  vs.	  
35.9±6.2	  nM	   (JAK2	   II)	   vs.	  20.9±2.6	  nM	   (STAT	  3	   III)	   vs.	  35.2±8.9	  nM	   (STAT3	  VIII)),	  however	   the	  
level	  on	  calcium	  release	  was	  significantly	  lower	  at	  75	  nM	  CCL3	  stimulation	  for	  cells	  treated	  with	  
STAT3	   inhibitors.	   STAT3	   inhibitor	   III	   reduced	   calcium	   release	   induced	  by	   75nM	  CCL3	   in	   THP-­‐1	  
cells	  by	  46%±14	  vs.	  vehicle	  control	  (p≤0.05,	  n=3)	  and	  STAT3	  VIII	  showed	  reduced	  calcium	  flux	  by	  
82%±9	   vs.	   vehicle	   (p≤0.01,	   n=3).	   This	   was	   supported	   by	   the	   calculated	   efficacy,	   that	   was	  
significantly	   lower	   for	   STAT3	   III	   and	   VIII	   compared	   to	   the	   vehicle	   bases	   on	   the	   sigmoidal	  
concentration	  response	  fitted	  with	  an	  assumed	  Hill	  coefficient	  of	  1.	  	  JAK2	  inhibitor	  2	  showed	  no	  
significant	   reduction	   in	   the	   level	  of	   calcium	  mobilisation	   stimulated	   (p>0.05,	  n=3).	   These	  data	  
are	   surprising	   considering	   that	   cucurbitacin	   I	   did	   not	   affect	   calcium	   release.	   If	   JAK2	   inhibition	  
had	   resulted	   in	   inhibition	   of	   calcium	   release	   and	   STAT3	   had	   not	   then	   this	   would	   at	   least	   be	  
consistent	  with	  a	  canonical	  JAK2/STAT5	  dependent	  signalling	  axis	  but	  as	  JAK2	  inhibition	  should	  
result	   in	   indirect	   reduction	   of	   STAT3	   phosphorylation	   these	   observations	   were	   puzzling.	   One	  
explanation	   maybe	   a	   redundancy	   in	   the	   signalling	   axis	   with	   JAK1	   acting	   in	   place	   of	   JAK2,	  
however	  more	  investigation	  would	  be	  required	  to	  add	  support	  to	  this	  hypothesis.	  To	  determine	  
if	   the	   inhibitors	  were	   reducing	   STAT3	  phosphorylation	   in	   the	  model	   system,	   a	   STAT3	   tyrosine	  
705	   (Tyr705)	   phosphorylation	   ELISA	   (described	   in	   Materials	   and	   Methods)	   was	   employed	   to	  
determine	   if	   phosphorylation	   of	   STAT3	  was	   reduced	   in	   the	   presence	   of	   the	   inhibitors.	   STAT3	  
Tyr705	   is	   required	   for	  STAT3	  homodimer	   translocation	   to	   the	  nucleus	  and	   is	  used	  widely	  as	  a	  
marker	   for	   STAT3	   activation	   [256].	   IL-­‐6	  was	   elected	   as	   a	   stimulator	   in	   this	   assay	   as	   it	   is	   well	  
characterised	  as	  an	  activator	  of	  STAT3	  via	  JAK2	  and	  JAK3	  [256]	  and	  would	  reduce	  the	  need	  to	  




Figure	   5.9:	   STAT3	   inhibitors	   III	   and	   VIII	   significantly	   reduce	   IL-­‐6	   stimulated	   STAT3	  
phosphorylation	   in	   THP-­‐1	   cells.	   (a)	   Significant	   reduction	   STAT3	   Tyr705	   phosphorylation	   as	  
determined	   in	   the	   InstantOne™	   ELISA.	   (b)	   STAT3	   Tyr705	   phosphorylation	   in	   HeLa.RC49	  
stimulated	   by	   40	   nM	   IL-­‐6	   is	   reduced	   to	   non-­‐stimulated	   levels	   in	   the	   presence	   of	   Stat3	  
inhibitors	   III	   and	   VIII.	   Results	   represent	   the	   mean	   ±	   SEM	   of	   at	   least	   3	   independent	  
experiments	   (One-­‐way	   ANOVA,	   Bonferroni	   multiple	   comparison.	   **	   indicates	   p≤0.01	   &	  





	  STAT3	   Tyr705	   phosphorylation	   was	   stimulated	   by	   40	   nM	   IL-­‐6	   in	   THP-­‐1	   cells	   above	   the	   non-­‐
stimulated	  control	  and	  both	  STAT3	  inhibitors	  were	  able	  to	  significantly	  reduce	  phosphorylation	  
(STAT3	   III	   p≤0.001,	   n=3.	   STAT3	   VIII	   p≤0.01,	   n=3)	   however	   JAK2	   inhibitor	   2	   had	   no	   significant	  
effect	   on	   STAT3	   phosphorylation	   (Figure	   5.9a).	   The	   STAT3	   inhibitors	   were	   also	   tested	   in	  
HeLa.RC49	   to	  determine	   if	   the	   inhibitors	  were	  affective	  between	  cell	   types	  and	  again	  showed	  
the	  ability	  to	  prevent	  STAT3	  Tyr705	  phosphorylation	  vs.	   IL-­‐6	  stimulated	  controls	  although,	  due	  
to	   the	   relatively	   low	   level	  of	   activation	   in	  HeLa.RC49	  cells	   this	   relationship	  was	  observed	  as	  a	  
non-­‐significant	  trend	  (p>0.05,	  n=3).	  Despite	  the	  lack	  of	  significance	  the	  data	  clearly	  confirm	  the	  




Figure	   5.10:	   STAT	   3	   inhibitor	   III	   significantly	   reduces	   THP-­‐1	   chemotaxis.	   THP-­‐1	   pre-­‐treated	  
with	   STAT3	   inhibitor	   III	   (STAT3	   III)	   demonstrates	   a	   significant	   reduction	   in	  migration.	   THP-­‐1	  
cells	  treated	  with	  JAK2	  inhibitor	  II	  (JAK2	  II),	  STAT3	  inhibitor	  VIII	  (STAT3	  VIII)	  and	  combinations	  
of	   JAK2	   +	   STAT3	   III	   and	   JAK2	   II	   +	   STAT3	   VIII	   showed	   no	   significant	   reduction	   in	  migration.	  
Results	   represent	   the	   mean	   ±	   SEM	   of	   at	   least	   3	   independent	   experiments	   (***	   indicates	  
p≤0.001	  vs.	  vehicle	  control,	  ns	  =	  not	  significant).	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  In	  order	  to	  determine	  if	  either	  JAK2	  or	  STAT3	  could	  be	  attributed	  to	  the	  effects	  seen	  using	  the	  
combined	   JAK2+STAT3	   inhibitor	   cucurbitacin	   I	   in	   chemotaxis,	   the	   JAK2	   and	   STAT3	   inhibitors	  
were	   used	   to	   pre-­‐treat	   THP-­‐1	   cells	   prior	   to	   a	   chemotaxis	   assay	   towards	   1	   nM	   CCL3.	   The	  
inhibitors	  were	  also	  used	  in	  conjunction	  with	  one	  another	  (JAK2+STAT3	  III	  and	  JAK2	  +	  STAT3	  VIII)	  
to	   determine	   if	   the	   effects	   of	   cucurbitacin	   I	   could	   be	   replicated.	   Interestingly,	   only	   STAT3	  
inhibitor	   III	   treatment	  had	  a	  significant	  effect	  on	  migration	   (p≤0.001,	  n=3),	  but	   this	  affect	  was	  
completely	   abrogated	   (p>0.05,	   n=3	   vs.	   vehicle	   control)	  when	   combined	  with	   JAK2	   inhibitor	   II	  
inhibition	  (Figure	  5.10).	  	  The	  reason	  for	  this	  observation	  is	  not	  clear	  as	  a	  combined	  JAK2/STAT3	  
inhibition	  would	   be	   expected	   to	   reduce	   STAT3	  phosphorylation	   but	  may	   be	   explained	   if	   JAK2	  
inhibitor	  2	  interacted	  with	  or	  allosterically	  out-­‐competed	  binding	  of	  STAT3	  inhibitor	  3.	  Statistical	  
comparison	   of	   the	   two	   treatments	   reveals	   that	   they	   are	   not	   significantly	   different	   from	   one	  
another	   (p>0.05),	   suggesting	   an	   aberrant	   result.	   This	   comparison	   is	   not	   ideal	   due	   to	   the	  
different	   vehicle	   levels,	   but	   offers	   an	   explanation	   for	   the	   observation,	  which	   agrees	  with	   the	  
other	   data.	   The	   other	   point	   to	   consider	   is	   that	   despite	   being	   shown	   to	   inhibit	   STAT3	   Tyr705	  
phosphorylation,	  STAT3	  VIII	  had	  no	  significant	  effect	  on	  migration,	  which	  suggests	  that	  either	  1)	  
the	   differences	   in	   STAT3	   binding	   between	   the	   two	   compounds	   results	   in	   alterations	   in	   their	  
functionality	  with	  other	  proteins	  or	  2)	  STAT3	   III	  has	  off-­‐target	  or	   cytotoxic	  effects.	  Taken	  as	  a	  
whole	  the	  data	  from	  the	  chemotaxis	  assays	  shows	  that	  JAK2	  is	  not	  involved	  in	  cytoplasmic	  signal	  
transduction	  to	  chemotaxis	  and	  that	  combined	  inhibition	  of	  JAK2+STAT3	  does	  not	  replicate	  the	  
effect	  on	  migration	  seen	  with	  cucurbitacin	  I.	  The	  function	  of	  STAT3	  was	  less	  clear	  and	  warranted	  
further	   investigation;	   the	   taught	  Master’s	  degree	   student	  S.	  Khabbazi	  undertook	   the	   research	  
into	   this	  question	  with	   supervision	   from	   the	  author.	   The	   resulting	   findings	  were	  published	  by	  




Figure	  5.11:	  JAK2	  inhibitor	  II,	  STAT3	  inhibitors	  II	  and	  VIII	  and	  combinations	  do	  not	  affect	  actin	  
polymerisation	   in	   HeLa.RC49.	   Micrographs	   of	   HeLa.RC49	   monolayers	   treated	   with	   100	   nM	  
CCL3	   and	   JAK/STAT	   inhibitors.	   Cells	  were	   fixed	   and	   stained	  with	   Alexa-­‐488	   phalloidin	   actin	  
stain	  (green).	  Images	  representative	  of	  population.	  Acquired	  with	  Leica	  imaging	  suite.	  
	  
Since	   the	   THP-­‐1	   cells	   were	   capable	   of	   migration	   even	   in	   the	   presence	   of	   the	   Jak2/Stat3	  
inhibitors,	   we	   did	   not	   expect	   the	   inhibitors	   to	   have	   a	   similar	   disruptive	   effect	   on	   the	   actin	  
cytoskeleton	  as	   cucurbitacin	   I.	  HeLa.RC49	  were	   treated	  with	   JAK2	   II,	   STAT3	   III,	   STAT3	  VIII	   and	  
combinations	  of	  JAK2	  II	  +	  STAT3	  III	  and	  JAK2	  +	  STATVIII	  for	  0.5hr	  before	  activation	  for	  1hr	  with	  
100	  nM	  CCL3	  and	  fixing	  and	  staining	  with	  Alexa-­‐488	  tagged	  phalloidin	  (Figure	  5.11).	  
CCL3 CCL3 + 
JAK2 II 
CCL3 + STAT3 VIII CCL3 + STAT3 
III 
CCL3 + JAK2 II + STAT3 
III 
CCL3 + JAK2 II + STAT3 VIII 
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  All	  treatments	  showed	  no	  pronounced	  differences	  from	  the	  control	  and	  there	  was	  	  no	  evidence	  
of	  abnormalities	  in	  the	  actin	  cytoskeleton	  with	  the	  combined	  treatments.	  This	  provides	  further	  
evidence	   that	   the	   effects	   observed	  with	   cucurbitacin	   I	  were	   not	   associated	  with	   its	   ability	   to	  




The	   aim	   of	   this	   chapter	   was	   to	   determine	   if	   JAK2/STAT3	   signalling	   played	   any	   role	   in	   CCR5	  
mediated	   signal	   transduction	   to	   chemotaxis.	   JAK/STAT	   signalling	   represents	   a	  well-­‐researched	  
oncogenic	  signalling	  axis	   in	  association	  with	   it	   canonical	  activation	   through	  cytokine	   receptors	  
[249].	   There	   is	   growing	   evidence	   that	   chemokines	   receptors	   [125,	   252]	   and	   specifically	   CCR5	  
[40,	   122]	   interact	   with	   and	   can	   activate	   JAK/STAT.	   Signalling	   through	   JAK2/STAT3	   has	   been	  
shown	  to	  be	  prevalent	  in	  numerous	  cancers	  and	  because	  CCR5	  is	  known	  to	  activate	  JAK2	  [122],	  
the	   inhibitor	   of	   JAK2/STAT3	   [126]	   cucurbitacin	   I	   was	   used	   to	   determine	   if	   JAK2	   or	   STAT3	  	  
inhibition	   would	   disrupt	   the	   cytoplasmic	   signalling	   events	   associated	   with	   CCR5	   activation.	  
Cucurbitacin	   I	   had	   no	   effect	   on	   CCR5	  mediated	   calcium	   release	   but	   reduced	   the	  migration	   in	  
treated	  THP-­‐1	  cells	  to	  zero.	  As	  discussed	  earlier	  (chapter	  3)	  the	  ability	  of	  an	  inhibitor	  to	  reduce	  
migration	   to	   below	   basal	   levels	   warrants	   investigation	   to	   determine	   if	   a	   disruption	   of	  
cytoskeletal	  structures	  has	  occurred.	  This	  is	  particularly	  pertinent	  because	  there	  is	  evidence	  that	  
cucurbitacin	   I	   does	   disrupt	   actin	   dynamics	   in	   some	   cells	   [254].	   To	   explore	   this	   idea	   and	   to	  
determine	   if	   calcium	   mobilisation	   can	   occur	   with	   a	   disrupted	   actin	   cytoskeleton	   the	   actin	  
polymerisation	   inhibitor	   [257]	   cytochalasin	   D	   was	   used	   to	   disrupt	   THP-­‐1	   cell	   actin	   formation	  
before	   calcium	   flux	   and	   chemotaxis	   assay.	   Cytochalasin	   D	   treatment	   did	   not	   affect	   calcium	  
release	  but	  completely	  blocked	  chemotaxis.	  Indeed	  the	  reduction	  was	  comparable	  to	  that	  seen	  
with	   cucurbitacin	   I	   treatment.	   Phalloidin	   actin	   staining	   in	   HeLa.RC49	   and	   CHO.CCR5	   cells	  
activated	  with	  CCL3	  confirmed	  that	  cucurbitacin	  I	  was	  affecting	  actin	  polymerisation.	  Again	  the	  
observed	  disruption	  was	  similar	  to	  that	  seen	  with	  cytochalasin	  D	  treatment.	  Disruption	  of	  actin	  
fibers	   in	   THP-­‐1	   cells	   could	   not	   be	   determined	   by	   fluorescence	   microscopy	   due	   to	   a	   lack	   of	  
resolution.	  A	  flow	  cytometry	  based	  method	  was	  validated	  as	  a	  technique	  for	   identifying	  actin-­‐
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  disrupted	  THP-­‐1	  cells	  however	  the	  evidence	  provided	  by	  HeLa.RC49	  and	  CHO.CCR5	  was	  taken	  to	  
be	  sufficient	  to	  draw	  conclusions	  about	  the	  effects	  of	  cucurbitacin	  on	  the	  cytoskeleton	  of	  cells.	  
The	  data	  did	  not	  explain	  whether	   the	  effects	  of	   cucurbitacin	   I	  were	  a	   result	  of	   JAK2	  or	  STAT3	  
inhibition	  or	  both	  combined	  or	  were	  due	  to	  non-­‐specific	  effects	  of	  the	  inhibitor.	  To	  investigate	  
this	  further,	  inhibitors	  specific	  for	  only	  JAK2	  [127]	  and	  STAT3	  [128,	  255]	  were	  used	  to	  treat	  THP-­‐
1	  cells.	  The	  JAK2	   inhibitor	   II	  was	  unable	  to	  significantly	  affect	  CCL3	  stimulated	  calcium	  release	  
but	   both	   STAT3	   inhibitors,	   while	   having	   no	   effect	   on	   EC50	   values,	   did	   reduce	   the	   level	   of	  
stimulated	   calcium	   release	   in	   THP-­‐1	   cells	   and	   corresponded	   to	   significant	   reductions	   in	  
calculated	   efficacy.	   STAT3	   tyrosine	   705	   phosphorylation	   is	   required	   for	   translocation	   of	   the	  
homodimerised	   protein	   to	   the	   nucleus	   [256].	   A	   pTyr750	   ELISA	   was	   used	   to	   validate	   if	   the	  
inhibitor	  were	  blocking	  protein	  function;	  the	  assay	  revealed	  that	  JAK2	  inhibition	  did	  not	  affect	  
IL-­‐6	   stimulated	   STAT3	   Tyr705	   phosphorylation	   in	   THP-­‐1.	   STAT3	   inhibitors	   III	   and	   VIII	   blocked	  
STAT3	   Tyr705	   phosphorylation	   in	   THP-­‐1	   and	  HeLa.RC49	   cells	   suggesting	   that	   the	   reduction	   in	  
calcium	  release	  could	  have	  been	  attributed	  to	  inhibition	  of	  STAT3.	  The	  failure	  of	  JAK2	  inhibitor	  II	  
to	   prevent	   STAT3	   phosphorylation	   could	   be	   explained	   by	   redundancy	   in	   JAK/STAT	   signalling	  
(Figure	   5.12);	   ‘canonical’	   IL-­‐6R	   signalling	   through	   JAK1	   to	   STAT3	   would	   explain	   the	   lack	   of	  
efficacy	  seen	  with	  JAK2	  inhibitor	  II.	  	  
152
	  Figure	  5.12:	  JAK/STAT	  signal	  transduction	  and	  inhibition	  explored	   in	  chapter	  5.	  Activation	  of	  
STAT3	  via	  the	  interleukin	  6	  receptor	  (IL6-­‐R)	  can	  occur	  via	  JAK1	  or	  JAK2.	  	  
	  
The	  effects	  of	  the	  two	  STAT	  inhibitors	  were	  less	  clear	  as	  cucurbitacin	  I	  had	  shown	  no	  significant	  
effect	  on	  calcium	  release.	  There	  are	  no	  reports	  in	  the	  literature	  of	  STAT3	  inhibition	  leading	  to	  a	  
block	   with	   calcium	   release	   being	   shown	   to	   operate	   upstream	   of	   STAT3	   activation	   in	   some	  
signalling	   axes	   [258].	   This	   suggested	   that	   either	   a	   novel	   signal	   transduction	   pathway	   was	  
operating	  or	  the	  inhibitors	  were	  affecting	  THP-­‐1	  cells	  through	  ‘off-­‐target’	  mechanisms.	  	  
	  
Assessment	   of	   the	   JAK2	   and	   STAT3	   inhibitors	   in	   THP-­‐1	   chemotaxis	   assays	   also	   produced	  
conflicting	   data:	   JAK2	   inhibitor	   2	  was	   shown	   to	  have	  no	   significant	   effect	   on	  migration	  which	  
provided	   strong	  evidence	   that	  any	   JAK2	  activity	  associated	  with	  CCL3	  activated	  CCR5	  was	  not	  
involved	  in	  the	  cytoplasmic	  signal	  transduction	  to	  chemotaxis.	  Of	  the	  STAT3	  inhibitors	  STAT3	  III	  
was	  able	  to	  significantly	  reduce	  migration	  whilst	  STAT3	  VIII	  was	  not;	  as	  both	  inhibitors	  blocked	  
Tyr705	   phosphorylation	   this	   provided	   evidence	   that	   STAT3	   phosphorylation	  was	   not	   required	  
for	  migration	  but	  that	  the	  mode	  of	  binding	  of	  STAT3	  III,	  which	  is	  different	  from	  STAT3	  VIII	  [128,	  
255],	  may	  have	  been	  important.	  	  Pre-­‐treatment	  with	  a	  combination	  of	  JAK2	  II	  with	  STAT3	  III	  and	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  STAT3	  VII	  had	  no	  significant	  effect	  on	  migration,	  which	  showed	  that	  the	  dual	  inhibitory	  effect	  of	  
cucurbitacin	   I	  was	  not	  responsible	  for	  actin	  disruption.	  This	  was	  supported	  by	  actin	  staining	   in	  
HeLa.RC49	   cells	   that	   showed	   no	   abnormalities	   in	   actin	   formation	  with	   combined	   JAK2/STAT3	  
inhibitor	  treatment.	  The	  observed	  effect	  of	  combined	  treatment	  on	  chemotaxis	  was	  confusing	  
however	  because	  JAK2	  II	  treatment	  in	  combination	  with	  STAT3	  seemed	  to	  reverse	  the	  effects	  of	  
STAT3	  treatment	  alone.	  	  The	  only	  feasible	  explanation	  for	  this	  would	  be	  if	  JAK2	  inhibitor	  II	  was	  
interacting	  with	  STAT3	  III	  directly,	  or	  with	  its	  binding	  site	  on	  STAT3	  to	  prevent	  it	  functioning	  as	  
an	   inhibitor	   however	   the	   lack	   of	   statistical	   difference	   between	   treatments	   does	   indicate	   an	  
aberrant	  result	  may	  have	  occurred.	  Taken	  as	  a	  whole	  the	  data	  support	  the	  idea	  that	  JAK2/STAT3	  
signalling	   is	  not	   involved	  with	  CCR5	  mediated	   chemotaxis	   at	   a	   cytoplasmic	   level;	  whether	   the	  
increase	   in	   protein	   expression	   promoted	   by	   the	   JAK/STAT	   axis	   affects	   THP-­‐1	   migration	   over	  
longer	  time	  periods	  was	  not	  explored,	  but	  fall	  into	  the	  canonical	  function	  of	  these	  proteins.	  As	  
discussed	  in	  the	  previous	  chapter	  4	  the	  effects	  of	  the	  c-­‐Src	  family	  non-­‐receptor	  tyrosine	  kinase	  
inhibitor	   bosutinib,	  which	   has	   been	   shown	   to	   inhibit	   STAT	   activation	   [79],	   are	   for	   this	   reason	  
also	  not	  likely	  to	  be	  a	  result	  of	  STAT	  inhibition.	  	  	  
	  
The	   discrepancy	   with	   STAT3	   inhibitor	   III	   did	   require	   further	   investigation	   though.	   Using	   the	  
results	  from	  this	  chapter	  as	  a	  basis	  Khabazzi	  et	  al.	   [47]	   investigated	  further	  the	  mechanism	  by	  
which	  STAT3	  inhibitor	  II	  affects	  CCR5	  mediated	  migration.	  The	  conclusions	  of	  this	  investigation	  
were	   that	   STAT3	   III	   showed	   high	   levels	   of	   cytotoxicity	   over	   the	   time	   period	   of	   chemotaxis	  
assays,	   which	   resulted	   in	   the	   decreased	  migration	   with	   none	   of	   the	   effects	   of	   the	   inhibitors	  









	  5.5.	  Chapter	  Conclusions	  
	  
The	  final	  conclusions	  to	  be	  drawn	  from	  this	  chapter	  are:	  
1) JAK2/STAT3	   inhibitor	   cucurbitacin	   I	   completely	   bocks	   chemotaxis	   in	   THP-­‐1	   by	  
disrupting	  actin	  polymerisation.	  
2) Simultaneous	   inhibition	  with	   specific	   JAK2	   and	   STAT3	   inhibitors	   cannot	   replicate	   the	  
detrimental	   effects	   on	   actin	   formation,	  which	  must,	   therefore,	   be	   attributed	   to	   ‘off-­‐
target’	  effects	  specific	  to	  cucurbitacin	  I.	  
3) JAK2	  inhibition	  has	  no	  effect	  on	  IL-­‐6	  induced	  STAT3	  phosphorylation	  in	  THP-­‐1,	  however	  
JAK/STAT	  signalling	  redundancy	  may	  explain	  this	  observation.	  	  
4) JAK2/STAT3	  play	  no	  transcription	  independent,	  cytoplasmic	  signal	  transduction	  role	  in	  
CCR5	  mediated	  chemotaxis	   in	  THP-­‐1	  cells,	  which	  supports	  the	   idea	  that	  the	  effects	  of	  
















	  CHAPTER	   6:	   A	   pharmacological	   investigation	   of	  





Chapter	   4	   suggests	   that	   signalling	   from	   the	   CCR5/CCR1	   receptors	   to	   chemotaxis	   operates	  
through	   an	   arrestin	   dependent	   mechanism.	   Other	   signalling	   points	   were	   also	   identified,	  
including	   non-­‐receptor	   tyrosine	   kinases	   and	   the	   Rho	   kinase	   (ROCK).	   Inhibition	   of	   these	   two	  
proteins	   results	   in	   a	   blockade	   of	   migration	   indicating	   that	   they	   represent	   points	   of	  
pharmacological	   access	   to	   CCR5	  mediated	  migration.	   These	   findings	   also	   left	   some	   questions	  
unanswered:	   one	   of	   them	   being	   whether	   internalisation	   itself	   is	   required	   for	   migration.	   The	  
importance	   of	   internalisation	   may	   be	   an	   alternative	   explanation	   for	   the	   observations	   made	  
using	  PKC	  and	  GRK2	   inhibitors.	  The	  exact	   signalling	  partners	  of	  non-­‐RTKs	  and	  ROCK	  were	  also	  
not	   confirmed,	   as	   was	   the	   question,	   whether	   PI3K	   function	   is	   required	   in	   CCR5	   mediated	  
migration.	   This	   is	  of	  particular	   importance	   considering	   the	   conflicting	   reports	   in	   the	   literature	  
[115,	  248].	   This	   chapter	  will	   attempt	   to	  address	   some	  of	   these	  questions	  by	   investigating	   the	  
role	  of	  receptor	  internalisation	  and	  endocytosis	  on	  migration	  by	  direct	  blockade	  of	  the	  process	  
and	  by	  inhibition	  of	  the	  machinery	  of	  endocytosis	  identified	  in	  the	  introduction.	  Proteins	  such	  as	  
clathrin	  and	  dynamin	  are	  of	  particular	  interest	  because	  they	  have	  been	  shown	  to	  interact	  with	  
arrestins	   [64],	   Gβγ	   	   [107],	   phosphoinositides	   [259]	   and	   Rho	   kinases	   	   [192]	   and	   have	   links	   to	  
migration	  [77,	  188].	  The	  role	  of	  non-­‐RTKs	  will	  also	  be	  investigated	  by	  examining	  the	  role	  of	  SH2	  
domain	   containing	   adaptor	   proteins	   identified	   in	   the	   literature.	   These	   experiments	  will	   allow	  
the	   relationships	  of	   the	  different	   signalling	   stations	   identified	   in	  chapter	  4	   to	  be	   resolved	  and	  




	  6.2.	  Chapter	  Aims	  
	  
Initially	  the	  role	  of	  internalisation	  in	  endocytosis	  will	  be	  determined	  by	  small	  molecule	  inhibition	  
of	  clathrin	  and	  dynamin.	  A	  range	  of	  chemically	  diverse	  dynamin	  inhibitors	  are	  available	  which	  
allow	  the	  resolution	  of	  specific	  dynamin	  interactions	  which	  could	  be	  important	  in	  THP-­‐1	  
migration.	  The	  adaptor	  protein	  Grb2	  has	  links	  with	  dynamin,	  CCR5	  and	  migration	  so	  the	  role	  of	  
this	  protein	  will	  be	  investigated	  through	  small	  molecule	  inhibition	  as	  a	  possible	  link	  between	  




6.3.1.	  CCR5	  mediated	  endocytosis	  is	  not	  required	  for	  migration	  in	  THP-­‐1	  cells	  	  
	  
Chapter	  4	  showed	  that	  overexpression	  of	  arrestin	  2	  and	  3	  results	  in	  a	  decrease	  in	  CCR5	  induced	  
calcium	   release	   that	  was	   assumed	   to	  be	   a	   consequence	  of	   increased	   receptor	   desensitisation	  
and	   internalisation.	   The	   effect	   of	   arrestin	   overexpression	   in	   THP-­‐1	   migration	   could	   not	   be	  
experimentally	  determined	  due	  to	  adverse	  effects	  of	  the	  electroporation	  transfection	  process.	  
Inhibition	   of	   GRK2	   and	   PKC	   in	   THP-­‐1	   cells,	   which	   can	   recruit	   arrestins	   to	   activated	   GPCRs,	  
revealed	  potentially	  divergent	  roles	  of	  arrestin	  in	  CCR5	  signalling	  to	  migration,	  which	  is	  thought	  
to	  be	  based	  on	  their	  mode	  of	  recruitment	  to	  the	  CCR5	  Carboxyl-­‐terminus	  (Chapter	  4).	  It	  was	  not	  
clear	  however	  whether	  the	  effects	  of	  the	  inhibition	  of	  GRK2	  and	  PKC	  were	  due	  to	  decreases	  in	  
arrestin	  mediated	  signalling	  or	  increases	  in	  internalisation	  and	  desensitisation.	  The	  increases	  in	  
migration	   seen	   with	   PKC	   inhibitor	   treatment	   was	   theorised	   to	   be	   a	   result	   of	   alterations	   to	  
arrestin	   signalling	   bias,	   however,	   because	   the	   effect	   on	   internalisation	  was	   not	  measured	   an	  
increase	  or	  decrease	  in	  endocytosis	  may	  also	  have	  been	  responsible.	  Investigation	  into	  whether	  
receptor	  endocytosis	  is	  required	  for	  THP-­‐1	  cell	  chemotaxis	  will	  allow	  a	  further	  clarification	  of	  the	  
role	  of	  arrestins.	  Endocytosis	  inhibitors	  were	  used	  to	  investigate	  whether	  internalisation	  is	  a	  key	  
requisite	   in	   the	   migration	   of	   cells,	   even	   though	   these	   processes	   are	   thought	   to	   occur	  
independently	  of	  the	  formation	  of	  arrestin	  dependent	  signalling	  complexes	  [35].	  CCR5	  receptor	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  internalisation	   has	   been	   shown	   to	   occur	   through	   clathrin	   and	   caveolin	   dependent	   pathways	  
[213].	  Clathrin	  dependent	  endocytosis	  can	  be	  inhibited	  by	  hyperosmolar	  sucrose	  solutions	  [178]	  
and	   caveolae	   are	   sensitive	   to	   cholesterol	   disruption	   through	   filipin	   treatment	   [74].	   It	   was	  
elected	  to	  treat	  THP-­‐1	  with	  a	  hyperosmolar	  sucrose	  and	  a	  combination	  of	  hyperosmolar	  sucrose	  
and	  filipin	  to	  block	  both	  forms	  of	  internalisation.	  The	  clathrin	  endocytosis	  inhibitor	  sucrose	  was	  
used	  on	  its	  own	  and	  in	  conjunction	  with	  the	  caveolae	  specific	  inhibitor	  filipin	  (Figure	  6.1a).	  The	  
cell	  permeable	  clathrin	  inhibitor	  Pit	  stop	  2	  was	  also	  used	  (Figure	  6.1b).	  	  
	  
Treatment	  with	  hyperosmolar	  sucrose	  did	  not	  affect	  THP-­‐1	  migration	  toward	  1	  nM	  CCL3	  (p>0.05	  
vs.	   control)	   nor	   did	   treatment	  with	   hyperosmolar	   sucrose	   and	   filipin	   combined	   (p>0.05,	   n=3)	  
(Figure	   D1a).	   These	   data	   indicate	   that	   endocytosis	   is	   not	   required	   for	   functional	  migration	   in	  
THP-­‐1	  cells.	  The	  non-­‐significant	  trend	  towards	   increased	  migration	  with	  the	  combined	  sucrose	  
and	  filipin	  was	  also	  interesting	  as	  it	  suggested	  that	  stalling	  the	  internalisation	  process	  enhanced	  
migration,	  possibly	  by	  allowing	  prolonged	  arrestin	  signalling.	  To	  determine	  if	  these	  observation	  
can	   be	   reproduced	   from	   ‘the	   inside	   out’	   via	   cytoplasmic	   inhibition	   of	   clathrin,	   the	   recently	  
described	  inhibitor	  of	  clathrin	  coated	  pit	  formation	  pit	  stop	  2	  [260]	  was	  used	  to	  treat	  THP-­‐1	  cells	  
(Figure	  6.1b).	  Pit	  stop	  2	  demonstrated	  an	  ability	  to	   increase	  migration	   in	  THP-­‐1	  cells:	  1.25	  µM	  
treatment	  showed	  no	  significant	  effect	  (p>0.05,	  n=6	  vs.	  negative	  control	  compound)	  but	  30	  µM	  
(the	   recommended	   treatment	   level	   [260])	   increasing	   THP-­‐1	   cell	   migration	   towards	   1	   nM	   by	  
30±4%	   (vs.	   negative	   control	   adjusted	   for	   basal	   migration).	   These	   data	   support	   the	   non-­‐
significant	   observation	   seen	   with	   sucrose	   +	   filipin	   treatment	   and	   suggest	   that	   maintaining	  
activated	   CCR5	   at	   the	   cell	   surface	   increases	   signalling	   to	   chemotaxis.	   This	   combined	  with	   the	  
data	  from	  chapter	  4	  suggest	  that	  arrestin	  dependent	  signalling	  formed	  an	  important	  component	  





Figure	  6.1:	   Inhibition	  of	  CCR5	  internalisation	  does	  not	  reduce	  CCL3	  stimulated	  chemotaxis	   in	  
THP-­‐1	  cells.	  (a)	  Treatment	  with	  a	  hyperosmolar	  sucrose	  solution	  and	  sucrose	  +	  fillipin	  has	  no	  
significant	  effect	  on	  CCR5	  mediated	  chemotaxis	   in	  THP-­‐1	  cells	   (n=3).	   (b)	  Treatment	  of	  THP-­‐1	  
cells	   with	   the	   inhibitor	   of	   clathrin	   mediated	   endocytosis,	   Pit	   stop	   2	   (30	   µM),	   significantly	  
increases	  migration	  towards	  1	  nM	  CCL3	  by	  30%±4	  (p	  0.01	  n=6)	  vs.	  negative	  control	  compound	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  (PS2N).	  Results	   represent	   the	  mean	  ±	  SEM	  of	  at	   least	  3	   independent	  experiments	   (One-­‐way	  
ANOVA,	  Bonferroni	  multiple	  comparison.	  **	  =	  p≤0.01	  vs.	  vehicle	  control,	  ns	  =	  not	  significant).	  
	  
	  
Figure	   6.2:	  Pit	   stop	   2	   prevents	   CCR5	   internalisation	   in	  HeLa.RC49	   cells.	   (a)	  Negative	   control	  








	  CCL3	   for	   1hr	   promotes	   CCR5	   internalisation.	   (c)	   Pit	   stop	   2	   prevents	   CCL3	   stimulated	  
internalisation.	   (Nuclear	   stain	   with	   DAPI	   (blue),	   images	   representative	   of	   population.	  
Acquired	  with	  Leica	  imaging	  system)	  
The	   inhibitory	   effects	   of	   pit	   stop	   2	   were	   validated	   through	   the	   visualisation	   CCL3	   induced	  
internalisation	   of	   CCR5	   in	   HeLa.RC49	   after	   treatment	  with	   pit	   stop	   2.	   (Figure	   6.2).	   Untreated	  
control	  cells	  demonstrated	  significant	  amounts	  of	  membrane	  bound	  CCR5	  as	  demonstrated	  by	  a	  
continual	   ring	   of	   fluorescence	   around	   the	   periphery	   of	   the	   cell.	   Upon	   CCL3	   stimulation	   there	  
was	   a	   marked	   reduction	   in	   surface	   expressed	   CCR5	   as	   demonstrated	   by	   a	   reduction	   in	   the	  
continuity	   of	   the	   fluorescent	   ‘ring’.	   Cells	   pre-­‐treated	  with	   pit	   stop	   2	  were	   comparable	   to	   the	  
untreated,	  unstimulated	  control	  cells.	  These	  data	  indicate	  that	  internalisation	  of	  activated	  CCR5	  
receptors	   is	   indeed	   inhibited	  by	  pit	   stop	  2	   in	  HeLa	  cells,	  which	  shows	   that	  clathrin	  dependent	  
internalisation	  of	  CCR5	  is	  not	  likely	  to	  be	  required	  for	  CCL3	  induced	  THP-­‐1	  cell	  migration.	  	  
	  
In	   the	   introduction	   the	   conflicting	   evidence	   for	   the	   role	   of	   PI3K	   in	   migration	   was	   discussed.	  
Whilst	  it	  has	  been	  shown	  that	  PI3K	  is	  crucial	  for	  migration	  [57,	  95,	  248]	  and	  is	  activated	  by	  CCR5	  
as	  part	  of	  the	  arrestin	  scaffold	  [39]	  there	  is	  also	  evidence	  that	  monocytes	  such	  as	  THP-­‐1	  cells	  do	  
not	  require	  PI3K	  mediated	  polarisation	  for	  migration	  [115].	  	  
	  
PI3Ks	  have	  several	  isotypes	  which	  show	  significant	  differences	  in	  recruitment	  and	  functionality	  
[78]	  with	  PI3Kγ,	  and	  to	  a	  lesser	  extent	  PI3Kβ	  associated	  with	  GPCR	  signalling	  via	  Gβγ	  activation	  
[110,	  114,	  216].	  The	  pan	  isotype	  PI3K	  inhibitor	  LY294002	  is	  well	  characterised	  [116,	  261]	  and	  is	  




Figure	   6.3:	   CCL3	   stimulated	   chemotaxis	   in	   THP-­‐1	   cells	   is	   only	   sensitive	   to	   pan-­‐isotype	   PI3K	  
inhibitor	   LY294002	   at	   very	   high	   concentrations.	   (a)	   Migration	   in	   THP-­‐1	   cells	   can	   be	  
significantly	  reduced	  with	  concentrations	  of	  reversible	  pan-­‐isotype	  PI3K	  inhibitor	  LY294002	  at	  
and	  above	  100	  µM	  (p=0.001,	  n≤3).	   (b)	  Concentration	   response	  of	   for	   LY294002	   inhibition	  of	  
`THP-­‐1	   chemotaxis	   (n≥3).	   All	   results	   represent	   the	   mean	   ±	   SEM	   of	   at	   least	   3	   independent	  





	  THP-­‐1	   cells	   were	   pre-­‐treated	   with	   LY294002	   at	   concentrations	   between	   25	   and	   625	   µM	   to	  
determine	   the	   effect	   of	   PI3K	   inhibition	   on	   CCL3	   stimulated	   THP-­‐1	   migration	   (Figure	   D3a).	  
LY294002	   has	   no	   significant	   effect	   on	   THP-­‐1	   migration	   at	   25	   and	   50	   µM	   treatments,	   with	  
significant	  reductions	  in	  migration	  only	  seen	  after	  100	  µM	  treatment	  (Figure	  6.3a).	  The	  potency	  
of	   LY294002	   in	   this	   assay	  was	   calculated	   by	   fitting	   a	   sigmoidal	   concentration	   response	   curve	  
(with	   an	   assumed	   Hill	   coefficient	   of	   1)	   which	   produced	   an	   IC50	   =	   152±13	   µM,	   which	   is	  
significantly	  higher	  than	  the	  calculated	  value	  for	  PI3K	   inhibition	  [116]	  and	  normal	   inhibition	  of	  
chemotaxis	  [248].	  The	  potency	  level	  also	  suggested	  that	  secondary	  targets	  of	  LY294002	  such	  as	  
PIM1	  for	  which	  it	  shows	  an	  IC50	  4	  µM	  [261]	  might	  be	  targeted.	  These	  data	  suggest	  that	  PI3K	  is	  
not	   important	   for	   THP-­‐1	   cell	   migration.	   To	   clarify	   whether	   there	   is	   a	   role	   for	   PI3K	   in	   CCL3	  
induced	   migration	   the	   non-­‐reversible	   pan-­‐isotype	   PI3K	   inhibitor	   wortmannin	   and	   the	   PI3Kγ	  





Figure	   6.4:	   THP-­‐1	   cell	   migration	   towards	   CCL3	   is	   sensitive	   to	   pan-­‐isotype	   PI3K	   inhibitor	  
wortmannin	   but	   not	   PI3Kγ	   inhibitor	   AS605240.	   (a)	   Irreversible	   PI3K	   inhibitor	   wortmannin	  
(Wort)	   significantly	   reduces	   THP-­‐1	   chemotaxis	   at	   50	   nM	   (p≤0.001	   n=3).	   (b)	   PI3Kγ	   specific	  
reversible	   inhibitor	  AS605240	   (AS605)	   reduces	  migration	  at	  10	  µM	  (p≤0.001	  n=3).	  All	   results	  
represent	   the	   mean	   ±	   SEM	   of	   at	   least	   3	   independent	   experiments	   (One-­‐way	   ANOVA,	  
Bonferroni	  multiple	  comparison.***	  indicates	  p≤0.001	  vs.	  vehicle	  control).	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  Wortmannin	  is	  a	  highly	  potent,	  non-­‐reversible	  inhibitor	  of	  all	  human	  PI3ks	  with	  an	  IC50	  of	  1	  nM	  
[117].	  Pre-­‐treatment	  of	  THP-­‐	  cells	  with	  5,	  50	  and	  100	  nM	  wortmannin	   revealed	   that	  although	  
significant	  reductions	   in	  migration	  were	  seen	  at	  500	  and	  100	  nM	  (p≤0.001,	  n=3)	  there	  was	  no	  
significant	   reduction	   in	  migration	   seen	  with	   5	   nM	   treatment	   (Figure	   6.4a).	  As	  with	   LY294002,	  
wortmannin	   has	   a	   secondary	   target,	   polo	   like	   kinases	   [262],	   for	   which	   it	   shows	   inhibitory	  
potency	   of	   around	   25	   nM	   [263].	   These	   data	   show	   that	  wortmannin	   inhibitory	   concentrations	  
are	   higher	   than	   expected	   for	   effects	   due	   to	   PI3K	   alone	   and	   fall	   into	   concentrations	   where	  
secondary	   target	   inhibition	   has	   to	   be	   considered.	   	   AS605240	   is	   a	   rationally	   designed	   PI3K	  
inhibitor	   described	   as	   ‘specific’	   for	   PI3Kγ	  due	   to	   the	   fact	   that	   its	   IC50	  for	   PI3Kγ	  of	   5	   nM	   is	   7.5	  
times	   lower	  that	  the	  α-­‐isotype	  and	  30	  times	   lower	  than	  the	  δ	  and	  β-­‐isotypes	  [118].	  AS065240	  
has	   been	   shown	   to	   effectively	   inhibit	   PKB	   phosphorylation	   in	   THP-­‐1	   cells	   signalling	   through	  
GPCRs	  and	  has	  no	  known	  secondary	  targets	  [216].	  The	  use	  of	  increasing	  inhibitor	  concentration	  
from	   low	   nanomolar	   upwards	   should	   allow	   for	   a	   determination	   of	   functional	   PI3K	   isotypes	  
which	   are	   present	   in	   CCL3	   stimulated	   THP-­‐1	   cells.	   However,	   treatment	   of	   THP-­‐1	   cells	   with	  
AS605240	  from	  1-­‐500	  nM	  had	  no	  significant	  effect	  on	  migration	  (data	  not	  shown).	  At	  1	  µM,	  6	  
fold	  higher	   than	   the	   IC50	   for	   the	   least	   specific	   PI3K	   isotypes,	  AS605240	   continued	   to	   show	  no	  
significant	  effect	  on	  THP-­‐1	  migration	  towards	  1	  nM	  CCL3	  (Figure	  6.4b)	  (p>0.05,	  n=6).	  Treatment	  
with	  AS605240	  at	  10	  µM,	  5000	   fold	  higher	   than	   the	   reported	  PI3Kγ	   IC50,	   showed	  a	   significant	  
ability	   to	   reduce	  THP-­‐1	  migration	   towards	  CCL3	   (p≤0.001m	  n=3),	  however,	   this	   reduction	  was	  
only	   partial,	   and	   considering	   the	   high	   inhibitor	   concentration,	   did	   not	   provide	   convincing	  
evidence	   that	   PI3K	   inhibition	   was	   responsible	   or	   the	   observation.	   The	   evidence	   that	   PI3Ks,	  
classical	   mediators	   of	   migration,	   appeared	   not	   to	   be	   involved	   which	   raises	   some	   interesting	  
questions	  but	  supports	  the	  work	  of	  Volpe	  et	  al.	  	  
	  
Clathrin	   is	   known	   to	   interact	  with	   a	  number	  of	  other	  proteins,	   such	  as	   arrestin	   and	  dynamin,	  
which	  have	  strong	  links	  to	  migration	  outside	  of	  their	  ‘classical	  roles’	  as	  mediators	  of	  endocytosis	  
[180,	  188,	  264].	   In	   recent	  years	  a	   large	  number	  of	  chemically	  diverse	  dynamin	   inhibitors	  have	  
been	  described	  (Table	  1.3)	   [158,	  204,	  205,	  209].	  These	   inhibitors,	  whilst	   initially	   identified	  and	  
developed	  for	  their	  efficacy	  to	   inhibit	  dynamin	  GTPase,	  also	  showed	  varying	  abilities	  to	   inhibit	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  receptor	  mediated	  endocytosis	  (RME),	  stabilise	  dynamin	  polymers	  [202]	  and	  to	  target	  different	  
regions	  of	  the	  dynamin	  protein	  (Figure	  1.3.).	  The	  role	  of	  dynamin	  itself	  in	  migration	  is	  not	  well	  
understood	   and	   therefore	   the	   effect	   of	   the	   panel	   of	   inhibitors	   on	   THP-­‐1	   migration	   was	  
investigated	  	  
	  
6.3.2	  The	  effect	  of	  dynamin	  inhibition	  on	  C-­‐C	  motif	  chemokine	  receptor	  mediated	  chemotaxis	  
	  
As	  discussed	   in	   the	   introduction	   the	  dynamin	  1	  and	  2	  GTPase	   inhibitor	  dynasore	  was	   the	   first	  
small	  molecule	  dynamin	  inhibitor	  that	  was	  discovered.	  The	  inhibition	  of	  dynamin	  GTP	  turnover	  
prevents	   the	   ‘pinching’	   motor	   function	   of	   dynamin	   and	   prevents	   scission	   of	   clathrin-­‐coated	  
vesicles	  however	   the	  binding	  of	   inhibitors	   to	  protein	  also	  has	   the	  ability	   to	  affect	   the	  way	  the	  
protein	   can	   interact	  with	   the	   cytoplasmic	  milieu.	   The	   effects	   of	   dynasore	  on	   THP-­‐1	  migration	  
were	   therefore	   determined.	   Based	  on	   the	   observations	  with	   pit	   stop	   2	   and	   sucrose	   it	   can	   be	  
expected,	   that	  dynasore	   treatment	  will	   have	  either	  no	  effect	  or	   indeed	   increase	  migration	  by	  
prolonging	  the	  signalling	  if	  dynamin	  is	  solely	  acts	  as	  part	  of	  the	  endocytosis	  machinery.	  There	  is,	  
however,	   also	   a	   large	   body	   of	   evidence	   that	   demonstrates	   a	   role	   for	   dynamin	   outside	   of	  




Figure	   6.5:	   Dynasore	   prevents	   CCR5	   mediated	   chemotaxis	   in	   THP-­‐1	   cells.	   (a)	   The	   dynamin	  
GTPase	   inhibitor	   dynasore	   (Dyn)	   reduces	   THP-­‐1	  migration	   towards	   1	   nM	   CCL3	   to	   sub-­‐basal	  
levels	   vs.	   vehicle	   control	   (p=0.001	   n=6).	   All	   results	   represent	   the	  mean	   ±	   SEM	  of	   at	   least	   3	  
independent	   experiments	   (One-­‐way	  ANOVA,	   Bonferroni	  multiple	   comparison.	   ***	   indicates	  
p≤0.001	  vs.	  vehicle	  control	  ns	  =	  not	  significant).	  
	  
Pre-­‐treatment	  of	  THP-­‐1	  with	  dynasore	  significantly	  reduced	  THP-­‐1	  cell	  migration	  towards	  CCL3	  
(p≤0.001,	  n=6	  vs.	  vehicle	  control)	   to	  sub-­‐basal	   levels	   (Figure	  6.5).	  This	   inhibition	  occurred	  only	  
over	  a	  narrow	  range	  of	  concentration,	  with	  treatment	  at	  40	  and	  16	  µM	  showing	  no	  significant	  
reduction	  in	  chemotaxis	  (p>0.05,	  n=6).	  To	  determine	  if	  dynasore	  was	  functioning	  as	  an	  inhibitor	  
of	  CCR5	  internalisation,	  HeLa.RC49	  cells	  were	  used	  to	  visualise	  internalisation	  in	  the	  presence	  of	  
the	  inhibitor.	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Figure	  6.6:	  Dynasore	  prevents	  CCL3	   stimulated	   internalisation	  of	  CCR	   in	  HeLa.RC49	  cells.	   (a)	  
HeLa.RC49	   cells	   stimulated	   with	   100	   nM	   CCL3	   for	   1hr	   show	   an	   increase	   in	   receptor	  
internalisation	  when	  compared	  to	  (b)	  cells	  treated	  for	  0.5hr	  with	  80	  µM	  Dynasore.	  (Anti-­‐CCR5	  
Ab	  counterstained	  with	  Alexa-­‐488	  tagged	  Ab,	  DAPI	  nuclear	  stain).	   Images	  are	  representative	  









	  HeLa.RC49	  stimulated	  with	  100	  nM	  CCL3	  showed	  a	  marked	  reduction	   in	  surface	  expression	  of	  
HEK1/85/7a	   Ab	   stained	   CCR5	   (Figure	   6.6).	   Pre-­‐treatment	   of	   HeLa.RC49	  with	   80	   µM	   dynasore	  
before	  CCL3	  stimulation	  resulted	  in	  significantly	  more	  surface	  expressed	  receptors	  compared	  to	  
the	  untreated	  control	  cells.	  These	  results	  indicated	  that	  dynasore	  did	  indeed	  inhibit	  endocytosis,	  
but	  based	  on	  the	  results	  seen	  with	  sucrose/fillip	  and	  pit	  stop	  these	  results	  were	  contradictory,	  
and	   suggested	   that	   other	   functions	   of	   dynamin	   may	   have	   been	   responsible.	   Despite	   the	  
evidence	   that	   calcium	   flux	   and	   chemotaxis	   are	   independent	   in	   THP-­‐1	   cells,	   the	   effect	   of	  
dynasore	  on	  CCL3	  stimulated	  calcium	  release	  was	  determined	  to	  provide	  a	  broader	  picture	  of	  






Figure	   6.7:	   Dynasore	   inhibits	   CCL3	   stimulated	   calcium	   flux	   in	   THP-­‐1	   cells.	   (a)	   Concentration	  
response	  for	  calcium	  release	  in	  THP-­‐1	  stimulated	  by	  CCL3	  in	  cells	  treated	  for	  0.5hr	  with	  80	  µM	  
dynasore	  vs.	  control	  (n≥3).	  (b)	  Calcium	  flux	  in	  THP-­‐1	  stimulated	  by	  75	  nM	  CCL3	  is	  significantly	  
reduced	  by	  treatment	  with	  80	  µM	  dynasore	  (p≤0.001	  n≥3).	  Results	  represent	  the	  mean	  ±	  SEM	  








	  Pre-­‐treatment	   of	   THP-­‐1	   with	   80	   µM	   dynasore	   demonstrates	   that	   the	   inhibitor	   has	   a	  marked	  
effect	   on	   the	   ability	   of	   CCL3	   to	   induce	   calcium	   release	   (Figure	   6.7a).	   Efficacy	   for	   dynasore	  
treated	   cells	   could	   not	   be	   predicted	   due	   to	   the	   inability	   to	   fit	   a	   sigmoidal	   concentration	  
response	   curve,	   however	   calcium	   mobilisation	   stimulated	   by	   75	   nM	   CCL3	   was	   significantly	  
reduced	   (p≤0.001,	  n=3	  vs.	  control)	   to	  almost	  negligible	   levels.	  Despite	  HeLa.RC49	  visualisation	  
indicating	  that	  cytotoxicity	   is	  not	  a	  major	   issue,	  the	  obvious	  interpretation	  of	  the	  observations	  
made	   for	   THP-­‐1	   treatment	   with	   dynasore	   was	   that	   a	   reduction	   in	   cell	   viability	   could	   be	  
responsible	  for	  the	  lack	  of	  signalling.	  	  
	  
	  
Figure	  6.8:	  Dynasore	  shows	  no	  cytotoxicity	  in	  THP-­‐1	  after	  5h	  exposure.	  There	  is	  no	  significant	  
reduction	   in	  viability	   in	  THP-­‐1	   treated	  with	  dynasore	   for	  0.5hr	   then	   incubated	  with	  MTS	   for	  
5hr	  (n=3).	  Results	  represent	  the	  mean	  ±	  SEM	  of	  at	   least	  3	  independent	  experiments.	  Results	  
represent	  the	  mean	  ±	  SEM	  of	  at	  least	  3	  independent	  experiments	  vs.	  vehicle	  control.	  
	  
The	  MTS	   cytotoxicity	   assay	   was	   performed	   on	   THP-­‐1	   treated	   with	   varying	   concentrations	   of	  
dynasore	  over	  a	  time	  period	  equivalent	  to	  that	  during	  chemotaxis	  assay	  (Figure	  6.8).	  Dynasore	  
concentrations	  of	  80,	   40	  and	  8	  µM	  did	  not	   significantly	   affect	   THP-­‐1	   viability	   (p>0.05,	  n=3	  vs.	  
untreated	  control)	  which	   showed	   that	   the	  effect	  of	  dynasore	  on	  THP-­‐1	  cellular	   responses	  can	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Figure	  6.9:	  Dynamin	   localises	  at	  cytoskeletal	  structures	   in	  CHO.CCR5	  and	   is	  present	   in	  THP-­‐1	  
cells.	  (a)	  Confocal	  microscopy	  revealed	  that	  dynamin	  localises	  around	  the	  nucleus	  and	  at	  the	  
leading	   edges	   of	   CCL3	   stimulated	   CHO.CCR5.	   (b)	   Localisation	  with	   tubular	   structures	   is	   also	  
observed.	   (c)	   Localisation	  with	   fibrous	   structures	   in	   filopodia	   is	   also	   observed.	   (d)	  Western	  
blotting	   confirms	   the	   100	   kD	   protein	   dynamin	   2	   is	   present	   in	   THP-­‐1	   cells.	   Images	   obtained	  
with	  Zeiss	  laser	  scanning	  confocal	  microscope	  system.	  	  
	  
Although	   dynamin	   2	   is	   ubiquitously	   expressed	   it	   is	   important	   to	   validate	   the	   presence	   of	  
dynamin	  2	   in	  the	  model	  cell	   lines	  before	  further	  conclusions	  can	  be	  drawn	  about	  the	  effect	  of	  
dynasore.	  CHO.CCR5,	  which	  were	  used	  for	  visualisation	  of	  cytoskeletal	  structures,	  were	  stained	  
with	   anti-­‐dynamin	   2	   polyclonal	   Ab	   and	   with	   Alexa-­‐594	   tagged	   secondary	   Ab.	   Confocal	  














	  secondary	  Ab	   control,	   not	   shown)	  with	   various	   structure	   including	   lamellapodia	   (Figure	  6.9a),	  
tubular	  structures	  reminiscent	  of	  microtubules	  (Figure	  6.9b)	  and	  fibers	  and	  the	  terminal	  regions	  
of	  filopodia	  (Figure	  6.9c).	  These	  observations	  are	  supported	  by	  the	  literature	  [163,	  164].	  THP-­‐1	  
cells	   are	   not	   conducive	   to	   imaging	   due	   to	   their	   small	   size,	   but	   western	   blotting	  was	   used	   to	  
demonstrate	  a	  protein	  identified	  with	  rabbit	  polyclonal	  anti-­‐dynamin	  2	  antibody	  at	  around	  100	  




Figure	   6.10:	   Dynamin	   localisation	   is	   prevalent	   along	   tubular	   structures	   and	   at	   the	   terminal	  
regions	  of	  actin	  stress	  fibers.	  CHO.CCR5	  activated	  with	  CCL3	  (100	  nM,	  0.5hr)	  and	  stained	  with	  
anti-­‐dynamin	   2	  Ab	   counterstained	  with	  Alexa-­‐594	   tagged	   secondary	  Ab	   (red).	   Actin	   stained	  
with	   Alexa-­‐488	   tagged	   phalloidin	   (green)	   and	   DAPI	   nuclear	   stain	   (blue).	   Image	   is	  





	  Disruption	  of	   the	  actin	  cytoskeleton	   is	  another	  obvious	  explanation	   for	   the	  observed	  effect	  of	  
dynasore	   on	   THP-­‐1	   cell	   migration	   although	   this	   will	   not	   explain	   the	   observed	   reduction	   in	  
calcium	  release.	  CHO.CCR5	  cells	   treated	  with	  80	  µM	  dynasore	  and	  stained	   for	  dynamin	  2	  and	  
actin	  at	  the	  same	  time	  showed	  no	  disruption	  of	  actin	  polymerisation	  as	  seen	  with	  cytochalasin	  D	  
(Chapter	  5).	  Dynasore	  did	  not	  appear	  to	  affect	  dynamin	  localisation	  with	  the	  tubular	  structures	  
that	   did	   not	   stain	  with	   phalloidin	   (Figure	   6.10).	   These	   tubular	   structures	  were	   thought	   to	   be	  
microtubules	  as	  dynamin	   interaction	  with	  microtubules	   is	  well	  characterised	  and	   is	  thought	  to	  
be	   responsible	   for	   some	  of	   the	  effects	  of	  dynamin	   inhibitors	  on	  cancer	  cell	  proliferation	   [163,	  
266].	   As	   microtubules	   have	   also	   been	   linked	   with	   migration	   [267]	   the	   microtubule	  
polymerisation	   inhibitor	   nocodazole	   was	   used	   to	   detect	   whether	   dynamin	   modulation	   of	  












Figure	   6.11:	   Microtubule	   polymerisation	   inhibitor	   does	   not	   inhibit	   THP-­‐1	   cell	   chemotaxis.	  
Treatment	  of	   THP-­‐1	   cells	  with	   3	   and	  7.5	  µM	  nocodozole	   (Noc)	   for	   2hrs	   prior	   to	   chemotaxis	  
assay	   shows	   no	   significant	   effect	   on	   THP-­‐	  migration	   towards	   1	   nM	  CCL3	   (One-­‐way	  ANOVA,	  
Bonferroni	  multiple	  comparison.	  n=3,	  ns=not	  significant	  p>0.05).	  	  
	  
Pre-­‐treatment	  of	  THP-­‐1	  cells	  with	  3	  and	  7.5	  µM	  nocodazole	  prior	  to	  chemotaxis	  assay	  shows	  in	  
no	   significant	   alterations	   to	   the	   way	   THP-­‐1	   cells	   respond	   (p>0.05,	   n=3	   vs.	   vehicle	   controls)	  
(Figure	  6.11).	  Nocodazole	  pre-­‐treatment	  for	  12-­‐18hrs	  is	  typically	  employed	  for	  disruption	  of	  the	  
entire	  microtubule	   network	   however	   treatment	   for	   1hr	   at	   low	   µM	   levels	   has	   been	   shown	   to	  
inhibit	  additional	  microtubule	  polymerisation	  of	  existing	  microtubules	  [268].	  These	  data	  suggest	  
that	  microtubule	  polymerisation	  post	  stimulus	  is	  not	  required	  for	  CC	  motif	  chemokine	  receptor	  







Figure	  6.12:	   Transient	   transfection	  with	  dominant	  negative	  mutant	  dynamin	  K44A	  does	  not	  
significantly	   affect	   CCR5	   mediated	   calcium	   release.	   (a)	   Concentration	   response	   for	   calcium	  
release	  in	  THP-­‐1	  stimulated	  by	  CCL3	  in	  cells	  transfected	  with	  dynamin	  K44A	  plasmid	  (controls	  
electroporated	  without	  plasmid)	  with	   (+)	   and	  without	   (-­‐)	   sodium	  butyrate	   (Na	  But)	   (Results	  
represent	  the	  mean	  ±	  SEM	  of	  2	  independent	  experiments).	  (b)	  Calcium	  release	  stimulated	  by	  
75	   nM	   CCL3	   is	   not	   significantly	   different	   in	   dynamin	   K44A	   transfected	   cells	   (n=2)(Unpaired	  




	  THP-­‐1	   are	   sensitive	   to	   electroporation	   transfection	   in	   such	   a	  way	   that	  migration	   is	   disrupted;	  
calcium	   release	   however,	   is	   unaffected	   by	   this	   procedure.	   The	   dominant	   negative	   dynamin	   2	  
mutant	  K44A	  was	  used	  to	  investigate	  whether	  the	  GTPase	  inhibitory	  activity	  of	  dynasore	  could	  
be	   attributed	   to	   dynamin	   GTPase	   function	   on	   calcium	   release	   stimulated	   through	   CCR5.	  
Dynamin	   K44A	   shows	   no	   ability	   to	   catalyse	   GTP	   turn	   over	   and	   has	   been	   shown	   to	   reduce	  
migration	  in	  cells	  over	  expressing	  the	  protein	  [149].	  	  THP-­‐1	  cells	  were	  transfected	  with	  dynamin	  
K44A	   plasmid	   or	   exposed	   to	   the	   transfection	   procedure	   without	   plasmid	   DNA	   as	   a	   control.	  
Sodium	  butyrate	  was	   also	   used	   in	   an	   attempt	   to	   enhance	   plasmid	   protein	   expression	   (Figure	  
6.12).	   Both	   transfected	   and	   non-­‐transfected	   cells	   demonstrated	   high	   variability	   in	   calcium	  
release	  in	  stimulation	  with	  CCL3	  and	  there	  was	  certainly	  no	  correlation	  between	  dynamin	  K44a	  
transfected	  cells	  and	  the	  reduced	  calcium	  release	  seen	  with	  dynasore.	  	  
	  
6.3.3.	  Pharmacological	  assessment	  of	  dynamin	  inhibitors	  on	  CCL3	  mediated	  THP-­‐1	  migration	  	  
	  
The	  breadth	  of	   recently	  described	  dynamin	  GTPase	   inhibitors	   is	  discussed	   in	   the	   introduction;	  	  
these	   inhibitors	   have	   a	   range	   of	   different	   GTPase	   and	   RME	   inhibition	   potencies,	   different	  
dynamin	  binding	  sites	  and	  diverse	  effects	  on	  migration	  (Table	  1.3.).	  The	  systematic	  treatment	  of	  
THP-­‐1	   cells	   with	   these	   inhibitors	   should	   allow	   the	   function	   of	   dynamin	   in	   chemotaxis	   to	   be	  
clarified.	  The	  systematic	  inhibition	  of	  dynamin	  was	  started	  with	  the	  long-­‐chain	  ammonium	  salts	  
MiTMAB	   and	   OcTMAB.	   MiTMAB	   and	   OcTMAB	   have	   been	   shown	   to	   inhibit	   dynamin	   GTPase	  
function	  and	  RME	  and	   to	   function	   through	   interaction	  with	   the	  dynamin	  pleckstrin	  homology	  
domain	  [203,	  204].	  The	  negative	  control	  compound	  pro-­‐mystric	  acid	  shares	  structural	  homology	  
with	   MiTMAB	   and	   OcTMAB	   but	   has	   no	   function	   against	   dynamin	   GTPase	   or	   endocytosis	  




Figure	  6.13:	  Other	  dynamin	  inhibitors	  have	  no	  significant	  effect	  on	  THP-­‐1	  cell	  chemotaxis.	  (a)	  
MiTMAB	  (MM)	  and	  OcTMAB	  (OM)	  do	  not	  significantly	  affect	  THP-­‐1	  migration	  towards	  1	  nM.	  
(b)	   Dynole	   34-­‐2	   (D34-­‐2)	   and	   Iminodyn	   22	   (I22)	   also	   have	   no	   significant	   effect.	   Results	  
represent	   the	  mean	  ±	  SEM	  of	  at	   least	  3	   independent	  experiments	  vs.	   vehicle	   control.	   (One-­‐
way	  ANOVA,	  Bonferroni	  multiple	  comparison.	  ns	  =not	  significant).	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  Pre-­‐treatment	  of	  THP-­‐1	  cells	  with	  10	  µM	  MiTMAB	  and	  5	  µM	  OcTMAB	  resulted	  in	  no	  significant	  
reduction	  in	  the	  ability	  of	  THP-­‐1	  cells	  to	  migrate	  towards	  a	  stimulus	  of	  1	  nM	  CCL3	  compared	  to	  
both	  the	  untreated	  vehicle	  control	  and	  cells	  treated	  with	  15	  µM	  promystric	  acid	  (Figure	  6.13a)	  
(p>0.05,	   n=6).	   The	   non-­‐competitive	   dynamin	   inhibitors	   dynole	   34-­‐2	   and	   its	   inactive	   negative	  
compound	  dynole	  31-­‐2	  and	  iminodyn	  22	  and	  its	   inactive	  control	  compound	  iminodyn	  17	  were	  
also	  used	  to	  treat	  THP-­‐1	  cells.	  These	  inhibitors	  exhibit	  higher	  GTPase	  IC50	  values	  than	  dynasore.	  
Pre-­‐treatment	   of	   THP-­‐1	   cells	   with	   dynoles	   34-­‐2	   and	   31-­‐2	   and	   iminodyns	   22	   and	   17	   did	   not	  
significantly	   affect	   THP-­‐1	  migration.	   Inhibitory	   compounds	   showed	  no	   significant	   reduction	   in	  
THP-­‐1	  cell	  migration	  vs.	  their	  control	  compounds	  or	  the	  vehicle	  control.	  (p>0.05,	  n≥3).	  Although	  
the	  migration	  was	  not	   significantly	   inhibited	  by	  MiTMAB,	  OcTMAB	  and	   the	  control	   compound	  
iminodyn	   17,	   a	   trend	   towards	  migration	   inhibition	  was	   visible	   in	   THP-­‐1	   cells.	   This	   could	   be	   a	  
reflection	  of	  already	  published	  data	  by	  other	  groups	  that	   	  suggests	  MiTMAB	  and	  OcTMAB	  can	  
reduce	  cancer	  proliferation	  [269].	  These	  results	  were	  interesting	  because	  at	  the	  concentrations	  
used	  for	  the	  experiments,	  the	  tested	  inhibitor	  should	  reduce	  the	  	  GTPase	  function	  of	  dynamin	  	  
via	   distinct	   protein-­‐inhibitor	   interactions.	   There	   are	   conflicting	   views	   of	   the	   importance	   of	  
GTPase	   turn-­‐over	   and	   the	   role	   of	   dynamin	   in	  migration	   [100,	   149].	   To	   examine	  whether	   the	  
effect	  of	  dynasore	  on	  THP-­‐1	  migration	  was	  due	  to	  its	  inhibitory	  effect	  on	  GTPase	  turn–over,	  the	  
dynasore	   analogue	   dyngo-­‐4a,	  which	   has	   higher	   potency	   for	   dynamin	   2	  GTPase	   inhibition	  was	  







Figure	  6.14:	  Dynasore	  is	  more	  potent	  inhibitor	  of	  CCR5	  mediated	  THP-­‐1	  cell	  chemotaxis	  than	  
its	   analogue	   dyngo-­‐4a.	   Concentration	   response	   curves	   for	   inhibition	   of	   THP-­‐1	   migration	  
towards	  1	  nM	  CCL3	   in	  the	  presence	  on	  dynasore	  and	  its	  close	  structural	  analogue	  dyngo-­‐4a.	  
Results	  represent	  the	  mean	  ±	  SEM	  of	  at	  least	  3	  independent	  experiments	  plotted	  as	  the	  ratio	  
of	  stimulated	  over	  basal	  migration.	  	  
	  
The	   effect	   of	   pre-­‐treatment	   of	   THP-­‐1	   cells	  with	   increasing	   concentrations	   if	   dynasore	   and	   its	  	  
analogue	   dyngo-­‐4a,	   which	   shows	   a	   higher	   potency	   for	   GTPase	   inhibition,	   were	   used	   to	   plot	  
concentration	  response	  curved	  for	  the	  inhibition	  of	  chemotaxis	  toward	  1	  nM	  CCL3	  (Figure	  6.14).	  
Sigmoidal	   concentration	   response	   curves	  were	   fitted	   and	   IC50	   values	   for	   dynasore	   (52±4	   nM)	  
and	   dyngo-­‐4a	   (103±7	   nM)	   were	   calculated.	   These	   data	   provide	   strong	   evidence	   that	   GTPase	  
inhibition	  is	  not	  the	  most	  important	  factor	  for	  the	  effect	  of	  dynasore.	  The	  data	  also	  suggest	  that	  
a	   structure-­‐activity	   relationship	   can	   be	   formed	   based	   around	   alterations	   in	   the	   dynasore	  
terminal	  aryl-­‐ring	  hydroxyl	  moieties.	  To	  exemplify	  these	  functional	  differences	  and	  to	  determine	  
if	   the	  other	  dynamin	   inhibitors	  have	  any	  effect	  on	  migration	  at	  higher	  molarity,	  an	  equimolar	  




Figure	   6.15:	   Equimolar	   comparison	   of	   structurally	   homologous	   dynamin	   inhibitors.	   (a)	  
Chemical	   structures	   of	   most	   similar	   dynamin	   inhibitors.	   (b)	   Inhibition	   of	   THP-­‐1	   migration	  
towards	   1	   nM	   CCL3	   reveals	   structure	   activity	   relationship	   (One-­‐way	   ANOVA,	   Bonferroni	  
multiple	  comparison.	  ***	  indicates	  p≤0.001	  vs.	  vehicle	  control.	  Results	  represent	  the	  mean	  ±	  
SEM	  of	  at	  least	  3	  independent	  experiments).	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  Being	  analogues,	  dynasore	  and	  dyngo-­‐4a	  share	  a	  high	  level	  of	  structural	  similarity	  however,	  the	  
iminodyn	  22	  inhibitor	  also	  has	  obvious	  structural	  homology	  and	  has	  also	  been	  shown	  to	  have	  a	  
significantly	   higher	   GTPase	   inhibition	   IC50	   [206]	   (Figure	   6.15a).	   When	   used	   at	   80	   µM	   clear	  
comparisons	  can	  be	  made	  about	  the	  efficacy	  of	  these	  dynamin	  inhibitors	  to	  block	  migration	  and	  
how	  this	  efficacy	  has	  no	  bearing	  on	  their	  GTPase	  IC50	  values	  (Figure	  6.15b).	  Based	  on	  these	  three	  
compounds	   it	   can	   be	   concluded	   that	   the	   inhibitory	   effects	   of	   a	   compound	   on	  migration	   are	  
inversely	   proportional	   to	   their	   GTPase	   inhibitory	   potency.	   The	   remaining	   inhibitors	  were	   also	  
used	  at	  80	  µM	  to	  determine	  if	  this	  correlation	  was	  maintained.	  	  
	  
	  
Figure	  6.16:	  Equimolar	  comparison	  of	  MiTMAB,	  OcTMAB	  and	  Dynole	  34-­‐2.	  Only	  cells	  treated	  
with	  80	  µM	  MiTMAB	  show	  a	  significant	  reduction	  in	  THP-­‐1	  migration	  towards	  (p≤0.001	  n≥3).	  
Results	  represent	  the	  mean	  ±	  SEM	  of	  at	  least	  3	  independent	  experiments	  (One-­‐way	  ANOVA,	  
Bonferroni	   multiple	   comparison.	   ***	   indicates	   p≤0.001	   vs.	   vehicle	   control.	   ns	   =	   not	  
significant).	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  Of	  the	  remaining	  dynamin	   inhibitors,	  only	  MiTMAB	  was	  able	  to	  significantly	   reduce	  THP-­‐1	  cell	  
migration	  toward	  CCL3	  at	  80	  µM	  (p≤0.001,	  n=3),	  with	  OcTMAB	  and	  dynole	  34-­‐2	  showing	  a	  non-­‐
significant	  trend	  towards	  inhibition	  (p>0.05,	  n≥3)	  (Figure	  6.16).	  Before	  conclusions	  can	  be	  drawn	  
about	   these	   observations	   it	   is	   important	   to	   determine	   if	   the	   80	   µM	   treatments	   used	   are	  
showing	  any	  cytotoxic	  effects.	  	  
	  
	  
Figure	   6.17:	   MiTMAB	   and	   Dynole	   34-­‐2	   show	   significant	   cytotoxicity	   at	   80	   µM.	   THP-­‐1	   cells	  
treated	  with	  80	  µM	  dynamin	   inhibitors	   for	  0.5hr	  before	   incubation	  with	  MTS	   for	  5hr	   reveal	  
significant	   reduction	   in	   viability	   associated	   with	   MM	   and	   D34-­‐2	   (p≤0.001	   n≥3).	   Results	  
represent	   the	   mean	   ±	   SEM	   of	   at	   least	   3	   independent	   experiments	   (One-­‐way	   ANOVA,	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  MTS	   cytotoxicity	   assessment	   of	   THP-­‐1	   cells	   treated	   with	   80	   µM	   iminodyn	   22,	   dynole	   34-­‐2,	  
MiTMAB	  and	  OcTMAB	  revealed	  that	  dynole	  34-­‐2	  and	  MiTMAB	  significantly	  reduced	  THP-­‐1	  cell	  
viability	  after	  5hr	  treatment	  (Figure	  6.17)	  (p0≤0.001,	  n=3).	  Iminodyn	  22	  and	  OcTMAB	  showed	  no	  
significant	   reduction	   in	  viability	  although	  a	   trend	  was	  observed	  towards	  reduced	  viability	  with	  
OcTMAB	   treatment	   (p>0.05,	   n=3).	   Considering	   MiTMAB	   and	   OcTMAB	   are	   analogues	   of	   one	  
another	  this	  reduction	  in	  viability	  seen	  with	  OcTMAB	  treatment	  is	   likely	  to	  represent	  cytotoxic	  
affects	  and	   is	  sufficient	  to	  explain	  the	  non-­‐significant	  trend	   in	  migration	  observed	  with	  80	  µM	  
treatment	  of	  THP-­‐1.	  	  Taken	  as	  a	  whole	  these	  data	  suggest	  that	  any	  reduction	  in	  migration	  seen	  
with	  higher	  concentrations	  of	  dynamin	   inhibitors	  other	   than	  dynasore	  and	  dyngo-­‐4a	   is	  due	   to	  
cytotoxicity	   and	   that	   the	   anti-­‐migratory	   effects	   of	   these	   inhibitors	   is	   not	   due	   to	   dynamin	   2	  
GTPase	  inhibition	  as	  their	  potency	  does	  not	  correlate	  with	  their	  GTPase	  IC50.	  
	  
To	  validate	  the	  observations	  seen	  in	  THP-­‐1	  cells,	  the	  dynamin	  inhibitors	  dynasore	  and	  dyngo-­‐4a	  
were	  used	  to	  treat	  HeLa.RC49	  cells	  in	  the	  wound-­‐healing	  assay.	  Confluent	  HeLa.RC49	  cells	  in	  a	  
low	  serum	  environment	  show	  an	  ability	  to	  migrate	  into	  a	  scratch,	  which	  allows	  an	  assessment	  of	  
the	  effect	  of	  inhibitors	  on	  migration.	  HeLa.RC49	  cells	  show	  an	  un-­‐stimulated	  basal	  regrowth	  that	  
is	   increased	   by	   stimulation	   of	   CCR5	   and	   is	   blocked	   by	   80	   µM	  dynasore	   pre-­‐treatment.	   Figure	  





Figure	  6.18:	  The	  scratch	  or	  ‘wound	  healing’	  assay	  reveals	  the	  effect	  of	  dynasore	  on	  HeLa.RC49	  
migration.	   Scratch	   assay	   performed	   on	   confluent	   HeLa.RC49	   monolayer	   demonstrates	   the	  
differences	  between	  basal	  and	  CCL3	  stimulated	  healing	  and	  that	  for	  cells	  treated	  with	  80	  µM	  
dynasore	  for	  0.5hr	  before	  stimulation.	  
Control – t=0 
Control – t=48hr 
+CCL3 t=0 





Figure	   6.19:	   Quantification	   of	   HeLa.RC49	  wound	   healing	   assay	   in	   the	   presence	   of	   dynasore	  
and	   dyngo-­‐4a.	   (a)	   A	   graphical	   representation	   of	   wound	   healing	   in	   HeLa.RC49	   treated	   with	  
dynasore	   (Dyn)	   and	   dyngo-­‐4a	   (D4)	   in	   comparison	   to	   basal	   and	   stimulated	   controls	  
(quantification	   method	   described	   in	   materials	   and	   methods).	   	   (b)	   dynasore	   and	   dyngo-­‐4a	  
significantly	   reduce	   wound	   healing	   in	   HeLa.RC49	   vs.	   CCL3	   stimulated	   control.	   Results	  
represent	  the	  mean	  ±	  SEM	  of	  3	  independent	  experiments	  run	  in	  duplicate	  (One-­‐way	  ANOVA,	  




	  Both	  dynasore	  and	  dyngo-­‐4a	  are	  able	  to	  significantly	  reduce	  CCL3	  stimulated	  HeLa.RC49	  wound	  
healing	   (Figure	   6.19)	   (p0.001,	   n=3	   vs.	   stimulated	   control).	  Wound	   healing	   is	   decreased	   to	   2%	  
compared	  to	  40%	  for	  simulated	  controls.	  Dyngo-­‐4a	  appears	  to	  be	  more	  efficacious	  in	  this	  assay,	  
although	  this	  observation	  is	  not	  significant.	  These	  data	  clearly	  support	  the	  idea	  that	  dynamin	  is	  
required	   for	   fibroblast	  migration	   [158].	  There	   is,	  however,	   some	  evidence	  which	   supports	   the	  
idea	  that	   the	  mechanisms	  of	  migration	   in	   large	  adherent	  cells	  and	  monocytes	  differ	   regarding	  
the	   polarisation	   via	   PI3K	   function.	   To	   test	   if	   PI3K	   is	   required	   for	   HeLa.RC49	   migration,	   the	  
inhibitors	  LY294002	  and	  wortmannin	  were	  used	  to	  pre-­‐treat	  cells	  before	  a	  scratch	  healing	  assay.	  
	  
Both	   LY294002	   and	   wortmannin	   pre-­‐treatment	   of	   HeLa.RC49	   cells	   results	   in	   a	   significant	  
reduction	  in	  wound	  healing	  vs.	  the	  stimulated	  controls	  (p0.001,	  n=3)	  (Figure	  6.20).	  Cells	  treated	  
with	  LY294002	  completely	  detach	  from	  the	  mounting	  medium	  after	  48hr,	  which	  indicates	  that	  
the	  cells	  are	  either	  dying	  or	  are	  unable	  to	  remain	  adherent	  due	  the	  effect	  of	  PI3K	  inhibition.	  This	  
can	  be	  taken	  as	  evidence	  that	  HeLa.RC49	  fibroblasts	  are	  more	  sensitive	  to	  PI3K	  inhibition	  than	  




Figure	   6.20:	   PI3K	   inhibitors	   reduce	   CCL3	   stimulated	   wound	   healing	   in	   HeLa.RC49	   cells.	   A	  
graphical	   representation	   of	   wound	   healing	   in	   HeLa.RC49	   treated	   with	   LY294002	   and	  
wortmannin	   (Wort)	   in	   comparison	   to	   basal	   and	   stimulated	   controls.	   (b)	   LY294002	   and	  
Wortmannin	   significantly	   reduce	   wound	   healing	   in	   HeLa.RC49	   vs.	   CCL3	   stimulated	   control.	  
Results	  represent	  the	  mean	  ±	  SEM	  of	  3	   independent	  experiments	  run	   in	  duplicate	  (One-­‐way	  







Figure	  6.21:	  Dynasore	  does	  not	  affect	  dynamin	  localisation	  but	  does	  alter	  membrane	  structure	  
and	  the	  ability	   for	  CHO.CCR5	  cells	   to	  polarise.	  Fluorescence	  microscopy	   images	  of	  Alexa-­‐488	  
phalloidin	   (Phal)	  anti-­‐dynamin	  Ab	  stain	   (Dyn)	  and	  overlay	  +	  DAPI	   (o/l).	   (a)	  Negative	  control.	  
(b)	   +	   2hr	   100nM	   CCL3	   stimulation.	   (c)	   0.5hr	   dynasore	   80	   µM	   (d)	   +	   2hr	   100	   nM	   CCL3	  
stimulation.	  (e)	  24hr	  dynasore	  80	  µM	  (f)	  +	  2hr	  100	  nM	  CCL3	  stimulation.	  Acquired	  with	  Zeiss	  
axiovision	  2	  system.	  	  è 	  =	  direction	  of	  scratch.	  
189
	  The	  effect	  of	  dynasore	  on	  dynamin	   localisation	   in	  CHO.CCR5	  cells	  was	  assessed	   in	  order	  to	  try	  
and	   determine	   abnormal	   dynamin	   localisation	   might	   explain	   the	   observed	   reduction	   in	  
migration.	  CHO.CCR5	  monolayers	  were	  cultured	  and	  scratched	  prior	   to	  treatment	  with	  80	  µM	  
dynasore	   for	   0.5hr	   or	   24hrs	   and	   stimulation	   with	   100	   nM	   CCL3	   for	   2hr.	   The	   scratches	   were	  
introduced	  to	  allow	  observations	  regarding	  the	  ability	  of	  cells	  to	  polarise	  to	  be	  made.	  Dynamin	  
localisation	  was	  observed	  in	  both	  unstimulated	  and	  stimulated	  controls	  around	  the	  nucleus	  and	  
at	  the	  tips	  of	  actin	  stress	  fibers	  (Figure	  6.21a&b)	  at	  locations	  thought	  to	  relate	  to	  base	  filopodia	  
or	   focal	   adhesions.	   Controls	   cells	   show	   a	   clear	   polarisation	   towards	   scratches	   that	   is	   more	  
pronounced	  in	  CCL3	  stimulated	  cells.	  Cells	  treated	  with	  dynasore	  for	  0.5hr	  prior	  to	  stimulation	  
show	  similar	  levels	  of	  polarisation	  as	  control	  unstimulated	  cells	  which	  could	  be	  attributed	  to	  the	  
basal	  polarisation	  during	  24h	  incubation	  period,	  but	  these	  cells	  also	  show	  dynamin	  localisation	  
at	  the	  nucleus	  and	  at	  actin	  fibre	  termini	  (Figure	  6.21c&d).	  Cells	  treated	  for	  the	  24hr	  incubation	  
with	   80	   µM	   dynasore	   showed	   a	   distinct	   lack	   of	   polarisation	   although	   once	   again	   dynamin	  
localisation	  was	  not	  altered	  noticeably.	  	  These	  cells	  also	  seemed	  to	  exhibit	  a	  higher	  number	  of	  
membrane	  protrusions,	  reminiscent	  of	  filopodia,	  which	  may	  suggest	  that	  whilst	  dynasore	  does	  
not	   prevent	   dynamin	   localisation	   but	   prevent	   cells	   polarising	   under	   basal	   conditions	   or	   in	  
stimulation,	  by	  CCL3.	  This	  may	  have	  explained	  the	  increase	  in	  filopodia	  which	  would	  normally	  be	  
associated	  with	   the	   leading	  edge	  of	  cells;	  where	   this	   leading	  edge	  could	  not	  be	   ‘identified’	  by	  
the	  cell	  the	  filopodia	  appear	  uniformly.	  	  
	  
6.3.4.	   Dynamin	   inhibitors	   reduce	   CCL3	   stimulated	   calcium	   release	   through	   non	   specific	  
mobilisation	  of	  calcium	  stores	  
	  	  
The	   evidence	   provided	   in	   chapter	   4	   and	   in	   the	   literature	   [75]	   supports	   the	   idea	   that	   calcium	  
release	  and	  migration	  are	  independent	  phenomena	  downstream	  of	  CCR5,	  this	  does	  not	  explain	  
fully	   the	   effects	   	   of	   dynasore.	   To	   determine	   if	   the	   observed	   reduction	   in	   calcium	   release	   is	   a	  
result	  of	  dynamin	  inhibition	  all	  available	  dynamin	  inhibitors	  were	  used	  to	  treat	  THP-­‐1	  cells	  prior	  




Figure	  6.22:	  OcTMAB	  inhibits	  CCL3	  stimulated	  intracellular	  calcium	  release	  in	  THP-­‐1	  cells.	   (a)	  
Concentration	   response	   for	   CCL3	   stimulation	   of	   THP-­‐1	   cells	   with	   and	   without	   0.5hr	   pre-­‐
treatment	  with	  10	  	  µM	  MiTMAB	  (MM),	  5	  µM	  OcTMAB	  (OM)	  and	  negative	  control	  compound	  
promystric	  acid	  (PMA).	  (b)	  OM	  significantly	  reduces	  calcium	  release	  stimulated	  by	  75	  nM	  CCL3	  
(p≤0.01	   n≤3).	   Results	   represent	   the	   mean	   ±	   SEM	   of	   3	   independent	   experiments	   run	   in	  







Pre-­‐treatment	  of	  THP-­‐1	  cells	  with	  MiTMAB,	  OcTMAB	  and	  control	  compound	  promystric	  acid	  for	  
0.5hr	  prior	  to	  calcium	  flux	  assay	  revealed	  that	  OcTMAB	  treatment	  significantly	  reduces	  calcium	  
release	   (Figure	   6.22.).	   Predicted	   efficacy	   and	   EC50	   values	   for	   promystric	   acid	   and	   MiTMAB	  
treated	   cells	   are	  not	   significantly	  different	   than	   the	  untreated	   control	   (p>0.05,	  n=4).	  OcTMAB	  
treatment	   results	   in	   a	   significant	   reduction	   in	   calcium	   release	   stimulated	   by	   75	   nM	   CCL3	  
(p≤0.001,	  n=4	  vs.	  negative	  control),	  promystric	  acid	  and	  MiTMAB	  showed	  no	  significant	  effect	  
(p>0.05,	  n=4).	  	  
	  
The	  predicted	  maximal	  calcium	  release	  (stimulation	  over	  basal)	  for	  dynole	  31-­‐2	  treated	  cells	  was	  
0.847±0.156.	  A	  sigmoidal	  fit	  was	  not	  possible	  for	  dynole	  34-­‐2	  (assuming	  hill	  co-­‐efficient	  of	  1),	  so	  
efficacy	   predictions	   could	   not	   be	  made.	   CCL3	   stimulated	   calcium	   release	   at	   75	   nM	  CCL3	  was	  
however	   significantly	   lower	   vs.	   dynole	   31-­‐2	   treated	   cells	   (p≤0.001,	   n=4).	   CCL3	   stimulated	  
calcium	   release	   in	   iminodyn	   17	   treated	   THP-­‐1	   cells	   showed	   an	   efficacy	   of	   0.723±0.118	   vs.	  
0.762±0.184	  for	  iminodyn	  22	  treated	  cells.	  The	  predicted	  maximal	  CCL3	  efficacy	  for	  dynole	  31-­‐2	  
and	  iminodyns	  17	  and	  22	  were	  not	  significantly	  different	  from	  one	  another	  (p>0.05,	  n=4,	  one-­‐
way	  ANOVA	  with	  Bonferroni	  multiple	  comparison)	  and	  calcium	  release	  at	  75	  nm	  CCL3	  was	  not	  




Figure	  6.23:	  Dynole	  34-­‐2	  (D34-­‐2)	  inhibits	  CCL3	  stimulated	  intracellular	  calcium	  release	  in	  THP-­‐
1	  cells.	  (a)	  Concentration	  response	  for	  stimulation	  of	  THP-­‐1	  with	  increasing	  concentrations	  of	  
CCL3	  with	  and	  without	  0.5hr	  pre-­‐treatment	  with	  15	  	  µM	  D34-­‐2	  and	  its	  negative	  control	  dynole	  
31-­‐2	  (D31-­‐2)	  and	  1	  µM	  iminodyn	  22	  (I22)	  and	  its	  negative	  control	  iminodyn	  17	  (I17).	  (b)	  D34-­‐2	  
significantly	   reduced	   calcium	   release	   stimulated	   by	   75	   nM	   CCL3	   (p≤0.001	   n≤3)	   Results	  
represent	  the	  mean	  ±	  SEM	  of	  3	  independent	  experiments	  run	  in	  duplicate	  (One-­‐way	  ANOVA,	  





Figure	  6.24:	  Dynamin	  inhibitors	  that	  block	  calcium	  release	  do	  so	  in	  a	  concentration	  dependent	  
fashion.	   A	   reduction	   in	   inhibitor	   concentration	   by	   1/2	   and	   1/5	   allows	   recovery	   of	   THP-­‐1	  
calcium	   release	   stimulated	  by	  75	  nM	  CCL3.	  Results	   represent	   the	  mean	  ±	   SEM	  of	   at	   least	   2	  
independent	  experiments.	  
	  
Dynasore	  (80	  µM)	  OcMAB	  (5	  µM)	  and	  Dynole	  34-­‐2	  (15	  µM)	  significantly	  affect	  calcium	  release,	  
however,	  the	  means	  by	  which	  this	  occurs	  does	  not	  seem	  to	  be	  based	  on	  their	  known	  potency	  to	  
block	   the	  GTPase	   activity	   of	   dynamin.	   A	   correlation	   of	   inhibitor	   effects	  with	   dynamin	   binding	  
sites	  is	  also	  not	  detectable;	  the	  observed	  effect	  of	  OcTMAB	  is	  absent	  in	  the	  analogue	  MiTMAB.	  
To	   determine	   if	   the	   effects	   of	   these	   inhibitors	   are	   concentration	   dependent,	   calcium	   release	  
was	   assayed	   in	   the	   presence	   of	   the	   original	   concentration	   then	   cells	   were	   treated	   with	  
decreasing	  concentrations	  of	  inhibitor.	  THP-­‐1	  cells	  (Figure	  6.24)	  demonstrate	  that	  the	  effects	  of	  
dynasore,	  OcTMAB	  and	  dynole	  34-­‐2	  are	  concentration	  dependent	  suggesting	  the	  molecules	  are	  
acting	   as	   inhibitors	   of	   a	   process	   on	   which	   calcium	   release	   is	   dependent.	   Dynasore	   has	   been	  
shown	  to	  be	  non-­‐cytotoxic	  at	  treatment	  concentrations,	  but	  before	  the	  effects	  of	  OcTMAB	  and	  
dynole	   34-­‐2	   can	   be	   explained	   it	   is	   important	   to	   show	   the	   results	   are	   not	   the	   result	   of	  




Figure	  6.25:	  OcTMAB	  and	  dynole	  34-­‐2	  do	  not	  show	  cytotoxicity	  at	  concentrations	  that	  inhibit	  
calcium	  release	  in	  THP-­‐1	  cells.	  (a)	  There	  is	  no	  significant	  reduction	  in	  viability	  in	  THP-­‐1	  treated	  
with	  OcTMAB	  for	  0.5hr	  then	  incubated	  with	  MTS	  for	  5hr	  (n=3).	  (b)	  Likewise	  dynole	  34-­‐2	  (D34-­‐
2)	  treatment	  shows	  no	  significant	  reduction	  in	  viability.	  Results	  represent	  the	  mean	  ±	  SEM	  of	  
at	  least	  3	  independent	  experiments.	  (One-­‐way	  ANOVA,	  Bonferroni	  multiple	  comparison).	  
	  
MTS	  cytotoxicity	  assay	  was	  used	  to	  determine	  if	  the	  observed	  decrease	  in	  calcium	  release	  seen	  
in	  THP-­‐1	  treated	  with	  OcTMAB	  and	  dynole	  34-­‐2	  could	  be	  attributed	  to	  concentration	  dependent	  
cell	  death	  (Figure	  6.25).	  THP-­‐1	  cells	  treated	  with	  5,	  2.5	  and	  1	  µM	  OcTMAB	  showed	  no	  significant	  
reduction	   in	   cell	   viability	   after	   5	   hours	   compared	  with	   untreated	   cells	   	   (Figure	   6.25a)(p>0.05,	  


















MTS$ +" +" +" +" #"


















MTS$ +" +" +" +" #"





15 7.5 3 
195
	  calcium	  flux	  assay	  also	  showed	  no	  significant	  reduction	  in	  cell	  viability	  (p>0.05,	  n=3	  vs.	  vehicle	  
control).	  These	  data	  demonstrate	  that	  the	  reduction	  in	  calcium	  release	  seen	  with	  the	  dynamin	  
inhibitors	  is	  not	  based	  on	  cytotoxic	  effects	  which	  presents	  an	  interesting	  conundrum	  as	  to	  why	  
other	   dynamin	   inhibitors	   show	   an	   ability	   to	   alter	   calcium	   release	   and,	   where	   dynasore	   is	  
concerned,	   represent	   a	   potential	   link	   between	   chemotaxis	   and	   calcium	   release	   which	   are	  
considered	  to	  be	  independent	  in	  THP-­‐1	  cells.	   	  Before	  the	  mechanisms	  of	  the	  effect	  on	  calcium	  
release	   of	   these	   drugs	   can	   be	   investigated	   further	   it	   was	   important	   to	   determine	   if	   the	  
observations	   can	   be	   a	   result	   of	   non-­‐specific	   calcium	   releases	   induced	   by	   the	   inhibitors.	  
Nonspecific	   calcium	   release	  occurs	  when	   compounds	   act	   directly	   on	   calcium	   stores	  bypassing	  
receptor	  mediated	  signalling.	  Thapsigargin	  is	  a	  widely	  used	  ‘non-­‐specific’	  stimulator	  of	  calcium	  
release	   (although	   its	  mode	  of	  action	   is	   specific)	  and	   it	   can	  be	  used	   to	  determine	   the	  effect	  of	  
other	  drugs	  on	  calcium	  stores	  [93,	  270].	  	  	  
	  
THP-­‐1	   cells	   were	   pre-­‐treated	   for	   0.5hr	   with	   decreasing	   concentrations	   of	   dynasore,	   OcTMAB	  
and	   D-­‐34	   (as	   used	   previously)	   prior	   to	   calcium	   flux	   assay	   stimulated	   by	   1	   µM	   thapsigargin	  
(Figure	  6.26a).	  The	  rationale	  behind	  the	  experiment	  is	  that	  should	  any	  of	  the	  dynamin	  inhibitors	  
directly	  affect	  calcium	  stores	  than	  the	  amount	  of	  calcium	  released	  by	  thapsigargin	  stimulation	  
would	  be	  reduced	  compared	  to	  control	  cells.	  Because	  receptor	  activation	  is	  not	  taking	  place	  in	  
this	  assay,	  any	  effects	  could	  then	  be	  categorised	  as	  ‘non-­‐specific’	  calcium	  release.	  All	  treatment	  
concentrations	  of	  dynasore	  and	  OcTMAB	  and	  all	  but	  the	  lowest	  treatment	  concentration	  of	  D-­‐
34	  resulted	  in	  a	  significant	  reduction	  in	  thapsigargin	  stimulated	  calcium	  release	  (p≤0.001,	  n=3).	  
The	   reductions	   in	   thapsigargin	   stimulated	   calcium	   release	   also	   followed	   a	   concentration	  
dependent	   pattern	   further	   validating	   the	   idea	   that	   ‘non-­‐specific’	   calcium	   release	   is	   occurring	  
through	  dynamin	  inhibitor	  treatment.	  The	  implications	  of	  this	  observation	  are	  far	  reaching	  both	  
with	   regard	   to	   the	   actual	  mechanism	   and	   to	   relevance	   to	   other	   cell	   lines	   where	   dynasore	   is	  
often	  used	  in	  calcium	  release	  based	  experimentation	  [201].	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Figure	  6.26:	  Dynasore	  reduces	  thapsigargin	  stimulated	  calcium	  release	  in	  THP-­‐1	  cells.	  (a)	  Pre-­‐
treatment	  of	  THP-­‐1	  with	  dynasore	  (Dyn),	  OcTMAB	  (OM)	  and	  dynole	  34-­‐2	  (D34-­‐2)	  significantly	  
reduces	   thapsigargin	   (TG	   1µM)	   stimulated	   calcium	   release	   in	   a	   concentration	   dependent	  
fashion	  (p≤0.001	  n≥3).	  (b)	  Single	  traces	  of	  calcium	  mobilisation	  over	  time.	  All	  results	  represent	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  the	  mean	  ±	  SEM	  of	  at	  least	  3	  independent	  experiments	  (One-­‐way	  ANOVA,	  Bonferroni	  multiple	  
comparison.***	  indicates	  p≤0.001	  vs.	  control).	  
	  
Figure	  6.27:	  Dynamin	   inhibitor	  negative	  controls	  with	  the	  exception	  of	  promystric	  acid	  have	  
no	   significant	   effect	   on	   TG	   induced	   calcium	   release.	   (a)	   Promystric	   acid	   (PMA)	   at	   higher	  
concentrations	  significantly	  reduces	  calcium	  release	  in	  THP-­‐1	  stimulated	  by	  75	  nM	  CCL3,	  lower	  
concentrations	   and	  dynole	   31-­‐2	  have	  no	   significant	   effect.	  All	   results	   represent	   the	  mean	  ±	  
SEM	   of	   at	   least	   3	   independent	   experiments	   (One-­‐way	   ANOVA,	   Bonferroni	   multiple	  










The	   negative	   control	   compounds	   for	   the	   dynamin	   inhibitors	   that	   had	   been	   shown	   to	   reduce	  
calcium	  flux	  were	  also	  used	  to	  treat	  THP-­‐1	  cells	  prior	  to	  thapsigargin	  stimulated	  calcium	  release	  
(Figure	   6.27.).	   These	   compounds	   validated	   the	   model	   and	   demonstrated	   that	   all	   treatment	  
concentrations	   (with	   the	   exception	   of	   10	   µM	   promystric	   acid)	   had	   no	   significant	   effect	   on	  
calcium	   release	   (p>0.05,	   n=3).	   The	   significant	   (p≤0.001,	   n=3)	   but	   partial	   reduction	   in	  
thapsigargin	  stimulated	  calcium	  release	  shown	  by	  10	  µM	  promystric	  acid	  treatment	  is	  less	  easy	  
to	  explain.	  	  Promystric	  acid	  did	  show	  a	  non-­‐significant	  trend	  toward	  reducing	  calcium	  release	  in	  
THP-­‐1	   cells,	   which	   might	   indicate	   the	   observed	   effects	   of	   OcTMAB	   are	   a	   result	   of	   structural	  
effects	  of	  the	  homology	  series	  which	  do	  not	  affect	  dynamin	  GTPase	  function.	  	  
	  
	  
Figure	   6.28:	  Dynasore	   stimulates	   calcium	   release	   in	   THP-­‐1	   cells.	   	   Stimulation	  with	   dynasore	  
(stim	  Dyn)	  causes	  intracellular	  calcium	  release	  in	  THP-­‐1	  in	  a	  concentration	  dependent	  fashion.	  
Late	   inhibition	   of	   THP-­‐1	   cells,	   1	   minute	   prior	   to	   stimulation	   (late	  Dyn),	   blocks	   stimulatory	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  effects	  of	  Dyn	  and	  75	  nM	  CCL3.	  All	  results	  represent	  the	  mean	  ±	  SEM	  of	  at	  least	  3	  independent	  
experiments.	  
	  
Finally,	   dynasore	  was	   used	   to	   stimulate	   untreated	   THP-­‐1	   cells	   to	   determine	   if	   the	   compound	  
could	  stimulate	  calcium	  release.	  Untreated	  THP-­‐1	  cells	  were	  prepared	  for	  calcium	  release	  assay	  
as	   usual	   and	   then	   stimulated	  with	   16,	   40	   and	   80	   µM	   dynasore	   or	   75	   nM	   CCL3	   as	   a	   positive	  
control	  (Figure	  6.28).	  Stimulation	  with	  80	  µM	  dynasore	  resulted	  in	  a	  stimulated	  calcium	  release	  
not	   significantly	   different	   from	   75	   nM	   CCL3	   and	   the	   concentration	   dependent	   nature	   of	   the	  
simulation	  was	  maintained.	  	  
	  
6.3.5.	  Grb2	  plays	  a	  functional	  role	  in	  CCR5	  mediated	  chemotaxis	  in	  THP-­‐1	  cells	  
	  
As	  discussed	  in	  the	  introduction,	  modulation	  of	  dynamin	  by	  protein	  interactions	  at	  the	  PRD	  can	  
not	   only	   increase	  GTPase	   function	   of	   dynamin,	   but	   also	   its	   ability	   to	   polymerise	   and	   interact	  
with	  actin	  fibres.	  This	  interaction	  has	  been	  shown	  to	  promote	  the	  removal	  of	  gelosin	  caps	  from	  
actin	  barbed	  ends	  which	  promotes	  polymerisation	  and	  podosome	  formation	  [164].	  SH3	  domain	  
containing	   protein	   interactions	   with	   dynamin	   via	   its	   PRD	   enhance	   the	   ability	   of	   dynamin	   to	  
polymerise	  and	  also	   complexes	   the	  protein	  with	   crucial	   signal	   transduction	  mediators	   such	  as	  
GTP	  exchange	  factors	  and	  non-­‐receptor	  tyrosine	  kinases	  [100,	  135,	  159].	  Grb2	  interaction	  with	  
the	   dynamin	   2	   PRD	   domain	   is	   well	   documented	   [158,	   165,	   271]	   and	   knock	   down	   and	   over	  
expression	   of	   the	   protein	   has	   been	   shown	   to	   effect	   migration	   [135].	   Grb2	   represented	   an	  
interesting	  target	  for	  investigation	  of	  CCR5	  mediated	  migration	  as	  there	  is	  some	  evidence	  that	  




Figure	   6.29.	   Grb2	   is	   present	   in	   THP-­‐1,	   HeLa.RC49	   and	   CHO.CCR5	   cells	   with	   cytosolic	  
distribution.	  (a)	  Anti-­‐Grb2	  stain	  with	  Alexa-­‐488	  tagged	  secondary,	  in	  unstimulated	  HeLa.RC49.	  
(b)	  In	  the	  presence	  of	  100	  nM	  CCL3	  (DAPI	  nuclear	  stain).	  (c)	  Western	  blotting	  reveals	  Grb2	  is	  
present	   in	   HeLa.RC49,	   THP-­‐1	   and	   CHO.CCR5.	   Images	   representative	   of	   population,	   acquired	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  An	  anti-­‐Grb2	  monoclonal	  antibody	  was	  used	  to	  determine	   if	  Grb2	   is	  present	   in	   the	  model	  cell	  
lines.	  Initially	  Hela.RC49	  cells	  treated	  with	  100	  nM	  for	  CCL3	  for	  1hr	  or	  left	  untreated	  were	  fixed	  
and	  stained	  with	  anti-­‐Grb2	  Ab	  and	  FITC	  tagged	  anti	  mouse	  Ab.	  Grb2	  is	  localised	  throughout	  the	  
cytoplasm,	   but	   not	   in	   the	   nucleus.	   In	   CCL3	   treated	   cells	   a	   slight	   increase	   in	   Grb2	   around	   the	  
ER/Golgi	  was	  observed,	  but	  this	  was	  not	  quantified	  (Figure	  6.29b).	   	  Western	  blotting	  was	  used	  
to	   identify	  Grb2	  expression	   in	  CHO.CCR5,	  HeLa.RC49	  and	  THP-­‐1	   cells	   (Figure	  6.29c).	   The	  Grb2	  
SH2	  domain	  inhibitor	  CGP78850	  is	  a	  rationally	  designed	  molecule	  and	  has	  been	  shown	  to	  inhibit	  
RTK	   mediated	   chemotactic	   signalling.	   RTK	   chemotaxis	   relies	   on	   the	   Grb2-­‐RAS-­‐SOS-­‐PI3K	   axis	  
[112,	  113]	  which	  is	  distinct	  from	  signal	  transduction	  via	  chemokine	  receptors.	  The	  effect	  of	  Grb2	  
inhibition	  on	  chemokine	  receptor	  mediated	  migration	  has	  not	  been	  explored	  yet,	  so	  the	  effect	  
of	  CGP78850	  on	  THP-­‐1	  migration	  was	  investigated.	  The	  Ic50	  of	  CGP78850	  for	  isolated	  Grb2	  is	  in	  
the	   low	   µM	   range,	   however,	   due	   to	   its	   hydrophilic	   nature	   cell	   permeability	   is	   poor	   with	  
cytoplasmic	  concentrations	  approximately	  50	   fold	   lower	  than	  those	  outside	  the	  cell	   [113].	  For	  
this	  reason	  the	  treatment	  concentrations	  used	  were	  significantly	  higher	  than	  might	  be	  expected	  




Figure	  6.30:	  Grb2	  SH2	  domain	   inhibitor	  CGP78850	   significantly	   reduces	  THP-­‐1	   cell	  migration	  
towards	  CCL3.	   (a)	   100	  µM	  CGP78850	   (CGP)	   significantly	   reduces	   THP-­‐1	  migration	   towards	   1	  
nM	  CCL3.	   Inhibition	  is	  concentration	  dependent	  (b	  &	  c)	  with	  500µM	  CGP	  reducing	  migration	  
to	  basal	   levels.	  All	   results	  represent	  the	  mean	  ±	  SEM	  of	  at	   least	  3	   independent	  experiments	  
(One	  way	  ANOVA,	  Bonferroni	  multiple	  comparison.	  ***	  indicates	  p≤0.001	  vs.	  vehicle	  control).	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  Pre-­‐treatment	  of	   THP-­‐1	   cells	   for	   0.5hr	  with	  100,	   250	   and	  500	  µM	  CGP78850	   for	   0.5hr	  before	  
chemotaxis	   assay	   towards	   1	   nM	   CCL3	   resulted	   in	   a	   significant,	   concentration	   dependent	  
reduction	   in	  migration	  (p≤0.001,	  n≥3)	   (Figure	  6.30).	  At	  250	  µM	  migration	  was	  not	  significantly	  
different	  from	  unstimulated	  basal	  migration	  (p>0.05,	  n≥3).	  These	  data	  suggest	  that	  Grb2	  plays	  a	  
crucial	  role	  in	  CCR5	  mediated	  chemotaxis	  however	  any	  cytotoxic	  effects	  of	  CGP78850	  treatment	  
need	  to	  be	  determined	  before	  the	  observations	  can	  be	  attributed	  to	  Grb2	  inhibition.	  	  
	  
	  
Figure	   6.31:	   CGP78850	   does	   not	   demonstrate	   cytotoxicity	   in	   THP-­‐1	   cells	   up	   to	   500	   µM.	  
Treatment	   with	   increasing	   concentrations	   of	   CGP78850	   (CGP)	   for	   0.5hr	   prior	   to	   incubation	  
with	  MTS	  for	  5hr	  shows	  no	  significant	  decrease	  in	  viability.	  	  All	  results	  represent	  the	  mean	  ±	  
SEM	   of	   at	   least	   3	   independent	   experiments	   (One-­‐way	   ANOVA,	   Bonferroni	   multiple	  
comparison.	  All	  treatments	  not	  significant	  =	  p>0.05).	  
	  
	  
Pre-­‐treatment	  of	  THP-­‐cells	  with	  100,	  250	  and	  500	  µM	  CGP78850	   for	  0.5hr	  prior	   to	   incubation	  
with	  MTS	   for	  5hr	  demonstrated	   that	   the	   treatment	   concentrations	  did	  not	  affect	   cell	   viability	  
significantly	   (p>0.05,	  n=3)	   (Figure	  6.31).	   	  These	  data	   indicated	  that	   the	  reduction	   in	  THP-­‐1	  cell	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Figure	  6.32:	  CGP78850	  does	  not	  prevent	  actin	  polymerisation	   in	  CHO.CCR5	  cells.	   	  CHO.CCR5	  
treated	  with	  250	  µM	  CGP78850	  shown	  no	  effect	  on	  actin	  stress	  fiber	  formation	  in	  cells	  treated	  
with	   100	   nM	   for	   2hr.	   Actin	   stained	   with	   Alexa-­‐488	   phalloidin	   (green),	   anti-­‐dynamin	   Ab	  
counterstained	   with	   Alexa-­‐594	   tagged	   Ab	   (red)	   DAPI	   (blue).	   Image	   representative	   of	  
population,	  acquired	  using	  Zeiss	  axiovision	  2	  system.	  	  
	  
As	   observed	  with	   the	   cucurbitacin	   I,	   disruption	   of	   the	   actin	   cytoskeleton	   can	   result	   in	   a	   non-­‐
specific	  reduction	  in	  migration.	  So	  it	  is	  important	  to	  ascertain	  if	  CGP78850	  can	  affect	  actin	  stress	  
fiber	  formation	  (Figure	  6.32).	  CHO.CCR5	  cells	  were	  treated	  with	  250	  µM	  CGP78850	  for	  0.5hr	  and	  
then	  stimulated	  with	  100	  nM	  CCL3	  for	  and	  stained	  with	  Alexa	  488	  tagged	  and	  anti-­‐dynamin	  2	  Ab	  
and	   corresponding	   secondary	   antibody.	   Wide	   field	   fluorescence	   microscopy	   revealed	   that	  
CGP78850	  treatment	  does	  not	  affect	  the	  ability	  of	  CHO.CCR5	  cells	  to	  form	  actin	  stress	  fibers	  nor	  




Figure	  6.33:	  Dynasore	  and	  CGP87750	  increase	  potency	  of	  PI3K	  inhibitors	  but	  not	  each	  other.	  
(a)	  CGP78850	  significantly	   increases	  potency	  of	  wortmannin	   (Wort)	  as	  an	   inhibitor	  of	  THP-­‐1	  
migration	   but	   not	   that	   of	   dynasore	   (p≤0.01	   n=3).	   (b)	   Dynasore	   increases	   potency	   of	   PI3K	  
inhibitors	  LY294002	  (LY)	  and	  Wort	  (p≤0.001	  n=3).	  All	  results	  represent	  the	  mean	  ±	  SEM	  of	  at	  
least	  3	   independent	  experiments.	   (One-­‐way	  ANOVA,	  Bonferroni	  multiple	   comparison,	  ***	  =	  
p≤0.001).	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  To	  investigate	  the	  role	  of	  Grb2	  and	  dynamin	  inhibitors	  further,	  THP-­‐1	  cells	  were	  simultaneously	  
treated	  with	  different	   combinations	  of	  dynamin,	  Grb2	  and	  PI3K	   inhibitors	   to	  determine	   if	   the	  
potency	  of	  these	  inhibitors	  can	  be	  enhanced	  in	  the	  presence	  of	  one	  another.	  THP-­‐1	  treated	  with	  
50	  µM	  dynasore	  resulted	   in	  a	  ≈50%	  reduction	   in	  migration	  (p0.001,	  n≥3	  vs.	  vehicle),	  however,	  
simultaneous	   treatment	   with	   50	   µM	   dynasore	   and	   100	   µM	   CGP78850	   showed	   no	   significant	  
reduction	   in	  migration	  (p>0.05,	  n≥3	  vs.	  dynasore	  50	  µM	  treatment)	   (Figure	  6.33a).	  These	  data	  
indicate	   that	   the	   combined	   inhibitory	   effects	   of	   dynasore	   and	   CGP78850	   are	   not	   cumulative,	  
which	  suggests	  the	  molecules	  function	  downstream	  of	  one	  another.	  Cumulative	  inhibition	  was	  
seen	   with	   the	   simultaneous	   treatment	   of	   THP-­‐1	   cells	   with	   100	   µM	   CGP78850	   and	   10	   nM	  
wortmannin,	   which	   significantly	   reduces	   THP-­‐1	   migration	   compared	   to	   10	   nM	   wortmannin	  
alone	   (p≤0.01,	   n≥3).	   The	   reduction	   in	   migration	   was	   not	   significantly	   different	   to	   20	   nM	  
wortmannin	   pre-­‐treatment	   (p>0.05,	   n≥3)	   which	   demonstrates	   that	   combined	   treatment	  
effectively	   doubled	   the	   potency	   of	   wortmannin.	   100	   µM	   CGP78850	   pre-­‐treatment	   in	  
conjunction	   with	   20	   nM	   wortmannin	   shows	   a	   non-­‐significant	   trend	   towards	   decrease	   in	  
migration	  vs.	  20	  nM	  wortmannin	  alone	  (p>0.05,	  n≥3),	  however,	  this	  combined	  treatment	  is	  also	  
not	   significantly	  different	   from	   the	  unstimulated	  basal	  migration	   (p>0.05,	  n≥3).	  Dynasore	  was	  
also	  used	  in	  conjunction	  with	  PI3K	  inhibitors	  (Figure	  6.33b).	  Pre-­‐treatment	  of	  THP-­‐1	  with	  50	  µM	  
dynasore	  was	  used	  as	  a	  baseline	  and	  significantly	  reduces	  migration	  (p≤0.001,	  n=3	  vs.	  vehicle).	  
Combined	  treatment	  with	  50	  µM	  and	  the	  PI3K	  inhibitors	  LY294004	  (50	  µM)	  and	  wortmannin	  (10	  
nM)	  significantly	  reduced	  migration	  below	  this	  baseline	  (p≤0.001,	  n=3	  vs.	  50	  µM	  dynasore	  pre-­‐
treatment).	  Interpretation	  of	  these	  observations	  needs	  to	  be	  carefully	  considered.	  	  
	  
Combined	   treatment	   of	   CGP78850	  with	  MiTMAB	   and	  OcTMAB	  was	   used	   to	   determine	   if	   the	  




Figure	  6.34:	  CGP78850	  does	  not	  increase	  potency	  of	  MiTMAb	  or	  OcTMAB	  as	  inhibitors	  of	  CCR5	  
mediated	   THP-­‐1	   cell	   chemotaxis.	   Treatment	   of	   THP-­‐1	   with	   50	   µM	   CGP78850	   (CGP)	   in	  
combination	  with	  10	  µM	  MitMAB	  (MM)	  and	  5	  µM	  OcTMAB	  shows	  no	  significant	  reduction	  in	  
THP-­‐1	  chemotaxis	  towards	  1	  nM	  vs.	  CGP	  alone	  or	  the	  vehicle	  control	  (n=3	  ns=	  not	  significant).	  
All	   results	   represent	   the	   mean	   ±	   SEM	   of	   at	   least	   3	   independent	   experiments.	   (One-­‐way	  
ANOVA,	  Bonferroni	  multiple	  comparison).	  
	  
Pre-­‐treatment	  of	  THP-­‐1	  cells	  with	  50	  µM	  CGP78850	  is	  unable	  to	  significantly	  reduce	  migration	  
towards	   1	   nM	   CCL3	   (p>0.05,	   n=3	   vs.	   vehicle	   control)	   and	   combined	   treatment	   with	   50	   µM	  
CGP78850	  and	  MiTMAB	  (10	  µM)	  and	  OcTMAB	  (5	  µM)	  also	  showed	  no	  significant	   reduction	   in	  
migration	  vs.	   the	  vehicle	  control	   (p>0.05,	  n=3)	   (Figure	  6.34).	  These	  data	  support	   the	   idea	  that	  
dynasore	   specific	   interactions	   with	   the	   PRD	   interfere	   with	   the	   conformation	   of	   GRB2,	   which	  






	  6.3.6.	   Signalling	   to	   chemotaxis	   through	   CCR5	   does	   not	   involve	   transactivation	   of	   receptor	  
tyrosine	  kinases	  
	  
Grb2	  inhibition	  appeared	  to	  be	  able	  to	  reduce	  CCR5	  signalling	  to	  migratory	  machinery	  however	  
there	  are	  well	  established	  signal	  transduction	  pathways	   involving	  Grb2	  which	   	  first	  need	  to	  be	  
investigated	  before	  the	  observations	  can	  be	  attributed	  to	  disruption	  of	  CCR5	  signalling.	  Cytokine	  
receptor	  signalling	   is	  known	  to	   involve	  signal	   transduction	  through	  Ras,	  Sos	  and	  Grb2	  to	  PI3K.	  
This	  pathway	  may	  be	  relevant,	  because	  there	  is	  evidence	  to	  suggest	  that	  chemokine	  receptors	  
can	   transactivate	   cytokine	   receptors	   [85,	   96].	   Although	   other	   observations	   suggest	  
transactivation	   is	   not	   a	   likely	   explanation:	   for	   example	   the	   insensitivity	   to	  PI3K	   inhibition,	   the	  
fact	  that	  PKCζ	  inhibition	  shows	  no	  significant	  effect	  and	  the	  sensitivity	  to	  non-­‐receptor	  tyrosine	  
kinase	   inhibition	   with	   bosutinib.	   Inhibition	   of	   Ras	   will	   provide	   definitive	   evidence	   for	   the	  
involvement	  of	  transactivation.	  If	  treatment	  with	  a	  Ras	  inhibitor	  is	  unable	  to	  significantly	  reduce	  







Figure	  6.35:	  Ras	   inhibitor	   farnesylthiosalysilic	   acid	   significantly	   reduces	   THP-­‐1	   cell	  migration	  
above	   100	   µM.	   Treatment	   of	   THP-­‐1	   for	   0.5hr	   with	   increasing	   concentrations	   of	  
farnesylthiosalysilic	   acid	   (FTS)	   prior	   to	   migration	   assay	   reveal	   significant	   inhibition	   at	   and	  
above	  100µM	  (p≤0.001	  n≥3).	  All	  results	  represent	  the	  mean	  ±	  SEM	  of	  at	  least	  3	  independent	  
experiments	   (One-­‐way	   ANOVA,	   Bonferroni	   multiple	   comparison.	   **	   indicates	   p≤0.01	   vs.	  
control	  &	  ***	  =	  ≤0.001,	  ns	  =	  not	  significant).	  
	  
Farnesylthiosalysilic	  acid	  is	  small	  molecule	  inhibitor	  of	  Ras	  which	  prevents	  Ras	  binding	  to	  the	  cell	  
membrane	  and	  hence	  rendering	  it	  non-­‐functional	  (Figure	  6.35).	  The	  inhibitor	  has	  a	  low	  µM	  IC50	  
in	   isolated	   membrane	   systems,	   but	   due	   to	   poor	   membrane	   permeability	   must	   be	   used	   at	  
concentrations	  between	  25	  and	  100	  µM	  in	  whole	  cells	  [272].	  	  THP-­‐1	  cell	  pre-­‐treatment	  for	  0.5hr	  
with	  50,	  100	  and	  200	  µM	  farnesylthiosalysilic	  acid	  demonstrate	  that	  concentrations	  of	  100	  µM	  





Figure	  6.36:	  Farnesylthiosalysilic	  acid	  shows	  high	  cytotoxicity	  at	  200	  µM.	  Cytotoxicity	  assay	  of	  
various	   inhibitors	   used	   in	   this	   chapter	   reveals	   farnesylthiosalysilic	   acid	   (FTS)	   significantly	  
reduces	  viability	   in	  THP-­‐1	   (p≤0.001	  n=3).	   LY294002	   (LY)	   shows	  significant	  cytotoxicity	  at	  250	  
µM	  (p≤0.05	  n=3).	  All	  results	  represent	  the	  mean	  ±	  SEM	  of	  at	  least	  3	  independent	  experiments	  
(One-­‐way	   ANOVA,	   Bonferroni	   multiple	   comparison.	   *	   indicates	   p≤0.05	   vs.	   control	   &	   ***	   =	  
p≤0.001).	  
	  
The	   effects	   of	   farnesylthiosalysilic	   acid	   are	   likely	   due	   to	   cytotoxic	   properties	   as	   200	   µM	  
treatment	   is	  able	  to	  completely	  prevent	  THP-­‐1	  cell	  viability	  (p≤0.001,	  n=3)	  (figure	  6.36).	  These	  
data	   suggest	   that	   the	   reduction	   in	  migration	   observed	  with	   100	   µM	   farnesylthiosalysilic	   acid	  
treatment	  could	  be	  due	  to	  cell	  cytotoxicity	  rather	  than	  inhibition	  of	  Ras.	  This	  idea	  is	  supported	  
by	  the	  fact	  that	  50	  µM	  pre-­‐treatment	  shows	  no	  effect	  on	  migration,	  despite	  being	  at	  sufficiently	  
high	   concentration	   according	   to	   the	   literature	   [272].	   These	   data	   combined	   with	   the	   other	  
relevant	  observations	  provide	  strong	  evidence	   that	  Grb2	   inhibition	   is	  affecting	  CCR5	  signalling	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  As	  described	  in	  chapter	  4,	  it	  is	  important	  to	  translate	  the	  observation	  made	  in	  THP-­‐1	  to	  primary	  
human	  tissue	  to	  determine	   if	   the	  conclusions	  are	   limited	  to	  cell	   type	  or	   if	   they	  show	  receptor	  
specific	  function	  across	  cell	  types.	  Moving	  the	  experimental	  procedures	  into	  activated	  PBLs	  also	  
allows	  comparisons	   to	  be	  drawn	  against	  α-­‐chemokine	  receptors	   to	  determine	   if	   the	  proposed	  
signalling	  mechanism	  is	  conserved	  in	  other	  chemokine	  receptor	  families.	  	  
	  




Figure	   6.37:	   THP-­‐1	   cells	   do	   not	   migrate	   towards	   CXCR3	   agonist	   CXCL11.	   	   THP-­‐1	   cells	   show	  
significant	   migration	   towards	   1	   nM	   CCL3	   however	   migration	   toward	   20	   nM	   CXCL11	   is	   not	  
significantly	  different	   from	  basal	  unstimulated	  migration	   (p≤0.001	  n≥3)	  All	   results	   represent	  
the	  mean	  ±	  SEM	  of	  at	  least	  3	  independent	  experiments	  (One-­‐way	  ANOVA,	  Bonferroni	  multiple	  





	  The	  α-­‐chemokine	  receptor	  ligand	  CXCL11	  and	  has	  a	  sole	  receptor	  CXCR3	  which	  is	  known	  to	  be	  
expressed	  in	  IL2	  activated	  PBLs.	  To	  determine	  whether	  THP-­‐1	  cells	  expressed	  functional	  CXCR3	  
receptors	   untreated	   cells	   were	   stimulated	  with	   20	   nM	   CXCL11.	   Positive	   control	   cells	   showed	  
normal	  migration	   but	   20	   nM	   CXCL11	  was	   unable	   to	   produce	   a	   significant	  migration	   in	   THP-­‐1	  
cells	  (Figure	  6.37)	  (p>0.05,	  n=6	  vs.	  unstimulated	  cells).	  Although	  the	  absence	  of	  CXCR3	  receptor	  
from	   THP-­‐1	   cells	   cannot	   be	   ruled	   out	   with	   these	   data,	   they	   do	   indicate	   that	   there	   is	   no	  
functional	  signalling	  to	  chemotaxis	  via	  this	  receptor.	  	  
	  
Activated	  PBLs	  derived	  from	  peripheral	  blood	  mononuclear	  cells	  are	  known	  to	  up	  regulate	  CXC	  
and	   CC	   motif	   chemokine	   receptor	   expression	   and	   therefore	   make	   an	   ideal	   primary	   human	  
model	   for	   the	   observation	   seen	  with	   THP-­‐1	   cells.	   PLBs	  were	   stained	  with	   anti-­‐CCR5	   antibody	  
(Figure	  6.38a)	  and	  showed	  expression	  of	  the	  receptor	  (Figure	  6.38a’).	  CCR5	  expressed	  in	  these	  
cells	  seems	  to	  be	  functional	  as	  PBLs	  can	  migrate	  towards	  1	  nM	  CCL3	  (p≤0.001,	  n=3	  unstimulated	  
vs.	  stimulated.	  It	  should	  be	  noted	  that	  this	  migration	  might	  be	  mediated	  through	  CCR1	  which	  is	  
also	  present	  on	  some	  activated	  PBLs	  [273].	  This	  migration	  can	  be	  completely	  abrogated	  by	  pre-­‐
treatment	  of	  PBLs	  with	  80	  µM	  dynasore	  for	  0.5hr	  prior	  to	  chemotaxis	  assay	  (p>0.05,	  n=3	  non-­‐
stimulated	  vs.	  stimulated)	  as	  seen	  with	  THP-­‐1	  cells.	   	  PBLs	  also	  migrated	  towards	  20	  nM	  CXCL3	  
(p≤0.001,	  n=3	  vs.	  unstimulated	   controls)	   indicating	   functional	  CXCR3	   receptors	  are	  expressed.	  
These	   data	   indicate	   that	   CCR5	   function	   in	   relation	   to	   dynamin	   inhibition	   appears	   to	   be	  
conserved	  suggesting	  that	  the	  observations	  made	  in	  THP-­‐1	  cells	  are	  not	  cell	  line	  specific.	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Figure	   6.38:	   Activated	   peripheral	   blood	   lymphocyte	   migration	   towards	   CCL3	   is	   dynasore	  
sensitive.	  (a)	  Activated	  peripheral	  blood	  lymphocytes	  (PLBs)	  show	  expression	  of	  CCR5	  after	  10	  
days	  incubation	  with	  IL-­‐2	  and	  concanavalin-­‐A.	  Anti-­‐CCR5	  stain	  counterstained	  with	  Alexa-­‐488	  
tagged	   Ab.	   (a’)	   secondary	   control.	   (B)	   PBLs	   show	   significant	   migration	   towards	   1	   nM	   CCL3	  
which	   is	   inhibited	   by	   0.5hr	   pre-­‐incubation	   with	   80	   µM	   dynasore	   (dyn)	   (p≤0.01	   n=3).	   PBLs	  
significantly	  migrate	  towards	  20	  nM	  CXCL11	  (p≤0.001	  n=3).	  All	   results	  represent	  the	  mean	  ±	  
SEM	  of	   at	   least	   3	  donor’s	   PBLs	  where	  n=1	   is	   the	  mean	  of	   3	   independent	   experiments	   for	   1	  
donor	  	  (One-­‐Way	  ANOVA,	  Bonferroni	  multiple	  comparison.	  **	  indicates	  p≤0.01	  &	  ***	  ≤0.001	  
vs.	  unstimulated	  	  control,	  ns	  =	  not	  significant).	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Figure	  6.39:	  Activated	  peripheral	  blood	  lymphocyte	  migration	  towards	  CXCL11	  is	  not	  sensitive	  
to	   dynasore	   but	   is	   inhibited	   by	   dyngo-­‐4a.	   (a)	   Treatment	   of	   activated	   PBLs	   with	   80	   µM	  
dynasore	   (Dyn)	  has	  no	  significant	  effect	  on	  migration	   towards	  20	  nM	  CXCL11	   (n=3).	   (b)	  Pre-­‐
treatment	  with	   80	   µM	  dyngo-­‐4a	   (D4)	   significantly	   reduces	   PBL	  migration	   (p≤0.001	   n=3).	   All	  
results	   represent	   the	  mean	   ±	   SEM	   of	   at	   least	   3	   donor’s	   PBLs	   where	   n=1	   is	   the	   mean	   of	   3	  
independent	   experiments	   for	   1	   donor	   	   (One-­‐Way	   ANOVA,	   Bonferroni	  multiple	   comparison.	  
***	  indicates	  p≤0.01	  vs.	  unstimulated	  control,	  ns	  =	  not	  significant).	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  Interestingly,	  pre-­‐treatment	  of	  PBLs	  with	  80	  µM	  dynasore	  did	  not	  block	  PBL	  migration	  towards	  
20	  nM	  CXCL11	   (Figure	  6.39a)	   (p>0.05,	  n=3	  vs.	  untreated	  control),	  which	   is	   in	  stark	  contrast	   to	  
the	   results	   observed	   with	   CC-­‐chemokine	   receptor	   stimulation	   in	   PBLs	   and	   THP-­‐1	   cells.	   Pre-­‐
treatment	  with	  80	  µM	  dyngo-­‐4a	  results	   in	  a	  significant	  reduction	   in	  PBL	  migration	  towards	  20	  
nM	  CXCL11	  stimulation	  (p≤0.001,	  n=3	  vs.	  stimulated	  control).	  	  
	  
Experimental	  results	  presented	  in	  chapter	  4	  indicate	  that	  PBL	  chemotaxis	  is	  sensitive	  to	  gallein	  
treatment,	   whereas	   THP-­‐1	   cell	   chemotaxis	   via	   CCR5	   is	   not.	   This	   suggests	   that	   CXCR3	   signal	  
transduction	   to	   migration	   occurs	   via	   the	   Gβγ	   mediated	   route,	   unlike	   the	   CCR5	   signalling	  
network.	  It	  is	  therefore	  important	  to	  ascertain	  whether	  there	  are	  other	  differences	  in	  signalling	  
between	   CCR5	   and	   CXCR3,	   which	   can	   identified	   pharmacologically	   and	   may	   allow	   a	   clearer	  
picture	  of	  the	  CCR5	  specific	  signalling	  events	  seen	  THP-­‐1	  cells.	  	  THP-­‐1	  cells	  have	  a	  low	  sensitivity	  
to	  PI3K	   inhibitor	  LY294002	  and	  are	  unaffected	  by	  PI3Kγ	   inhibitor	  AS605240.	  There	   is	  evidence	  
that	   small	   highly	   mobile	   cells	   such	   as	   monocytes	   do	   not	   require	   PI3K	   for	   polarisation	   in	  
migration	   [115]	   in	   the	   same	   way	   as	   larger	   adherent	   cells	   do,	   but	   there	   is	   also	   evidence	   to	  
suggest	  that	  T-­‐cells	  do	  required	  PI3K	  [248].	  To	  determine	  if	  the	  observation	  made	  in	  THP-­‐1	  cell	  
with	   regard	   to	   PI3K	   inhibitors	   were	   receptor	   or	   cells	   specific,	   PBLS	   were	   pre-­‐treated	   with	  




Figure	   6.40:	   PBL	   migration	   is	   sensitive	   to	   LY294002	   but	   not	   AS605240	   inhibition.	   (a)	   Pre-­‐
treatment	   of	   activated	   PBLs	   with	   125	   µM	   LY294002	   (LY)	   significantly	   reduces	   migration	  
towards	   20nM	   CXCL11	   (p≤0.001	   n=3).	   (b)	   1	   µM	   AS605240	   (AS605)	   has	   no	   significant	   effect	  
(n=3).	  All	  results	  represent	  the	  mean	  ±	  SEM	  of	  at	  least	  3	  donor’s	  PBLs	  where	  n=1	  is	  the	  mean	  
of	   3	   independent	   experiments	   for	   1	   donor	   (One-­‐Way	   ANOVA,	   Bonferroni	   multiple	  




	  PBLs	  pre-­‐treated	  with	  125	  µM	  LY294002	  for	  0.5hr	  prior	  to	  chemotaxis	  assay	  show	  significantly	  
reduced	   migration	   towards	   CXCL11	   (Figure	   6.40a)	   (p≤0.001,	   n=3	   vs.	   stimulated	   control)	  
Considering	   the	   normal	   inhibitory	   concentrations	   for	   LY294002	   are	   12	   fold	   lower	   than	   those	  
used,	   these	   data	   indicate	   that	   PBLs	   also	   show	   low	   sensitivity	   to	   LY294002,	   which	   may	   also	  
represent	  off-­‐target	  inhibition	  of	  PIM1	  or	  other	  non-­‐PI3K	  proteins.	  This	  data	  is	  supported	  by	  the	  
fact	  that	  1	  µM	  AS605240	  pre-­‐treatment	  did	  not	  significantly	  alter	  PBL	  migration	  (Figure	  6.40b)	  	  
(p>0.05,	  n=3	  vs.	  stimulated	  control).	  	  
	  
The	  Grb2	   inhibitor	  CGP78850	  was	  used	  to	  pre-­‐treat	  PBLs	  at	  a	  concentration	  of	  100	  µM	  which	  
has	  been	  shown	  to	  significantly	  decrease	  migration	   in	  THP-­‐1	  cells	   (Figure	  6.41a).	  Treated	  PBLs	  
showed	   no	   significant	   decrease	   in	   migration	   vs.	   the	   untreated	   control	   cells	   (p>0.05,	   n=3)	  
indicating	  that	  Grb2	  is	  not	  important	  in	  CXCR3	  mediated	  chemotaxis.	  It	  is	  therefore	  unlikely	  that	  
Ras	   is	   involved	   directly	   or	   through	   transactivation	   downstream	  of	   CXCR3.	   Pre-­‐treatment	  with	  
100	  µM	  farnesylthiosalysilic	  acid	  did	  not	  significantly	  reduce	  PBL	  migration	  in	  response	  to	  20	  nM	  




Figure	   6.41:	   CGP87750	   and	   farnesylthiosalysilic	   acid	   have	   no	   significant	   effect	   on	   activated	  
PBL	   chemotaxis.	   (a)	   Pre-­‐treatment	   of	   activated	   PBLs	   with	   100	   µM	   CGP78850	   (CGP)	   has	   no	  
significant	  effect	  on	  PBL	  migration	  towards	  CXCL11	  (n=3).	  (b)	  12.5	  µM	  farnesylthiosalysilic	  acid	  
also	  has	  no	  significant	  effect	  (n=3).	  All	  results	  represent	  the	  mean	  ±	  SEM	  of	  at	  least	  3	  donor’s	  
PBLs	   where	   n=1	   is	   the	   mean	   of	   3	   independent	   experiments	   for	   1	   donors	   PBLs.	   (One-­‐Way	  





	  6.4.	  Discussion	  
	  
6.4.1.	  Internalisation	  and	  the	  possible	  relationship	  to	  arrestin	  dependent	  signalling	  
	  
The	   primary	   objective	   for	   this	   chapter	   was	   to	   explore	   the	   questions	   raised	   in	   chapter	   4	  
regarding	   the	   role	  of	  endocytosis	  machinery,	   cytoskeletal	  mediators	  and	  polarisation	  on	  CCL3	  
mediated	   THP-­‐1	   cell	  migration.	   In	   particular,	   the	   role	   of	   arrestins	   needed	   to	   be	   expanded	   by	  
examining	   the	   relationship	   between	   internalisation	   and	   migration.	   It	   was	   also	   important	   to	  
further	  resolve	  the	  possible	  mechanisms	  by	  which	  non-­‐receptor	  tyrosine	  kinase	  signalling	  during	  
migration	  links	  to	  chemokine	  receptor	  activation.	  
	  
CCR5	   has	   been	   shown	   to	   internalise	   by	   both	   clathrin	   and	   caveolin	   mediated	   endocytosis	  
pathways	  [213].	  These	  processes	  can	  be	  inhibited	  by	  hyperosmolar	  sucrose	  [178]	  and	  filipin	  [74]	  
treatment	  respectively	  and	  have	  been	  validated	  to	  prevent	  internalisation	  in	  THP-­‐1	  [178,	  213].	  
Treatment	  of	  THP-­‐1	  cells	  with	  sucrose	  and	  a	  combination	  of	   sucrose	  and	   filipin	  demonstrated	  
that	  the	  physical	  process	  of	  internalisation	  is	  not	  required	  for	  migration.	  Interestingly,	  combined	  
sucrose/filipin	  treatment	  demonstrated	  a	  non-­‐significant	  trend	  of	  more	  cells	  migrating	  towards	  
a	   stimulus.	   This	   may	   be	   explained	   by	   an	   increase	   in	   arrestin	   dependent	   signalling,	   which	   is	  
allowed	   by	   the	   stalled	   CCP	   and	   caveolae.	   Although	   arrestins	   do	   not	   associate	  with	   caveolae,	  
dynamin	   does	   and	   the	   observed	   increase	   in	   migration	   may	   represent	   enhanced	   dynamin	  
function	  at	  the	  stalled	  caveolae.	  These	  results	  were	  confirmed	  with	  the	  small	  molecule	  inhibitor	  
of	   clathrin:	   pit	   stop	   2	   [260].	   Pit	   stop	   2	   inhibits	   clathrin	   coated	   pit	   formation	   by	   low	   affinity	  
binding	   to	   clathrin,	   which	   has	   been	   validated	   in	   numerous	   cell	   lines.	   Immunofluorescence	  
validated	  the	  effect	  of	  pit	  stop	  2	  in	  CCR5	  internalisation,	  but	  more	  interestingly	  demonstrated,	  
that	  THP-­‐1	  cells	  treated	  with	  pit	  stop	  2,	  significantly	  increased	  migration	  by	  30%.	  	  The	  observed	  
increase	   in	   chemotaxis	   supports	   the	   idea	   that	   internalisation	   is	   negatively	   associated	   with	  
migration.	   Arrestin	   dependent	   internalisation	   and	   signalling	   are	   also	   known	   to	   occur	  
independently	   of	   each	   other	   [35,	   66]	   and	   depend	   on	   differential	   post	   transcriptional	  
phosphorylation	  and	  ubiquitination	  [63].	   In	  summary,	  this	  observed	   increase	   in	  migration	  may	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  represent	  a	  shift	  towards	  arrestin	  dependent	  signalling	  (ADS).	  If	  arrestin	  ‘fate’	  to	  internalisation	  
or	   ADS	   scaffolds	   is	   in	   an	   equilibrium	   state	   determined	   by	   interactions	   cytoplasmic	   signalling	  
complement	  then	  preventing	   internalisation	  would	  be	  expected	  drive	  the	  equilibrium	  towards	  
ADS	   (Figure	  6.42).	   The	  observations	  made	  with	  PKC	  and	  GRK2	   inhibitors	   in	   chapter	  4	   support	  
these	   observations	   and	   suggest	   not	   only	   that	   CCR5	   mediated	   migration	   in	   THP-­‐1	   is	   arrestin	  
dependent	   but	   also	   that	   there	   are	   numerous	   routes	   to	   modulate	   this	   signalling.	   	   The	   exact	  
mechanism	  by	  which	  this	  shifting	  in	  arrestin	  signalling	  can	  occur	  will	  need	  to	  be	  the	  subject	  for	  
future	   investigation.	   Whether	   arrestins	   coordinated	   with	   internalisation	   machinery	   can	   have	  
their	   signalling	   fate	   changed	   by	   disassociation	   of	   this	   machinery	   and	   re-­‐association	   of	   ADS	  
machinery	  remains	  to	  be	  determined	  but	  would	  offer	  an	  explanation	  for	  the	  observed	  effect	  of	  
internalisation	   and	   arrestin	   recruitment	   inhibitors	   on	   migration.	   Being	   able	   to	   shift	   cellular	  
responses	   based	   on	   arrestin	   function	   clearly	   has	   therapeutic	   potential	   for	   anti-­‐migratory	  
therapies	  and	  demonstrates	  that	  ligand	  biased	  signalling	  can	  be	  artificially	  induced.	  	  
	  
	  
Figure	   6.42:	   A	   possible	   mechanism	   by	   which	   inhibition	   of	   endocytosis	   leads	   to	   increased	  
migration	   in	  THP-­‐1	   cells.	  Under	  normal	   conditions	  arrestin	   signalling	   to	   internalisation	   (INT)	  
and	   arrestin	   dependent	   signalling	   (ADS)	   proteins	   is	   in	   some	   kind	   of	   equilibrium	   based	   on	  
either	   cytoplasmic	   protein	   complement	   or	   arrestin	   recruitment	   protein	   function.	   Stalling	  
internalisation	  drives	  the	  equilibrium	  towards	  arrestin	  dependent	  signalling	  by	  disassociation	  
of	  internalisation	  machinery	  and	  association	  of	  signalling	  scaffolds.	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  6.4.2.	  PI3K	  mediated	  cell	  polarisation	  is	  not	  required	  for	  CCR5	  mediated	  chemotaxis	  in	  THP-­‐1	  
cells	  
	  
Chemotaxis	   involves	   movement	   of	   a	   cell	   towards	   an	   extracellular	   gradient	   of	   stimulant.	  
Intracellular	  gradients	  of	  signalling	  proteins	  are	  also	  formed	  in	  response	  to	  receptor	  activation	  
in	   a	   process	   called	   polarisation.	   Polarisation	   allows	   the	   intracellular	  machinery	   of	   a	  migrating	  
cell	  to	  function	  in	  a	  concerted	  effort	  producing	  motility	  towards	  the	  stimulus	  and	  is	  considered	  
essential	  to	  chemotaxis	  [115]	  in	  large	  adherent	  cells.	  Polarisation	  is	  generally	  believed	  to	  occur	  
though	   phosphorylation	   of	   phosphoinositides	   by	   PI3K	   at	   the	   leading	   edge	   of	   the	   cells	   [76].	  
Phosphatases	  such	  as	  PTEN	  and	  SHIP	  localise	  away	  from	  the	  leading	  edge	  of	  the	  cells	  and	  down	  
regulate	  the	  products	  of	  PI3Ks,	  which	  results	  in	  internal	  membrane	  bound	  gradients	  of	  PIP2	  and	  
PIP3	  that	  are	  focused	  around	  the	  leading	  edge	  of	  the	  cells.	  This	  internal	  polarisation	  allows	  the	  
targeting	  of	  the	  relevant	  cytoskeletal	  mediators	  to	  the	  leading	  edge	  where	  they	  can	  exert	  motile	  
efforts	  in	  a	  direction	  of	  stimulant	  gradient,	  but	  also	  allow	  the	  disassembly	  of	  focal	  adhesions	  at	  
the	  ‘tail	  end’	  of	  migrating	  cell.	  Rho	  family	  kinases	  are	  crucial	   for	  focal	  adhesion	  formation	  and	  
formation	  and	  disassembly	  of	  other	  membrane	  protrusions	  [108]	  and	  	  chapter	  4	  did	  show,	  that	  
this	   part	   of	   THP-­‐1	   chemotaxis	   functions	   in	   a	   predictable	   way.	   The	   evidence	   from	   chapter	   4	  
suggests	   that	   non-­‐classical	   signalling	   is	   occurring	   at	   the	   level	   of	   receptor	   transduction	   to	   the	  
upper	  echelons	  of	  chemotaxis	  signalling	  in	  THP-­‐1.	  It	  is	  therefore	  important	  to	  determine	  which	  
characteristics	  of	  Gβγ-­‐type	  migration	  CCR5	  mediated	  responses	  shared	  and	  hence,	  the	  effect	  of	  
PI3K	   inhibition	  on	  THP-­‐1	  chemotaxis	  was	  characterised.	  This	   is	  particularly	   interesting	  because	  
Volpe	  et	  al.	  propose	  that	  polarisation	  in	  THP-­‐1	  does	  not	  occur	  via	  PIP2	  and	  PIP3	  production	  by	  
PI3K	   [115].	   Volpe	   et	   al.	   however	   did	   not	   approach	   the	   observed	   lack	   of	   normal	   polarisation	  
pharmacologically,	   that	   is	   to	   test	   their	   claims	   with	   PI3K	   inhibitors,	   nor	   did	   it	   determine	   the	  
receptor	   specificity	   of	   their	   observations.	   As	   stated	   in	   the	   introduction	   there	   is	   a	   difference	  
between	  identifying	  a	  protein	  target	  and	  that	  target	  being	  pharmacologically	  accessible.	  The	  use	  
of	   small	  molecule	   inhibitors	  of	  PI3K	   in	  THP-­‐1	   chemotaxis	   assay	  may	   support	   the	  assertions	  of	  
Volpe	  et	  al.	  evidence	   from	  a	   ‘drug’	  but	  also	  determine	   if	   their	  observations	  are	   true	   for	  CCR5	  
mediated	  chemotaxis.	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  Both	   LY294002	   and	  wortmannin	   pre-­‐treatment	   affects	   THP-­‐1	  migration	   towards	   CCL3,	   but	   at	  
concentrations	  much	  higher	  than	  seen	  in	  the	  literature	  [274]	  and	  well	  beyond	  their	  determined	  
IC50	   values	   for	   PI3K	   inhibition	   [116,	   117].	   Both	   inhibitors	   are	   known	   to	   inhibit	   other	   proteins	  
[261-­‐263]	  at	  higher	  concentration	  below	  those	  seen	  to	  be	  efficacious	  against	  THP-­‐1	  migration,	  
so	  the	  possibility	   that	   the	  reduction	   in	  migration	  was	  a	  result	  of	   inhibition	  of	   these	  secondary	  
targets	  is	  real.	  To	  resolve	  whether	  or	  not	  LY294002	  and	  wortmannin	  are	  acting	  through	  PI3K	  or	  
their	  secondary	  targets,	  the	  rationally	  designed	  PI3Kγ	  inhibitor	  AS605240	  was	  also	  used	  to	  pre-­‐
treat	  THP-­‐1.	  GPCR	  signalling	  via	  Gβγ	  is	  thought	  to	  occur	  predominantly	  through	  PI3Kγ	  [110,	  118,	  
216]	  and	   to	  a	   lesser	  extent	   through	  PI3Kδ,	   so	   the	   inhibitor	  AS605240,	  which	  was	  designed	   to	  
have	  a	  higher	  affinity	  for	  PI3Kγ	  isotype	  [118]	  and	  has	  no	  known	  secondary	  targets,	  was	  used	  to	  
determine	   if	   PI3K	   is	   required	   for	   migration.	   Treatment	   of	   THP-­‐1	   cells	   with	   AS605240	   at	   a	  
concentration	   of	   1	   µM,	   sufficient	   to	   inhibit	   all	   PI3K	   isotypes,	   has	   no	   significant	   effect	   on	  
migration.	   Partial	   effects	   can	   only	   be	   seen	   at	   concentrations	   at	   about	   10	   µM,	   which	   is	   of	  
sufficiently	  high	  concentration	  that	  non-­‐specific	  or	  cytotoxic	  affects	  could	  play	  a	  role.	  AS605240	  
has	   been	   shown	   to	   reduce	   PKB	   phosphorylation	   in	   THP-­‐1	   at	   100	   nM	   [216].	   These	   data	   as	   a	  
whole	  support,	  but	  also	  pharmacologically	  validate,	  the	  findings	  of	  Volpe	  et	  al.	  [115]	  and	  show	  
that	  CCR5	  mediated	  migration	  in	  THP-­‐1	  does	  not	  differ	  from	  β-­‐Adrenergic	  receptor	  signalling	  in	  
this	  regard.	  These	  data	  also	  bolster	  the	  evidence	  that	  CCR5	  signalling	  to	  chemotaxis	  in	  THP-­‐1	  is	  
Gβγ	   independent,	   which	   represents	   an	   original	   observation.	   The	   activation	   of	   PI3Kγ	  
downstream	  of	  Gβγ	  is	  the	  route	  by	  which	  signalling	  to	  Gβγ	  dependent	  migration	  is	  thought	  to	  
occur	  [57].	  	  
	  
6.4.3.	   A	   pharmacological	   investigation	   of	   dynamin	   inhibitors	   in	   CCR5	   mediated	   THP-­‐1	  
chemotaxis	  
	  
The	  small	  molecule	  inhibitor	  of	  dynamin	  dynasore	  was	  initially	  used	  to	  further	  explore	  the	  role	  
of	   internalisation	   on	   migration.	   Interestingly,	   this	   inhibitor	   proved	   to	   have	   high	   potency	   in	  
blocking	  THP-­‐1	  migration.	   This	  was	   surprising	   initially	   due	   to	   the	  observation	  made	  with	  PKC,	  
GRK2	  and	  internalisation	  inhibitors	  however	  dynamin	  is	  also	  known	  to	  play	  a	  role	   in	  migration	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  as	  described	   in	   the	   introduction	   [77,	  135].	  Dynamin	   is	   known	   to	   interact	  with	  both	  Gβγ	   [199]	  
and	   arrestin	   [65],	   so	   it	   seems	   plausible	   	   that	   dynamin	   forms	   part	   of	   the	   arrestin	   dependent	  
signalling	  complex	  to	  migration	   in	  THP-­‐1.	  Gallein	  treatment	  had	  not	  affected	  THP-­‐1	  migration,	  
suggesting,	   that	   dynamin-­‐Gβγ	   interaction	   is	   not	   crucial	   for	   migration	   and	   other	   interactions	  
should	  be	  given	  priority	  for	  investigation.	  	  
	  
In	  order	   to	  gain	  more	   information	  about	   cellular	  activation,	   	   a	   calcium	  release	  assay	  was	  also	  
used	  to	  investigate	  the	  effect	  of	  dynasore,	  despite	  the	  fact	  that	  calcium	  release	  and	  migration	  
are	  independent	  in	  this	  cell	  line	  [75].	  Dynasore	  completely	  blocks	  calcium	  release	  stimulated	  by	  
CCL3,	  which	  was	  surprising	  but	  not	  without	  precedent	  [201].	  The	  reduction	   in	  calcium	  release	  
and	  migration	   is	  not	  a	   result	  of	   cytotoxicity,	  which	  made	  dynasore	   the	   first	   inhibitor	   to	   link	  a	  
reduction	   in	   calcium	  with	  migration	   in	  THP-­‐1	   cells.	   The	  presence	  of	  dynamin	  was	  validated	   in	  
the	  model	  cell	  lines	  and	  internalisation	  of	  CCR5	  receptors	  in	  HeLa.RC49	  is	  blocked	  by	  treatment	  
with	   the	   inhibitor.	   These	   data	   together	   with	   the	   already	   published	   validation	   of	   dynasore	   in	  
THP-­‐1	  cells	  in	  the	  literature	  by	  other	  groups	  [134,	  178]	  suggest	  that	  the	  observations	  are	  indeed	  
a	  result	  of	  dynamin	  inhibition.	  
	  
Dynamin	  has	  been	  shown	  to	  regulate	  actin	  fibre	  polymerisation	  and	  localisation	  but	  treatment	  
of	   CHO.CCR5	   cells	   with	   dynasore	   did	   not	   have	   the	   obviously	   disruptive	   effects	   on	   actin	  
polymerisation	   seen	  with	   cytochalasin	   D	   or	   cucurbitacin	   I	   as	   seen	   in	   chapter	   5.	   This	   suggests	  
that	   any	  effects	   the	  dynamin	   inhibition	  was	  having	  on	  actin	  dynamics	  occur	   at	   a	  more	   subtle	  
level	   and	   this	   supports	   others	   findings,	   that	   although	   actin	   polymerisation	   is	   decreased	   by	  
dynamin	  inhibition	  and	  K44A,	  some	  actin	  stress	  fibres	  can	  still	  form	  in	  the	  absence	  of	  dynamin	  
GTPase	  activity	  [100,	  164].	  	  	  
	  
Immunofluorescence	  shows	  that	  dynamin	  localises	  at	  fibrous	  structures	  in	  the	  cytoplasm	  which	  
did	  not	  stain	  with	  phalloidin.	  These	  structures	  were	  thought	  to	  be	  microtubules,	  which	  would	  fit	  
with	  what	  is	  known	  about	  dynamin	  function	  [130,	  275].	  There	  is	  some	  evidence	  in	  the	  literature	  
that	   the	   microtubule-­‐actin	   fibre	   interactions	   play	   a	   role	   in	   migration	   [76,	   102,	   267]	   and	   to	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  determine	  if	  microtubule	  polymerisation	  is	  required	  for	  migration,	  nocodazole	  was	  used	  to	  treat	  
THP-­‐1	  cells.	  Nocodazole	   treatment	  does	  not	  block	  THP-­‐1	  cell	   chemotaxis,	  which	   suggests	   that	  
dynamin	   interactions	  at	   this	   locus	  are	  not	   crucial	   for	  migration.	   This	  observation	   fits	  with	   the	  
literature	   where	   dynamin/microtubule	   interactions	   are	   more	   associated	   with	   cell	   cycle	  
progression	  [150,	  266,	  276].	  	  
	  
THP-­‐1	   cells	   have	   been	   shown	   to	   be	   adversely	   affected	   by	   the	   electroporation	   process	   which	  
limited	   the	   scope	   for	  mutant	   arrestin	   transfection	   in	   this	  model	   of	  migration.	   However	   K44A	  
transfection	   can	   still	   be	   useful	   to	   evaluate	   the	   effect	   of	   dominant	   negative	   mutant	   over	  
expression	  on	   calcium	   release.	   THP-­‐1	   cells	   transfected	  with	  K44A	  mutant	  dynamin	   show	  non-­‐
significant	   alteration	   in	   calcium	   release	   compared	   to	   control	   cells	   which	   indicates	   that	   the	  
effects	   of	   dynasore	   on	   calcium	   release	   are	   either	   due	   to	   functions	   of	   dynamin	  which	   are	   not	  
dependent	   on	   GTPase	   turnover	   or	   are	   a	   result	   of	   non-­‐specific	   interaction	   specific	   to	   the	  
molecule.	  	  
	  
The	   recent	   spate	   of	   dynamin	   inhibitors	   which	   have	   been	   described	   earlier	   offer	   a	   unique	  
opportunity	   to	   investigate	   the	   function	   of	   specific	   functional	   domains	   of	   the	   protein	   whilst	  
allowing	  comparative	  analysis	  of	  other	  factors	  such	  as	  GTPase	  and	  internalisation	  efficacy.	  The	  
dynamin	   inhibitors	  MiTMAB,	  OcTMAB,	  dynole	  34-­‐2	  and	   iminodyn	  22	  have	  a	  range	  of	  dynamin	  
GTPase	  inhibitory	  potencies	  that	  are	  higher	  than	  that	  of	  dynasore	  and	  were	  used	  to	  treat	  THP-­‐1	  
cells	   at	   concentrations	   above	   these	   IC50	   values.	   None	   of	   the	   tested	   compound	   showed	   any	  
significant	   ability	   to	   block	   THP-­‐1	   migration	   at	   the	   concentrations	   used.	   This	   was	   surprising	  
considering	  the	  effect	  of	  dynasore	  and	  the	  literature	  which	  has	  shown	  MiTMAB	  and	  OcTMAB	  to	  
reduce	   migration	   in	   some	   adherent	   cells.	   Critically	   though	   this	   experiment	   shows	   that	   the	  
potency	  these	  inhibitors	  have	  in	  blocking	  the	  dynamin	  GTPase	  function	  does	  not	  correlate	  with	  
the	   observed	   effect	   on	   migration.	   Dynasore	   has	   a	   much	   lower	   dynamin	   GTPase	   IC50	   than	  
iminodyn	   22	   and	   dynole	   34-­‐4,	   but	   these	   inhibitors	   do	   not	   reduce	  migration	   significantly.	   The	  
literature	   has	  mixed	   reports	   on	  whether	   dynamin	  GTPase	   turnover	   is	   required	   for	  migration,	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  with	  GTPase	  function	  thought	  to	  be	  necessary	  for	  dynamin	  mediated	  actin	  polymerisation	  [164]	  
but	  not	  to	  be	  required	  for	  PRD	  interactions	  with	  actin	  mediators	  such	  as	  cortactin	  [100].	  	  
The	  effect	  of	  dynasore,	  therefore,	  may	  have	  been	  a	  result	  of	  steric	  hindrance	  of	  other	  protein	  
interactions	  around	  the	  GTPase	  allosteric	  site	  that	  it	  binds.	  This	  is	  supported	  by	  the	  fact	  that	  the	  
uncompetitive	   inhibitors	   dynole	   34-­‐1	   and	   iminodyn	   22,	   which	   must	   bind	   to	   the	   GTPase-­‐GTP	  
complex,	   limiting	   potential	   interaction	   to	   this	   locus	   distal	   from	   the	   PRD	   (Figure	   6.43),	   do	   not	  
inhibit	  migration.	  To	  explore	  this	  idea,	  the	  dynasore	  analogue	  dyngo-­‐4a	  was	  used	  to	  treat	  THP-­‐1	  
cells	   prior	   to	   chemotaxis	   assay.	   Dyngo-­‐4a	   resulted	   from	   a	   structure	   activity	   development	   of	  
dynasore	  against	  GTPase	  activity	  and	  differs	  by	  only	  one	   terminal	  aryl	  hydroxyl	  group	  but	  has	  
significantly	  improved	  potency	  against	  dynamin	  GTPase	  turnover	  [142].	  Concentration	  response	  
curves	  for	  dynasore	  and	  dyngo-­‐4a	  revealed	  that	  the	  potencies	  of	  dynasore	  and	  dyngo-­‐4a	  against	  
THP-­‐1	  migration	  are	  52	  and	  103	  µM,	   respectively.	   This	  observation	   indicate	  not	  only	   that	   the	  
GTPase	  potency	  has	  no	  correlation	  to	  the	  effect	  the	  inhibitor	  has	  on	  migration,	  but	  also	  tuning	  
of	   inhibitors	   towards	   higher	   GTPase	   efficacy	   detracts	   from	   their	   potency	   as	   inhibitors	   of	  
migration.	   These	   data	   clearly	   show	   that	   there	   is	   scope	   for	   structure	   activity	   relationship	  
development	   for	   dynamin	   inhibitors	   which	   act	   preferentially	   on	   migration	   rather	   than	  
GTPase/internalisation.	   This	   point	   is	   exemplified	   by	   the	   equimolar	   comparison	   between	  
dynasore,	   dyngo-­‐4a	   and	   the	   structurally	   similar	   iminodyn	   22,	   which	   show	   increasing	   GTPase	  
inhibition	  potency,	  but	  which	  demonstrate	  a	  clear	  structure	  activity	  relationship	  for	  inhibition	  of	  
chemotaxis.	   Although	   other	   inhibitors	   also	   appeared	   to	   inhibit	   migration	   at	   80	   µM,	   this	   was	  
shown	  to	  be	  due	  to	  cytotoxic	  effects.	  This	  observation	  suggests	   that	   inhibition	  of	  migration	   in	  
the	   literature	   [149]	   using	  MiTMAB	   and	   OcTMAB	   were	   in	   cells	   were	   dynamin	   recruitment	   to	  
phoshoinositides	   is	   important	   or	   where	   GTPase	   function	   is	   crucial	   for	   migration.	   The	  
observations	  made	  with	  the	  dynamin	   inhibitors	  also	  did	  not	  correlate	  to	  their	  ability	  to	   inhibit	  
receptor	  mediated	  internalisation	  or	  their	  ability	  to	  stabilise	  dynamin	  rings	  which	  supports	  the	  
idea	  that	  the	  effect	  of	  dynasore	  and	  dyngo-­‐4a	  is	  based	  not	  on	  these	  processes	  but	  a	  structure	  
specific	   inhibition	   of	   other	   protein	   interactions,	   possibly	   at	   the	   PRD	   where	   the	   dynasore	  
analogues	  closely	  bind	   to.	   	  The	  effects	  of	  dynasore	  and	  dyngo-­‐4a	   inhibition	  were	  also	   seen	   in	  
HeLa.RC49	  wound	  healing	  assay	  suggesting	  the	  effect	  of	  dynamin	  inhibition	  is	  relevant	  between	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  cell	  types	  although	  the	  difference	  between	  transwell	  and	  wound	  healing	  assay	  as	  described	  in	  
chapter	  4	  make	  direct	  comparison	  difficult.	  	  
	  
Migration	   towards	   a	   scratch	   was	   used	   to	   examine	   the	   effect	   of	   dynasore	   on	   dynamin	  
localisation	  during	  wound	  healing.	  As	  stated	  previously,	  dynamin	  did	  not	  affect	  actin	  stress	  fibre	  
formation	  in	  CHO.CCR5	  and	  HeLa.RC49	  cells	  and	  was	  shown	  also	  not	  to	  affect	  the	  localisation	  of	  
dynamin	  at	  the	  terminal	  regions	  of	  actin	  stress	  fibres	  in	  CHO.CCR5	  treated	  for	  0.5hr	  and	  24hrs.	  
These	   cells	   did	   however	   show	   differences	   in	   the	   way	   they	   polarised	   towards	   scratches;	   cells	  
treated	  for	  0.5hr	  appeared	  similar	  to	  control	  cells	  with	  obvious	  polarisation	  towards	  the	  wound.	  
Cells	   treated	   for	   24hr	  with	   dynasore,	   however,	  were	   not	   clearly	   polarised	   towards	   scratches,	  
although	   they	   did	   show	  numerous	  membrane	   extensions	   around	   the	   cells.	   Cells	   treated	  with	  
dynasore	   for	   both	  0.5	   and	  24hr	   also	   showed	  a	   trend	   towards	   increased	   filopodia.	   These	  data	  
indicate	   that	   dynamin	   inhibition	   affects	   the	   cells	   ability	   to	   polarise,	   which	   is	   known	   to	   be	  
important	   in	   fibroblasts	   and	  adherent	   cells	  but	  how	   relevant	   this	   is	   to	  THP-­‐1	   cell	  migration	   is	  
unclear	  as	  polarisation	  appears	  not	  to	  occur	  though	  the	  same	  PI3K	  dependent	  route	  [115].	  THP-­‐
1	   migration	   is	   affected	   by	   0.5hr	   treatment,	   which	   suggests	   high	   turnover-­‐rate	   membrane	  
structures	   such	   as	   podosomes	   [100]	   are	   more	   likely	   to	   be	   involved	   as	   opposed	   to	   the	   low	  
turnover	   focal	   adhesions	   seen	   in	   large	   adherent	   cells.	   	   This	   is	   supported	   by	   the	   HeLa.RC49	  
wound-­‐healing	   assay	  where	   sensitivity	   to	   LY294002	   is	   high	  with	   cells	   actually	   detaching	   after	  
24hrs.	   In	   this	  system,	  CCR5	  mediated	  chemotaxis	  might	   recruit	  PI3Ks	   in	  order	   to	  polarise	  cells	  
and	  this	  also	  makes	  possible	  interaction	  between	  dynamin	  and	  phosphoinositides	  such	  as	  PIP2	  a	  
possibility.	  	  
	  
The	   function	   of	   PH	   domain	   recruited	   dynamin	   in	   fibroblast	   migration	   may	   require	   different	  
dynamin-­‐effector	   interactions	   and	   may	   even	   be	   GTPase	   turn	   over	   dependent	   which	   would	  
explain	  the	  similar	  behaviours	  of	  dynasore	  and	  dyngo-­‐4a	   in	  this	  assay.	   It	  should	  be	  noted	  that	  
unusual	  alterations	  in	  cell	  morphology	  were	  noted	  (not	  shown)	  with	  dyngo-­‐4a,	  which	  may	  also	  
suggest	   the	  molecule	  has	   some	  cytotoxicity	  of	  non-­‐specific	  effects	  at	   longer	   incubation	   times.	  
Taken	   as	   a	   whole	   these	   data	   suggest	   that	   dynamin	   is	   required	   for	   CCR5	   mediated	   THP-­‐1	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  migration,	   but	   that	   dynamin	   GTPase	   turnover	   is	   not	   required.	   The	   observations	   made	   with	  
bosutinib	   in	  chapter	  4	  suggest	  that	  SH2	  targeting	  plays	  a	  role	  on	  migration,	  which	  means	  that	  
the	  effects	  of	  dynasore	  and	  dyngo-­‐4	  may	  have	  been	  as	  a	  result	  of	  disruption	  of	  adaptor	  proteins	  
at	  the	  PDR	  (Figure	  6.43).	  Due	  to	  the	  conformation	  of	  dynamin,	  the	  PRD	  is	  close	  to	  the	  GTPase	  
domain;	  so	  allosteric	  binding	  of	  dyngo-­‐4a	  and	  dynasore	  may	  induce	  conformational	  changes	  in	  
the	  PRD	  which	  can	  alter	  its	  function.	  It	  should	  be	  noted	  that	  dynasore	  has	  been	  shown	  to	  have	  
no	  effect	  on	  Grb2	  binding,	  but	   that	  does	  not	   rule	  out	   induction	  of	  disruptive	   interaction	  with	  
Grb2	  [158].	  Tyrosine	  phosphorylation	  is	  a	  recurring	  theme	  in	  dynamin’s	  role	  in	  actin	  regulation	  
[100,	  135,	  159]	  and	  an	  investigation	  with	  SH2	  inhibitors	  was	  the	  natural	  progression.	  
	  
In	   the	   first	   instance,	   there	   were	   unanswered	   questions	   regarding	   the	   effect	   of	   dynasore	   on	  
calcium	  release	  to	  be	  considered.	  These	  were	  investigated	  by	  treatment	  of	  THP-­‐1	  cells	  with	  the	  
other	  dynamin	   inhibitors.	  Unlike	  with	  chemotaxis,	  the	  dynamin	   inhibitors	  OcTMAB	  and	  dynole	  
34-­‐2	  significantly	  reduces	  calcium	  release,	  but	  again	  there	  appears	  to	  be	  no	  correlation	  with	  the	  
potency	  to	  act	  as	  a	  dynamin	  GTPase	  inhibitor	  or	  other	  inhibitory	  effects.	  Dynasore,	  OcTMAB	  and	  
dynole	  34-­‐2	  inhibit	  calcium	  release	  in	  a	  concentration	  dependent	  fashion	  as	  would	  be	  expected	  
with	   true	   CCR5	   mediated	   signalling	   to	   calcium	   release.	   However,	   it	   became	   immediately	  
apparent	  that	  the	  inhibitors	  are	  acting	  as	  nonspecific	  stimulators	  of	  calcium	  release	  when	  they	  
reduced	   thapsigargin	   stimulated	   calcium	   release.	   This	   nonspecific	   release	   was	   validated	   with	  
dynasore,	  which	  directly	  stimulates	  calcium	  release	  in	  THP-­‐1	  cells.	  These	  results	  are	  interesting	  
but	  of	  significantly	  less	  importance	  to	  the	  investigation	  of	  chemotaxis	  as	  they	  do	  not	  contradict	  
the	   earlier	   observations	  of	   Cardaba	  et	   al.	   that	   calcium	   release	   is	   independent	  of	  migration	   in	  





Figure	   6.43:	  Dynamin	   inhibitor	   overview.	   The	   theorised	  dynamin	   inhibitor	   binding	   locations	  
and	   their	   relationship	   to	   inhibition	   of	   cellular	   responses	   are	   shown.	   Values	   for	   dynamin	  
inhibition	  are	  taken	  from	  Table	  1.3.	  	  
	  
The	  importance	  of	  these	  results	  is	  for	  other	  investigators	  who	  might	  be	  using	  these	  compounds	  
to	   investigate	   calcium	   sensitive	   cellular	   processes,	   for	   example	   Douthitt	   et	   al.	   observed	   an	  
unexplained	   increase	   in	   neuronal	   cell	   calcium	   after	   dynasore	   treatment	   which	   these	   data	  
explain	   through	   nonspecific	   release	   of	   calcium	   [201].	   Investigation	   of	   endocytosis	   in	   calcium	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  sensitive	   systems	   such	   as	   neurones	   will	   need	   to	   be	   undertaken	   with	   caution	   when	   using	  
dynasore,	   OcTMAB	   or	   dynole	   34-­‐2	   treatment	   as	   these	   inhibitors	   may	   alter	   disrupt	   normal	  
signalling	  by	  non-­‐specific	  calcium	  release.	  	  
	  
6.4.4.	  Grb2	  inhibition	  and	  THP-­‐1	  chemotaxis	  
	  
The	  presence	  of	  Grb2	  in	  THP-­‐1	  cells	  was	  confirmed	  by	  western	  blotting.	  The	  protein	  appears	  to	  
localise	   throughout	   the	   cytoplasm	   in	   HeLa.RC49	   cells	   with	   no	   significant	   alterations	   in	  
localisation	  upon	  CCR5	  activation.	  The	   small	  molecule	  CGP78850	  was	  designed	  by	  Novartis	   to	  
inhibit	  Grb2	  SH2	  domains,	  which	  made	  it	  ideal	  for	  investigating	  the	  effect	  of	  Grb2	  SH2	  function	  
in	   THP-­‐1,	   mediated	   chemotaxis.	   CGP78850	   is	   not	   an	   ideal	   drug,	   due	   to	   poor	   membrane	  
permeability	   and	   the	  ester	   conjugated	  prodrug	  was	  designed	   to	  overcome	   this	   [113].	  Neither	  
CGP78850	   nor	   the	   prodrug	   CGP85793	   are	   commercially	   available.	  Novartis	  were	   only	   able	   to	  
release	  CGP78850	  however	  and	  the	  function	  of	  this	  inhibitor	  is	  characterised	  sufficiently	  in	  that	  
cytoplasmic	   concentrations	   have	   been	   shown	   to	   be	   20-­‐50	   times	   lower	   than	   dose	   [112].	   This	  
meant	   that	   although	  higher	   concentrations	  of	  CGP78850	  were	  used	   the	  effective	   cytoplasmic	  
concentrations	  were	  around	  those	  expected	  to	  inhibit	  Grb2	  without	  nonspecific	  effects	  being	  a	  
problem.	   CPG78850	   treatment	   of	   THP-­‐1	   cells	   resulted	   in	   significant	   reductions	   in	   observed	  
migration	  towards	  CCL3	  that	  could	  not	  be	  explained	  by	  cytotoxicity	  or	  disruption	  of	  actin	  stress	  
fibre	   formation.	   Combined	   treatment	   of	   THP-­‐1	   cells	   with	   CGP78850	   and	   dynasore	   provided	  
evidence	   that	   dynamin	   and	   Grb2	   function	   in	   the	   same	   linear	   signalling	   axis	   as	   the	   combined	  
treatment	  showed	  further	  decrease	  in	  migration.	  This	  may	  also	  support	  the	  idea	  that	  Grb2	  and	  
dynamin	  interact	   in	  a	  1:1	  stoichiometry.	  The	  combined	  effect	  or	  dynasore	  and	  CGP78850	  with	  
PI3K	   inhibitors	   is	   explained	   less	   easily.	   Combined	   treatments	   of	   dynasore	   together	   with	  
wortmannin	   or	   LY294002	   and	   CGP78850	   with	   wortmannin	   or	   LY294002	   reduce	   chemotaxis	  
further	   than	   either	   treatment	   alone.	   This	  may	   be	   a	   result	   of	   disruption	   of	   arrestin	   signalling	  
scaffolds,	  where	  PI3K	   is	  known	  to	  associate	  or	  could	  represent	  a	  shift	   toward	  PI3K	  dependent	  
signalling	   in	   cells	   where	   dynamin	   and	   Grb2	   are	   inhibited.	   The	   exact	   mechanism	   for	   these	  
reductions	  requires	  further	  investigation	  before	  conclusions	  can	  be	  drawn	  with	  confidence.	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  Based	   on	   the	   observations	   from	   this	   and	   the	   previous	   chapter	   it	   is	   possible	   to	   propose	   a	  
hypothetical	   signal	   transduction	   mechanism	   for	   CCR5	   mediated	   chemotaxis	   in	   THP-­‐1	   (Figure	  
6.44).	  Upon	  ligand	  binding	  CCR5	  undergoes	  phosphorylation	  by	  GRK2	  and	  PKC	  and	  a	  proportion	  
of	   receptors	   are	   bound	   by	   arrestins	   to	   which	   the	   arrestin	   dependent	   signalling	   scaffolds	   will	  
bind.	  These	  scaffolds	  contain	  proteins	  such	  as	  ERK,	  PI3K	  and	  non-­‐receptor	  tyrosine	  kinases	  such	  
as	   Lyn.	   These	  non-­‐receptor	   tyrosine	   kinases	   target	  Grb2	  bound	  dynamin	  monomers	  or	   target	  
SH2	  domains	  of	  Grb2	  which	  bind	   to	  monomeric	  dynamin	  and	   recruit	  other	  actin	  cytoskeleton	  
mediators	   such	   as	   n-­‐WASp	   and	   cortacin.	   Dynamin	   binding	   to	   the	   Grb2	   complex	   nucleates	  
dynamin	   polymerisation	   which	   acts	   to	   uncap	   actin	   and	   promotes	   actin	   polymerisation	   or	  
promotes	   direct	   dynamin	   interaction	   with	   actin.	   This	   process	   instigates	   the	   formation	   of	  
membrane	  protrusions	  mediated	  by	  ROCK,	  which	  may	  be	  targeted	  by	  interaction	  with	  dynamin,	  
and	   promotes	   migration.	   In	   this	   model	   PI3K	   mediated	   polarisation	   in	   not	   required	   because	  
arrestin	  bound	  non-­‐RTKs	  act	  as	  polarisation	  indicators.	  
Figure	  6.44:	  CCR5	   signalling	   to	   chemotaxis	   in	  THP-­‐1	   cells.	   This	  putative	   signalling	  diagram	   is	  
based	  on	   results	   obtained	   from	   this	   thesis	   and	   known	   interaction.	   The	   site	  of	   non-­‐receptor	  
tyrosine	   kinase	   phosphorylation	   ‘X’	   which	   may	   act	   to	   target	   Grb2	   bound	   dynamin	   is	   not	  
known.	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  Whilst	   Grb2	   appears	   to	   be	   involved	   with	   CCR5	   signalling	   to	   chemotaxis,	   it	   is	   important	   to	  
explore	  whether	  the	  observations	  can	  be	  explained	  by	  receptor	  tyrosine	  kinase	  transactivation.	  
CCR5	   is	   known	   to	   transactivate	   RTKs	   [85]	   and	  RTK	   activation	   has	   been	   linked	  with	  migration.	  	  
Grb2	  forms	  a	  part	  of	  the	  well	  characterised	  signal	  transduction	  from	  RTKs	  to	  PKB	  via	  Ras	  [112].	  
There	  is	  good	  reason	  to	  believe	  that	  transactivation	  is	  not	  playing	  a	  major	  role	  in	  CCR5	  mediated	  
chemotaxis:	   Firstly	   CGP78850	   completely	   abolishes	   chemotaxis	   which	   would	   mean	   if	  
transactivation	   occurs,	   than	   CCR5	   mediated	   chemotaxis	   is	   completely	   signalling	   through	  
transactivated	  RTKs.	  Whilst	  this	  seemed	  unlikely	  it	  is	  not	  impossible.	  The	  fact	  that	  inhibition	  of	  
PKCζ,	  which	   has	   been	   shown	   to	   be	   vital	   for	   RTK	  mediated	   chemotaxis	   in	   THP-­‐1	   cells	   [235]	   is	  
unable	   to	   affect	   CCL3	   stimulated	  migration	   and	   the	   dependence	   of	   THP-­‐1	  migration	   on	   non-­‐
receptor	   tyrosine	  kinases	  provided	   strong	   support	   for	   little	   involvement	  of	   transactivation.	  To	  
resolve	  the	  issue	  more	  clearly,	  the	  Ras	  inhibitor	  farnesylthiosalysilic	  acid	  was	  used	  to	  treat	  THP-­‐
1	   cells.	   Like	   CGP78850,	   farnesylthiosalysilic	   acid	   is	   poorly	   membrane	   permeable,	   however,	  
significant	   reductions	   in	   Ras	  mediated	   signalling	   can	   be	   achieve	  with	   higher	   treatment	   levels	  
[272].	  Farnesylthiosalysilic	  acid	  is	  not	  able	  to	  block	  THP-­‐1	  cell	  migration	  at	  concentrations	  where	  
it	  did	  not	  have	  a	   toxic	  effect	  on	  cells.	  This	  demonstrates	   that	  CCR5	  signalling	   to	  chemotaxis	   is	  
Grb2	  dependent	  which	  represents	  a	  unique	  observation.	  	  
	  
It	   is	   important	   to	  validate	   the	  observation	  made	   in	  THP-­‐1	  cells	   in	  peripheral	  human	   tissue	   for	  
the	  reason	  described	   in	  previous	  chapters.	  The	  chemokine	  CXCL11	  was	   first	  used	  to	  stimulate	  
THP-­‐1	   cells	   to	   determine	   if	   CXCR3	   is	   expressed	   on	   these	   cells	   and	   capable	   of	   inducing	  
chemotaxis.	   THP-­‐1	   showed	  no	  propensity	   to	  migrate	   towards	   CXCL11	   above	  basal	  movement	  
demonstrating	   that	   CXCR3	   receptor	   signalling	   in	   activated	   PBLs	   represents	   a	   distinct	   receptor	  
system	  for	  comparison	  with	  CCR5	  mediated	  events	  in	  THP-­‐1.	  	  Activated	  PBLs	  are	  also	  known	  to	  
express	   CCR5,	   which	   was	   confirmed	   by	   immunofluorescence	   staining	   with	   HEK	   1/85/7a	  
antibody	  and	  also	  by	  the	  fact	  that	  activated	  PBLs	  migrated	  towards	  CCL3,	  although,	  as	  discussed	  
this	   may	   represent	   CCR1	   activation.	   Interestingly	   dynasore	   treatment	   of	   PBLs	   prior	   to	  
chemotaxis	   assay	   towards	   20	   nM	   CXCL11	   has	   no	   significant	   on	   migration	   towards	   CCL3	   was	  
completely	   abrogated	   by	   the	   same	   treatment.	   Although	   dynasore	   had	   no	   effect	   on	   PBL	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  migration	   towards	   CXCL11	   dyngo-­‐4a	  was	   able	   to	   significantly	   reduced	  migration	   towards	   this	  
chemokine.	  There	  are	  two	  possible	  explanations	  for	  this	  observation:	  firstly	  dyngo-­‐4a	  may	  have	  
cytotoxic	  or	  non-­‐specific	  effects	  on	  PBL	  migration	  or	  secondly	  dynamin	  GTPase	  function	  is	  more	  
important	  to	  PBL	  migration	  than	  THP-­‐1	  cell	  migration.	  As	  dyngo-­‐4a	  appears	  to	  affect	  HeLa.RC49	  
morphology	  after	  24hr,	  but	  dynasore	  did	  not,	  non-­‐specific	  cytotoxic	  effects	  of	  dyngo-­‐4a	  need	  to	  
be	   investigated	   further	   before	   conclusions	   can	   be	   made.	   Focusing	   on	   dynasore,	   this	   is	   an	  
important	   result	   because	   it	   indicates	   that	   CCR5	  mediated	   chemotaxis	   is	   dynamin	   dependent	  
across	  cell	  types,	  so	  long	  as	  the	  cell	  is	  small	  and	  motile	  and	  that	  chemokine	  receptor	  signalling	  
between	  receptor	  families	  can	  be	  different.	   	  The	  PI3k	  inhibitors	  AS605240	  and	  LY294002	  were	  
also	  used	  to	  treat	  activated	  PBLs.	  PBLs	  show	  a	  higher	  sensitivity	  to	  LY294003	  than	  THP-­‐1	  cells,	  
which	  suggests	  that	  CXCL3	  functions	  through	  classical	  signalling	  to	  chemotaxis.	  This	  is	  supported	  
by	  the	  previous	  experimentation	  which	  showed	  activated	  PBLs	  are	  sensitive	  to	  gallein	  treatment	  
(Chapter	   4).	   AS605240	   does	   not	   affect	   activated	   PLB	   migration.	   The	   inhibitor	   is	   well	  
characterised	   [216],	   	   but	   the	   continued	   negative	   results	   from	   both	   THP-­‐1	   cells	   and	   activated	  
PBLs	  raise	  question	  about	  its	  functionality.	  The	  induced	  reduction	  of	  PKB	  phosphorylation	  would	  
need	  to	  be	  assessed	  in	  THP-­‐1	  cells	  and	  PBLs	  to	  ensure	  the	  inhibitor	  is	  functioning	  properly.	  	  
	  
The	  treatment	  of	  PBLs	  with	  CGP78850	  strongly	  support	  the	  idea	  that	  dynamin	  is	  not	  important	  
in	  CXCR3	  mediated	  migration	   in	  PBLs	   and	   that	   the	  effect	  of	  dyngo-­‐4a	  are	  more	   likely	   to	  be	  a	  
result	  of	  non-­‐specific	  actions.	  CGP78850	  treatment	  at	  100	  µM	  has	  no	  significant	  effect	  on	  PBL	  
migration,	  demonstrating	  that	  signalling	  to	  chemotaxis	  in	  the	  cells	  was	  not	  dependent	  of	  Grb2	  
as	  it	  was	  in	  CCR5	  mediated	  THP-­‐1	  migration.	  The	  fact	  that	  farnesylthiosalysilic	  acid	  treatment	  is	  
also	   unable	   to	   block	   migration	   was	   unsurprising	   but	   did	   support	   the	   idea	   that	   signalling	   to	  
migration	  for	  activated	  CXCR3	  receptors	  follows	  a	  linear	  chemokine	  receptor	  specific	  path.	  	  
	  
6.5	  Chapter	  Conclusions	  
	  
This	   chapter	   represents	   a	   pharmacological	   investigation	   into	   the	   roles	   of	   endocytosis	   and	  
cytoskeletal	   machinery	   in	   CCR5	   mediated	   chemotaxis.	   As	   such	   some	   interesting	   and	   novel	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  conclusions	   can	   be	   drawn	   regarding	   how	   chemotaxis	   can	   be	   modulated	   by	   small	   molecule	  
means.	   Most	   interesting	   are	   the	   differential	   roles	   of	   dynamin	   in	   CCR5	   and	   CXCR3	   mediated	  
chemotaxis	  where,	  based	  on	  the	  treatment	  with	  dynasore,	  CCR5	  mediated	  chemotaxis	  in	  small	  
mobile	   cells	   is	   dynamin	   dependent,	   whilst	   CXCR3	   mediated	   chemotaxis	   is	   not.	   In	   the	  
introduction	  it	   is	  explained	  that	  dynamin	  is	  a	  protein	  with	  a	  large	  and	  diverse	  range	  of	  cellular	  
interactions	  which	  would	  make	  proteomic	  based	   investigation	  a	   long	  and	   costly	   exercise.	   The	  
broad	  but	  generally	  poorly	  characterised	  range	  of	  small	  molecule	  inhibitors	  for	  dynamin	  allows	  
a	  quick	  and	  cost	  effective	  analysis	  of	  its	  function.	  	  The	  use	  of	  a	  range	  of	  dynamin	  inhibitors	  with	  
different	   binding	   sites	   and	   inhibitory	   functions	   demonstrates	   that	   dynasore	   is	   particularly	  
effective	   at	   inhibiting	   CCR5	   mediated	   migration	   and	   this	   potency	   may	   be	   based	   around	   an	  
interaction	   between	   the	   inhibitor	   and	   dynamin	   that	   are	   not	   GTPase	   dependent.	   Indeed	   the	  
observed	   effects	   of	   dynamin	   inhibitors	   did	   not	   correlate	   to	   GTPase	   or	   receptor	   mediated	  
internalisation	   potency	   or	   their	   ability	   to	   stabilise	   dynamin	   rings	   which	   suggests	   something	  
unique	  about	  the	  structure	  of	  dynasore.	  If	  this	  is	  the	  case,	  then	  structure	  activity	  modification	  to	  
dynasore	   based	   around	   inhibition	   of	   migration	   rather	   than	   GTPase	   turnover	   may	   reveal	  
potential	  therapeutics	  which	  affect	  migration	  but	  not	  internalisation.	  Another	  point	  of	  interest	  
is	  the	  potential	   for	  CCR5	  chemotaxis	  to	  be	  reduced	  by	   inhibition	  of	  Grb2,	  a	  dynamin	  targeting	  
adaptor	  protein.	  If	  the	  inhibitor	  effects	  of	  CGP78850	  are	  a	  result	  of	  the	  targeting	  of	  dynamin	  to	  
sites	   of	   tyrosine	   phosphorylation,	   then	   Grb2	  may	   represent	   a	   novel	   anti-­‐migratory	   target	   for	  
CCR5	   stimulated	  migratory	   diseases.	   Grb2	   inhibition	  may	   represent	   a	  means	   of	   targeting	   the	  
chemotactic	   functions	   of	   dynamin	   without	   affecting	   its	   other	   roles	   in	   endocytosis	   or	   mitotic	  
progression,	  although	  these	  points	  remain	  to	  be	  investigated.	  Grb2	  may	  also	  be	  a	  better	  target	  
that	   the	   non-­‐receptor	   tyrosine	   kinases	   inhibited	   by	   bosutinib	   as	   the	   potential	   unwanted	  
interactions	  of	  this	  inhibitor	  include	  proteins	  involved	  with	  programmed	  cell	  death	  [79].	  	  
	  
Along	  with	  the	  benefits	  of	  speed,	  cost	  and	  target	  validation	  there	  are	  obvious	   limitations	  to	  a	  
predominantly	   pharmacological	   investigation.	   Although	   a	   potential	   mechanism	   for	   Grb2	  
mediated	  CCR5	   signalling	   to	   chemotaxis	  has	  been	  proposed	   the	  protein	   interactions	  between	  
any	  of	  the	  protein	  species	  in	  this	  may	  not	  be	  direct.	  The	  specifics	  of	  protein-­‐protein	  interactions	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  will	  fall	  into	  the	  remit	  of	  proteomics	  studies	  which,	  by	  knock	  down	  and	  overexpression	  studies,	  
will	   be	   able	   to	   clarify	   the	   interaction	   broadly	   outlined	   in	   this	   thesis.	   	  What	   can	   be	   said	   with	  
confidence	   is	   that	   dynamin	   2,	   Grb2	   and	   non-­‐receptor	   tyrosine	   kinases	   make	   up	   group	   of	  
proteins	   with	   strong	   evidence	   in	   the	   literature	   for	   interaction	   and	   with	   corresponding,	   and	  
pharmacologically	  accessible	  effects	  in	  THP-­‐1	  migration.	  This	  thesis	  has	  validated	  these	  proteins	  
as	   targets	   suitable	   for	   proteomic	   investigation	   with	   solid	   evidence	   that	   their	   disruption	   can	  
reduce	  migration	  downstream	  of	  CCR5.	  The	  questions	  left	  unanswered	  by	  this	  thesis	  such	  as	  do	  
arrestins	  and	  dynamin	  interact	  directly,	  where	  are	  Grb2	  SH2	  domains	  targeted	  and	  how	  exactly	  
does	  ROCK	  become	   involved	  with	  THP-­‐1	  migration	   remains	   to	  be	  answered.	   These	  questions,	  
rather	   than	  being	  detrimental,	   represent	   a	   large	   amount	  of	   potential	   future	  work	  with	  direct	  
relevance	   to	   potential	   future	   therapeutics.	   The	   broader	   aspects	   of	   the	   research	   presented	   in	  
this	  thesis	  will	  be	  presented	  in	  the	  final	  discussion	  chapter.	  	  
	  
6.5.1.	  Final	  conclusions	  
1) Endocytosis	  appears	  to	  be	  negatively	  associated	  with	  migration	  indicating	  arrestin	  
dependent	  signalling.	  
2) PI3K	  activation	  is	  not	  required	  for	  CCR5	  mediated	  migration	  in	  THP-­‐1	  cells.	  
3) Dynamin	   is	   involved	   with	   THP-­‐1	   migration	   but	   inhibition	   of	   dynamin	   GTPase	  
function	  does	  not	  correlate	  with	  decreased	  migration.	  
4) The	   dynamin	   binding	   protein	   Grb2	   is	   required	   for	   THP-­‐1	   migration	   and	   may	  












	  CHAPTER	  7:	  Final	  discussion	  and	  thesis	  conclusions	  
	  
	  
7.1.	  Final	  discussion	  
	  
In	   this	   thesis	   we	   have	   undertaken	   a	   pharmacological	   characterisation	   of	   CCL3	   stimulated	  
chemotaxis	   in	   THP-­‐1	   cell	   line	   with	   the	   aim	   of	   identifying	   potential	   cytoplasmic	   signal	  
transduction	  proteins	  that	  can	  be	  targeted	  as	  therapies	  for	  CCR5	  mediated	  chronic	  immune	  and	  
metastatic	  disease.	  The	  overarching	  conclusions	  from	  this	  research	  is	  as	  follows:	  
1. CCL3	  stimulated	  calcium	  release	  and	  migration	  in	  THP-­‐1	  cells	  occurs	  via	  CCR1	  and	  CCR5	  
in	   approximately	   equal	   proportions.	   CCR1	   antagonist	   J113863	   and	   CCR5	   antagonist	  
maraviroc	   cannot	   be	   used	   to	   isolate	   these	   responses	   from	   one	   another	   due	   to	   non-­‐
specific	  or	  agonistic	  effects	  demonstrated	  by	  the	  inhibitors.	  
2. Gβγ,	   ERK1/2,	   p38	   and	   PI3K	   are	   not	   important	   in	   THP-­‐1	   cell	   migration	   stimulated	   by	  
CCL3.	  
3. PKC	   and	   GRK2	   inhibition	   affect	   CCL3	   stimulated	   migration	   in	   THP-­‐1	   antagonistically.	  
This	   suggests	   CCL3	   stimulated	   migration	   through	   (CCR1	   &	   CCR5)	   occurs	   via	   arrestin	  
dependent	  signalling.	  
4. JAK/STAT	  signalling	  does	  not	  form	  part	  of	  the	  cytoplasmic	  signal	  transduction	  pathway	  
linking	  activated	  CCR5	  to	  migration.	  	  
5. Internalisation	  of	   clathrin	  or	   caveolin	  dependent	  means	   is	  not	   required	   for	  migration	  
but	  inhibition	  of	  internalisation	  increases	  migration.	  
6. Dynamin	   inhibition	   completely	   abrogates	   CCL3	   mediated	   migration	   in	   THP-­‐1	   and	  
HeLa.RC49,	  but	  CXCL3	  stimulated	  migration	  in	  PBLs	  is	  unaffected.	  
7. Dynamin	   inhibitors	  do	  not	   function	  equally:	   this	  may	  represent	  a	  potential	  avenue	  of	  
SAR	  development.	  Some	  dynamin	   inhibitors	  also	  have	  non-­‐specific	  effects	  on	  calcium	  
mobilisation	  in	  THP-­‐1	  cells.	  	  
8. Grb2	  and	  c-­‐Src	   inhibition	  decreases	  CCL3	  stimulated	  migration	  in	  a	  way	  not	  explained	  
by	  receptor	  tyrosine	  kinase	  inhibition.	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  It	   is	   important	   to	   analyse	   these	   conclusions	   in	   context	   of	   the	   initial	   hypotheses	   stated	   in	   the	  
introduction.	   This	   was	   to	   identify	   potential	   cytoplasmic	   points	   of	   access	   to	   CCR5	   mediated	  
chemotaxis	   to	  by-­‐pass	   the	  problems	  with	   receptor	   redundancy	  and	   transactivation.	  There	   is	  a	  
need	   for	   therapies	   which	   will	   block	   cell	   migration,	   since	   there	   is	   a	   major	   involvement	   of	  
chemokine	   receptors	   in	   both	   chronic	   inflammatory	   and	  metastatic	   disease	   [277-­‐279].	   So	   far,	  
chemokine	   receptor	   as	   therapeutic	   targets	   have	   not	   resulted	   in	   sufficiently	   efficacious	  
therapies,	   which	   is	   probably	   due	   to	   the	   intrinsic	   problems	   of	   extracellular	   inhibition	   of	  
chemokine	   receptors	   such	   as	   receptor-­‐ligand	   redundancy	   [278].	   This	   is	   exemplified	   by	  
conclusion	  1	  which	  demonstrates	  both	  the	  redundancy	  in	  chemokine	  receptor	  induced	  cellular	  
responses	   and	   the	   difficulties	   in	   antagonist	   blockade	   of	   chemokine	   receptors.	   	   It	   should	   be	  
noted	  that	  in	  this	  particular	  instance	  the	  effect	  of	  the	  chemokine	  receptor	  antagonists	  was	  due	  
to	  previously	  unreported	  effects;	  non-­‐specific	   for	   J113863	  and	  partial	   agonistic	   for	  maraviroc.	  
These	   unreported	   effects	   clearly	   indicate	   the	   potential	   for	   rationally	   designed	   small	  molecule	  
inhibitors	   to	   affect	   chemokine	   receptor	   signalling	   in	   unforeseen	   and	   ways	   adding	   to	   the	  
complications	  of	  redundancy	  and	  receptor	  cross-­‐talk.	  There	  is	  some	  evidence	  that	  the	  failure	  for	  
the	  production	  of	  effective	  chemokine	  based	  therapies	  is	  not	  due	  to	  signalling	  redundancy	  but	  
failure	  to	  select	  valid	  biological	  targets	  [277].	  If	  this	  were	  the	  case	  this	  would	  still	  not	  eliminate	  
the	   problems	   observed	   with	   J113863	   and	   maraviroc	   and	   supports	   the	   idea	   that	   identifying	  
intracellular	  targets	  specific	  to	  chemokine	  receptor	  signalling	  maybe	  a	  more	  elegant	  solution.	  
	  
Resolving	   the	   intracellular	   signal	   transduction	   specific	   to	   CCR5	   is	   not	   possible	   due	   to	   the	  
problems	   with	   J113863	   and	   maraviroc,	   however,	   CCL3	   receptors	   CCR1	   and	   CCR5	   share	   high	  
levels	  of	  sequence	  homology	  and	  resolution	  of	  signal	  transduction	  at	  the	  level	  of	  two	  receptors	  
is	  still	  useful.	  CCL3	  stimulated	  responses	   in	  THP-­‐1	  were	  not	  sensitive	  to	  Gβγ,	  PI3k,	  ERK	  or	  p38	  
MAPK	  inhibition	  (conclusion	  2).	  This	  provides	  strong	  evidence	  that	  Gβγ	  and	  Gαi	  (see	  Figure	  1.5)	  
[96]	  are	  not	  involved	  in	  signalling	  to	  migration,	  supporting	  the	  observations	  from	  Cardaba	  et	  al.	  
[75]	  where	  calcium	  release	  was	  also	  not	  required.	  These	  observations	  highlight	  the	  potential	  for	  
inhibitors	  of	  well	  validated	  signalling	  targets	  such	  as	  PI3K	  [78,	  109],	  ERK	  [58,	  82],	  and	  Gβγ	  [57]	  to	  
be	  ineffective	  against	  certain	  diseases	  where	  CCR1/5-­‐like	  signalling	  occurs.	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  By	   process	   of	   elimination,	   arrestin	   dependent	   signalling	   appears	   to	   be	   responsible	   for	   CCL3	  
stimulated	  migration	  in	  THP-­‐1	  cells.	  The	  use	  of	  PKC	  and	  GRK2	  inhibitors	  supports	  this	  assertion	  
and	   indicates	   that	   the	  mechanism	  by	  which	  arrestin	   recruitment	  occurs	  has	   significant	  effects	  
on	   signalling	   to	   chemotaxis	   (conclusion	   3).	   Inhibition	   of	   internalisation	   increases	   migration	  
(conclusion	  5),	  supporting	  the	  role	  of	  arrestin	  dependent	  signalling	  in	  this	  system.	  Arrestin,	  GRK	  
and	  PKC	  appear	  to	  be	  involved	  with	  migration,	  but	  their	  suitability	  as	  targets	  for	  anti-­‐migration	  
therapeutics	   is	   low	   due	   to	   their	   lack	   of	   ubiquitous	   involvement	   in	   GPCR	   signalling	   and	   the	  
potential	   for	   inhibition	   to	   increase	   pathological	   signalling	   by	   preventing	   desensitisation.	  
Identifying	  players	  in	  arrestin	  dependent	  signalling	  to	  migration	  is	  likely	  to	  offer	  higher	  validity	  
targets.	  	  
	  
JAK/STAT	   signalling	   is	   not	   an	   important	   player	   in	   the	   cytoplasmic	   signalling	   events	   associated	  
with	  CCL3	  stimulated	  migration	  in	  THP-­‐1	  cells	  (conclusion	  4),	  which	  correlates	  with	  the	  observed	  
lack	  of	  sensitivity	  to	  PI3K	  inhibition.	  Treatment	  with	  the	  dynamin	  inhibitor	  dynasore,	  however,	  
reveales	  a	  potential	   role	   for	  dynamin	   in	  CCL3	  stimulated	  migration	  (conclusion	  6).	  Dynasore	   is	  
not	   effective	   in	   blocking	   CXCR3	   stimulated	   PBL	   migration	   but	   it	   blocks	   CCL3	   stimulated	  
migration	  in	  the	  same	  system,	  suggesting	  a	  receptor	  family	  specific	  point	  of	  access	  to	  migration.	  
CXCR3	   and	   CCR5	   have	   different	   signalling	   and	   desensitisation	   with	   CXCR3	   mediated	   T-­‐cell	  
chemotaxis	   occurring	   in	   a	   PTX	   and	   PLC	   dependent	   fashion	   [280].	   This	   correlates	   with	   the	  
observed	   effect	   of	   the	   Gβγ	   inhibitor	   gallein	   in	   activated	   PBLs	   and	   suggests	   that	  migration	   in	  
these	   cells	   might	   also	   be	   calcium	   sensitive,	   unlike	   CCL3	   stimulated	   migration	   in	   THP-­‐1	   cells.	  
Interestingly,	  dynamin	  inhibitors	  vary	  widely	  in	  their	  ability	  to	  affect	  CCL3	  stimulated	  migration	  
in	   THP-­‐1	   cells.	   Cross	   analysis	   of	   different	   dynamin	   inhibitors	   revealed	   that	   dynamin	   GTPase,	  




Figure	   7.1:	   Basic	   synthetic	   strategy	   for	   SAR	   of	   migration	   specific	   dynamin	   inhibitors.	   (a)	  
Existing	   analogues	   of	   dynasore,	   their	   structure	   and	   activity	   as	   GTPase	   and	   migration	  
inhibitors.	  Compound	  DD-­‐11	  has	  been	  synthesised	  by	  Lee	  et	  al.	  and	  displays	   similar	  GTPase	  
inhibition	  to	  dynasore	  but	  has	  not	  been	  tested	  in	  migration	  assays.	  Also	  shown	  are	  proposed	  
structures	   to	   explore	   the	   relationship	   between	   migration	   inhibition	   and	   terminal	   aryl	  
functional	   group.	   (b)	   Proposed	   ideas	   for	   structurally	   divergent	   migration	   specific	   dynamin	  
inhibitors.	   Route	   ‘A’	   explores	   heteroatom	   in	   place	   of	   hydroxyl	  moieties;	   route	   ‘B’	   explored	  
ring	  size	  and	  route	  ‘C’	  explores	  the	  effect	  of	  increase	  ring	  flexibility.	  Reagents	  and	  conditions	  
are	  conducive	  for	  fast,	  cheap	  production	  of	  a	  compound	  library.	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  The	  dynasore	  analogue	  dyngo-­‐4a	  has	  a	  higher	  GTPase	  inhibitory	  potency	  than	  dynasore	  (Table	  
1.3)	  but	  is	  less	  potent	  as	  an	  inhibitor	  of	  migration.	  The	  fact	  that	  these	  compounds	  differ	  by	  one	  
terminal	   aryl	   hydroxyl	   moiety	   and	   that	   this	   difference	   has	   such	   a	   profound	   effect	   on	   anti-­‐
migratory	  potency	  suggests	  that	  a	  SAR	  study	  to	  uncover	  potent	  inhibitors	  of	  migration	  that	  are	  
poor	   inhibitors	   or	   dynamin	   GTPase	   function	   and	   therefore	   internalisation	   would	   be	   useful	  
(Figure	  7.1.).	  	  
	  
Inhibition	   of	   dynamin	   that	   completely	   blocks	   endocytosis	   is	   likely	   to	   be	   detrimental	   to	   the	  
normal	   functioning	   of	   cells	   and	   cellular	   processes;	   this	   thesis	   suggests	   that	   synthesis	   of	  
‘migration	   specific’	   dynamin	   inhibitors	   maybe	   possible	   using	   chemotaxis	   assay	   as	   the	   test	  
criteria.	   Figure	   7.1a	   highlights	   dynasore	   analogues	   found	   in	   the	   literature:	   the	   differences	  
between	  dynasore	  and	  dyngo-­‐4a	  pivot	  on	  one	  terminal	  hydroxyl	  (Figure	  7.1a),	  suggesting	  subtle	  
modifications	  around	  this	  locus	  may	  yield	  significant	  changes	  in	  GTPase	  and	  migration	  inhibition	  
efficacy.	  Compound	  DD-­‐11,	  synthesised	  by	  Lee	  et	  al.	  [281]	  showed	  comparable	  RME	  efficacy	  to	  
dynasore,	  indicating	  that	  the	  effect	  of	  modification	  at	  the	  terminal	  hydroxyls	  has	  some	  plasticity	  
with	  regard	  to	  functional	  group	  type.	  This	  compound	  was	  not	  tested	   in	  GTPase	  or	  chemotaxis	  
assay,	   so	   direct	   comparisons	   cannot	   be	  made.	   Due	   to	   the	   ease	   of	   synthesis	   and	   low	   cost	   of	  
reagents,	  relatively	  divergent	  chemical	  species	  could	  be	  generated	  and	  tested	  with	  little	  effort	  
(Figure	   7.1b),	   allowing	   better	   understanding	   of	   the	   inhibitor-­‐protein	   interaction	   to	   be	   gained	  
quickly.	  	  	  
	  
As	   dynasore	   and	   its	   analogue	   are	   the	   most	   effective	   inhibitors	   of	   migration	   and	   their	  
hypothesised	  binding	   location	   is	   proximal	   to	  dynamin’s	   regulatory	  PRD	  domain	  exploring	  PRD	  
interacting	  proteins	  was	   an	  obvious	   step.	  Grb2	   inhibitors	   block	  CCL3	  mediated	  migration,	   the	  
first	   time	   such	   a	   relationship	   has	   been	   established.	  Grb2	   inhibition	  may	   represent	   a	   route	   to	  
indirectly	   inhibit	   the	   migration	   specific	   functions	   of	   dynamin	   and	   showed	   some	   specificity	  
towards	  CCL3	  stimulated	  migration.	  	  Grb2	  is	  known	  to	  target	  SH2	  bound	  targets	  to	  SH3	  domains	  
activated	  by	  tyrosine	  kinases	  [112];	  the	  c-­‐Src	  inhibitor	  bosutinib	  was	  used	  to	  demonstrate	  that	  
cytosolic	  non-­‐receptor	  tyrosine	  kinases	  were	  vital	  for	  CCL3	  mediated	  migration.	  Bosutinib	  is	  also	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  effective	  at	  reducing	  CXCR3	  stimulated	  PBL	  migration,	  which	  raises	  question	  as	  to	  its	  specificity	  
to	  any	  particular	  receptor	  signalling	  system.	  The	  use	  of	  bosutinib	  allows	  a	  comparative	  analysis	  
of	  the	  efficacy	  of	  dynamin	  and	  Grb2	  inhibitors	  against	  a	  drug	  that	  is	  soon	  to	  be	  released	  as	  an	  
anti-­‐cancer	  therapeutic	  [282].	  Although	  their	  potencies	  are	  lower,	  both	  CGP78850	  and	  dynasore	  
are	  as	  effective	  at	  reducing	  migration	  as	  bosutinib,	  supporting	  the	  validity	  of	  Grb2	  and	  dynamin	  
inhibition	  as	  a	  potential	  therapeutic	  avenue	  for	  metastatic	  disease.	  	  
	  
Table	   7.1	   lists	   the	   protein	   targets	   described	   in	   this	   thesis	   with	   regard	   to	   their	   validity	   as	  
therapeutic	   targets	   against	   CCL3	   (CCR1/CCR5)	   mediated	   chemotaxis.	   The	   blockade	   of	   the	  
extracellular	  portions	  of	  the	  receptors	  themselves	  has	  not	  resulted	  in	  the	  production	  chemokine	  
receptor	   antagonist	  based	   treatments	   for	   any	  disease.	   The	  difficulty	   in	   isolating	  CCR5	   specific	  
signalling	  from	  CCR1	  specific	  events	  in	  vitro	  is	  exemplified	  in	  chapter	  3,	  where	  both	  redundancy	  
through	   lack	   of	   ligand	   specificity	   and	   non-­‐specific	   antagonistic	   effects	   were	   observed.	   These	  
problems	  are	  likely	  to	  be	  exacerbated	  in	  vivo	  where	  other	  factors	  such	  as	  increased	  extracellular	  
ligand	  diversity	  are	   sure	   to	   reduce	  chemokine	   receptor	  antagonist	  efficacy.	  Taken	  as	  a	  whole,	  
targeting	   chemokine	   receptors	   directly	   represents	   a	   poor	   target	   choice	   for	   anti-­‐migratory	  
therapeutics.	   Arrestin	   dependent	   signalling	   was	   identified	   as	   a	   likely	   route	   for	   signal	  
transduction	   to	  migration	   in	   THP-­‐1	   cell	   upon	   CCL3	   stimulation	   (chapter	   4).	   Targeting	   arrestin	  
directly	  does	  not	  represent	  a	  valid	  strategy	  for	  two	  reasons;	  firstly	  all	  GPCRs	  require	  arrestin	  for	  
regulation.	  Inhibiting	  arrestin	  may	  result	  in	  a	  decrease	  in	  arrestin	  dependent	  signalling,	  where	  it	  
occurred,	   but	  would	   also	   lead	   to	   a	   reduction	   in	   desensitisation	   in	   GPCRs	  where	   ‘classical’	   G-­‐
protein	   mediated	   signalling	   was	   occurring	   which	   could	   have	   severe	   negative	   effects	  
physiologically.	  Secondly	  there	  are	  presently	  no	  small	  molecule	  inhibitors	  of	  arrestin	  described	  







	  Table	  7.1:	  Validity	  of	  proteins	  as	  targets	  in	  CCL3	  stimulated	  chemotaxis.	  
	  
Protein	   Target	  validity	   Rationale	   References	  
CCR1/5	   Very	  poor	   Blockade	   of	   chemokine	   receptor	   signalling	  
fails	  due	  signalling	  redundancy	  resulting	  from	  
lack	   of	   receptor-­‐ligand	   specificity	   as	  
exemplified	   by	   the	   effects	   of	   maraviroc	   and	  
J113863	  on	  THP-­‐1	  cell	  chemotaxis.	  
Chapter	  3,	  	  
	  
Arrestin	   Poor	   Outside	   of	   arrestin	   dependent	   signalling,	  
arrestin	   is	   required	   for	   desensitisation	   of	   all	  
GPCRs	   therefore	   is	   likely	   to	   impact	   other	  
GPCR	   signalling	   adversely.	   β	   arrestin	   isotype	  
specificity	   would	   also	   need	   to	   be	   taken	   into	  
account.	  
Chapter	  4,	  	  
	  
PI3K	   Poor	   Although	  validated	  as	  a	  therapeutic	  target	  for	  
numerous	  cancers	  PI3K	  has	  an	  unclear	  role	  in	  
CCL3	   induced	   migration	   which	   may	   or	   may	  




Dynamin	  2	   Moderate	   Complete	   inhibition	   of	   dynamin	  would	  make	  
a	  poor	   target	   for	   the	  blockade	  of	   chemokine	  
receptor	   mediated	   migration	   as	   endocytosis	  
is	   vital	   for	   normal	   cellular	   function.	   If	  
migration-­‐specific	   dynamin	   inhibitors	   can	   be	  
developed	  however	  targeting	  the	  protein	  may	  
be	  a	  realistic	  route	  for	  migration	  blockade.	  
Chapter	  6,	  
	  
c-­‐Src	   Good	   c-­‐Src	  inhibition	  is	  effective	  in	  THP-­‐1	  and	  HeLa	  
cells	   and	   PBLs	   but	   may	   lack	   specificity	  
between	   receptor	   types	  and	  has	  been	   linked	  
to	  negative	  cellular	  responses.	  	  
Chapter	  4,	  
	  
Grb2	   Very	  Good	   Grb2	   inhibition	   appears	   to	   affect	   CCL3	  
induced	   responses	   more	   than	   CXCR3	  
stimulated	   responses	   which	   may	   indicate	  
specificity	  toward	  C-­‐C	  motif	  ligand	  stimulated	  
responses.	   Also	   has	   the	   potential	   to	   access	  





	  PI3K	  also	  represents	  a	  poor	  target	  in	  the	  CCL3-­‐CCR5/CCR1	  signalling	  axis,	  as	  its	  exact	  role	  could	  
not	  be	  defined	  and	  sensitivity	  to	  PI3K	   inhibitors	   is	   lower	  than	  seen	   in	  systems	  where	  PI3K	  has	  
been	  identified	  as	  a	  valid	  target	  [248].	  The	  observed	  lack	  of	  efficacy	  of	  PI3K	  inhibitors	  (chapter	  
6)	  may	  have	  been	  a	  result	  of	  cell	   type	  specific	   responses	  however	  cell	   type	  diversity	   in	  vivo	   is	  
high.	  This	  suggests	  that	  the	  efficacy	  of	  PI3K	  inhibitors	  in	  vivo	  may	  vary	  accordingly	  which	  is	  not	  
ideal	  when	  dosing	  regimes	  and	  patient	  responsiveness	  need	  to	  be	  considered.	  	  
	  
Dynamin	   may	   represent	   a	   valid	   target	   for	   inhibition	   provided	   that	   inhibitors	   which	   target	  
migration	  specific	  functions	  can	  be	  produced.	  Failing	  this,	  dynamin	  does	  not	  represent	  a	  much	  
better	  target	  than	  arrestin;	  systemic	  blockade	  of	  internalisation	  is	  likely	  to	  have	  severe	  negative	  
physiological	   effects.	   The	   dynamin	   interacting	   protein	   Grb2	   represents	   the	   most	   valid	   target	  
described	  in	  this	  thesis;	  efficacy	  of	  Grb2	  inhibition	  is	  comparable	  to	  the	  c-­‐Src	  inhibitor	  bosutinib,	  
which	   suggests	   with	   enhanced	   potency	   a	   Grb2	   inhibitor	   may	   represent	   a	   point	   of	  
pharmacological	   access	   to	   chemokine	   receptor	   mediated	   migration.	   The	   Grb2	   inhibitor	  
CGP78850	   shows	   better	   efficacy	   in	   CCL3	   mediated	   THP-­‐1	   migration	   than	   it	   did	   in	   CXCL11	  
stimulated	   PBL	   migration,	   which	   correlates	   with	   the	   observed	   effects	   of	   dynasore	   in	   these	  
systems.	   This	   conclusion	   comes	   with	   the	   caveat	   that	   the	   interactions	   of	   Grb2	   in	   chemokine	  
receptor	   signalling	   are	   very	   poorly	   characterised;	   resolution	   of	   Grb2-­‐Dynamin-­‐chemokine	  
receptor	  interaction	  proteomically	  will	  be	  important	  in	  validating	  this	  research.	  	  
	  
7.2.	  Future	  work	  
	  
As	   described	   in	   the	   introduction	   (chapter	   1)	   the	   aim	   of	   this	   thesis	   is	   to	   resolve,	   by	   small	  
molecule	   intervention,	   signal	   transduction	   from	   the	   chemokine	   receptor	   CCR5.	   This	   was	  
achieved	   to	   a	   certain	   extent;	   although	   CCR5	   specific	   events	   could	   not	   be	   isolated.	   Signalling	  
stimulated	  by	  CCL3	  via	  CCR1/5	  was	  shown	  to	  occur	  through	  arrestin	  dependent	  signalling	  and	  to	  
involve	   dynamin,	   Grb2	   and	   c-­‐Src.	   There	   are	   limitations	   to	   the	   conclusions	   that	   can	   be	   drawn	  
from	  a	  predominantly	  small	  molecule	  based	  investigation;	  this	  was	  understood	  from	  the	  outset	  
with	  the	  aim	  that	  the	  conclusions	  drawn	  from	  this	  thesis	  would	  allow	  more	  in-­‐depth	  proteomic	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  characterisations	   to	   be	   undertaken.	   A	   relationship	   between	   dynamin	   inhibitors	   and	   anti-­‐
migratory	  efficacy	  was	   also	  discovered	  however,	   so	   the	   future	  work	  based	  on	   this	   thesis	   falls	  
into	  four	  areas.	  	  
	  
1. Further	   in	   vitro	   small	   molecule	   investigation	   to	   validate	   observations	   made	   in	   the	  
thesis.	  
2. A	  proteomic	  investigation	  of	  Grb2	  and	  dynamin	  and	  their	  interaction	  in	  vitro.	  	  
3. In	  vitro	  and	  ex	  vivo	  validation	  of	  the	  protein	  targets	  in	  disease	  models.	  
4. Synthesis	  of	  dynasore	  analogues	  to	  form	  SAR	  that	  allows	  ‘migration	  specific’	  dynamin	  
inhibitors	  to	  be	  produced.	  	  
	  
Area	   1	  would	   involve	   experiments	   such	   as	   further	   small	  molecule	   validation	   of	   the	   identified	  
protein	  targets.	  Obtaining	  or	  synthesising	  the	  pro-­‐drug	  form	  of	  CGP78850	  would	  allow	  the	  true	  
potency	  of	  Grb2	  inhibition	  to	  be	  determined	  and	  compared	  to	  clinically	  approved	  therapeutics	  
such	  as	  bosutinib.	  A	   range	  of	  new	  dynamin	   inhibitors	  have	   recently	  been	  described	  based	  on	  
dynole	  34-­‐2	  [283];	  testing	  these	  inhibitors	  may	  validate	  the	  hypothesised	  relationship	  between	  
inhibitor	  binding	  and	  anti-­‐migratory	  efficacy.	  	  Area	  2	  would	  involve	  basic	  proteomics	  such	  as	  the	  
effect	  of	  Grb2	  knock	  down	  and	  overexpression	  on	  migration	  and	  the	  effect	  of	  siRNA	  on	  dynamin	  
interacting	  proteins	  which	  do	  not	  have	   small	  molecule	   inhibitors	   such	  as	   cortactin	  and	  gridin.	  
More	  complex	  proteomics	  such	  as	  the	  production	  of	  PRD	  modified	  dynamin	  for	  overexpression	  
or	   production	   of	   monovalent	   Grb2	   might	   outline	   the	   exact	   functions	   of	   these	   proteins.	  
Development	   of	   methodology	   to	   allow	   reliable	   transfection	   of	   THP-­‐1	   cells	   which	   does	   not	  
impact	  migration	  assay	  is	  also	  an	  important	  point	  for	  future	  research.	  
	  
Area	  3	  will	  validate	  the	  effect	  of	   the	   identified	  proteins	   in	  disease	  models.	  Animal	  models	  are	  
the	  obvious	  choice	  but	  ex	  vivo	  studies	  such	  as	  monocyte	  migration	  towards	  rheumatoid	  arthritis	  
synovial	   fluid	   offer	   a	   less	   costly	  way	   to	   validate	   the	   likely	   anti-­‐migratory	   effects	   of	   Grb2	   and	  
dynamin	  inhibition	  in	  vivo.	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  Finally	   the	  design	  and	  synthesis	  of	  dynasore	  analogues	  with	   the	  structure	  activity	   relationship	  
geared	  towards	  migration	  instead	  of	  dynamin	  GTPase	  function	  may	  allow	  novel	  small	  molecules	  
that	  are	  poor	   inhibitors	  of	   internalisation	  but	  potent	   inhibitors	  of	  chemotaxis	  to	  be	  described.	  
The	   simplicity	  of	   the	   synthetic	   route	  and	   low	  cost	  of	   synthetic	   reagents	  means	   that	   a	  diverse	  
library	  of	  potential	   compounds	  could	  be	  produced	  and	   tested	  quickly.	   	  As	  a	  whole	   this	   future	  
work,	   in	   addition	   to	   the	   research	   presented	   in	   the	   thesis,	   has	   the	   potential	   to	   enhance	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